<SEC-DOCUMENT>0000950170-24-060075.txt : 20240515
<SEC-HEADER>0000950170-24-060075.hdr.sgml : 20240515
<ACCEPTANCE-DATETIME>20240515085734
ACCESSION NUMBER:		0000950170-24-060075
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		52
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240515
DATE AS OF CHANGE:		20240515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alaunos Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001107421
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				841475642
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33038
		FILM NUMBER:		24947421

	BUSINESS ADDRESS:	
		STREET 1:		2617 BISSONNET ST
		STREET 2:		SUITE 225
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77005
		BUSINESS PHONE:		(346) 355-4099

	MAIL ADDRESS:	
		STREET 1:		2617 BISSONNET ST
		STREET 2:		SUITE 225
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZIOPHARM ONCOLOGY INC
		DATE OF NAME CHANGE:	20050919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EASYWEB INC
		DATE OF NAME CHANGE:	20010213
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>tcrt-20240331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-05-15T07:52:04.8260+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2023" xmlns:tcrt="http://alaunos.com/20240331" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_573aa50a-8660-4899-8300-e5834ed98d42" name="dei:EntityCentralIndexKey" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54">0001107421</ix:nonNumeric><ix:nonNumeric id="F_be485a2c-e9b1-4a7d-988e-fb85faee85f6" name="dei:AmendmentFlag" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_912f67c0-ee7a-4ea9-a9f6-fa771e079b85" name="dei:DocumentFiscalPeriodFocus" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54">Q1</ix:nonNumeric><ix:nonNumeric id="F_e866ea43-ac5b-4c3c-b32e-8d305031edcb" name="dei:CurrentFiscalYearEndDate" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54">--12-31</ix:nonNumeric><ix:nonFraction id="F_d489a1a3-4066-4111-8fa4-da4de611e5f0" name="us-gaap:CommitmentsAndContingencies" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" unitRef="U_USD" xsi:nil="true"/><ix:nonFraction id="F_4fe26983-f996-40e5-8f1c-85312879ee23" name="us-gaap:CommitmentsAndContingencies" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" unitRef="U_USD" xsi:nil="true"/></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tcrt-20240331.xsd"/></ix:references><ix:resources><xbrli:context id="C_e2f5fa39-2c4c-4a31-9dba-9b302e6163aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-08-17</xbrli:startDate><xbrli:endDate>2015-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e2a059d-282e-4250-8c99-11315e2fb9ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db32a880-2ad0-470e-8702-ccd0f5ec87bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3ae250c-9ef9-4e50-b001-e026832b5546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a6c29fff-7446-403d-9ae5-f2ab3b978cc5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a4ac29e-7e17-4f4e-8ca5-1a9b13dce527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f929b6c-a393-480f-b2d8-4b64cbcc35fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_afd87759-7cd4-4535-a126-67b00b692ba6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:NewWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06f78440-3bd6-4263-b564-21c6263d6ac1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_318d2bef-2b78-48b2-9bf0-7f8d81ddf304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tcrt:AgreementTypeAxisAxis">tcrt:CantorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-29</xbrli:startDate><xbrli:endDate>2022-11-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e421c5e-d96b-4a7c-84cb-11656fb4e700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69b6b7d3-41a2-4d80-aee3-85fbf3416f62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a4a2144-53c6-473a-a17e-948eca082f68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_699c4514-89e0-4171-a8dd-a4bb94caddc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2004-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05086637-454b-451e-ba2f-b6e9dac6f1bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f5ae535-f6d0-484b-b23f-ef9a9da46789"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:DuneLakeCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf8b4b8c-26b2-4415-90c9-ba9e666f9956"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a9f3d32-f84f-4b13-8b49-7ba3cda42ef8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_373d470e-fec0-416f-bd2c-474750080aee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5aaa9322-5f00-4afe-8d8b-410a6b78fc05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86b01827-f0d2-4c97-bbb5-1f488e3fa49f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95a30d90-929e-45eb-82ad-23f6fc64e994"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tcrt:AgreementTypeAxis">tcrt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-11</xbrli:startDate><xbrli:endDate>2018-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe3fc5c4-0c6a-404b-8a06-a203f7a1b9c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dae15987-4a72-452e-bffe-37b8c8ff2004"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7868565d-837f-4c4e-a465-218189cb407e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96de5e3d-ec20-471c-8b74-4754e48554be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4794af2c-583f-4aeb-8161-0074b8016cb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4dd2c47b-4df3-4a07-bb67-521f620934a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87dc43db-b832-4e32-9d47-a96ea1328b91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-17</xbrli:startDate><xbrli:endDate>2023-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c448816-7d5b-4d6c-8eae-4e4d68502072"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb264759-9de1-4b9f-acc7-aa907a4f72c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:DuneLakeCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aeb70e75-70ac-4afa-88cd-62bbcaee35fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_94aa9eb4-37eb-4c0d-b5f9-9e0dd0d7fb5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcrt:TcellReceptorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3cf5907-2650-4723-90f5-2fbb4565112b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_170c0509-c56f-4761-bdf6-22de08ad77fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c27b046-6702-4a71-8e61-6ba81f191fea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3cf7f842-3616-4d7d-a8d1-b72415a7dc2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">tcrt:ZiopharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">tcrt:EdenBioCellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3efa5cb2-5a15-4829-bf1f-70ca2555bcc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4bd3b321-13c5-4e4c-a083-a14aeb2b41c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:NewWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-12</xbrli:startDate><xbrli:endDate>2019-09-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_459f2708-7ef7-43f4-a5f4-b66c0656e6b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tcrt:AgreementTypeAxisAxis">tcrt:CantorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-05</xbrli:startDate><xbrli:endDate>2023-01-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31821ab4-d999-49bb-b9d4-9b4dd0c91cb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3354c043-11e9-441d-8243-0c39e040d0c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6270e901-6735-4c63-9513-8fb545fff59f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_729e1616-09f9-46a9-a428-b5c7fb8de61a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58a539c3-32e6-40ab-81e3-7460cfa16a02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-08-17</xbrli:startDate><xbrli:endDate>2015-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_081cf75e-7342-44b3-be87-434671a576d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47601be9-83e3-443d-bbcb-b0ba3efb137d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_307719b1-83d4-4843-8da2-94558ade533e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84fba74a-d852-4278-a598-763f3de703a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0bc55a8f-887f-4070-9865-fd66f24117bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-12</xbrli:startDate><xbrli:endDate>2019-09-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_499d880c-c83e-4094-9801-9f067ded9cb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4c893ed4-2fab-4607-8dfd-4e3ede2ebc02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e6444ec-337d-440e-ae0f-2c013e8670a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-11</xbrli:startDate><xbrli:endDate>2018-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35078a72-b5fc-4657-9c90-f59660c54ff7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a6df5e6-87bf-4b67-8430-063789b2272d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6046fec4-c22d-43b6-ba9b-95ebb064d3de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_727a2f22-62eb-4547-b383-db9f11e5e1ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b46b0e83-a6fe-4373-960c-564ab0754cde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f534694-1370-4e1c-8929-649408ad27f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbfeed30-f20b-44da-b3ca-39d3d35097bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_289f7d65-cf86-4803-859d-4037fea6fa0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_655a3713-d843-4e68-b88b-1e572769c0e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b01cd0f9-f0ef-4fe1-89dd-e53ec38d0b9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9263274-e6c8-4931-ba30-9ba9d76c89f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_481d4dca-c2e0-4a6d-a1aa-cb7b99c9e7e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_06ec8ddd-a6ca-4458-b361-e0082cad4a4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04d2b6bc-59f0-497b-ad0b-246c6e2342a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-28</xbrli:startDate><xbrli:endDate>2021-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_82917f35-4e10-4373-8317-e2e998187578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c8496d52-7c42-49e6-b1a1-90623138bd33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bbf27f91-17b6-4ae0-ad7c-8ead5a875486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad2cf5bf-7a86-4612-a507-a31f59be56ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tcrt:AgreementTypeAxisAxis">tcrt:CantorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-29</xbrli:startDate><xbrli:endDate>2022-11-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_feb2760d-82be-46cd-ac00-b75cb7214032"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9ea1296-e67e-4c96-9b52-f8fb4490bf1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-14</xbrli:startDate><xbrli:endDate>2023-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8baabce6-ac11-4af5-8a5f-c37dac90e95a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_30b081ac-90e4-47f2-90f6-835d27c36c54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8013c772-ccba-4aa2-b4a1-652bb9ef35c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5f3c58ea-f897-4151-a1ad-8f8690250ebe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8cb0a4ff-691a-4757-b2eb-fbbd3b39dfe9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-22</xbrli:startDate><xbrli:endDate>2019-10-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_131aee97-1b4f-446a-8c75-66998adcc711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-12</xbrli:startDate><xbrli:endDate>2019-09-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc6be139-4d29-491a-ac06-ae207788d63f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-14</xbrli:startDate><xbrli:endDate>2023-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0fe9cdfc-046e-4935-a0e2-2577ae6a7cf2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58b07922-742e-4d1e-8e94-cc27df08f5e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_05763aa1-65a6-4ed2-aa0e-21d87146369c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82df7c7b-262a-4272-aced-862f49a97569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:EdenBiocellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-18</xbrli:startDate><xbrli:endDate>2018-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a620055d-3725-42b7-9bb4-54550ba559d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62447313-6131-42f8-98d0-6c78900cb176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e202e528-177e-4db6-adec-6869d8137344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5c46026b-b792-4f5a-b3d6-cd9c0eb096c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcrt:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-29</xbrli:startDate><xbrli:endDate>2022-11-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27f693e7-6abd-4a93-b50d-4206e1b22623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-20</xbrli:startDate><xbrli:endDate>2023-10-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a5053d79-f95f-4469-83c1-e72e88a19a19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:SiliconValleyBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd66aa2a-1923-408f-ad01-68d671934a39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f17db39b-f553-4323-b229-bec623ac9226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3afa3256-b142-4067-84fa-31003618cdf3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonAgreementAndWorldwideLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-13</xbrli:startDate><xbrli:endDate>2015-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1da774e-81d4-427f-b25c-7a2574c834ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_478a5db8-cf73-4704-b31d-d3f5d829c87e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_529a077c-2067-46ae-a95e-3d29d884679c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-06</xbrli:startDate><xbrli:endDate>2021-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98a802f2-0e70-4585-9cc4-a79b60e487e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-28</xbrli:startDate><xbrli:endDate>2021-12-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d87a9b62-f8b3-496c-813b-ff57b12f4f20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2118d568-df96-4de0-9724-e8edfa283612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-31</xbrli:startDate><xbrli:endDate>2024-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d188ee19-8efb-40f4-bfc1-15d99d4dcdb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:EdenBiocellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52953abd-cae9-408c-bc3a-1c32bbcbd88a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf29daca-a7b6-4083-bfa6-78d85df7567f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f5aa7ee8-5428-4b9d-b069-2e72b206cbaa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b355e022-e0e9-4da2-8a04-f3b2546fe32b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb3569a0-1c09-487b-a964-8d604ab02e26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-12</xbrli:startDate><xbrli:endDate>2022-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f7de99b6-d374-4e48-911c-1cd00129ec98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9080476-f0f7-430a-80b4-880ed65fc6e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tcrt:ClassOfWarrantOrRightAxisAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_228ec118-b1e2-4f75-9b40-90b271c238f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-10-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0e1c5bb-bb46-4bb5-b672-44110a621fdf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2998239-c729-4024-b9be-d75e1a53f26d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tcrt:AgreementTypeAxisAxis">tcrt:CantorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c594780d-4524-4d01-9ec4-b90f13b9d953"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_531cd4a1-a78c-4276-b3b6-3bea9219ed8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001107421</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:5pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">Form </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_851be3c1-43fa-4eee-b985-0ef8bff5134f" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">10-Q</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:5pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:4.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_3d87f659-7701-4f74-8a74-195a1ccfffd0" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_283d6365-48a8-43c9-b2a0-d765f6a0ff89" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91dfe2c9-5afa-4a6e-b257-5cd42c9749da" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OR</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4%;"/>
    <td style="width:96%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_1c4a916e-1d42-4a8c-a07b-f9deb7bf6c16" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:DocumentTransitionReport" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6352218d-10ab-4bb0-aeba-e06793b143c0" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">001-33038</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:5pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e2131396-9084-471f-a623-f20839fbc93e" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_aba7ba88-b747-435d-8490-13926b06333d" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_070610bd-b6d0-4dc8-bdce-0bd83b060422" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">84-1475642</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="2" style="vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_20c73e40-f0da-4e02-9a82-4fd6d4081236" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2617 Bissonnet Street</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_d7b10b2d-a98b-4780-b000-5b1b68a6e6fe" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 225</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span><ix:nonNumeric id="F_347fe572-2cc0-45a7-886b-71a237b6fdf5" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Houston</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_f805550c-276a-4c23-a45a-3ba945ca4c0d" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TX</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_5db5ce42-4a7f-4cbb-802f-af10d581349c" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">77005</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span><ix:nonNumeric id="F_e235c9ce-7e58-4bb5-9f27-3adbe8a65659" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">346</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">) </span><span><ix:nonNumeric id="F_07c3a9b7-ae2c-4715-af93-d1f4f3fbd41c" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">355-4099</span></ix:nonNumeric></span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)</span></p><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;"/>
    <td style="width:1%;"/>
    <td style="width:15%;"/>
    <td style="width:1%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_66e548cb-cb26-45e4-b676-e43989489b58" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_5b6448a1-921f-4210-88c0-9e8f022fe4f4" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TCRT</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_cc4b0799-2f24-4ba5-82d1-ce7dd15d65f2" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;Capital Stock Market</span></p></td>
   </tr>
  </table>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bdbb4d79-27a0-4760-95f0-38822708d9b2" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;    No  &#9744;</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed0e4e1e-bb31-4a8d-9701-e36baef19ff5" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;    No  &#9744;</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32%;"/>
    <td style="width:1%;"/>
    <td style="width:2%;"/>
    <td style="width:30%;"/>
    <td style="width:32%;"/>
    <td style="width:1%;"/>
    <td style="width:2%;"/>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large Accelerated Filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated Filer</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_3263ff9a-433b-4669-aa5e-9ec76aa30c1e" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-Accelerated Filer</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller Reporting Company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_ee46cc66-4ab9-41e4-b127-a573d243fe4e" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging Growth Company</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:9pt;"><ix:nonNumeric id="F_02e27e78-c266-432c-bccf-6e2df7e0f285" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes  &#9744;    No  </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_66449430-63f8-4471-961b-be86b7232c11" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:5.333%;font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">As of May 12, 2024, the number of outstanding shares of the registrant's common stock, $0.001 par value, was </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_293f3114-9249-4246-862e-143b9a0764af" contextRef="C_b46b0e83-a6fe-4373-960c-564ab0754cde" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">16,012,522</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> shares.</span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are all statements contained in this Quarterly Report that are not historical fact, and in some cases can be identified by terms such as: &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; "potential," &#8220;will&#8221; and other words and terms of similar meaning.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These statements are based on management&#8217;s current beliefs and assumptions and on information currently available to management. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this Quarterly Report include, but are not limited to, statements about:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to successfully implement our strategic reprioritization or realize any or all of the anticipated benefits once implemented;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to raise substantial additional capital to continue as a going concern and fund our planned operations in the near term and our strategic reprioritization in the longer term;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to successfully consummate any strategic transactions, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">estimates regarding our expenses, use of cash, timing of future cash needs and anticipated capital requirements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to license additional intellectual property to support our strategic reprioritization or out-license our intellectual property and to comply with our existing license agreements; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to enter into partnerships or strategic collaboration agreements and our ability to achieve the results and potential benefits contemplated from relationships with collaborators; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to maintain collaborations and licenses; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectation of developments and projections relating to competition from other pharmaceutical and biotechnology companies or our industry; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the anticipated amount, timing and accounting of contract liabilities, milestones and other payments under licensing, collaboration or acquisition agreements, research and development costs and other expenses; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to remain listed on the Nasdaq Capital Market; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our intellectual property position, including the strength and enforceability of our intellectual property rights.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any forward-looking statements in this Quarterly Report on Form 10-Q reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievements to be materially different from any future results,  level of activity, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part II, Item 1A, &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless the context requires otherwise, references in this Quarterly Report to &#8220;Alaunos,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to Alaunos Therapeutics, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We own or have rights to trademarks, service marks and trade names that we use in connection with the operation of our business, including our corporate name, logos and website names. We own the trademarks Alaunos&#174;, Ziopharm&#174; and hunTR&#174; as well as the graphic trademark found on our website. Other trademarks, service marks and trade names appearing in this Quarterly Report are the property of their respective owners. Solely for convenience, some of the trademarks, service marks and trade names referred to in this Quarterly Report are listed without the &#174; and &#153; symbols, but we will assert, to the fullest extent under applicable law, our rights to our trademarks, service marks and trade names.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">i</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SUMMARY OF SELECTED RISKS ASSOCIATED WITH OUR BUSINESS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business faces significant risks and uncertainties. If any of the following risks are realized, our business, financial condition, results of operations, cash flows and prospects could be materially and adversely affected. You should carefully review and consider the full discussion of our risk factors in the section titled &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report. Some of the more significant risks include the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our strategic reprioritization may not be successful, may not yield the desired results and we may be unsuccessful in identifying and implementing any strategic transaction.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a strategic transaction is not consummated, our Board of Directors may decide to pursue a dissolution and liquidation. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may require substantial additional financial resources to continue as a going concern, including through the strategic review process, and if we raise additional funds it may affect the value of your investment in our common stock. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to consummate a strategic transaction depends on our ability to retain our current employees and consultants.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our corporate restructuring and the associated headcount reduction may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could significantly disrupt our business.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may become involved in litigation, including securities class action litigation, that could divert management&#8217;s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We received a Delisting Determination from Nasdaq in 2023 that while we have addressed with our recent reverse stock split and stock price trends, we remain subject to panel monitoring until February 2025, at any time during which we could be delisted again if we again fail to comply with the Minimum Bid Price Rule. Delisting could prevent us from maintaining an active, liquid and orderly trading market for our common stock and may impact our ability to consummate certain strategic transactions.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have approval by our shareholders for a second reverse stock split of our common stock to enable the Board of Directors to respond to a Panel if we fail to comply with the Minimum Bid Price Rule during the monitor period.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we do get approval and effectuate a second reverse stock split, the trading price of our common stock may not meet the Minimum Bid Price Rule.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In light of the recent reverse stock split, or if we implement a second reverse stock split during the monitor period, liquidity of our common stock may be materially and adversely affected.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may identify material weaknesses in the future or otherwise fail to maintain an effective internal controls system, which may result in material misstatements of our financial statements or have a material adverse effect on our business or stock price.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The recent termination of our licenses and research and development agreement with the National Cancer Institute could limit our ability to resume our clinical trial or begin new clinical trials focused on TCR-T.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any termination of our licenses with Precigen or MD Anderson or our research and development agreements with MD Anderson could result in the loss of significant rights and could materially harm our ability to develop and commercialize our product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should we resume development of our product candidates, we may not be able to commercialize them, generate significant revenues, or attain profitability. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may incur substantial liabilities and may be required to limit commercialization of our products in response to product liability lawsuits.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We relied and, should we in the future resume development of our product candidates, will rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology or loss of data, including any cybersecurity incidents, could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability which could harm our ability to operate our business effectively and materially and adversely affect our business and reputation.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should we resume development of our product candidates, we may encounter difficulties enrolling patients in our clinical trials, and our clinical development activities could be delayed or otherwise materially and adversely affected.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ii</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates are subject to extensive regulation and compliance, which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates, should we resume development.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have halted development of our product candidates early in our development efforts. Our most advanced product candidates were only in an early-stage clinical trial, which is very expensive and time-consuming. We cannot be certain if or when we will be able to submit a Biologics License Application, or BLA, to the U.S. Food and Drug Administration, or the FDA, and the delay, or any failure, in completing clinical trials for our product candidates could significantly harm our business. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following any potential marketing approval.  </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The gene transfer vectors from our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> system used to manufacture our product candidates may incorrectly modify the genetic material of a patient&#8217;s T cells, potentially triggering the development of a new cancer or other adverse events.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should we resume development of our product candidates, any candidate for which we obtain marketing approval could be subject to post-marketing restrictions or withdrawal from the market and we may be subject to significant penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should we resume development of our product candidates, our inability to obtain the necessary U.S. or worldwide regulatory approvals to commercialize any product candidate, our business will suffer materially. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable either to create sales, marketing and distribution capabilities or enter into agreements with third parties to perform these functions, we will be unable to commercialize our product candidates successfully.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If physicians and patients do not accept and use our product candidates, once approved, our ability to generate revenue from sales of our products will be materially and adversely impaired. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to generate product revenues will be diminished if our products do not obtain coverage and adequate reimbursement from payors. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our immuno-oncology product candidates may face competition in the future from biosimilars and/or new technologies and our pending patent applications may not be granted, further limiting our ability to compete with other companies. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or our licensors fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of our intellectual property rights would diminish and our ability to successfully commercialize our products may be materially impaired. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party claims of intellectual property infringement would require us to spend significant time and money and could prevent us from developing or commercializing our products. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our stock price has been, and may continue to be, volatile. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we do not expect to pay dividends, you will not realize any income from an investment in our common stock unless and until you sell your shares at a profit. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to use net operating loss carryforwards and research tax credits to reduce future tax payments may be limited or restricted.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iii</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The exercise of outstanding warrants, and issuance of equity awards may have a dilutive effect on our stock, and negatively and materially impact the price of our common stock.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our principal stockholders, executive officers and directors have substantial control over the Company, which may prevent you and other stockholders from influencing significant corporate decisions and may significantly harm the market price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">iv</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Table of Contents</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.1%;"/>
    <td style="width:82.82%;"/>
    <td style="width:7.08%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART I.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">FINANCIAL INFORMATION</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Financial Statements (unaudited)</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#balance_sheet_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Balance Sheets as of March 31, 2024 (unaudited) and December 31, 2023</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#statements_of_operation_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Statements of Operations for the three months ended March 31, 2024 and 2023 (unaudited)</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#stockholders_equity_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Statements of Changes in Stockholders&#8217; Equity for the three months ended March 31, 2024 and 2023 (unaudited)</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#cashflow_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Statements of Cash Flows for the three months ended March 31, 2024 and 2023 (unaudited)</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:6.85pt;vertical-align:middle;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Condensed Financial Statements (unaudited)</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures about Market Risk</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PART II.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">OTHER INFORMATION</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_legal_proceeding_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factor_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_unregistered_sale_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_default_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Defaults Upon Senior Securities</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_other_information_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_exhibit_"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits</span></a></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART I&#8212;FINANCIAL INFORMATION</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 1. Condensed Financial Statements</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="balance_sheet_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONDENSED </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BALANCE SHEETS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p>
  <p style="font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share data)</span></p>
  <p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ASSETS:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74266b1d-2b11-4426-a87b-ea4770e960ef" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,145</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e46a84e-3639-42ba-8325-b0b757651d80" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,062</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Receivables</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_007d05ed-3817-421f-aff9-5f4d33a30502" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:ReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4dcd67c7-8320-4994-9188-700498a65ee7" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:ReceivablesNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b0ac75a-9e80-4fb2-8c4b-33d28eaa7c35" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,891</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c100ff4d-5575-43e2-9079-1ecc64ef22ab" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,198</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a61df71e-fed9-43ac-8b95-26c57fb3e168" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,037</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_467318fe-0830-48a9-bc49-8f35be900a5a" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,261</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bbf31f63-57cb-4754-9fce-1e99712e48d3" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83592d24-ab09-4b94-9e49-e0f3f717bc55" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:50pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:50pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0eea78db-e9b9-441e-a9cf-24044702ec02" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,037</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e5e0455-e13d-4726-9e7f-fe2141b7c6e3" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,263</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">LIABILITIES AND STOCKHOLDERS' EQUITY</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5897c1ff-969a-40ed-9e95-3d1abb345875" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">597</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89c57997-18fe-42d1-b5c2-25f3ab3699d4" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">616</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_303c12e4-69a9-44e4-88ca-ad85d8da8485" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">643</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d007039f-1c4f-42e1-895e-11ab939a6d96" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,340</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9efcb91a-77e9-43cf-98ca-d0fab3919cd2" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,240</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ceeaad7-d70f-403a-ab6f-b77df975e7f0" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,956</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_370d52b1-5f66-443e-bc4b-b330d66f25fb" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,240</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_47dff093-b7b0-4afa-8c4f-3cb53bda5ca9" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,956</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_d489a1a3-4066-4111-8fa4-da4de611e5f0;"><span style="-sec-ix-hidden:F_4fe26983-f996-40e5-8f1c-85312879ee23;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies (Note 8)</span></span></span></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders' equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7628467a-aa1c-488e-bc6e-9fb59a48bcf7" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b3c0bd6e-7f77-4cf5-a13d-5bda0407948b" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1aaf42a8-287d-4d96-bce1-4f031ba5644d" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_59fb5d68-87b6-4a2d-9e66-39650a06d931" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">34,666,667</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e0e7b13-e1d6-4328-b0bc-4e866d239592" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_668e483a-4311-4ed8-92e9-b41515bf829b" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_462a1030-adf1-4189-ad0e-3e27009af99d" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_08f5ae8e-6cdf-49ca-b552-ee399efd0640" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,012,522</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding at March 31, 2024 and at December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5bf9b8d9-e5d3-4b89-b7d9-a4e37ad4955e" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db82c6ff-ace6-4b7a-ade1-ac7e07f21672" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81921160-9eb5-4185-9789-05f25cdecba7" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">922,230</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f6b0be5-0b0d-45bd-93f6-c75795d7d81d" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">922,058</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b760a1a-1977-490c-a3ef-ad270bc1a280" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">917,449</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb1a0a75-4747-4d0f-a4d2-ed4d09f371e1" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">915,767</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders' equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7269fde-c067-445d-834d-83bf3415d2d8" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,797</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f88c12c-d7cc-44b9-9432-8bf36e98817b" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,307</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:40pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders' equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5c37d3c-d184-41d3-9e97-a2ba195bf5d0" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,037</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00dbf9c0-0deb-4550-a407-9e20b2841e61" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,263</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these condensed financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_of_operation_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONDENSED </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">STATEMENTS OF OPERATIONS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p>
  <p style="font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share data)</span></p>
  <p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">For the Three Months Ended March 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8aa47a7a-efa7-4958-9767-fead4a3e72f5" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b56888ab-6ff5-4f8a-8fe1-a2d7cac7435a" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aeb7230c-3c53-4b86-922b-ccfb253c9c4c" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">126</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07a5eb0e-8ecd-4bc4-a292-6efc10e7ef59" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,504</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e286f9d2-12fc-4cc4-a13e-88843e9ccef2" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,617</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bd3991c-36de-4f2f-af34-8251d4433e73" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,168</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0d3e3ff0-0ab9-41d2-a90a-9c988baf0936" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,743</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8069b38a-6c99-4ddc-9b0f-389c7315ddb3" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,672</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f7154f2-ba3d-440e-ba57-7dfe6f5121ad" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,742</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d523636f-7627-4173-a5a6-bfa9912e258c" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,672</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_570d3a24-98f2-4a54-aed8-6828c1798157" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80acac51-69b7-4eb9-a055-c93c88f02108" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">853</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_374c834f-d309-4b23-a75e-0fa9dc1ace5a" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d41ac6e-c055-4ac5-825a-ac4b03c9e38b" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">477</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b98f058-1281-4aea-8c99-504e1093f0ef" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5166143-fe9b-4071-b281-41544e4e6b31" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">376</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f28820d1-3be3-46ef-b4c5-c45073c45180" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,682</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9472aec7-ccd5-470f-9d67-b7906c948a88" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,048</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic and diluted net loss per share</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1037fb9-3317-409b-9dad-9802a272a8d5" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f9320b6b-f07f-4405-9a98-54a3a307b5e3" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.11</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_096a80d8-97b5-415b-8c8c-1f28e46f687f" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_581e973d-a526-456d-b063-572b3bd7f462" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.63</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted average common shares outstanding, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0c9f40c-3937-4404-a6ee-d24ed9d9c1ca" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8a555777-dee5-4281-9cfa-7ec2a79958de" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">16,012,522</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c67f139-a326-49b4-a6e9-95975228ae0b" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_76be8e3b-4fe5-4d76-966f-e4a8b2f8508f" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">15,978,623</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these condensed financial statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="stockholders_equity_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONDENSED </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p>
  <p style="font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share data)</span></p>
  <p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">For the Three Months Ended March 31, 2024</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.42%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.42%;"/>
    <td style="width:1%;"/>
    <td style="width:1.08%;"/>
    <td style="width:1%;"/>
    <td style="width:7.960000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.08%;"/>
    <td style="width:1%;"/>
    <td style="width:7.960000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.08%;"/>
    <td style="width:1%;"/>
    <td style="width:7.960000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.08%;"/>
    <td style="width:1%;"/>
    <td style="width:7.960000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional Paid in Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Stockholders' Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f6d4a47-9950-4a39-beef-b70fb6c5370a" contextRef="C_47601be9-83e3-443d-bbcb-b0ba3efb137d" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,012,522</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ad0cb87-bcb4-4cdb-9757-060a0530c566" contextRef="C_47601be9-83e3-443d-bbcb-b0ba3efb137d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c7a98f0-bdf0-4be4-858c-1b132ffa84ae" contextRef="C_a0e1c5bb-bb46-4bb5-b672-44110a621fdf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">922,058</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcafd41f-3229-464b-8dbe-688a663df3d2" contextRef="C_a6c29fff-7446-403d-9ae5-f2ab3b978cc5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">915,767</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc9e9282-8184-43d2-976d-be8bc07d0653" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,307</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_778b3ce2-fa9c-4941-b7e9-e5123821beb3" contextRef="C_1a9f3d32-f84f-4b13-8b49-7ba3cda42ef8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76348105-b4e8-4fc8-bcc0-a442811b2566" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e6b0a88-7987-4ba1-b6ca-eeda582672fa" contextRef="C_30b081ac-90e4-47f2-90f6-835d27c36c54" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,682</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b311968-d326-4afb-8e5c-2b8275732378" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,682</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at March 31, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89ac2196-d5e5-46d8-8575-7ea59c02b392" contextRef="C_7868565d-837f-4c4e-a465-218189cb407e" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,012,522</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f933b7bb-f211-4918-88b7-5c9f1bb44363" contextRef="C_7868565d-837f-4c4e-a465-218189cb407e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bfdd9a1a-0c1a-4866-b108-d0b0fdd69462" contextRef="C_4c893ed4-2fab-4607-8dfd-4e3ede2ebc02" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">922,230</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50b8a568-80cc-4bfa-8b56-25f5d978c929" contextRef="C_9a6df5e6-87bf-4b67-8430-063789b2272d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">917,449</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_69f29f87-39ef-4ca5-bc3c-f7ebdb7b76f4" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,797</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:2.32%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">For the Three Months Ended March 31, 2023</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.42%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:8.42%;"/>
    <td style="width:1%;"/>
    <td style="width:1.08%;"/>
    <td style="width:1%;"/>
    <td style="width:7.960000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.08%;"/>
    <td style="width:1%;"/>
    <td style="width:7.960000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.08%;"/>
    <td style="width:1%;"/>
    <td style="width:7.960000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.08%;"/>
    <td style="width:1%;"/>
    <td style="width:7.960000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional Paid in Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total Stockholders' Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4dbf77c2-40a1-47c1-9336-a383ab5f7d57" contextRef="C_a620055d-3725-42b7-9bb4-54550ba559d3" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,027,384</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b87a22ee-a089-496a-9c72-27082d0a13dd" contextRef="C_a620055d-3725-42b7-9bb4-54550ba559d3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ffff30e8-63a2-4aab-94f8-fed6ae16fdb7" contextRef="C_e9263274-e6c8-4931-ba30-9ba9d76c89f4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">919,166</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be26a904-64c1-440b-846c-4416be6de625" contextRef="C_3354c043-11e9-441d-8243-0c39e040d0c6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">880,627</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e86144a3-b775-4dcd-9b49-fb9451fa4641" contextRef="C_f7de99b6-d374-4e48-911c-1cd00129ec98" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,555</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67b96971-d061-41be-ba94-0c321636c669" contextRef="C_06ec8ddd-a6ca-4458-b361-e0082cad4a4b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">910</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a96e9ecc-e636-4588-9601-a4c862891abb" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">910</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Issuance of common stock, net of expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7ed8673-683c-44bc-8a7f-ad6daf8f8e1d" contextRef="C_aeb70e75-70ac-4afa-88cd-62bbcaee35fe" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">14,420</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8b38c0b-e3e6-4a34-90db-aa210de0ce38" contextRef="C_06ec8ddd-a6ca-4458-b361-e0082cad4a4b" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fee01773-540f-4f85-9877-6b556897adfb" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bf91f24a-12c4-4ba7-8526-39134ce40c09" contextRef="C_531cd4a1-a78c-4276-b3b6-3bea9219ed8e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,048</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3617f72d-f85e-4326-bf65-15eed130d5a1" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,048</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at March 31, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f3966e7-ff77-4e36-9eba-88551e9c281a" contextRef="C_86b01827-f0d2-4c97-bbb5-1f488e3fa49f" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,041,804</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95b8733d-f6a8-4495-b5fb-b5aebc24053e" contextRef="C_86b01827-f0d2-4c97-bbb5-1f488e3fa49f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a9b898f-651a-44b9-92c7-5a413323a709" contextRef="C_feb2760d-82be-46cd-ac00-b75cb7214032" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">920,168</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af012b05-a035-4272-a575-a60be9118b9a" contextRef="C_5e421c5e-d96b-4a7c-84cb-11656fb4e700" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">890,675</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cefe3a19-91f6-403c-9b92-568c799d2fe6" contextRef="C_2a4ac29e-7e17-4f4e-8ca5-1a9b13dce527" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,509</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these condensed financial statements.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p>
  <p style="font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="cashflow_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONDENSED </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">STATEMENTS OF CASH FLOWS</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p>
  <p style="font-size:10pt;margin-top:5.4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">For the Three Months Ended March 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e775f89f-3e26-48f8-b0ce-c35ea3a29b9a" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,682</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c859709-d76e-4d40-8a03-5d5a0b91a385" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,048</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49fd7a3b-06ef-49c4-9d9f-71998e0afdfc" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_447d54d2-90f5-4671-a8db-90c94bf81a42" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">696</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization of financing costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2137dc4-0ea1-4420-ac40-a9425d94b982" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fe19a3e-98f3-4c64-8ad7-8863b2799c56" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">472</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_093c36bd-8ed3-42a8-bfc6-1894061ff0c2" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94c3d5f7-51a9-433e-b563-7937b8bc57a9" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">910</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Decrease in the carrying amount of right-of-use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4d009d2-972f-4707-bb01-c1f893132f3f" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="tcrt:IncreaseDecreaseInRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e10005c-8bad-450d-8d78-4efcc65d5c0e" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="tcrt:IncreaseDecreaseInRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">113</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Increase) decrease in:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Receivables</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e9f4436-3008-4b5c-9778-e5c7fec832f0" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:IncreaseDecreaseInReceivables" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce678647-d3e3-4355-b129-550bbf62dde8" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:IncreaseDecreaseInReceivables" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08266003-c48f-47bc-8a4f-973bd07bddfa" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">307</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ae84cec-01d9-4b2a-bbdc-ba378afc8688" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:20pt;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase (decrease) in:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb2b7357-97e7-4600-bec7-0d2e81efd364" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02f3b87e-a531-40db-b90d-fbea63113f89" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">110</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff7ce97f-0e9a-4feb-b151-b7b0466c9a42" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">697</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_540cb493-f2b0-4f4b-a3d5-2c3ac6eb5e30" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,334</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ad2dcbe-6a5f-44ce-b401-93c9cc8efc55" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="tcrt:IncreaseDecreaseInLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf1a75fb-44e7-4f84-a9cb-56d2e019492c" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="tcrt:IncreaseDecreaseInLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">133</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:40pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9b5b3e6-325d-47d2-852a-1319d9b534ad" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,917</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7764264c-4452-493c-8495-b18c4e0c6b76" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,381</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b45b3596-53d1-40b5-bde6-de0cb89114db" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e15664ba-b039-4305-bc8f-88462f20a510" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from the disposal of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b3fe3b2-5313-4cb6-b6cf-4f44a5695b61" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5434c18c-b8c0-4629-a09d-5f2c5ce1317e" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:40pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:40pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b17757c-de85-47d3-9f15-95c07c3d6f2c" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7077d67b-7759-4151-83a4-bf44d99182eb" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from financing activities:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from the issuance of common stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_182563df-c8f4-40cd-b3a2-956b8fcecb47" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81840fdf-e9ab-483d-a5c7-b830201d4dcf" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repayment of long-term debt</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d25dfbc2-914d-4234-b74a-a8e6785bc212" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be48337e-4edb-48bd-8653-4e1d42bfd9d9" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,250</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:30pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash used in financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ffe9cdb-f2b2-4b82-9c48-fa3a7d838136" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1657050c-a048-4ef1-9f3a-a6201318204f" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,158</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net decrease in cash, cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f3bd36d-c8eb-44a0-867f-443ea6490676" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,917</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29831922-77a7-4940-bc05-a32945ff259a" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,562</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash, beginning of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcb80498-6114-4be2-ab91-7fa2fafd2d85" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,062</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a38d38f8-5c61-467a-86f2-997d5b25c653" contextRef="C_f7de99b6-d374-4e48-911c-1cd00129ec98" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,996</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents, end of period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a903917f-b6d1-4c8b-b79c-52bbdd1c2b2d" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,145</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8b67575-8fa5-4c0c-bbb7-190d40a2750c" contextRef="C_2a4ac29e-7e17-4f4e-8ca5-1a9b13dce527" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,434</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplementary disclosure of cash flow information:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for interest</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c89bd954-892e-4cc6-8e7c-616da4acc80c" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_862b8a18-9286-4889-8691-b801613cb112" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">439</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amounts included in accrued expenses and accounts payable related to property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de88ae31-bd49-4ef5-b88b-8488ab388c4c" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa8355c3-38cf-4f15-9bcb-52bee55740e2" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying notes are an integral part of these condensed financial statements.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="notes_">&#160;</p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_992aebda-be25-4a10-8182-5de0d05457a2" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true"><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Organization</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc., which is referred to herein as &#8220;Alaunos,&#8221; or the &#8220;Company,&#8221; is a clinical-stage oncology-focused cell therapy company that was historically involved in the development of adoptive TCR therapies, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. The Company is leveraging its proprietary, non-viral </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">gene transfer platform and its novel cancer mutation hotspot TCR library to design and manufacture personalized cell therapies that target neoantigens arising from common tumor-related mutations in key oncogenic genes, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS, TP53 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s operations to date have consisted primarily of conducting research and development and raising capital to fund those efforts.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5cae25bf-c01d-4cae-a5af-eb0cf014ad89" contextRef="C_7868565d-837f-4c4e-a465-218189cb407e" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,012,522</ix:nonFraction></span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shares of common stock outstanding and an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e71b1c8-9055-4bcf-8e6d-516cc5b71c3e" contextRef="C_7868565d-837f-4c4e-a465-218189cb407e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,714,489</ix:nonFraction></span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shares of common stock reserved for issuance pursuant to outstanding stock options and warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2023, the Company announced a strategic reprioritization of its business and wind down of its TCR-T Library Phase 1/2 Trial. In connection with the reprioritization, the Company has significantly reduced its workforce and continues working to reduce costs in order to extend its cash runway. The Company continues to explore strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. The Company has engaged Cantor Fitzgerald &amp; Co., or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_042a5e23-1ae8-48b8-a902-42d6e0e92463" contextRef="C_cc6be139-4d29-491a-ac06-ae207788d63f" name="tcrt:StrategicAdvisorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cantor</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to act as strategic advisor for this process.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company follows the guidance of Accounting Standards Codification, or ASC, Topic 205-40, Presentation of Financial Statements - Going Concern, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its condensed financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management's plans that have not been fully implemented as of the date the condensed financial statements are issued. When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the condensed financial statements are issued and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the condensed financial statements are issued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has operated at a loss since its inception in 2003 and has no recurring revenue from operations.&#8239;The Company anticipates that losses will continue for the foreseeable future. As of March 31, 2024, the Company had approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25aa6d75-56d4-4655-b61b-538f27106ac1" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of cash and cash equivalents. The Company&#8217;s accumulated deficit at March 31, 2024 was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efedfe9d-ac83-4531-8b10-60685e327c82" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">917.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.&#8239;Given its current development plans and cash management efforts, the Company anticipates cash resources will be sufficient to fund operations into the third quarter of 2024.&#8239;The Company&#8217;s ability to continue operations after its current cash resources are exhausted depends on future events outside of the Company's control, including its ability to obtain additional financing or to achieve profitable results, as to which no assurances can be given. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If adequate additional funds are not available when required, or if the Company is unsuccessful in entering into partnership agreements for further development of its product candidates, management may need to curtail its development efforts and planned operations to conserve cash until sufficient additional capital is raised. There can be no assurances that such a plan would be successful.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the current cash forecast and the Company's dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the condensed financial statements, and substantial doubt as to the Company's ability to continue as a going concern exists. This forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_783b033d-291f-4f4f-a57e-9cc12621fc40" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited interim condensed financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information and note disclosures required by generally accepted accounting principles in the United States, or GAAP, have been condensed or omitted pursuant to such rules and regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is management&#8217;s opinion that the accompanying unaudited interim condensed financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair presentation of the financial position of the Company and its results of operations and cash flows for the periods presented. The unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2023, included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on April 1, 2024, or the Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results disclosed in the statements of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full fiscal year 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c1d97f28-dd3d-42ca-a520-22a492c0d5cd" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9ef53936-ef80-41f8-bf77-a9fff97f2358" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="tcrt:ReverseStockSplitPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Stock Split</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 31, 2024, the Company filed a Second Amended and Restated Certificate of Incorporation (the &#8220;Charter Amendment&#8221;) with the Secretary of State of the State of Delaware in order to effect a reverse stock split of the Company&#8217;s common stock at a ratio of 1-for-15 (the &#8220;Reverse Split&#8221;). The Charter Amendment decreased the number of authorized shares of common stock from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24c5c592-062b-49c1-a243-dbb7bf8e16a3" contextRef="C_3f929b6c-a393-480f-b2d8-4b64cbcc35fd" name="tcrt:PreStockSplitSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">520,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d98a3e97-713a-42f2-9574-2f4ddf5510a4" contextRef="C_3f929b6c-a393-480f-b2d8-4b64cbcc35fd" name="tcrt:PostStockSplitSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">34,666,667</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Charter Amendment does not affect the par value of the Company&#8217;s common stock or change the number of authorized shares or par value of the Company&#8217;s preferred stock. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_55e3e490-1366-45a2-8628-fbd91efcdf65" contextRef="C_2118d568-df96-4de0-9724-e8edfa283612" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Charter Amendment became effective on January 31, 2024 at 5:00 p.m. Eastern Time, at which time every 15 shares of the Company&#8217;s issued and outstanding common stock automatically combined and converted into 1 share of common stock.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No fractional shares were issued in connection with the Reverse Split. Stockholders of record who would otherwise have been entitled to receive fractional shares as a result of the Reverse Split received a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing sales price per share of the common stock (as adjusted for the Reverse Split) on The Nasdaq Capital Market on January 31, 2024.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All share and per share amounts of common stock, options, warrants, and restricted stock in the accompanying financial statements and notes thereto have been retroactively adjusted for all periods presented to reflect the Reverse Split as if it had occurred at the beginning of the earliest period presented.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_852161d7-2f90-45fe-81ed-fbe5957358b9" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="tcrt:FinancingArrangementsDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financings</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 Loan and Security Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 6, 2021, the Company entered into a Loan and Security Agreement, or the Loan and Security Agreement, with Silicon Valley Bank and affiliates of Silicon Valley Bank, or collectively, SVB. The Loan and Security Agreement provided for an initial term loan of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_409b94a4-c95e-4f6f-80d2-5af4c716de60" contextRef="C_a5053d79-f95f-4469-83c1-e72e88a19a19" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million funded at the closing, or the Term A Tranche, with an additional tranche of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33b4bfb6-cbb5-4e78-bb15-b20b76f778fa" contextRef="C_82917f35-4e10-4373-8317-e2e998187578" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million available if certain funding and clinical milestones were met by August 31, 2022, or the Term B Tranche.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective December 28, 2021, the Company, entered into an amendment to the Loan and Security Agreement, or the First Amendment. The First Amendment extended the interest-only period through August 31, 2022. The First Amendment also eliminated the Term B Tranche, which remained unfunded, leaving only the Term A Tranche, or the SVB Facility. Under the amended Loan and Security Agreement, the SVB Facility was to mature on August 1, 2023. On May 1, 2023, the Company repaid its outstanding debt obligations under the amended Loan and Security Agreement in their entirety.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refer to Note 4, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for further discussion of the Loan and Security Agreement and the First Amendment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2022 Equity Distribution Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 12, 2022, the Company entered into an Equity Distribution Agreement, or the Equity Distribution Agreement, with Piper Sandler &amp; Co., or Piper Sandler, pursuant to which the Company can offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d351761-11d8-4d9d-9c63-fe8fd9036192" contextRef="C_eb3569a0-1c09-487b-a964-8d604ab02e26" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million through Piper Sandler as its sales agent in an "at the market offering." Piper Sandler will receive a commission of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_578c24b5-5eea-4e7f-af36-71369fa37a09" contextRef="C_eb3569a0-1c09-487b-a964-8d604ab02e26" name="tcrt:PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the gross proceeds of any common stock sold under the Equity Distribution</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Agreement. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended March 31, 2024 and 2023, there have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_01d708c0-5eb3-407b-81d4-3702b2a9bd9a" contextRef="C_e202e528-177e-4db6-adec-6869d8137344" name="tcrt:StockOfferedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_41507a27-0df7-47ff-bd10-155127e661a8" contextRef="C_c8496d52-7c42-49e6-b1a1-90623138bd33" name="tcrt:StockOfferedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> sales of the Company's common stock under the Equity Distribution Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2022 Public Offering</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 29, 2022, the Company entered into an underwriting agreement, or the Underwriting Agreement, with Cantor as the sole underwriter, relating to the issuance and sale in an underwritten offering, or the Offering, of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f162e14-a964-4c56-be55-7aa8cc04e038" contextRef="C_318d2bef-2b78-48b2-9bf0-7f8d81ddf304" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,615,248</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, or the Firm Shares, of the Company&#8217;s common stock to Cantor at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9dc68dc2-4cab-4f30-868d-6794cd5c81a9" contextRef="C_f2998239-c729-4024-b9be-d75e1a53f26d" name="tcrt:UnderwriterParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4" format="ixt:num-dot-decimal">9.2865</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The net proceeds to the Company from the Offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3bf70ead-ea95-49d2-a510-9eb244043f06" contextRef="C_ad2cf5bf-7a86-4612-a507-a31f59be56ae" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (before accounting for the partial exercise of Cantor's option as described below) after deducting underwriting discounts and commissions and offering expenses payable by the Company.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Underwriting Agreement, the Company granted Cantor an option, exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_16b2a474-c8e1-4d25-83f1-80ba62af2d92" contextRef="C_318d2bef-2b78-48b2-9bf0-7f8d81ddf304" name="tcrt:ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30 days</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to purchase up to an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_286b00bb-cfc7-49fb-835c-450a70dd6fe4" contextRef="C_5c46026b-b792-4f5a-b3d6-cd9c0eb096c3" name="tcrt:NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">242,287</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, which we refer to, together with the Firm Shares, as the Shares, at the same price per share as the Firm Shares. On January 5, 2023, Cantor partially exercised its option to purchase an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e3d7551-9245-47bb-82a3-4b13ddb2baf3" contextRef="C_459f2708-7ef7-43f4-a5f4-b66c0656e6b2" name="tcrt:StockOfferedDuringPeriodShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">14,420</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_857bc0bb-4532-469a-917c-4232c813a4e6" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of Significant Accounting Policies</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s significant accounting policies were identified in the Company&#8217;s Annual Report. There have been no material changes in those policies since the filing of its Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_905999eb-d6bd-4853-ae50-013d5e9f9fdb" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:DebtDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Debt</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74634eb2-86be-4883-8b05-50d34f172f27" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ac6f7c99-9e5d-445f-a41d-05c26c64f243" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> debt obligations outstanding at March 31, 2024 and December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 6, 2021, the Company entered into the Loan and Security Agreement with SVB. The Loan and Security Agreement provided for the funding of the Term A Tranche at the closing, with the Term B Tranche available if certain funding and clinical milestones were met by August 31, 2022. The SVB Facility and related obligations under the Loan and Security Agreement were secured by substantially all of the Company's properties, rights and assets, except for its intellectual property (which was subject to a negative pledge under the Loan and Security Agreement). In addition, the Loan and Security Agreement contained customary representations, warranties, events of default and covenants.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 28, 2021, the Company entered into the First Amendment to the Loan and Security Agreement. The First Amendment eliminated the unfunded Term B Tranche, among other things. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3f724f9-8aca-4c8a-a591-a80a6f8bc0ec" contextRef="C_bf8b4b8c-26b2-4415-90c9-ba9e666f9956" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The SVB Facility bore interest at a floating rate per annum on outstanding loans, payable monthly, at the greater of (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5964862-5996-4442-b241-3812393eb3c5" contextRef="C_8013c772-ccba-4aa2-b4a1-652bb9ef35c1" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">7.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and (b) the current published U.S. prime rate, plus a margin of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c697fbd-23c1-4d58-a0a2-73a98204ab26" contextRef="C_529a077c-2067-46ae-a95e-3d29d884679c" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All outstanding obligations under the amended Loan and Security Agreement were due and payable on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_40c65851-331c-497f-87f4-f26c040826c7" contextRef="C_bf8b4b8c-26b2-4415-90c9-ba9e666f9956" name="us-gaap:DebtInstrumentMaturityDateRangeStart1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 1, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In connection with the payment of all of the Company's outstanding obligations, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f8336203-1713-48de-bb88-cf14ec8275f9" contextRef="C_cd66aa2a-1923-408f-ad01-68d671934a39" name="us-gaap:LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company also owed SVB </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e207f2e0-4b96-4b10-a628-74208cc9bfe5" contextRef="C_8013c772-ccba-4aa2-b4a1-652bb9ef35c1" name="tcrt:PercentageOfOriginalPrincipalDueAsAFinalPayment" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the original principal amounts borrowed as a final payment, or the Final Payment. Effective March 30, 2023, the Company entered into a Third Amendment to the Loan and Security Agreement, or the Third Amendment. Under the terms of the Third Amendment, the Company was no longer required to maintain all of its operating accounts, depository accounts and excess cash with SVB or one of its affiliates, and was instead only required to maintain a single operating or depository account at Silicon Valley Bank. The Third Amendment also modified the cash collateralization requirement, such that the Company was required to cash collateralize the entire sum of the outstanding principal amount of the SVB Facility, plus an amount equal to the Final Payment, which amount was to be reduced commensurate with each regularly scheduled monthly payment of principal and interest on the SVB Facility.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 1, 2023, the Company paid SVB an amount equal to the entire outstanding principal amount under the SVB Facility, all accrued and unpaid interest and the Final Payment. In accordance with the First Amendment, the payment was subject to a prepayment premium of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5949b23-02e4-4e0b-9e2e-67c0fd98c409" contextRef="C_06f78440-3bd6-4263-b564-21c6263d6ac1" name="tcrt:PercentageOfPrepaymentsPremium" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. During the second quarter of 2023, the Company recorded the remaining amounts associated with the Final Payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f09c1bf1-ecf9-4055-9570-4122c3db4351" contextRef="C_bf8b4b8c-26b2-4415-90c9-ba9e666f9956" name="us-gaap:ExtinguishmentOfDebtAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and the prepayment premium of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_197bd815-21fc-425c-9458-c17453b90219" contextRef="C_bf8b4b8c-26b2-4415-90c9-ba9e666f9956" name="tcrt:AmountOfPrepaymentsPremium" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as interest expense within the condensed statement of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with its entry into the Loan and Security Agreement in August 2021, the Company issued to SVB warrants to purchase (i) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f59ae81-2184-4a8f-aa1e-7caa3ff97c35" contextRef="C_5aaa9322-5f00-4afe-8d8b-410a6b78fc05" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">28,856</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock, in the aggregate, and (ii) up to an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d050810d-50b4-4bb9-8848-3ce2dbc2062c" contextRef="C_5aaa9322-5f00-4afe-8d8b-410a6b78fc05" name="tcrt:AdditionalNumberOfWarrantsIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">28,856</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, in the aggregate, in the event the Company achieved certain clinical milestones, in each case at an exercise price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_108b14bc-aef9-4873-824f-936e94d6e36e" contextRef="C_5aaa9322-5f00-4afe-8d8b-410a6b78fc05" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">33.30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with its entry into the First Amendment in December 2021, the Company amended and restated the warrants issued to SVB. As amended and restated, the warrants are for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d34f0e6-a4d3-48d3-b80d-29d4377cac7d" contextRef="C_98a802f2-0e70-4585-9cc4-a79b60e487e1" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">43,308</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, in the aggregate, with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_72b613fc-02fb-4493-8e4f-b8485bf3f8a1" contextRef="C_c594780d-4524-4d01-9ec4-b90f13b9d953" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.40</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, or the SVB Warrants. The SVB Warrants expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed52ddc6-1230-49e4-96e9-8c9d06ba9547" contextRef="C_98a802f2-0e70-4585-9cc4-a79b60e487e1" name="tcrt:WarrantsExpirationDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 6, 2031</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The issuance costs for the Loan and Security Agreement, including the First Amendment, were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4d301ee-4a21-4717-82a4-83aef44668c5" contextRef="C_655a3713-d843-4e68-b88b-1e572769c0e4" name="us-gaap:DeferredFinanceCostsNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and primarily related to the issuance of the SVB Warrants, which were amortized into interest expense over the term of the loan. Interest expense,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the amortization of issuance costs, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7ca8929-6960-4423-be11-171de425815e" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the three months ended March 31, 2024, compared to $0</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c686fbf9-10ce-4a10-b76f-36d23a64e007" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the three months ended March 31, 2023.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_48900eab-6ea2-4d45-ab7d-fcd4f86e963b" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</span></p><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_90d7d9e7-8476-4672-911f-47c0ca33d6b3" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of March 31, 2024 and December 31, 2023 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.01%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.603000000000002%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:10.542%;"/>
        <td style="width:1%;"/>
        <td style="width:1.12%;"/>
        <td style="width:1%;"/>
        <td style="width:9.302%;"/>
        <td style="width:1%;"/>
        <td style="width:1.12%;"/>
        <td style="width:1%;"/>
        <td style="width:9.302%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance as of<br/>March 31,<br/>2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e56673c3-7de1-4b0b-8a72-1656b4f02a47" contextRef="C_170c0509-c56f-4761-bdf6-22de08ad77fe" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,832</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e52a3b0b-000c-4c63-bcc7-63ba818d71a2" contextRef="C_dbfeed30-f20b-44da-b3ca-39d3d35097bf" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,832</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.02%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:10.203999999999999%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.924999999999999%;"/>
        <td style="width:1%;"/>
        <td style="width:1.12%;"/>
        <td style="width:1%;"/>
        <td style="width:9.303999999999998%;"/>
        <td style="width:1%;"/>
        <td style="width:1.12%;"/>
        <td style="width:1%;"/>
        <td style="width:9.303999999999998%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance as of<br/>December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99528e78-f276-4ca0-96fc-6a343f9ac26a" contextRef="C_4dd2c47b-4df3-4a07-bb67-521f620934a2" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,744</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42a2f2f6-be3f-4a8b-8342-f7b93afbfcbd" contextRef="C_96de5e3d-ec20-471c-8b74-4754e48554be" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,744</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The cash equivalents represent demand deposit accounts and deposits in a short-term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been no changes to the valuation methods during the three months ended March 31, 2024. We had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_68785316-4f7d-47e5-9fe1-75081a659f0f" contextRef="C_69b6b7d3-41a2-4d80-aee3-85fbf3416f62" name="us-gaap:FairValueNetAssetLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> financial assets or liabilities that were classified as Level 2 or Level 3 during the three months ended March 31, 2024.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_9645b3b3-e60c-48f0-8588-b333b6d8972f" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:EarningsPerShareTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net loss per share</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">net loss per share of common stock is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period, plus the dilutive effect of outstanding options and warrants, using the treasury stock method and the average market price of the Company's common stock during the applicable period, unless their effect on net loss per share is antidilutive. The effect of computing diluted net loss per common share was antidilutive for any potentially issuable shares of common stock from the conversion of stock options, unvested restricted stock and warrants and, as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">have been excluded from the calculation. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b201cc05-890f-4c20-a712-f704046b7509" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_b201cc05-890f-4c20-a712-f704046b7509_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such potentially dilutive shares of common stock consisted of the following as of March 31, 2024 and 2023:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b201cc05-890f-4c20-a712-f704046b7509_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f456f46-4a02-448d-85ff-aceb368cf83c" contextRef="C_729e1616-09f9-46a9-a428-b5c7fb8de61a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">251,457</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_197dccd4-73b5-4461-9497-5d6abaf054d9" contextRef="C_f3cf5907-2650-4723-90f5-2fbb4565112b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">887,549</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92ae7939-6144-442f-aa04-b79d54f33153" contextRef="C_bbf27f91-17b6-4ae0-ad7c-8ead5a875486" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:fixed-zero">-</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07fb49ca-1950-4158-b460-9194851f6500" contextRef="C_499d880c-c83e-4094-9801-9f067ded9cb2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">59,875</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f279461f-be77-4ce5-a30a-04dc2241ca57" contextRef="C_0e2a059d-282e-4250-8c99-11315e2fb9ce" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,452,399</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40dfc5a8-c82a-468d-83ac-38af5219dd75" contextRef="C_84fba74a-d852-4278-a598-763f3de703a2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,528,156</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41dd81b7-0a34-42a8-8d7c-01bc5ca79273" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,703,856</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4babf3c6-540b-4b76-8e30-776c042432bf" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,475,580</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3e2a0006-6f69-4cbe-bed9-597daaba90cd" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Related Party Transactions</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Joint Venture with TriArm Therapeutics/Eden BioCell</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 18, 2018, the Company and TriArm Therapeutics, Ltd., or TriArm, launched Eden BioCell, Ltd., or Eden BioCell, as a joint venture to lead commercialization of the Company&#8217;s </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-generated CAR-T therapies in the People&#8217;s Republic of China (including Macau and Hong Kong), Taiwan and Korea. The Company licensed to Eden BioCell the rights in Greater China for its third-generation </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-generated CAR-T therapies targeting the CD19 antigen. Eden BioCell is owned equally by the Company and TriArm and the parties share decision-making authority. TriArm contributed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46a0eab3-19f0-4ead-a0fe-09d8ab73f1fe" contextRef="C_82df7c7b-262a-4272-aced-862f49a97569" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to Eden BioCell and has committed up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac770fc0-6dd4-4820-a152-a58ab8b2b71b" contextRef="C_d188ee19-8efb-40f4-bfc1-15d99d4dcdb1" name="tcrt:AdditionalLoansCommitted" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to this joint venture. TriArm also managed all clinical development in the territory pursuant to a master services agreement between TriArm and Eden BioCell. James Huang was the founder and serves as managing partner of Panacea Venture, which is an investor in TriArm. Mr. Huang was the Chair of the Company's board of directors until September 22, 2023 and had been a director since July 2020. He also serves as a member of Eden BioCell&#8217;s board of directors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, TriArm and Alaunos mutually agreed to dissolve the Eden BioCell joint venture. The joint venture agreement has been terminated and the Eden BioCell entity has been dissolved as of July 2023. Refer to Note 13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Joint Venture</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, for further details.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration with Dune Lake Capital</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, the Company entered into a consulting agreement with Dune Lake Capital, LLC, or Dune Lake Capital, which was founded by Dale Curtis Hogue, Jr., the Company's interim Chief Executive Officer. During the three months ended March 31, 2024 and 2023, the Company recorded expenses of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98f668a0-eeaf-449b-a0a3-8f03801ca706" contextRef="C_7f5ae535-f6d0-484b-b23f-ef9a9da46789" name="us-gaap:ProfessionalAndContractServicesExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07ed8fde-9c59-469e-81d8-35e4982b58ed" contextRef="C_eb264759-9de1-4b9f-acc7-aa907a4f72c5" name="us-gaap:ProfessionalAndContractServicesExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand, respectively, for consulting services performed by Dune Lake Capital.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b6e2a66-6657-4e23-8b2e-3d4f75e1caa1" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commitments and Contingencies</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">License Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exclusive License Agreement with Precigen</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 5, 2018, the Company entered into an exclusive license agreement, or License Agreement, with PGEN Therapeutics, or PGEN, a wholly owned subsidiary of Precigen Inc., or Precigen, which was formerly known as Intrexon Corporation. Except where the context otherwise requires, the Company refers to PGEN and Precigen together as Precigen. Pursuant to the terms of the License Agreement, the Company had exclusive, worldwide rights to research, develop and commercialize (i) TCR products designed for neoantigens for the treatment of cancer, (ii) products utilizing Precigen&#8217;s RheoSwitch&#174; gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products and (iii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) BCMA for the treatment of cancer, subject to certain obligations to pursue such target under the License and Collaboration Agreement effective March 27, 2015 between the Company, Precigen and ARES TRADING S.A., a subsidiary of Merck KGaA, as assigned by Precigen to PGEN. Under the License Agreement, the Company also had exclusive, worldwide rights for certain patents relating to the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company was responsible for all aspects of the research, development and commercialization and was required to use commercially reasonable efforts to develop certain products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In consideration of the licenses and other rights granted by Precigen, the Company was required to pay Precigen an annual license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_770c5d47-1ef0-4385-921a-5abd40736635" contextRef="C_dae15987-4a72-452e-bffe-37b8c8ff2004" name="tcrt:AnnualLicenseFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, reimburse Precigen for certain historical costs, pay Precigen milestones up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f3db4d1-73fa-476e-8e2f-5504774bb7e0" contextRef="C_dae15987-4a72-452e-bffe-37b8c8ff2004" name="tcrt:MaximumAmountOfAdditionalMilestonesPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">52.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for each exclusively licensed program upon the achievement of certain milestones, and pay Precigen tiered royalties up to a maximum royalty amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_558c18ae-a374-4c8e-838a-e8e425fa78ae" contextRef="C_94aa9eb4-37eb-4c0d-b5f9-9e0dd0d7fb5a" name="tcrt:MaximumAmountOfRoyaltyPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the aggregate. The Company was also obligated to pay Precigen </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e00eb05-977c-4392-a3d3-bb25c12347e0" contextRef="C_94aa9eb4-37eb-4c0d-b5f9-9e0dd0d7fb5a" name="tcrt:PercentageOfSubLicensingIncomePayableToRelatedParty" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of any sublicensing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">income </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">received by us relating to the licensed products. The Company was responsible for all development costs associated with each of the licensed products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Precigen was obligated to pay the Company royalties up to a maximum royalty amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_694205a6-279b-4a5b-aa3a-8ce3d7f16d75" contextRef="C_228ec118-b1e2-4f75-9b40-90b271c238f4" name="tcrt:MaximumRoyaltyAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_278dd74f-f513-4d3a-ad39-117282d8e1c2" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:RoyaltyExpense" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> royalty amounts were incurred during the three months ended March 31, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 3, 2023, the Company entered into the Amended and Restated Exclusive License Agreement with Precigen, or the A&amp;R License Agreement, which restated and amended the License Agreement in full. Under the A&amp;R License Agreement, the Company still has exclusive, worldwide rights to research, develop and commercialize TCR products designed for neoantigens or driver mutations for the treatment of cancer and non-exclusive rights to use non-driver mutation TCRs. The Company further maintains its exclusive, worldwide rights for certain patents relating to the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company remains solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. The (i) products utilizing Precigen&#8217;s RheoSwitch&#174; gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products and (ii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) BCMA for the treatment of cancer, subject to certain obligations to pursue such target under the License and Collaboration Agreement effective March 27, 2015 between the Company, Precigen and ARES TRADING S.A., a subsidiary of Merck KGaA, as assigned by Precigen to PGEN are no longer exclusively licensed to the Company. The Company is no longer obligated to use commercially reasonable efforts for the exclusively licensed products. The A&amp;R License Agreement further eliminates any royalty or milestone obligations to Precigen, with an annual license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb8ca06d-476b-4718-9aac-99777609c229" contextRef="C_0a4a2144-53c6-473a-a17e-948eca082f68" name="tcrt:AnnualLicenseFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand due on the anniversary of the A&amp;R License Agreement effective date. Precigen is no longer obligated to pay the Company royalties on the net sales derived from the sale of Precigen's CAR products.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreement and 2015 Research and Development Agreement &#8212;The University of Texas MD Anderson Cancer Center</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_42e32e37-6eb7-45d9-971e-411c0c1b620c" contextRef="C_3afa3256-b142-4067-84fa-31003618cdf3" name="tcrt:LicenseAgreementCommencingDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 13, 2015</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company, together with Precigen, entered into a license agreement, or the MD Anderson License with MD Anderson (which Precigen subsequently assigned to PGEN). Pursuant to the MD Anderson License, the Company, together with Precigen, holds an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR T-cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer, or NK Cells, and TCRs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 17, 2015, the Company, Precigen and MD Anderson entered into the 2015 R&amp;D Agreement to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the MD Anderson License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs. The rights and obligations of Precigen under the 2015 R&amp;D Agreement were assigned to the Company pursuant to the Fourth Amendment to 2015 R&amp;D Agreement which was entered into on September 19, 2019 (the &#8220;Fourth Amendment&#8221;) with an effective date of October 5, 2018. The activities under the 2015 R&amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As provided under the MD Anderson License, the Company provided funding for research and development activities in support of the research programs under the 2015 R&amp;D Agreement for a period of three years and in an amount of no less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bebd0c6f-2b17-472f-ab3d-6b03c908c7f9" contextRef="C_e2f5fa39-2c4c-4a31-9dba-9b302e6163aa" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and no greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_81bf01b1-bcaa-41ac-b086-f06c018fec1b" contextRef="C_58a539c3-32e6-40ab-81e3-7460cfa16a02" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million per year. On November 14, 2017, the Company entered into an amendment to the 2015 R&amp;D Agreement, extending its term until April 15, 2021. In connection with the execution of the 2019 R&amp;D Agreement described below, on October 22, 2019, the Company amended the 2015 R&amp;D Agreement to extend the term of the 2015 R&amp;D Agreement until December 31, 2026 and to allow cash resources on hand at MD Anderson under the 2015 R&amp;D Agreement to be used for development costs under the 2019 Research and Development Agreement, or the 2019 R&amp;D Agreement, which the Company entered into on October 22, 2019, with MD Anderson, pursuant to which the Company agreed to collaborate with respect to the TCR program. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31aa3869-b740-44c5-96c6-ad6c53e714ab" contextRef="C_05086637-454b-451e-ba2f-b6e9dac6f1bc" name="tcrt:ClinicalExpenses" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7803a340-df21-483b-8bed-e73b1df212b4" contextRef="C_b1da774e-81d4-427f-b25c-7a2574c834ba" name="tcrt:ClinicalExpenses" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t incur clinical costs from MD Anderson related to the 2015 R&amp;D Agreement for the three months ended March 31, 2024 and 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term of the MD Anderson License, the Company, together with Precigen, shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the MD Anderson License and subject to a 90-day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if the Company and Precigen are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third-party contract if the Company and Precigen are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by the Company and Precigen, if</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both the Company and Precigen and may be terminated by the mutual written agreement of the Company, Precigen, and MD Anderson.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2019 Research and Development Agreement&#8212;The University of Texas MD Anderson Cancer Center</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the 2019 R&amp;D Agreement, the Company and MD Anderson will, among other things, collaborate on programs to expand the Company's TCR library and conduct clinical trials. The activities under the 2019 R&amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will own all inventions and intellectual property developed under the 2019 R&amp;D Agreement and the Company will retain all rights to all intellectual property, patentable or not, for oncology products manufactured using non-viral gene transfer technologies under the 2019 R&amp;D Agreement, including the Company's</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology. The Company has granted MD Anderson an exclusive license for such intellectual property to develop and commercialize autologous TCR products manufactured using viral gene transfer technologies and any products outside the field of oncology and a non-exclusive license for allogenic TCR products manufactured using viral-based technologies.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the 2019 R&amp;D Agreement, the Company agreed, beginning on January 1, 2021, to reimburse MD Anderson up to a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ea93f79-a9c0-44d4-91ac-d9647b0fba67" contextRef="C_081cf75e-7342-44b3-be87-434671a576d8" name="tcrt:AggregateAmountPotentiallyReimburseableAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for development costs under the 2019 R&amp;D Agreement, after the funds from the 2015 R&amp;D Agreement are exhausted. In addition, the Company will pay MD Anderson royalties on net sales of its TCR products. The Company is required to make performance-based payments upon the successful completion of clinical and regulatory benchmarks relating to its TCR products. The aggregate potential benchmark payments are $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e4fd53cd-9e8b-45a8-a0a5-90c251b1c407" contextRef="C_081cf75e-7342-44b3-be87-434671a576d8" name="tcrt:AggregatePotentialBenchmarkPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">36.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, of which only $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f1105fc-b419-4e65-9428-7406af3736cb" contextRef="C_081cf75e-7342-44b3-be87-434671a576d8" name="tcrt:AccrualsPriorToFirstMarketingApproval" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million will be due prior to the first marketing approval of the Company's TCR products. The royalty rates and benchmark payments owed to MD Anderson may be reduced upon the occurrence of certain events. The Company also agreed to sell its TCR products to MD Anderson at preferential prices and will sell the Company's TCR products in Texas exclusively to MD Anderson for a limited period of time following the first commercial sale of the Company's TCR products. For the three months ended March 31, 2024 the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c96436eb-0c6b-433c-a762-b8fb54c8d787" contextRef="C_5f3c58ea-f897-4151-a1ad-8f8690250ebe" name="tcrt:QuarterlyExpenseIncurred" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t incur clinical expenses from MD Anderson related to the 2019 R&amp;D Agreement, compared to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c933c366-2f89-407b-bffe-b8ba3ca4ebae" contextRef="C_f5aa7ee8-5428-4b9d-b069-2e72b206cbaa" name="tcrt:QuarterlyExpenseIncurred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the three months ended March 31, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2019 R&amp;D Agreement will terminate on December 31, 2026 and either party may terminate the 2019 R&amp;D Agreement following written notice of a material breach. The 2019 R&amp;D Agreement also contains customary provisions related to indemnification obligations, confidentiality and other matters.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the execution of the 2019 R&amp;D Agreement, on October 22, 2019, the Company issued MD Anderson a warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c794a29a-d342-4daa-9fd8-604c1cc48d08" contextRef="C_d9080476-f0f7-430a-80b4-880ed65fc6e8" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">222,222</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, which is referred to as the MD Anderson Warrant. The MD Anderson Warrant has an initial exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29287a94-fa65-4b02-a46c-26ca518fb769" contextRef="C_d9080476-f0f7-430a-80b4-880ed65fc6e8" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" decimals="INF" format="ixt:num-dot-decimal">0.015</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_920987ea-07be-4ef5-8035-b1e88f522f30" contextRef="C_d9080476-f0f7-430a-80b4-880ed65fc6e8" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and vests upon the occurrence of certain clinical milestones. As of March 31, 2024, the milestones have not been met.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreement with the NCI</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 28, 2019, the Company entered into a patent license agreement, or the Patent License, with the NCI. Pursuant to the Patent License, the Company held an exclusive, worldwide license to certain intellectual property to develop and commercialize patient-derived (autologous), peripheral blood T-cell therapy products engineered by transposon-mediated gene transfer to express TCRs reactive to mutated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS, TP53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">neoantigens. In addition, pursuant to the Patent License, the Company held an exclusive, worldwide license to certain intellectual property for manufacturing technologies to develop and commercialize autologous, peripheral blood T-cell therapy products engineered by non-viral gene transfer to express TCRs, as well as a non-exclusive, worldwide license to certain additional manufacturing technologies. On May 29, 2019, January 8, 2020, September 28, 2020, April 16, 2021, May 4, 2021 and August 13, 2021 the Company amended the Patent License to expand its TCR library to include additional TCRs reactive to mutated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TP53 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">neoantigens licensed from the NCI.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 27, 2023, the Company provided the NCI the requisite notice of its intent to terminate the Patent License, effective December 26, 2023. The Company discovered multiple proprietary TCRs targeting driver mutations through its hunTR TCR discovery platform, including many of the same </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TP53 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mutations licensed from the NCI.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the three months ended March 31, 2024, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1b7214e1-5977-4d14-93a0-8325650e9cd5" contextRef="C_6270e901-6735-4c63-9513-8fb545fff59f" name="tcrt:LicenseExpense" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t incur expenses to the NCI under this agreement, compared to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_411444e2-fa43-4a43-b354-795d692a2b97" contextRef="C_b01cd0f9-f0ef-4fe1-89dd-e53ec38d0b9e" name="tcrt:LicenseExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the three months ended March 31, 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cooperative Research and Development Agreement (CRADA) with the NCI</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 9, 2017, the Company entered into a Cooperative Research and Development Agreement, or the CRADA, with the NCI. The purpose of this collaboration was to advance a personalized TCR-T approach for the treatment of solid tumors. Using the Company's</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology, the NCI would analyze a patient&#8217;s own cancer cells, identify their unique neoantigens and TCRs reactive against those neoantigens and then use the Company's </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology to transpose one or more TCRs into T cells for re-infusion. Research conducted under the CRADA was under the direction of Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI, in collaboration with the Company's researchers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2023, the Company announced that it had provided the requisite notice to terminate the CRADA, pursuant to its terms, effective </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3f6cea43-0ab0-4d31-9980-309649b7b50c" contextRef="C_d9ea1296-e67e-4c96-9b52-f8fb4490bf1c" name="tcrt:AgreementTerminationDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 13, 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, in light of the Company&#8217;s exploration of strategic alternatives.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f56905c1-fd5e-49c6-b5da-fce00ce86fe9" contextRef="C_b355e022-e0e9-4da2-8a04-f3b2546fe32b" name="tcrt:AnnualExpenseIncurred" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t record expenses under the CRADA for the three months ended March 31, 2024, compared to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_569c3d6c-ecc7-426a-9342-f3801608ed83" contextRef="C_0fe9cdfc-046e-4935-a0e2-2577ae6a7cf2" name="tcrt:AnnualExpenseIncurred" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the three months ended March 31, 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent and Technology License Agreement&#8212;The University of Texas MD Anderson Cancer Center and the Texas A&amp;M University System</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 24, 2004, the Company entered into a patent and technology license agreement with MD Anderson and the Texas A&amp;M University System, which the Company refers to, collectively, as the Licensors. Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) for the manufacture and commercialization of two classes of organic arsenicals (water- and lipid-based) for human and animal use. The class of water-based organic arsenicals includes darinaparsin.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the agreement, the Company may be required to make additional payments to the Licensors upon achievement of certain milestones in varying amounts which, on a cumulative basis could total up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c81dddf-815f-49b4-95da-38cbf7a247ec" contextRef="C_699c4514-89e0-4171-a8dd-a4bb94caddc4" name="tcrt:MilestonePaymentsMaximumAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. In addition, the Licensors are entitled to receive royalty payments on sales from a licensed product and will also be entitled to receive a portion of any fees that the Company may receive from a possible sublicense under certain circumstances. During the three months ended March 31, 2024 and 2023, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a2f068b-5ea8-4c32-82c0-a18cbe000910" contextRef="C_cf29daca-a7b6-4083-bfa6-78d85df7567f" name="tcrt:PaymentUnderLicenseAgreement" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_6137a055-2825-466f-a591-7df9f0419390" contextRef="C_fe3fc5c4-0c6a-404b-8a06-a203f7a1b9c0" name="tcrt:PaymentUnderLicenseAgreement" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t incur any milestone expenses or royalty expenses on sales under this agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Agreement with Solasia Pharma K.K.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 7, 2011, the Company entered into a License and Collaboration Agreement with Solasia Pharma K. K., or Solasia, which was amended on July 31, 2014 to include an exclusive worldwide license and amended on October 14, 2021 to revise certain payment schedule details, or, as so amended, the Solasia License and Collaboration Agreement. Pursuant to the Solasia License and Collaboration Agreement, the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both intravenous and oral forms and related organic arsenic molecules, in all indications for human use.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As consideration for the license, the Company is eligible to receive from Solasia development- and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenue generated by Solasia. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The Company&#8217;s licensors, as defined in the Solasia License and Collaboration Agreement, will receive a portion of all milestone and royalty payments made by Solasia to the Company in accordance with the terms of the Solasia License and Collaboration Agreement with the licensors, as described above.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, Solasia announced that darinaparsin had been approved from relapsed or refractory Peripheral T-Cell Lymphoma by the Minis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">try of Health, Labor and Welfare in Japan. During the three months ended March 31, 2024 and 2023, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_756105a1-340c-48c5-a4d4-54ad2fb1c8eb" contextRef="C_62447313-6131-42f8-98d0-6c78900cb176" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0e9a6b4a-b379-4502-a03b-7f33f5a7f679" contextRef="C_d87a9b62-f8b3-496c-813b-ff57b12f4f20" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t earn collaboration revenue and earned royalty revenues of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f32f60c-44c8-4c85-a207-78e50368a8f0" contextRef="C_a3ae250c-9ef9-4e50-b001-e026832b5546" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d212e04a-7226-459c-ba14-861ae7daa342" contextRef="C_481d4dca-c2e0-4a6d-a1aa-cb7b99c9e7e3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, of royalty revenues on net sales under the Solasia License and Collaboration Agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KBI Biopharma Litigation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 17, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c47944b7-17f9-4969-b1f7-285cc555cc4c" contextRef="C_87dc43db-b832-4e32-9d47-a96ea1328b91" name="us-gaap:LossContingencyNameOfPlaintiff"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KBI Biopharma</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Inc., or KBI, filed a complaint against the Company in the District Court of Harris County, Texas, 165th Judicial District, asserting breach of an Amended and Restated Master Services Agreement between the Company and KBI relating to the development of an autologous gene modified T-cell therapy product, or the KBI Agreement. KBI was primarily seeking unspecified monetary damages in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e883bdc-60ec-4d12-9171-d6946470317f" contextRef="C_87dc43db-b832-4e32-9d47-a96ea1328b91" name="us-gaap:LossContingencyDamagesSoughtValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. On May 1, 2023, the Company filed an answer generally denying all of KBI&#8217;s allegations and asserting affirmative and other defenses as well as counterclaims for breach of the KBI Agreement and conversion. On October 20, 2023, the Company entered into an agreement with KBI to settle all claims asserted by KBI against the Company and the Company's counterclaims against KBI at issue in the litigation for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44af67df-a5ad-4bd6-bf74-bd530e05754d" contextRef="C_27f693e7-6abd-4a93-b50d-4206e1b22623" name="us-gaap:LitigationSettlementExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_99e19d46-726f-4e02-8120-2736a77d7a7c" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="tcrt:StockOptionsAndRestrictedStockAwardsTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-Based Compensation</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1ae826d-d95c-484e-bdbd-118960dd2b81" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized stock-based compensation expense on all employee and non-employee awards as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:63.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.713%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:12.643%;"/>
        <td style="width:1%;"/>
        <td style="width:1.56%;"/>
        <td style="width:1%;"/>
        <td style="width:15.523%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60fb5361-31f2-42e4-9381-277815d40b6a" contextRef="C_478a5db8-cf73-4704-b31d-d3f5d829c87e" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b81ee1e-9abf-4ecc-a451-b798a5585ea5" contextRef="C_58b07922-742e-4d1e-8e94-cc27df08f5e4" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">175</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbafd89c-8bc9-4e41-b1ec-bd564993b76a" contextRef="C_4794af2c-583f-4aeb-8161-0074b8016cb4" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">161</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97ce42f4-41b5-4a98-b1e7-429bf937a0c5" contextRef="C_5c448816-7d5b-4d6c-8eae-4e4d68502072" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">735</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_699f7874-6c05-4e6e-a2a2-432194a72a66" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aab17248-2142-4486-be63-f8e527c241c9" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">910</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company granted an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76db299a-54a0-454f-8bdc-75cdf3ced48a" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">40,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options during the three months ended March 31, 2024, with a weighted-average grant date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0ec382c-fe9d-4a0b-ba35-8bf35bc2f9ef" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, and granted an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c548dccb-2cba-48b1-9624-8e3ab7283ccf" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">204,344</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options during the three months ended March 31, 2023, with a weighted-average grant date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b34f075-2890-4620-9425-bd71eae282f7" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8bc8bfac-2da3-4135-b1b0-29eef5c72eae" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the three months ended March 31, 2024 and 2023, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions:</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:79.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.173%;"/>
        <td style="width:1.62%;"/>
        <td style="width:13.443%;"/>
        <td style="width:1.62%;"/>
        <td style="width:16.143%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb7ebec8-7e81-4885-8504-bb14196ea90b" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.09</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1966c4aa-10e3-4fd7-a8fa-78a4cb9651f8" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.58</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f037e69a-7130-4add-8363-9ad92ba08ac9" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.87</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected life in years</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_f406ab1a-ea54-42b3-8fbb-f474cdd2a5ff" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.27</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_777cc266-43de-4781-a792-6c6863ab6248" contextRef="C_f17db39b-f553-4323-b229-bec623ac9226" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.06</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><ix:nonNumeric id="F_0b94a599-12d6-4cfb-8f9e-2b5301349eef" contextRef="C_3efa5cb2-5a15-4829-bf1f-70ca2555bcc6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65ff259f-9d51-4900-80a0-199a09883566" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">114.65</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2340ba04-77cd-4783-ab16-e64f42c48a42" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">89.69</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_62192b92-7dad-4733-a01b-56da1db186d6" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">95.63</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a833a823-15ad-4dc8-85bc-34e9aa9570f4" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b45e234-f059-4787-b420-35b85c8c70cd" contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.528%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:4.743198935713313%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f9b9f256-e0ed-43a5-8c1c-277de144e6b4" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option activity under the Company&#8217;s stock option plans for the three months ended March 31, 2024 was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.662%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:8.942%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.662%;"/>
        <td style="width:1%;"/>
        <td style="width:1.22%;"/>
        <td style="width:1%;"/>
        <td style="width:9.182%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted- Average Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted- Average Contractual Term (Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c08beae-dd05-423a-b241-cfa65e10d9e8" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">465,898</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20d17d07-17c6-4c6d-af07-9b756baf2e65" contextRef="C_307719b1-83d4-4843-8da2-94558ade533e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">26.85</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a6ae238-77d4-46a1-9b8a-dc338fa96ee1" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">40,000</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3061e5ca-b67f-4b15-9554-7e23b91b01e9" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.80</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_120ee62c-e1b4-4b4f-9c3e-f81678db8705" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">254,441</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89b3c607-634f-40f6-a516-d6c8fd27cd38" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">19.61</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34284dc7-1318-4301-b725-af2942f2ecab" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">251,457</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_864b24a2-94bc-48f3-bc45-0c6eea11f736" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">21.15</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_42aeb63d-c457-49e2-9f12-91f039ce81a1" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.92</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_202f55c8-b693-4c75-a987-1d0c395d7ebe" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercisable, March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_839d04e3-f912-4105-9547-ffbef8e82039" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">161,844</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2c8d332-1324-4ac2-819a-274efb6e3a3b" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">28.28</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_15d352a8-19bf-4b5e-a172-1aeba347b60e" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.53</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8756a0f1-190c-4a02-b392-484d48888d54" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options available for future grant, March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0b1a5c7-99d8-4cd0-8a16-082dc2c8b089" contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,514,087</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At March 31, 2024, total unrecognized compensation costs related to unvested stock options outstanding amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1259fbe4-62a3-48b1-a677-c7735763f97a" contextRef="C_31821ab4-d999-49bb-b9d4-9b4dd0c91cb9" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The cost is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d240d50-23d1-4473-b5cf-2c4cf2744677" contextRef="C_8baabce6-ac11-4af5-8a5f-c37dac90e95a" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.28</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f5baf808-cb23-4f85-a2f3-30dd54e4c552" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="tcrt:WarrantTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warrants</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Company&#8217;s November 2018 private placement that provided net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40665e34-8015-460d-ac88-17612ad34cdd" contextRef="C_95a30d90-929e-45eb-82ad-23f6fc64e994" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">47.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, the Company issued warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_180eb886-aea1-4e0e-8358-230c072b0cdb" contextRef="C_35078a72-b5fc-4657-9c90-f59660c54ff7" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,262,626</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, which became exercisable six months after the closing of the private placement, or the November 2018 Warrants. The November 2018 Warrants had an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5daa3b3d-dc1b-4e19-8fd6-cd27437e3f8d" contextRef="C_35078a72-b5fc-4657-9c90-f59660c54ff7" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">45.15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and have a five-year term. The fair value of the November 2018 Warrants was estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a8959be-7a2c-4ec2-87ce-f356c0617a91" contextRef="C_5e6444ec-337d-440e-ae0f-2c013e8670a1" name="tcrt:FairValueOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">18.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million using a Black-Scholes model with the following assumptions: expected volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebc52f90-ebc8-4048-a01b-5f4b93dab526" contextRef="C_5e6444ec-337d-440e-ae0f-2c013e8670a1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">71</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, risk free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80aeaed5-5a5b-463d-93c7-51adef660856" contextRef="C_5e6444ec-337d-440e-ae0f-2c013e8670a1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.99</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, expected life of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_955be387-a409-4568-b5db-fb1323adb54e" contextRef="C_5e6444ec-337d-440e-ae0f-2c013e8670a1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cce479a5-aaad-40e0-8aef-84bd5486b5ec" contextRef="C_5e6444ec-337d-440e-ae0f-2c013e8670a1" name="us-gaap:Dividends" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 26, 2019 and September 12, 2019, the Company entered into agreements with existing investors whereby the investors exercised the November 2018 Warrants for an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e5e2b07-c475-4f12-bf1a-eeee96f7fb83" contextRef="C_6046fec4-c22d-43b6-ba9b-95ebb064d3de" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,186,869</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_076a3b93-a316-4a08-9138-0a13a611fc59" contextRef="C_6046fec4-c22d-43b6-ba9b-95ebb064d3de" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">45.15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. Proceeds from the warrant exercise after deducting placement agent fees and other related expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d093dcbf-7742-4466-8c40-dcf607aee663" contextRef="C_0bc55a8f-887f-4070-9865-fd66f24117bf" name="tcrt:PlacementAgentFeesAndOtherRelatedExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8843e8af-0bde-4686-ab46-d2de571d82c0" contextRef="C_131aee97-1b4f-446a-8c75-66998adcc711" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">52.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company issued participating investors new warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_562bac86-3dc0-4279-bc3e-c2f06c35ce06" contextRef="C_afd87759-7cd4-4535-a126-67b00b692ba6" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,186,869</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shares of common stock (the "2019 Warrants") as consideration for the warrant holders to exercise their November 2018 Warrants. The 2019 Warrants will expire on the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fifth </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">anniversary of the initial exercise date and have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dad7f986-7c8d-4d54-8258-48d1f527e499" contextRef="C_afd87759-7cd4-4535-a126-67b00b692ba6" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:num-dot-decimal">105.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The 2019 Warrants were valued using a Black-Scholes valuation model and resulted in a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00c0205d-af3b-4904-97c7-18460068b870" contextRef="C_4bd3b321-13c5-4e4c-a083-a14aeb2b41c5" name="tcrt:NonOperatingIncomeExpenseInducementOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">60.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million non-cash charge in the Company&#8217;s statement of operations in 2019.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 22, 2019, the Company entered into the 2019 R&amp;D Agreement with MD Anderson. In connection with the execution of the 2019 R&amp;D Agreement, the Company issued the MD Anderson Warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1a5d07a-464c-4759-be42-ab613b27adfd" contextRef="C_05763aa1-65a6-4ed2-aa0e-21d87146369c" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">222,222</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The MD Anderson Warrant has an initial exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83724884-8620-4cc0-a6b8-4318978b3a19" contextRef="C_05763aa1-65a6-4ed2-aa0e-21d87146369c" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.015</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and grant date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cc46161-ae67-4f65-b47b-de4412c0eab5" contextRef="C_8cb0a4ff-691a-4757-b2eb-fbbd3b39dfe9" name="tcrt:FairValueOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The MD Anderson Warrant expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3e59d907-1bd3-4e1e-91b9-b2ef30552405" contextRef="C_05763aa1-65a6-4ed2-aa0e-21d87146369c" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2026 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and vests upon the occurrence of certain clinical milestones. The Company will recognize expense on the MD Anderson Warrant in the same manner as if the Company paid cash for services to be rendered. For the three months ended March 31, 2024 and 2023, the Company did not recognize any expense related to the MD Anderson Warrant as the clinical milestones had not been achieved.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 6, 2021, the Company entered into the Loan and Security Agreement with SVB. Refer to Note 4, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In connection with the Loan and Security Agreement, the Company issued SVB warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0cfe78c-677b-43d1-aa2f-3a2d99f09fa6" contextRef="C_52953abd-cae9-408c-bc3a-1c32bbcbd88a" name="us-gaap:CommonStockSharesSubscribedButUnissued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">28,856</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f74e1d87-2ba5-4702-96c3-910351e28369" contextRef="C_db32a880-2ad0-470e-8702-ccd0f5ec87bd" name="us-gaap:CommonStockCallOrExerciseFeatures"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33.30</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The warrants have a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fed6ca2e-76b6-444a-967f-86d793e487b0" contextRef="C_52953abd-cae9-408c-bc3a-1c32bbcbd88a" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> life and were fully vested upon issuance. The fair value of the warrants was estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_30d196d6-ebc6-4278-916b-c59b0cd01b88" contextRef="C_373d470e-fec0-416f-bd2c-474750080aee" name="tcrt:FairValueOfWarrants" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million using a Black-Scholes model with the following assumptions: expected volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fada389-953a-4709-bd7c-ce0dd7dcf4a4" contextRef="C_373d470e-fec0-416f-bd2c-474750080aee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">79</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, risk free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9e4ff37-8d72-4d9a-962a-eafdce7d0289" contextRef="C_373d470e-fec0-416f-bd2c-474750080aee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">1.31</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, expected life of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e6be1bfd-ba5c-4df0-90a0-c57398c3da21" contextRef="C_373d470e-fec0-416f-bd2c-474750080aee" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_23becda1-b01a-4b03-bd96-f007faa28571" contextRef="C_373d470e-fec0-416f-bd2c-474750080aee" name="us-gaap:Dividends" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends. On December 28, 2021, the Company entered into the First Amendment, as described in Note 4, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in connection with which, the original warrants issued to SVB were amended and restated. As amended and restated, the SVB Warrants are for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_929ddcf2-c402-47f3-9343-23ef21946dfd" contextRef="C_727a2f22-62eb-4547-b383-db9f11e5e1ac" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">43,308</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, in the aggregate, with an exercise price of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9e050702-1611-4c5f-ac33-427049ba84e8" contextRef="C_04d2b6bc-59f0-497b-ad0b-246c6e2342a9" name="us-gaap:CommonStockCallOrExerciseFeatures"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$17.40 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">per share. The SVB Warrants expire on August 6, 2031 and were fully vested upon issuance. As of March 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8aec0f2d-058b-4c00-a3a8-1b814e6937b5" contextRef="C_8f534694-1370-4e1c-8929-649408ad27f3" name="tcrt:ClassOfWarrantOrRightWarrantsExercised" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the SVB Warrants have been exercised.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_05636566-7ce5-4ad9-ae32-7058d2d46333" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" escape="true"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Joint Venture</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 18, 2018, the Company entered into a Framework Agreement with TriArm whereby the parties agreed to launch Eden BioCell, to lead clinical development and commercialization of certain </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-generated CAR-T therapies as set forth in a separate license agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 3, 2019, Eden BioCell was incorporated in Hong Kong as a private company. Eden BioCell, the Company and TriArm entered into a Share Subscription Agreement on January 23, 2019, where the Company and TriArm agreed to contribute certain intellectual property, services and cash (only with respect to TriArm) to Eden BioCell to subscribe for a certain number of newly issued ordinary shares in the share capital of Eden BioCell.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The closing of the transaction occurred on July 5, 2019. The Framework Agreement and Share Subscription Agreements were each respectively amended to be effective as of this date. Upon consummation of the joint venture, Eden BioCell and the Company also entered into a license agreement, pursuant to which the Company licensed the rights to Eden BioCell for third generation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-generated CAR-T therapies targeting the CD19 antigen for the territory of China (including Macau and Hong Kong), Taiwan and Korea. TriArm and the Company each received a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_885b4c31-92ab-49c1-bc4f-91ce000307c4" contextRef="C_3cf7f842-3616-4d7d-a8d1-b72415a7dc2e" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% equity interest in the joint venture in exchange for their contributions to Eden BioCell.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined that Eden BioCell was considered a variable interest entity, or VIE, and concluded that it was not the primary beneficiary of the VIE as it did not have the power to direct the activities of the VIE. As a result, the Company accounted for the equity interest in Eden BioCell under the equity method of accounting as it had the ability to exercise significant influence.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, TriArm and the Company mutually agreed to dissolve the joint venture, which has now been terminated. The Eden BioCell entity has been dissolved as of July 2023.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ce16218-e257-4305-af61-598df4ea005f" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="us-gaap:SubsequentEventsTextBlock" escape="true"><div style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subsequent Events</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has evaluated subsequent events from the balance sheet date through the date on which these condensed financial statements were issued. Other than as described in the notes above, the Company did not have any material subsequent events that impacted its condensed financial statements or disclosures.</span></p></ix:nonNumeric></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited financial information and related notes included in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission, or the SEC, on April 1, 2024, or the Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Except for the historical financial information contained herein, the matters discussed in this Quarterly Report on Form 10-Q may be deemed to contain forward-looking statements that reflect our plans, estimates and beliefs. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. In this Quarterly Report on Form 10-Q, words such as &#8220;may,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan&#8221; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our actual results could differ materially from those contained in or implied by any forward-looking statements. Factors that could cause or contribute to these differences include those risks identified under Part II, Item 1A. Risk Factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">All share amounts presented in this Item1 2 give effect to the 1-for-15 reverse stock split of our outstanding shares of common stock that occurred on January 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have operated as a clinical-stage oncology-focused cell therapy company developing adoptive TCR-T cell therapy, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. We were working to leverage our cancer hotspot mutation TCR library and our proprietary, non-viral </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> gene transfer platform to design and manufacture patient-specific cell therapies that target neoantigens arising from shared tumor-specific mutations in key oncogenic genes, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TP53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In collaboration with the MD Anderson Cancer Center, or MD Anderson, we were enrolling and treating patients for a Phase 1/2 clinical trial which was evaluating 12 TCRs reactive to mutated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS, TP53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">from our TCR library for the investigational treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers, which we refer to as our TCR-T Library Phase 1/2 Trial.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2023, we announced a strategic reprioritization of our business and wind down of our TCR-T Library Phase 1/2 Trial. In connection with the reprioritization, we have significantly reduced our workforce, and we continue working to reduce costs in order to extend our cash runway. We continue to explore strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. We have engaged Cantor Fitzgerald &amp; Co., or Cantor, to act as strategic advisor for this process. In addition, on August 14, 2023, we announced that we had provided the requisite notice to the NCI to terminate the Cooperative Research and Development Agreement, dated January 9, 2017, by and among us, the National Cancer Institute, or the NCI, and Intrexon Corporation, or Intrexon, as amended (such agreement referred to herein as the CRADA), pursuant to its terms, effective October 13, 2023. In addition, on October 27, 2023, we provided notice of termination of the Patent License with the NCI, effective December 26, 2023.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not generated any product revenue and have incurred significant net losses in each year since our inception. For the three months ended March 31, 2024, we had a net loss of $1.7 million, and as of March 31, 2024, we have incurred approximately $917.4 million of accumulated deficit since our inception in 2003. We expect to continue to incur significant operating expenditures and net losses for the foreseeable future.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent Developments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TCR-T Library Phase 1/2 Trial</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Eight patients were treated and evaluated in our TCR-T Library Phase 1/2 Trial. Patients with pancreatic (3), colorectal (4) and non-small cell lung cancer (1) were treated, with certain pancreatic and colorectal patients also having lung metastases. Overall, the trial showed our T-cells were generally well-tolerated in all evaluable participants with no dose-limiting toxicities (DLTs) and no immune effector cell-associated neurotoxicity syndrome (ICANS) were observed. All cytokine release syndrome (CRS) events were within grades 1-3 and were self-limiting or resolved with standard clinical management and, in some cases, a single dose of tocilizumab.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">One patient with non-small cell lung cancer (NSCLC) achieved an objective partial response with six months progression-free survival. Six other patients achieved a best overall response of stable disease. The total overall response rate was 13% and disease control rate was 87% in evaluable patients with advanced, metastatic, refractory solid tumors. Disease control was measured by objective responses and stable disease. Increased secretion of interferon-gamma relative to baseline was detected in all patients' serum post-cell transfer suggesting recognition of the tumor by the infused TCR-T cells. Persistence of TCR-T cells in peripheral blood was detected in all evaluable patients at their last follow-up, including up to six months in one patient. Infiltration of TCR-T cells into the tumor was also detected in three samples where a fresh biopsy was collected suggesting homing to the tumor microenvironment. All patients have</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">progressed or withdrawn from the trial and long-term follow-up is ongoing for a subset of patients with no further intervention per the treatment protocol. This trial established proof-of-concept that Sleeping Beauty TCR-T cells can result in objective clinical responses and recognize established tumors in vivo.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite the encouraging TCR-T Library Phase 1/2 Trial data, based on the substantial cost to continue development and the current financing environment, we announced in August 2023 that we would not pursue any further development of our clinical programs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">hunTR&#174; Platform</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have discovered multiple proprietary TCRs targeting driver mutations through our hunTR TCR discovery platform. In addition to TCRs that recognize KRAS and TP53 mutations similar to those licensed from the NCI, we identified additional TCRs that bind to other driver mutations and TCRs that are restricted to additional HLAs. We believe that the hunTR library has the potential to allow for the treatment of a large patient population.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Strategic Alternatives</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We continue to explore strategic alternatives, which may include but are not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. In connection with the strategic reprioritization, we have reduced our workforce by approximately 95% to date in order to streamline the organization and to maximize our cash runway.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Nasdaq Delisting Determination</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As previously disclosed on January 4, 2023, we were notified by the Listing Qualifications Department, or the Staff, of The Nasdaq Stock Market LLC, or Nasdaq, that we were in breach of Listing Rule 5450(a)(1), or the Minimum Bid Price Rule, for continued listing on the Nasdaq Global Select Market because the minimum bid price of our listed securities for 30 consecutive business days had been less than $1 per share. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), or the Compliance Period Rule, we were provided a period of 180 calendar days, or until July 3, 2023, or the Compliance Date, to regain compliance with the Bid Price Requirement. On June 22, 2023, we applied to transfer our listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, or the Transfer. On July 5, 2023, Nasdaq notified us that the Transfer was approved, and that, in connection with the Transfer, we were eligible for an additional 180 calendar day period, or until January 2, 2024, or the Extended Compliance Date, to regain compliance with the Minimum Bid Price Rule. On November 8, 2023, we received a Staff Delisting Determination letter, or the Delisting Determination, from the Staff notifying us that, because the closing bid price for our common stock was below $0.10 per share for 10 consecutive trading days during the Extended Compliance Period, the Staff has determined to suspend trading of our common stock on Nasdaq pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii), effective November 17, 2023, and file a Form 25-NSE with the SEC to remove our common stock from listing and registration under the Securities Exchange Act of 1934, as amended, unless we timely request an appeal of the Delisting Determination to a Nasdaq Hearings Panel, or the Panel. We timely requested a hearing before the Panel to appeal the Delisting Determination and were granted a hearing before the Panel on January 25, 2024.  This timely request for a hearing stayed the suspension or delisting of our common stock so our common stock continued to trade on the Nasdaq Capital Market under the symbol &#8220;TCRT&#8221; while the appeal process was pending.  By letter dated February 16, 2024, we were notified by The Nasdaq Stock Market LLC that we regained compliance with the minimum $1.00 bid price requirement, and otherwise satisfied all applicable criteria for continued listing on The Nasdaq Capital Market. As such, the listing matter was closed. Pursuant to Nasdaq Listing Rule 5815(d)(4)(B), we will be subject to a mandatory panel monitor for the one-year period through February 16, 2025.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Overview</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Revenue</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We recognize research and development funding revenue over the estimated period of performance. To date we have not generated product revenue. Unless and until we receive approval from the U.S. Food and Drug Administration, or the FDA, and/or other regulatory authorities for our product candidates, we cannot sell our products and will not have product revenue.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our research and development expenses have historically consisted primarily of salaries and related expenses for personnel, costs of contract manufacturing services, costs of facilities, reagents, and equipment, fees paid to professional service providers in conjunction with our clinical trials, fees paid to contract research organizations, or CROs, in conjunction with clinical trials, fees paid to CROs in conjunction with costs of materials used in research and development, consulting, license and milestone payments and sponsored research fees paid to third parties.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist primarily of salaries, benefits and stock-based compensation, consulting and professional fees, including patent related costs, general corporate costs and facility costs not otherwise included in research and development expenses.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income (Expense)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income (expense) consists primarily of interest expense associated with our amended Loan and Security Agreement (as defined below), interest income on our cash balances and sublease income.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Three Months Ended March 31, 2024 Compared to Three Months Ended March 31, 2023</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Revenue</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaboration revenue during the three months ended March 31, 2024 and 2023 was as follows:</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.38%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.184000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.184000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:8.944%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.645%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaboration revenue during the three months ended March 31, 2024 was $1 thousand and was $0 for the three months ended March 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses during the three months ended March 31, 2024 and 2023 were as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.38%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.184000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.184000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:8.944%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.645%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">126</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,504</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(6,378</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(98</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses for the three months ended March 31, 2024 decreased by $6.4 million</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">when compared to the three months ended March 31, 2023, primarily due to lower program expenses of $3.7 million as a result of the wind-down of our clinical activities, a $1.5 million decrease in employee-related expenses due to our reduced headcount and a $0.8 million decrease in facility related cost due to the wind-down.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the three months ended March 31, 2024, our clinical stage projects included our TCR-T Library Phase 1/2 Trial evaluating TCRs from our library for the investigational treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers, which we are currently in the process of winding down.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses during the three months ended March 31, 2024 and 2023 were as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.38%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.184000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.184000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:8.944%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.645%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,617</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,168</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,551</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(49</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses for the three months ended March 31, 2024 decreased by $1.6 million</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">as compared to the three months ended March 31, 2023, primarily due to a $1.3 million decrease in employee-related expenses due our reduced headcount, a $0.1 decrease in consulting expenses and a $0.1 decrease in facility cost due to the reduction in deprecation expenses and rent as a direct result of the lease termination in the prior period.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income (Expense)</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income (expense) during the three months ended March 31, 2024 and 2023 was as follows:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.38%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.184000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:9.184000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.22%;"/>
    <td style="width:1%;"/>
    <td style="width:8.944%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.645%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interest expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(853</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">853</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">477</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(417</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(87</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(376</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">436</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(116</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income, net, for the three months ended March 31, 2024 increased be $0.04 million as compared to the three months ended March 31, 2023, primarily due to no interest expense  associated with our former amended Loan and Security Agreement (as defined below).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sources of Liquidity</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not generated any revenue from product sales. Since inception, we have incurred net losses and negative cash flows from our operations.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we have financed our operations primarily through public offerings of our common stock, private placements of our equity securities, term debt and collaborations. Through December 31, 2023, we have received an aggregate of $729.2 million from issuances of equity. We have had no financing activity through March 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2023, we announced a strategic reprioritization of our business and wind down of our TCR-T Library Phase 1/2 Trial. In connection with the reprioritization, we have reduced our workforce,  and we continue working to reduce costs in order to extend our cash runway. We continue to explore strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. We have engaged Cantor to act as strategic advisor for this process.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We follow the guidance of Accounting Standards Codification, or ASC, Topic 205-40, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Presentation of Financial Statements - Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, in order to determine whether there is substantial doubt about our ability to continue as a going concern for one year after the date our condensed financial statements are issued. Given our current development plans and cash management efforts, we anticipate that our cash resources will be sufficient to fund operations into the third quarter of 2024. Our ability to continue operations after our current cash resources are exhausted depends on our ability to obtain additional financing, as to which no assurances can be given. Cash requirements may vary materially from those now planned because of changes in our focus and direction of our research and development programs, competitive and technical advances, patent developments, regulatory changes or other developments. If adequate additional funds are not available when required, management may need to curtail its development efforts and planned operations to conserve cash.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the current cash forecast, management has determined that our present capital resources will not be sufficient to fund our planned operations for at least one year from the issuance date of the condensed financial statements, which raises substantial doubt as to our ability to continue as a going concern. This forecast of cash resources and planned operations is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2022 Public Offering</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 29, 2022, we entered into an underwriting agreement, or the Underwriting Agreement, with Cantor as the sole underwriter, relating to the issuance and sale in an underwritten offering, or the Offering, of 1,615,247 shares of our common stock, or the Firm Shares, to Cantor at a price of $9.2865 per share.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our net proceeds from the Offering were $14.7 million (before accounting for the partial exercise of Cantor's option as described below) after deducting underwriting discounts and commissions and offering expenses payable by us.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Underwriting Agreement, we granted Cantor an option, exercisable for 30 days, to purchase up to an additional 242,287 shares of common stock, or, together with the Firm Shares, the Shares, at the same price per share as the Firm Shares. On January 5, 2023, Cantor partially exercised its option to purchase an additional 14,420 shares of common stock.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2022 Equity Distribution Agreement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 12, 2022, we entered into an Equity Distribution Agreement, or the Equity Distribution Agreement, with Piper Sandler &amp; Co., or Piper Sandler, pursuant to which we can offer and sell, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $50 million through Piper Sandler as our sales agent in an &#8220;at the market offering.&#8221; Piper Sandler will receive a commission of 3.0% of the gross proceeds of any common stock sold under the Equity Distribution Agreement. During the three months ended March 31, 2024 and 2023, there were no sales of our common stock under the Equity Distribution Agreement.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 Loan and Security Agreement</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 6, 2021, we entered into a Loan and Security Agreement, or the Loan and Security Agreement, with Silicon Valley Bank, or SVB. The Loan and Security Agreement provided for an initial term loan of $25.0 million funded at the closing, or the Term A Tranche, with an additional tranche of $25.0 million available if certain funding and clinical milestones were met by August 31, 2022. The SVB Facility and related obligations under the Loan and Security Agreement were secured by substantially all of our properties, rights and assets, except for our intellectual property (which was subject to a negative pledge under the Loan and Security Agreement). In addition, the Loan and Security Agreement contained customary representations, warranties, events of default and covenants.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">
Effective December 28, 2021, we entered into the First Amendment to the Loan and Security Agreement. Under the terms of the First Amendment, the additional tranche, which remained unfunded, was eliminated, leaving only the Term A Tranche, which is referred to as the SVB Facility. The SVB Facility bore interest at a floating rate per annum on the outstanding loans, payable monthly, at the greater of (a) 7.75% and (b) the current published U.S. prime rate, plus a margin of 4.5%. Commencing on September 1, 2022, aggregate outstanding borrowings became repayable in twelve consecutive, equal monthly installments of principal plus accrued interest.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All outstanding obligations under the amended Loan and Security Agreement were due and payable on August 1, 2023. We also owed SVB $1.4 million as a final payment, or the Final Payment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective March 30, 2023, we entered into a Third Amendment to the Loan and Security Agreement, or the Third Amendment. Under the terms of the Third Amendment, we were no longer required to maintain all of our operating accounts, depository accounts and excess cash with SVB, and were instead only required to maintain a single operating or depository account at Silicon Valley Bank. The Third Amendment also modified the cash collateralization requirement, such that we were required to cash collateralize the entire sum of the outstanding principal amount of the SVB Facility plus an amount equal to the Final Payment, which amount was to be reduced commensurate with each regularly scheduled monthly payment of principal and interest on the SVB Facility.
</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 1, 2023, we paid SVB all amounts outstanding under the amended Loan and Security Agreement, comprised of the entire outstanding principal amount under the SVB Facility, all accrued and unpaid interest and the Final Payment. The payment was subject to a prepayment premium of 2.00%.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with our entry into the Loan and Security Agreement in August 2021, we issued to SVB warrants to purchase (i) up to 28,856 shares of our common stock, in the aggregate, and (ii) up to an additional 28,856 shares of Common Stock, in the aggregate, in the event we achieved certain clinical milestones, in each case at an exercise price per share of $33.30. In connection with our entry into the First Amendment in December 2021, we amended and restated the warrants issued to SVB. As amended and restated, the warrants are for up to 43,307 shares of our common stock, in the aggregate, with an exercise price of $17.40 per share, or the SVB Warrants. The SVB Warrants expire on August 6, 2031.
</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our net decrease in cash and cash equivalents for the three months ended March 31, 2024 and 2023:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.993%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.62%;"/>
    <td style="width:1%;"/>
    <td style="width:12.883000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">($ in thousands)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash provided used in:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,917</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(9,381</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(23</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(6,158</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,917</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(15,562</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Cash flows from operating activities are derived by adjusting our net loss for:</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Non-cash operating items such as depreciation, amortization, impairment charges, stock-based compensation and reduction in right-of-use assets; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.571084182443509%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in operating activities for the three months ended March 31, 2024 was $1.9 million, as compared to net cash used in operating activities of $9.4 million for the three months ended March 31, 2023. The decrease in net cash used in operation activities was primarily related to changes in our net loss.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The net cash used in operating activities for the three months ended March 31, 2024 was primarily due to our net loss of $1.7 million</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> adjusted for $0.2 million of non-cash items such as depreciation and stock-based compensation and a $0.7 million decrease in accrued expenses, a decrease in accounts payable of $18 thousand, a decrease to prepaid expenses and other current assets of $0.3 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in investing activities was $0</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for the three months ended March 31, 2024, compared to $23 thousand for the three months ended March 31, 2023. The decrease is related to no investing activities during the current period as compared to the prior period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in financing activities for the three months ended March 31, 2024 was $0, compared to $6.2 million for the three months ended March 31, 2023. The decrease was primarily related to the repayment of long-term debt in 2023 that did not recur in 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating Capital and Capital Expenditure Requirements</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that losses will continue for the foreseeable future. As of March 31, 2024, our accumulated deficit was approximately $917.4 million. Our actual cash requirements may vary materially from those planned because of a number of factors, including changes in the focus, direction and pace of our development programs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, we had approximately $4.1 million of cash and cash equivalents. In light of our announced strategic reprioritization and concurrent exploration of strategic alternatives, including our decision to halt work on our TCR-T Library Phase 1/2 Trial, our development programs and reducing our workforce, we anticipate our cash resources will be sufficient to fund our operations into the third quarter of 2024. In order to continue our operations beyond our forecasted runway, including if necessary to continue to explore strategic alternatives, we will need to raise additional capital, and we have no committed sources of additional capital at this time. The forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of our expenses could vary materially and adversely as a result of a number of factors. We have based our estimates on assumptions that may prove to be wrong, and our expenses could prove to be significantly higher than we currently anticipate. Management does not know whether additional financing will be on terms favorable or acceptable to us when needed, if at all. If adequate additional funds are not available when required, we may be unable to persist as a going concern for sufficient time to identify or execute on any strategic alternatives.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Working capital as of March 31, 2024 was $4.8 million, consisting of $6.0 million in current assets and $1.2 million in current liabilities. Working capital as of December 31, 2023 was $6.3 million, consisting of $8.3 million in current assets and $2.0 million in current liabilities.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Leases</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 12, 2019, we entered into a lease agreement for office space in Houston at MD Anderson through April 2021. On October 15, 2019, we entered into another lease agreement for additional office and laboratory space in Houston through February 2027. On April 7, 2020, we entered into amendments to our existing lease to lease additional office and laboratory space in Houston through February 2027. On December 15, 2020, we entered into another lease in Houston with MD Anderson which provided us additional office and laboratory space through April 2028.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2023, we executed an agreement to terminate the lease for our remaining office space in Boston, Massachusetts. Under the terms of the lease termination, we were required to pay a $0.2 million termination fee. Additionally, we have been released from a sub-sublease of certain of our office space in Boston signed in June 2022 as it has been assigned to the Boston office space's landlord in conjunction with the agreement to terminate the lease for the remaining office space.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2023, in accordance with the lease agreement executed on December 15, 2020, we provided notification to the landlord to terminate office space of 3,228 square feet in Houston, Texas.  As a result, the associated lease liability and right-of-use asset were remeasured to $19 thousand, reflecting the revised lease payments and term end date of November 2023.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 1, 2023, we and MD Anderson, as landlord, agreed to mutually terminate the leases dated October 15, 2019 and April 7, 2020, which represent office space totaling 14,037 square feet, effective November 15, 2023. As a result, we agreed to make a final payment of $0.1 million to the landlord.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, we had terminated all operating leases and therefore have no remaining lease commitments, other than a short-term lease.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Royalty and License Fees</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 28, 2019, we entered into a patent license agreement, or the Patent License, with the NCI. The terms of the Patent License required us to pay the NCI minimum annual royalties in the amount of $0.3 million, which would be reduced to $0.1 million once the aggregate minimum annual royalties paid by us equaled $1.5 million. For the three months ended March 31, 2024, we did not recognize royalty payments under the Patent License, and for the three months ended March 31, 2023, we recognized $0.3 million related to royalty payments under the Patent License. As of March 31, 2024, we paid a total of $0.8 million in minimum annual royalty payments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">under the Patent License. On October 27, 2023, we provided notice of termination of the Patent License with the NCI, effective December 26, 2023.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 5, 2018, we entered into the License Agreement with PGEN Therapeutics, Inc., or PGEN, a wholly owned subsidiary of Precigen. Except where the context otherwise requires, we refer to PGEN and Precigen together as Precigen. Under the License Agreement, we were obligated to pay Precigen an annual licensing fee of $0.1 million expected to be paid through the term of the License Agreement and we had also agreed to reimburse certain historical costs of Precigen up to $1.0 million.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the A&amp;R License Agreement, annual license payments due to Precigen are $75 thousand. Payment of the licensing fee is scheduled annually, in the second quarter after the first payment in October 2023; therefore, in accordance with the terms of the agreement, no amounts were paid during the three months ended March 31, 2024 or 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, Solasia Pharma K. K., or Solasia, announced that darinaparsin had been approved from relapsed or refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare in Japan. During the three months ended March 31, 2024, we had $1 thousand in collaboration revenue, and we did not record collaboration revenue for the three months ended March 31, 2023.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Policies and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In our Annual Report on Form 10-K for the year ended December 31, 2023, our most critical accounting policies and estimates upon which our financial status depends were identified as those relating to clinical trial expenses and other research and development expenses; collaboration agreements; fair value measurements for stock-based compensation; and income taxes. We reviewed our policies and determined that those policies remain our most critical accounting policies for the three months ended March 31, 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_3_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 3. Quantitative and Qualitative Disclosures about Market Risk.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a smaller reporting company, as defined by Rule 12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, we are not required to provide the information under this item.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="item_4_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 4. Controls and Procedures.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our management, with the participation of our principal executive officer and principal accounting officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act) as of March 31, 2024. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal accounting officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2024, our principal executive officer and principal accounting officer concluded that, as of such date, our disclosure controls and procedures were effective.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were no changes in our internal control over financial reporting (as defined in Rule 13(a)-15(f) of the Exchange Act) that occurred during the quarter ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART II&#8212;OTHER INFORMATION</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_legal_proceeding_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 1. Legal Proceedings</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of business, we may periodically become subject to legal proceedings and claims arising in connection with ongoing business activities from time to time. The results of litigation and claims cannot be predicted with certainty, and unfavorable resolutions are possible and could materially affect our business, financial condition, results of operations, cash flows and prospects. In addition, regardless of the outcome, litigation could have an adverse impact on us because of defense costs, diversion of management attention and resources and other factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have any pending litigation that, separately or in the aggregate, would, in the opinion of management, be reasonably likely to have a material adverse effect on our business, financial condition, results of operations, cash flows or prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factor_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Item 1A. Risk Factors</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following important factors could cause our actual business and financial results to differ materially from those contained in forward-looking statements made in this Quarterly Report on Form 10-Q or elsewhere by management from time to time. The risk factors in this Quarterly Report have been revised to incorporate changes to our risk factors from those included in our Annual Report. The risk factors set forth below with an asterisk (*) before the title are new risk factors or ones containing substantive changes from the risk factors previously disclosed in Item 1A of our Annual Report, as filed with the SEC. The market price of our common stock could decline if one or more of these risks or uncertainties actually occur, causing you to lose all or part of your investment. This situation is changing rapidly and additional impacts may arise. Additional risks that we currently do not know about, or that we currently believe to be immaterial, may also impair our business. Certain statements below are forward-looking statements. See &#8220;Special Note Regarding Forward-Looking Statements&#8221; in this Quarterly Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RISKS RELATED TO OUR STRATEGIC REPRIORITIZATION</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our strategic reprioritization may not be successful, may not yield the desired results and we may be unsuccessful in identifying and implementing any strategic transaction.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2023, we announced a strategic reprioritization of our business and wind down of our TCR-T Library Phase 1/2 Trial. In connection with the reprioritization, we have reduced our workforce by approximately 95% to date and we continue working to reduce costs in order to extend our cash runway. We continue to explore strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. We have engaged Cantor Fitzgerald &amp; Co., or Cantor, to act as strategic advisor for this process. In addition, while we are evaluating several potential in-licensing opportunities in obesity, oncology and virology, there is no assurance that any of these potential opportunities will come to fruition.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe there is value in our hunTR&#174; TCR discovery platform. However, the platform is experimental. There can be no assurances that we can succeed in improving the platform&#8217;s appeal and increasing its value. We may be unable to successfully monetize the platform or any TCRs we discovered, either through partnerships or out-licensing.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to devote substantial time and resources to exploring strategic alternatives that our Board of Directors believes will maximize stockholder value. Despite devoting significant efforts to identify and evaluate potential strategic alternatives, there can be no assurance that this strategic review process will result in us pursuing any transaction or that any transaction, if pursued, will be completed on attractive terms or at all. We have not set a timetable for completion of this strategic review process, and our Board of Directors has not approved a definitive course of action. Additionally, there can be no assurances that any particular course of action, business arrangement or transaction, or series of transactions, will be pursued, successfully consummated or lead to increased stockholder value or that we will make any additional cash distributions to our stockholders.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The process of continuing to evaluate these strategic options may be very costly, time-consuming and complex and we have incurred, and may in the future incur, significant costs related to this continued evaluation, such as legal and accounting fees and expenses and other related charges. We may also incur additional unanticipated expenses in connection with this process. A considerable portion of these costs will be incurred regardless of whether any such course of action is implemented or transaction is completed. Any such expenses will decrease the remaining cash available for use in our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, potential counterparties in a strategic transaction involving the Company may place minimal or no value on our assets or our public listing. Further, should we resume the development of our product candidates, the development and any potential commercialization of our product candidates will require substantial additional cash to fund the costs associated with conducting the necessary preclinical and clinical testing and obtaining regulatory approval. Consequently, any potential counterparty in a strategic transaction involving the Company may choose not to spend additional resources and continue development of our product candidates and may attribute little or no value, in such a transaction, to those product candidates.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, any strategic business combination or other transactions that we may consummate in the future could have a variety of negative consequences and we may implement a course of action or consummate a transaction that yields unexpected results that adversely affect our business and decreases the remaining cash available for use in our business or the execution of our strategic plan. Any potential transaction would be dependent on a number of factors that may be beyond our control, including, among other things, market conditions, industry trends, the interest of third parties in a potential transaction with us, obtaining stockholder approval and the availability of financing to third parties in a potential transaction with us on reasonable terms. Any failure of such potential transaction to achieve the anticipated results could significantly impair our ability to enter into any future strategic transactions and may significantly diminish or delay any future distributions to our stockholders.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are not successful in setting forth a new strategic path for the Company, or if our plans are not executed in a timely fashion, this may cause reputational harm with our stockholders and the value of our securities may be adversely impacted. In addition, speculation regarding any developments related to the review of strategic alternatives and perceived uncertainties related to the future of the Company could cause our stock price to fluctuate significantly.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we successfully consummate a transaction from our strategic assessment, we may fail to realize all of the anticipated benefits of the transaction, those benefits may take longer to realize than expected, or we may encounter integration difficulties.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to realize the anticipated benefits of any potential business combination or any other result from our strategic assessment is highly uncertain. Any anticipated benefits will depend on a number of factors, including our ability to integrate with any future business partner, the success of any future business we may engage in following the transaction and our ability to obtain value for our product candidates or technologies, if divested. The process may be disruptive to our business and the expected benefits may not be achieved within the anticipated timeframe, or at all. The failure to meet the challenges involved and to realize the anticipated benefits of any potential transaction could adversely affect our business and financial condition. Furthermore, our stockholders may experience substantial dilution as a result of the transaction without receiving the expected commensurate benefit, or only receiving part of the commensurate benefit to the extent we are able to realize only part of the expected strategic and financial benefits currently anticipated from a transaction.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may require substantial additional financial resources to continue as a going concern, including through the strategic review process, and if we raise additional funds, this may materially and negatively affect the value of your investment in our common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not generated significant revenue and have incurred significant net losses in each year since our inception. For the three months ended March 31, 2024, we had a net loss of $1.7million, and, as of March 31, 2024, our accumulated deficit since inception in 2003 was $917.4 million. Although we are in the process of implementing a restructuring plan, or the Plan, whereby we are winding down our TCR-T Library Phase 1/2 Trial, other development programs and implemented a reduction in force, in order to reduce operating expenditures and net losses, as discussed above, there can be no assurances we will be successful at all, or in the amount we anticipate. In connection with our strategic reprioritization, we unilaterally terminated the CRADA in August 2023 and the Patent License in October 2023.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, we have approximately $4.1&#8239;million of cash and cash equivalents.&#8239;Following implementation of the Plan, we anticipate our cash resources will be sufficient to fund our operations into the third quarter of 2024. We have not set a timetable for completion of the strategic review process and the timing of consummating a strategic transaction, if any, is not entirely within our control. We have no committed sources of additional capital at this time. Accordingly, we could exhaust our current cash resources prior to the identification or consummation of a suitable strategic alternative, requiring the Company to raise additional capital.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that our exploration of strategic alternatives will make it more difficult to raise additional capital. To the extent that we raise additional capital by issuing equity securities, our existing stockholders&#8217; ownership will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, creating liens, making capital expenditures or declaring dividends, which may further constrain our ability to execute on strategic alternatives.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We follow the guidance of Accounting Standards Codification, or ASC, Topic 205-40, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Presentation of Financial Statements - Going Concern</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, in order to determine whether there is substantial doubt about our ability to continue as a going concern for one year after the date our financial statements are issued. Based on the current cash forecast, management has determined that our present capital resources will not be sufficient to fund our planned operations for at least one year from the issuance date of the financial statements, which raises substantial doubt as to our ability to continue as a going concern.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The forecast of cash resources is forward-looking information that involves risks and uncertainties, and our actual cash requirements may vary materially from our current expectations for a number of other factors that may include, but are not limited to, the progress of our strategic review and the pursuit of and progress on one or more options identified in such review. Global political and economic events, including the war in Ukraine and increased inflation, have already resulted in a significant disruption of global financial markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the disruption persists and deepens, we could experience an inability to access additional capital or make the terms of any available financing less attractive, which could in the future negatively affect our operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are successful in completing a strategic transaction, we may be exposed to other operational and financial risks.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although there can be no assurance that a strategic transaction will result from the process we have undertaken to identify and evaluate strategic alternatives, the negotiation and consummation of any such transaction will require significant time on the part of our management, and the diversion of management&#8217;s attention may disrupt our business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The negotiation and consummation of any such transaction may also require more time or greater cash resources than we anticipate and expose us to other operational and financial risks, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased near-term and long-term expenditures;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unknown liabilities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">higher than expected acquisition or integration costs;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">incurrence of substantial debt or dilutive issuances of equity securities to fund future operations;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">write-downs of assets or incurrence of non-recurring, impairment or other charges;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased amortization expenses;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficulty and cost in combining the operations and personnel of any counterparty business with our operations and personnel;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">impairment of relationships with key suppliers or customers of any acquired business due to changes in management and ownership;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to retain key employees of our company or any acquired business; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">possibility of future litigation.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of the foregoing risks could have a material adverse effect on our business, financial condition, results of operations, cash flows and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If a strategic transaction is not consummated, our Board of Directors may decide to pursue a dissolution and liquidation. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There can be no assurance that a strategic transaction will be completed. If a strategic transaction is not completed, our Board of Directors may decide to pursue a dissolution and liquidation. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such decision and, with the passage of time the amount of cash available for distribution will be reduced as we continue to fund our operations and exploration of strategic alternatives. In addition, if our Board of Directors were to approve and recommend, and our stockholders were to approve, a dissolution and liquidation, we would be required under Delaware corporate law to pay our outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to our stockholders. As a result of this requirement, a portion of our assets may need to be reserved pending the resolution of such obligations and the timing of any such resolution is uncertain. In addition, we may be subject to litigation or other claims related to a dissolution and liquidation. If a dissolution and liquidation were pursued, our Board of Directors, in consultation with our advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, holders of our common stock could lose all or a significant portion of their investment in the event of a liquidation, dissolution or winding up.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to consummate a strategic transaction depends on our ability to retain our remaining employees and consultants.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to consummate a strategic transaction depends upon our ability to retain our remaining employees and consultants, the loss of whose services may adversely impact our ability to consummate such transaction. In connection with the evaluation of strategic alternatives and in order to extend our resources, on August 14, 2023, we implemented the Plan that included reducing our workforce. The reduction in force has impacted approximately 95%</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of our workforce to date, including key members of our management team. Our cash conservation activities may yield unintended consequences, such as attrition beyond our planned reduction in workforce and reduced employee morale, which may cause remaining employees and consultants to seek alternative opportunities. If we are unable to successfully retain our remaining personnel, we are at risk of a disruption to our exploration and consummation of a strategic alternative as well as business operations.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our corporate restructuring and the associated headcount reduction may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could significantly disrupt our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2023, in connection with the evaluation of strategic alternatives and in order to extend our resources, our Board of Directors approved the Plan that included reducing our workforce, which has impacted approximately 95%</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of our workforce to date. In addition, the Plan included a discontinuation of our clinical development programs and further prioritization of our resources as we assess strategic alternatives. We incurred approximately $1.5 million for retention, severance and other employee termination-related costs starting in the third quarter of 2023 through to the fourth quarter of 2023. We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from the restructuring, our operating results and financial condition would be adversely affected. Furthermore, the Plan may be disruptive to our operations. For example, our headcount reductions could yield unanticipated consequences, such as increased difficulties in implementing our business strategy, including retention of our remaining employees and consultants. Any employee litigation related to the headcount reduction could be costly and prevent management from fully concentrating on the business.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees. Due to our limited resources, we may not be able to effectively manage our operations or recruit and retain qualified personnel, which may result in weaknesses in our infrastructure and operations, risks that we may not be able to comply with legal and regulatory requirements, and loss of employees and reduced productivity among remaining employees. For example, the workforce reduction may negatively impact our clinical, regulatory, technical operations, and commercial functions, should we choose to continue to pursue them, which would have a negative impact on our ability to successfully develop, and ultimately, commercialize our product candidates. Our future financial performance and our ability to develop our product candidates or additional assets will depend, in part, on our ability to effectively manage any future growth or restructuring, as the case may be.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may become involved in litigation, including securities class action litigation, that could divert management&#8217;s attention and harm the Company&#8217;s business, and insurance coverage may not be sufficient to cover all costs and damages.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the past, litigation, including securities class action litigation, has often followed certain significant business transactions, such as the sale of a company or announcement of any other strategic transaction, or the announcement of negative events, such as negative results from clinical trials. These events may also result in investigations by the SEC or other governmental agencies. We may be exposed to such litigation even if no wrongdoing occurred. Litigation is usually expensive and diverts management&#8217;s attention and resources, which could adversely affect our business and cash resources and our ability to consummate a potential strategic transaction or the ultimate value our stockholders receive in any such transaction.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RISKS RELATED TO OUR BUSINESS</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We received a Delisting Determination from Nasdaq. Delisting could prevent us from maintaining an active, liquid and orderly trading market for our common stock and may materially and adversely impact our ability to consummate certain strategic transactions.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if we are delisted from the Nasdaq Capital Market or if we are unable to transfer our listing to another stock market. On January 4, 2023, we were notified by The Nasdaq Stock Market LLC, or Nasdaq, that we were in breach of Listing Rule 5450(a)(1), or the Minimum Bid Price Rule, for continued listing on the Nasdaq Global Select Market because the minimum bid price of our listed securities for 30 consecutive business days had been less than $1 per share. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), or the Compliance Period Rule, we were provided a period of 180 calendar days, or until July 3, 2023, or the Compliance Date, to regain compliance with the Bid Price Requirement. On June 22, 2023, we applied to transfer our listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, or the Transfer. On July 5, 2023, Nasdaq notified us that the Transfer was approved, and that, in connection with the Transfer, we were eligible for an additional 180 calendar day period, or until January 2, 2024, or the Extended Compliance Date, to regain compliance with the Minimum Bid Price Rule.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 8, 2023, we received the Delisting Determination notifying us that, because the closing bid price for our common stock was below $0.10 per share for 10 consecutive trading days during the Extended Compliance Period, the Staff has determined to suspend trading of our common stock on Nasdaq, effective November 17, 2023, and file a Form 25-NSE with the SEC to remove our common stock from listing and registration under the Securities Exchange Act of 1934, as amended, unless we timely request an appeal of the Delisting Determination to the Panel. On November 14, 2023, we timely filed a notice requesting a hearing before the Panel to appeal the Delisting Determination.  A hearing was initially scheduled for February 15, 2024 and subsequently rescheduled to January 25, 2024. Our common stock continued to trade on the Nasdaq Capital Market Exchange, or the Exchange, under the symbol "TCRT" during this time. Following the hearing, on February 5, 2024, the Panel granted our request to continue listing on the Exchange subject to certain conditions until February 15, 2024. These conditions included the completion of the already shareholder approved 1-for-15 reverse stock split and compliance with the Minimum Bid Price Rule for ten consecutive trading days. We were required to provide</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prompt notification to the Panel of any "significant" events during the exception period.  We executed this reverse stock split on January 31, 2024. On February 16, 2024, we were notified by Nasdaq that we had regained compliance with the Minimum Bid Price Rule. While we are now in compliance, we are now subject to a Mandatory Panel Monitor until February 16, 2025. If we fail to comply with the Minimum Bid Price Rule during this period, we will not be permitted to provide the Staff with a compliance plan and Staff will not be permitted to grant extra time to us to regain compliance. In addition, we would be issued a Delist Determination Letter with the opportunity to request a new hearing with the initial Panel, or a newly convened Hearings Panel if the initial Panel is not available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our common stock is delisted by Nasdaq, it could lead to a number of negative implications, including an adverse effect on the price of our common stock, deterring broker-dealers from making a market in or otherwise seeking or generating interest in our common stock, increased volatility in our common stock, reduced liquidity in our common stock, the loss of federal preemption of state securities laws and greater difficulty in obtaining financing. Delisting could also cause a loss of confidence of our customers, collaborators, vendors, suppliers and employees, which could harm our business and future prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our common stock is delisted by Nasdaq, the price of our common stock may decline, and although our common stock may be eligible to trade on the OTC Bulletin Board, another over-the-counter quotation system, or on the pink sheets, an investor may find it more difficult to dispose of their common stock or obtain accurate quotations as to the market value of our common stock. If our common stock is delisted from Nasdaq, trading in our securities may be subject to the SEC&#8217;s &#8220;penny stock&#8221; rules. These &#8220;penny stock&#8221; rules will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our common stock. The additional burdens imposed upon broker-dealers by these requirements may discourage broker-dealers from recommending transactions in our securities, which could severely limit the liquidity of our securities and consequently adversely affect the market price for our securities. Furthermore, if our common stock is delisted, we would expect it to have an adverse impact on our ability to consummate certain strategic alternatives.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, if our common stock is delisted, we would incur additional costs under state blue sky laws in connection with any sales of our securities. These requirements could severely limit the market liquidity of our common stock and the ability of our stockholders to sell our common stock in the secondary market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not have approval by our shareholders for a second reverse stock split of our common stock to enable the Board of Directors to respond to a Panel if we fail to comply with the Minimum Bid Price Rule during the monitor period.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While our stockholders approved a reverse stock split of the issued and outstanding shares of our common stock, our treasury stock, and a proportionate reduction in the shares of our authorized common stock, if needed in the discretion of our Board of Directors to regain compliance with the Minimum Bid Price Rule, at a ratio between the range of 1-for-5 and 1-for-15, inclusive, at any time on or before June 6, 2024, we have already executed this approved stock split to achieve compliance to the November delisting notice.  If we receive a second delisting notice during the monitor period, we have to convene a special shareholder meeting to obtain approval for another reverse stock split.  There is no guarantee that the Panel will grant us an exception to convene such a meeting.  There is no guarantee that the shareholders would approve another reserve stock split.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Shareholders may not approve another reverse stock split.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we are able to convene a shareholders meeting within the time allowed by the Panel should we fail to comply with the Minimum Bid Price Rule during the monitor period, there is no guarantee that the shareholders would approve a reverse stock split.  Failure to acquire shareholder approval of a second reverse stock split would negatively effect our ability to regain compliance with the Minimum Bid Price Rule, which would result in our common stock being delisted from the Exchange.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we do get approval and effectuate a second reverse stock split, the trading price of our common stock may not meet the Minimum Bid Price Rule</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we do effect a second reverse stock split, there can be no assurance that the market price per new share of our common stock after the reverse stock split will remain unchanged or increase in proportion to the reduction in the number of old shares of our common stock outstanding before the reverse stock split. Other factors, such as our financial results, market conditions and the market perception of our business may adversely affect the market price of our common stock and there can be no assurance that a reverse stock split, if completed, will result in the intended benefits, that the market price of our common stock will increase in proportion to the reduction in the number of shares of our common stock outstanding before the reverse stock split or that the market price of our common stock will not decrease in the future. If the market price of our common stock does not increase the price per share of our common stock above Nasdaq&#8217;s minimum bid price threshold of $1.00 per share or if the market price of our common stock does not remain above Nasdaq&#8217;s minimum bid price threshold of $1.00 per share, our common stock may still be delisted from Nasdaq. There is also no guarantee that the Panel agrees that implementing a reverse stock split warrants reversing the Staff's delisting determination, regardless of the price at which our common stock would trade following the split.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In light of the recent reverse stock split, or if we implement a second reverse stock split during the monitor period, liquidity of our common stock may be materially and adversely affected.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In light of our recent reverse stock split, or if we have to effect a second reverse stock split to avoid a delisting pursuant to a new Delisting Determination during the monitor period, the liquidity of the shares of our common stock may be affected materially and adversely by any such reverse stock split given the reduced number of shares of common stock that will be outstanding following the reverse stock split, especially if the market price of our common stock does not increase as a result of the reverse stock split.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following any reverse stock split, the resulting market price of our common stock may not attract new investors and may not satisfy the investing requirements of those investors. Although we believe a higher market price of our common stock may help generate greater or broader investor interest, there can be no assurance that the reverse stock split will result in a share price that will attract new investors, including institutional investors. In addition, there can be no assurance that the market price of our common stock will satisfy the investing requirements of those investors. As a result, the trading liquidity of our common stock may not necessarily improve.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may identify material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, which may result in material misstatements of our financial statements or could have a material adverse effect on our business and trading price of our securities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and the rules and regulations of the Nasdaq Capital Market. Pursuant to Section 404 of the Sarbanes-Oxley Act, we are required to perform system and process evaluation and testing of our internal control over financial reporting to allow our management to report on the effectiveness of our internal control over financial reporting. We may also be required to have our independent registered public accounting firm issue an opinion on the effectiveness of our internal control over financial reporting on an annual basis.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have identified material weaknesses in our internal control over financial reporting in the past. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although the material weaknesses identified in the past have been remediated, we cannot assure you that any measures we have taken or may take in the future will be sufficient to avoid potential future material weaknesses. If we are unable to successfully remediate any future material weakness and maintain effective internal controls, we may not have adequate, accurate or timely financial information, and we may be unable to meet our reporting obligations as a public company, including the requirements of the Sarbanes-Oxley Act, we may be unable to accurately report our financial results in future periods, or report them within the timeframes required by the requirements of the SEC, Nasdaq or the Sarbanes-Oxley Act. Failure to comply with the Sarbanes-Oxley Act, when and as applicable, could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in the identification of additional material weaknesses or significant deficiencies, cause us to fail to meet our reporting obligations or result in material misstatements in our financial statements. Furthermore, if we cannot provide reliable financial reports or prevent fraud, our business, financial condition, results of operations, cash flows and prospects could be materially harmed and investors could lose confidence in our reported financial information.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The development and commercialization of non-viral adoptive TCR-T cell therapies could be considered a new approach to cancer treatment, the successful development of which is subject to significant challenges.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have employed technologies such as the technology licensed from MD Anderson pursuant to the MD Anderson License, described above, from Precigen, pursuant to the A&amp;R License Agreement, and from the NCI, pursuant to the Patent License described above, to pursue the development and commercialization of non-viral cellular therapies based on T-cells and TCRs, targeting solid tumor malignancy. Because this is a new approach to cancer immunotherapy and cancer treatment generally, developing and commercializing product candidates is subject to a number of challenges, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining regulatory approval from the FDA and other regulatory authorities that have very limited experience with the commercial development of genetically modified T-cell therapies for cancer; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">designing and conducting our clinical trials using this new approach or selecting the appropriate TCRs in a way that may lead to optimal results; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identifying and manufacturing appropriate TCRs from either the patient or third parties that can be administered to the patient; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developing and deploying consistent and reliable processes for engineering a patient&#8217;s and/or donor&#8217;s T-cells ex vivo and infusing the T cells back into the patient; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conditioning patients with chemotherapy in conjunction with delivery of the potential products, which may increase the risk of adverse side effects of the chemotherapy itself or of the potential products; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">educating medical personnel regarding the potential side effect profile of each of the potential products, such as the potential adverse side effects related to cytokine release; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">addressing any competing technological and market developments; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developing processes for the safe administration of these potential products, including long-term follow-up for all patients who receive the potential products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sourcing additional clinical and, if approved, commercial supplies for the materials used to manufacture and process the potential products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developing a manufacturing process with a cost of goods that allows for an attractive return on investment; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing sales and marketing capabilities after obtaining any regulatory approval to gain market acceptance; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developing therapies for types of cancers beyond those addressed by the current potential products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintaining and defending the intellectual property rights relating to any products we develop;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">not infringing the intellectual property rights, in particular, the patent rights, of third parties, including competitors, such as those developing T-cell therapies; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unless we revoke the notice to terminate the Patent License or subsequently acquire substantially similar rights, our inability to use the technology currently licensed to us pursuant to the Patent License. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should we resume our clinical programs, we cannot assure you that we will be able to successfully address these challenges, which could prevent us from achieving our research, development and commercialization goals. In addition, these challenges may diminish the value of our assets in the execution of any strategic alternative.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Should we resume development of our product candidates, we will need to recruit, hire and retain qualified personnel.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Following our strategic reprioritization in August 2023, we have reduced our workforce by approximately 95% to date. Our cash conservation activities may yield unintended consequences, such as attrition beyond our planned reduction in workforce and reduced employee morale, which may cause remaining employees and consultants to seek alternative opportunities. The reductions in force included employees responsible for key aspects of our clinical and other development programs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should we, in the future, resume development of our product candidates, we may not be able to attract or retain qualified management and commercial, scientific, manufacturing and clinical personnel due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. If we are not able to attract and retain necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The recent termination of our licenses and research and development agreement with the National Cancer Institute could significantly limit our ability to resume our clinical trial or begin new ones focused on TCR-T.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have terminated our TCR license with the National Cancer Institute. This will affect our ability to quickly resume TCR-T-based clinical trials as we will need to renegotiate this license or obtain approval from FDA to use TCRs that we validate internally. We may not obtain such approval or be able to validate TCRs internally quickly or at all, significantly hindering our ability to resume our clinical trial.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Any termination of our licenses with Precigen or MD Anderson or our research and development agreements with MD Anderson could result in the loss of significant rights and could significantly harm our ability to develop and commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our clinical programs, if resumed, depend on patents, know-how, and proprietary technology that are licensed from others, particularly MD Anderson and Precigen, as well as the contributions by MD Anderson under our research and development agreements. Any termination of these licenses or research and development agreements could result in the loss of significant rights and could harm our ability to develop or monetize our product candidates. Disputes may also arise between us and these licensors regarding intellectual property subject to a license agreement, including those relating to:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of rights granted under the applicable license agreement and other interpretation-related issues; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether and the extent to which our technology and processes, and the technology and processes of Precigen, MD Anderson and our other licensors, infringe intellectual property of the licensor that is not subject to the applicable license agreement;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our right to sublicense patent and other rights to third parties pursuant to our relationships with our licensors and partners; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether we are complying with our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our potential products under the MD Anderson License and the A&amp;R License Agreement; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether or not our partners are complying with all of their obligations to support our programs under licenses and research and development agreements; and </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the allocation of ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and by us. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements, particularly with MD Anderson and Precigen, on acceptable terms, we may be unable to successfully monetize the affected potential products. On October 27, 2023, we provided the NCI the requisite notice of our intent to terminate the Patent License, effective 60 days from such notice, which is now terminated. If we are unable to acquire the rights from the NCI that we currently have under the Patent License following its termination, on terms acceptable to us or at all, our clinical development programs will be negatively impacted. We are generally also subject to all of the same risks with respect to protection of intellectual property that we license as we are for intellectual property that we own. If we or our licensors fail to adequately protect this intellectual property, our ability to monetize potential products under our applicable licenses could suffer. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, and reexamination proceedings before the United States Patent and Trademark Office, or USPTO, or oppositions and other comparable proceedings in foreign jurisdictions. Recently, due to changes in U.S. law referred to as patent reform, new procedures including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review and post-grant review have been implemented, which adds uncertainty to the possibility of challenge to our or our licensors&#8217; patents in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be able to retain the rights licensed to us and Precigen by MD Anderson to technologies relating to TCR-T cell therapies and other related technologies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the MD Anderson License, we, together with Precigen, received an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel TCR-T cell therapies as well as either co-exclusive or non-exclusive licenses under certain related technologies. These proprietary methods and technologies, along with others within Precigen's technology suite and licensed to us by Precigen, may help realize the promise of genetically modified TCR-T cell therapies by controlling cell expansion and activation in the body, minimizing off-target and unwanted on-target effects and toxicity while maximizing therapeutic efficacy. The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term, we and Precigen shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After 10 years from the date of the MD Anderson License and subject to a 90-day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if we and Precigen are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third-party contract if we and Precigen are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by us or Precigen, if such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both us or Precigen and may be terminated by the mutual written agreement of us, Precigen and MD Anderson.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should we in the future resume development of our product candidates, there can be no assurance that we will be able to successfully perform under the MD Anderson License or regain our terminated rights under the Patent License and if the MD Anderson License is terminated, we may be prevented from achieving our business objectives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Should we resume development of our product candidates, we may not be able to commercialize them, generate significant revenues, or attain profitability.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, none of our product candidates have been approved for commercial sale in any country. The process to develop, obtain regulatory approval for, and commercialize potential product candidates is long, complex and costly. Should we resume clinical development, unless and until we receive approval from the FDA and/or other foreign regulatory authorities for our product candidates, we cannot sell our products and will not have product revenues. Even if we should in the future resume development of our product candidates and obtain regulatory approval for one or more of our product candidates, if we are unable to successfully commercialize our products, we may not be able to generate sufficient revenues to achieve or maintain profitability or to continue our business without raising significant additional capital, which may not be available. Our failure to achieve or maintain profitability could negatively impact the trading price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our operating history makes it difficult to evaluate our business and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not previously completed any pivotal clinical trials, submitted a BLA or demonstrated an ability to perform the functions necessary for the successful commercialization of any product candidates. If we resume development of our product candidates, successful commercialization of any product candidates will require us to perform a variety of functions, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Continuing to undertake preclinical development and clinical trials; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Participating in regulatory approval processes; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Formulating and manufacturing products; and </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Conducting sales and marketing activities. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations have been limited to organizing and staffing our company, acquiring, developing and securing our proprietary product candidates and undertaking preclinical and clinical trials of our product candidates. These operations provide a limited basis for you to assess our ability to commercialize our product candidates and the advisability of investing in our securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business subjects us to the risk of liability claims associated with the use of hazardous materials and chemicals.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our contract research and development activities have involved and may in the future involve the controlled use of hazardous materials and chemicals. Although we believe that our safety procedures for using, storing, handling and disposing of these materials complied with federal, state and local laws and regulations, we cannot completely eliminate the risk of accidental injury or contamination from these materials. In the event of such an accident, we could be held liable for any resulting damages, and any liability could have a materially adverse effect on our business, financial condition, results of operations, cash flows and prospects. In addition, the federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of hazardous or radioactive materials and waste products may require our contractors to incur substantial compliance costs that could materially adversely affect our business, financial condition, results of operations, cash flows and prospects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may incur substantial liabilities and may be required to limit commercialization of our products in response to product liability lawsuits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The testing and marketing of medical products entail an inherent risk of product liability, and we will face an even greater risk if we commercially sell any medicines that we may develop. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products, if approved. Even a successful defense would require significant financial and management resources. Regardless of the merit or eventual outcome, liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Decreased demand for our product candidates; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Injury to our reputation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Withdrawal of clinical trial participants; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Initiation of investigations by regulators;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Withdrawal of prior governmental approvals; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs of related litigation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Substantial monetary awards to patients; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Product recalls; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Loss of revenue; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The inability to commercialize our product candidates; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A decline in our share price. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we currently carry clinical trial insurance and product liability insurance which we believe to be reasonable, it may not be adequate to cover all liability that we may incur. An inability to renew our policies or to obtain sufficient insurance at an acceptable cost could prevent or inhibit the commercialization of pharmaceutical products that we develop, alone or with collaborators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations, and those of our clinical investigators, contractors and consultants, are based primarily in Houston, Texas. These operations could be subject to power shortages, telecommunications failures, water shortages, hurricanes, floods, earthquakes, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we maintain</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">customary insurance policies that we believe are appropriate. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We relied and, should we in the future resume development of our product candidates, will rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology or loss of data, including any cybersecurity incidents, could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability which could significantly harm our ability to operate our business effectively and adversely affect our business and reputation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the ordinary course of our business, we, our CROs and other third parties on which we rely collected and stored sensitive data, including legally protected patient health information, personally identifiable information about our employees, intellectual property, and proprietary business information. We manage and maintain our applications and data utilizing on-site systems. These applications and data encompass a wide variety of business-critical information including research and development information and business and financial information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy. Despite the implementation of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage from cyber-attacks, computer viruses, breaches, unauthorized access, interruptions due to employee error or malfeasance or other disruptions, or damage from natural disasters, terrorism, war and telecommunication and electrical failures. Any such event could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Although we have measures in place that are designed to detect and respond to such security incidents and breaches of privacy and security mandates, we cannot guarantee that those measures will be successful in preventing any such security incident. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, government enforcement actions and regulatory penalties. Such legal claims or proceedings, liability or government enforcement actions may make it more difficult to consummate opportunities presented to us during our search for a strategic alternative. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to resume research, development and commercialization activities, process and prepare Company financial information, manage various general and administrative aspects of our business and damage our reputation, in addition to possibly requiring substantial expenditures of resources to remedy, any of which could adversely affect our business. In addition, there can be no assurance that we will promptly detect any such disruption or security breach, if at all. If the technology supporting our hunTR discovery engine were to experience a cyber-incident resulting in the disclosure or theft of our proprietary screening software or library of TCRs, its value may decrease and our business, or ability to consummate a strategic transaction, may be materially and negatively impacted. While we are not aware of any such material system failure, accident or security breach to date, to the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our search for a strategic alternative negatively impacted.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RISKS RELATED TO THE CLINICAL TESTING, GOVERNMENT REGULATION AND MANUFACTURING OF OUR PRODUCT CANDIDATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Should we resume development of our product candidates, we may encounter difficulties enrolling patients in our clinical trials, and our clinical development activities could be delayed or otherwise materially and adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have experienced, and may in the future experience, difficulties in patient enrollment in our TCR-T Library Phase 1/2 Trial and any future clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to enroll a sufficient number of patients who remain in the clinical trial until its conclusion. The enrollment of patients depends on many factors, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our reputation as a result of halting our ongoing clinical development;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patient eligibility criteria defined in the clinical trial protocol;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The size of the patient population required for analysis of the clinical trial&#8217;s primary endpoints;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The proximity of patients to clinical trial sites;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The number of clinical trial sites;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The design of the clinical trial;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to recruit and retain clinical trial investigators with the appropriate competencies and experience;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to obtain and maintain patient consents;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Reporting of the preliminary results of any of our clinical trials;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patient insurance approvals of trial participation; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The risk that patients enrolled in clinical trials will drop out of the clinical trials before the manufacturing and infusion of our product candidates or clinical trial completion.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should we resume clinical development, our clinical trials would compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition could reduce the number and types of patients available to us because some of our potential patients may instead opt to enroll in a clinical trial being conducted by one of our competitors. In addition, patients may be unwilling to participate in our studies because of negative publicity from adverse events in the biotechnology industry or for other reasons. Since the number of qualified clinical investigators is limited, we would expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use if we resume development of our product candidates, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and hematopoietic stem cell transplantation, rather than enroll patients in any future clinical trial. Additionally, because our product candidates address patients with relapsed/refractory cancer, the patients are typically in the late stages of their disease and may experience disease progression independent from our product candidates, making them unevaluable for purposes of the clinical trial, which would require additional patient enrollment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delays in completing patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing and planned clinical trials, which could prevent completion or commencement of these clinical trials and adversely affect our ability to advance the development of our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates are subject to extensive regulation and compliance, which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates, should we resume development.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The clinical development, manufacturing, labeling, packaging, storage, record-keeping, advertising, promotion, import, export, marketing, distribution and adverse event reporting, including the submission of safety and other information, of our product candidates are subject to extensive regulation by the FDA in the United States and by comparable foreign regulatory authorities in foreign markets. The process of obtaining regulatory approval is expensive and often takes many years following the commencement of clinical trials. Approval policies or regulations may change, and the FDA has substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Regulatory approval is never guaranteed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective, or with respect to a biological product candidate, safe, pure and potent, for their intended uses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such authorities may disagree with the design or implementation of our or our collaborators&#8217; clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA or comparable foreign regulatory agencies for approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or by individuals using drugs or biologics similar to our therapeutic product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from that of the United States;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We, or any of our collaborators, may be unable to demonstrate that a product candidate is safe and effective, and that the therapeutic product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be unable to demonstrate to the satisfaction of such authorities that our companion diagnostics are suitable to identify appropriate patient populations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such authorities may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of a BLA, New Drug Application, premarket approval, or PMA, or other submission or to obtain regulatory approval in the United States or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such authorities may disagree regarding the formulation, labeling and/or the specifications of our product candidates;</span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such authorities may find deficiencies in the manufacturing processes, test procedures and specifications or facilities of our third-party manufacturers with which we or any of our current or future collaborators contract for clinical and commercial supplies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulations and approval policies of such authorities may significantly change in a manner rendering our or any of our potential future collaborators&#8217; clinical data insufficient for approval; or</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates should we resume clinical development, which would significantly harm our business, financial condition, results of operations, cash flows and prospects. In addition, even if we obtain regulatory approval of our product candidates, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request and may impose significant limitations in the form of narrow indications, warnings, or a Risk Evaluation and Mitigation Strategy, or REMS.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Events raising questions about the safety of certain marketed biopharmaceuticals may result in increased cautiousness by the FDA and comparable foreign regulatory authorities in reviewing new drugs or biologics based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our potential future collaborators from commercializing our product candidates.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have halted development of our product candidates very early in our development efforts. Our most advanced product candidates were only in an early-stage clinical trial, which is very expensive and time-consuming. We cannot be certain if or when we will be able to submit a BLA to the FDA and the delay, or any failure, in completing clinical trials for our product candidates could significantly harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our most advanced product candidates were in a Phase 1/2 trial when we ceased development activity and will require extensive clinical testing should we resume development. Human clinical trials are very expensive and difficult to design, initiate and implement, in part because they are subject to rigorous regulatory requirements. Failure can occur at any stage of a clinical trial, and we can encounter problems that cause us to delay the start of, abandon or repeat clinical trials. Some factors which may lead to a delay in the commencement or completion of our clinical trials, if resumed, include: requests for additional nonclinical data from regulators, unforeseen safety issues, dosing issues, lack of effectiveness during clinical trials, difficulty recruiting or monitoring patients, or difficulty manufacturing clinical products, among other factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As they enter later stages of development, product candidates generally will become subject to more stringent regulatory requirements, including the FDA&#8217;s requirements for chemistry, manufacturing and controls for product candidates entering Phase 3 clinical trials. There is no guarantee the FDA will allow us or any potential licensee to commence Phase 3 clinical trials for product candidates studied in earlier clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If the FDA does not allow our product candidates to enter later stage clinical trials or requires changes to the formulation or manufacture of our product candidates before commencing Phase 3 clinical trials, the ability to further develop, or seek approval for, such product candidates may be materially impacted. As such, if we resume clinical development of our product candidates, we cannot predict with any certainty if or when we might submit a BLA for regulatory approval of our product candidates or whether such a BLA will be accepted. Because we do not anticipate generating significant revenues unless and until we submit one or more BLAs and thereafter obtain requisite FDA approvals, the timing of our BLA submissions and FDA determinations regarding approval thereof will directly affect if and when we are able to generate significant revenues.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we have halted development of our product candidates. There is an additive degree of risk to any development program that is paused because the time to restart the program and the associated expense may be longer and more costly than previously anticipated. It may also not be possible to restart the program altogether.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences following any potential marketing approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As with many pharmaceutical and biological products, treatment with our product candidates, if resumed, may produce undesirable side effects or adverse reactions or events, including potential adverse side effects related to cytokine release. If our product candidates or similar products or product candidates under development by third parties demonstrate unacceptable adverse events, we may be required to halt or delay further clinical development of our product candidates, should we resume it. The FDA or foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. If a serious adverse event were to occur in a trial, the FDA may place a hold on the clinical trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The product-related side effects could affect patient recruitment or the ability of enrolled patients to resume and complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately or timely recognized or managed by the treating medical staff, particularly outside of the institutions that collaborate with us, as toxicities resulting from our novel technologies may not be normally encountered in the general patient population and by medical personnel. Should we resume product development or begin commercialization, we expect to have to train medical personnel using our product candidates to understand their side effect profiles. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in adverse effects to patients, including death. Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, including during any long-term follow-up observation period recommended or required for patients who receive treatment using our product candidates, a number of potentially significant negative consequences could result, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may withdraw approvals of such product; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require additional warnings on the product&#8217;s label; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to create a risk evaluation and mitigation strategy plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers and/or other elements to assure safe use; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we could be sued and held liable for harm caused to patients; and </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our reputation may suffer. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of the foregoing could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved. Furthermore, any of these occurrences may harm our business, financial condition and prospects significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our cellular therapy immuno-oncology product candidates relied on the availability of reagents, specialized equipment and other specialty materials and infrastructure, which may not be available to us on acceptable terms or at all if we resume our clinical trial. For some of these reagents, equipment and materials, we relied or may rely on sole source vendors or a limited number of vendors, which could significantly impair our ability to manufacture and supply our products, should we resume these activities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing our product candidates required many reagents, which are substances used in our manufacturing processes to bring about chemical or biological reactions, and other specialty materials and equipment, some of which are manufactured or supplied by small companies with limited resources and experience to support commercial biologics production. We have depended on a limited number of vendors for certain materials and equipment used in the manufacture of our product candidates, including DNA plasmids, which we used as the vector to insert our TCRs into human T cells. Should we resume product manufacturing, some or all of these suppliers may not have the capacity to support commercial products manufactured under current good manufacturing practices by biopharmaceutical firms or may otherwise be ill-equipped to support our needs, should we resume manufacturing. We also do not have supply contracts with some of these suppliers and may not be able to obtain supply contracts with them on acceptable terms or at all. Accordingly, we may experience significant delays in receiving key materials and equipment to support clinical or commercial manufacturing, should we resume those activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For some of these reagents, equipment, infrastructure, and materials, we may rely on sole source vendors or a limited number of vendors. An inability to source product from any of these suppliers, or source product on commercially reasonable terms, which could be due to, among other things, regulatory actions or requirements affecting the supplier, adverse financial or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demands, supply chain issues or quality issues, could materially and adversely affect our ability to satisfy demand for our product candidates, which could adversely and materially affect our ability to conduct clinical trials, should we resume them, which could significantly harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, some of the reagents and products used by us may be stored at a single vendor. The loss of materials located at a single vendor, or the failure of such a vendor to manufacture clinical product in accordance with our specifications, would impact our ability to conduct clinical trials and continue the development of our products, should we resume it. Further, manufacturing replacement material may be expensive and require a significant amount of time, which may further impact our clinical programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we resume developing and scaling our manufacturing process, we expect that we will need to obtain additional rights to and supplies of certain materials and equipment to be used as part of that process. We may not be able to maintain rights to such materials on commercially reasonable terms, or at all, and if we are unable to alter our process in a commercially viable manner to avoid the use of such materials or find a suitable substitute, it would have a material adverse effect on our business. Even if we are able to alter our process so as to use other materials or equipment, such a change may lead to a delay in clinical development and/or commercialization plans. If such a change occurs for a product candidate that is already in clinical trials, the change may require us to perform both ex vivo comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have limited experience producing and supplying our product candidates. We may be unable to consistently manufacture our product candidates to the necessary specifications or in quantities necessary to treat patients in clinical trials, should we resume the activities.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have limited experience in biopharmaceutical manufacturing. In 2021, we began manufacturing our product candidates at our in-house current good manufacturing practices, or cGMP, manufacturing facility at our leased headquarters in Houston, Texas. In connection with our exploration of strategic alternatives, we have halted manufacturing of our product candidates and eliminated positions relating to the same. Accordingly, should we elect to in the future, our ability to resume manufacturing our product candidates will depend on our hiring and retaining personnel with the appropriate background and training to staff and operate the facility on a daily basis. Should we be unable to hire or retain these individuals, we may need to train additional personnel to fill the needed roles or engage with external contractors. There are a small number of individuals with experience in cell therapy and the competition for these individuals is high.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Specifically, the operation of a cell-therapy manufacturing facility is a complex endeavor requiring knowledgeable individuals who have successful previous experience in cleanroom environments. Cell therapy facilities, like other biological agent manufacturing facilities, require appropriate commissioning and validation activities to demonstrate that they operate as designed. Additionally, each manufacturing process must be proven through the performance of process validation runs to guarantee that the facility, personnel, equipment, and process work as designed. Although we have developed our own manufacturing processes using an in-house team, there is timing risk associated with increased in-house product manufacture, including as a result of implementing the Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The manufacture of our product candidates is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial production and ensuring the absence of contamination. These include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. It is possible that stability or other issues relating to the manufacture of our product candidates could occur in the future. Before we halted clinical development, we had amended our clinical trial IND to use cryopreservation-based storage of clinical products. This process is new and should we resume clinical development and in-house manufacturing, we may experience manufacturing failures or difficulties producing sufficient quantities of our clinical products as a result of this change.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates have been manufactured on a patient-by-patient basis. Delays in manufacturing could adversely impact the treatment of each patient and may discourage participation in clinical trials should clinical development be resumed. We have not manufactured our clinical trial product candidates on a large scale and may not be able to achieve large scale clinical trial or commercial manufacturing and processing on our own to satisfy expected clinical trial or commercial demands for any of our product candidates, should development resume in the future. The manufacturing processes employed by us may not result in product candidates that will be safe and effective. If we are unable to manufacture sufficient number of TCR-T cells for our product candidates, development efforts would be delayed, which would adversely affect our business and prospects.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing operations are subject to review and oversight by the FDA. If we resume manufacturing operations, we will be subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration and corresponding state agencies to ensure strict compliance with cGMP and other government regulations. Our license to manufacture product candidates is subject to continued regulatory review.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not yet have sufficient information to reliably estimate the cost of commercial manufacturing and processing of our product candidates. The actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also may fail to manage the logistics of collecting and shipping patient material to our manufacturing site and shipping the product candidate back to the patient. Logistical and shipment delays and problems, whether or not caused by us or our vendors, could prevent or delay the delivery of product candidates to patients, should we resume the trial.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may have difficulty validating our manufacturing process as we manufacture our product candidates from an increasingly diverse patient population for our clinical trials, should we resume these activities.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During our development of the manufacturing process, our TCR-T cell product candidates have demonstrated consistency from lot to lot and from donor to donor. However, our sample size is small and the starting material used during our preclinical development work came from healthy donors. If our development work is continued, we may encounter unforeseen difficulties due to starting with material from donors who are not healthy, including challenges inherent in harvesting white blood cells from unhealthy patients.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we believe our manufacturing process is scalable for clinical development and commercialization, if any of our product candidates are approved or commercialized, we may encounter challenges in validating our process due to the heterogeneity of the product starting material. We cannot guarantee that any other issues relating to the heterogeneity of the starting material will not impact our ability to commercially manufacture our product candidates.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The gene transfer vectors from our </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> system used to manufacture our product candidates may incorrectly modify the genetic material of a patient&#8217;s T cells, potentially triggering the development of a new cancer or other adverse events.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our TCR-T cells were manufactured using our </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> system, a non-viral vector to insert genetic information encoding the TCR construct into the patient&#8217;s T cells. The TCR construct was then primarily integrated at thymine-adenine, or TA, dinucleotide sites throughout the patient&#8217;s genome and, once expressed as protein, is transported to the surface of the patient&#8217;s T cells. Because the gene transfer vector modifies the genetic information of the T cell, there is a theoretical risk that modification will occur in the wrong place in the T cell&#8217;s genetic code, leading to vector-related insertional oncogenesis, and causing the T cell to become cancerous. If the cancerous T cell is then administered to the patient, the cancerous T cell could trigger the development of a new cancer in the patient. We used non-viral vectors to insert genetic information into T cells, which we believe have a lower risk of insertional oncogenesis as opposed to viral vectors. However, the risk of insertional oncogenesis remains a concern for gene therapy, and we cannot assure you that it will not occur in any clinical trials of our product candidates. There is also the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of the vectors used to carry the genetic material. Although our product candidates use non-viral vectors, the FDA has stated that lentiviral vectors possess characteristics that may pose high risks of delayed adverse events. If any such adverse events occur from our non-viral vector, preclinical studies or clinical trials could be halted or delayed, which would have a material adverse effect on our business and operations.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Should we resume development of our product candidates, any product candidate for which we obtain marketing approval could be subject to post-marketing restrictions or withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include, among other things, submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including the requirement to implement a REMS, which could include requirements for a restricted distribution system. If any of our product candidates receives marketing approval, the accompanying label may limit the approved uses, which could limit sales of the product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of our approved products. The FDA closely regulates the post-approval marketing and promotion of products to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. However, companies may share truthful and not misleading information that is otherwise consistent with the labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we market our products outside of their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug and Cosmetic Act relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, later discovery of previously unknown adverse events or other problems with our product candidates, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Litigation involving patients taking our product; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restrictions on such products, manufacturers or manufacturing processes; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restrictions on the labeling or marketing of a product; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restrictions on product distribution or use; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Requirements to conduct post-marketing studies or clinical trials; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warning letters; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Withdrawal of the products from the market; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refusal to approve pending applications or supplements to approved applications that we submit; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recall of products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fines, restitution or disgorgement of profits or revenues; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Suspension or withdrawal of marketing approvals; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Damage to relationships with existing and potential collaborators; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unfavorable press coverage and damage to our reputation; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refusal to permit the import or export of our products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Product seizure; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Noncompliance with requirements regarding safety monitoring or pharmacovigilance can also result in significant financial penalties. Similarly, failure to comply with U.S. and foreign regulatory requirements regarding the development of products for pediatric populations and the protection of personal health information can also lead to significant penalties and sanctions.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RISKS RELATED TO OUR ABILITY TO COMMERCIALIZE OUR PRODUCT CANDIDATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Should we resume development of our product candidates, our inability to obtain the necessary U.S. or worldwide regulatory approvals to commercialize any product candidate would cause our business to suffer significantly.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we resume clinical development, we may not be able to obtain the approvals necessary to commercialize our product candidates, or any product candidate that we may acquire or develop in the future for commercial sale. We will need FDA approval to commercialize our product candidates in the United States and approvals from regulatory authorities in foreign jurisdictions equivalent to the FDA to commercialize our product candidates in those jurisdictions. In order to obtain FDA approval of any product candidate, we must submit to the FDA a BLA demonstrating that the product candidate is safe for humans and effective for its intended use. This demonstration requires significant research and animal tests, which are referred to as preclinical studies, as well as human tests, which are referred to as clinical trials. Satisfaction of the FDA&#8217;s regulatory requirements typically takes many years, depending upon the type, complexity and novelty of the product candidate, and will require substantial resources for research, development and testing. We cannot predict whether our research, development, and clinical approaches will result in products that the FDA will consider safe for humans and effective for their intended uses. The FDA has substantial discretion in the approval process and may require us to conduct additional preclinical studies and clinical trials or to perform post-marketing studies. The approval process may also be delayed by changes in government regulation, future legislation or administrative action or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining regulatory approvals may:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delay commercialization of, and our ability to derive product revenues from, our product candidates; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Impose costly procedures on us; and </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Diminish any competitive advantages that we may otherwise enjoy. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we comply with all FDA requests, the FDA may ultimately reject one or more of our BLAs. We cannot be sure that we will ever obtain regulatory approval for any of our product candidates even if we should resume development in the future. Failure to obtain FDA approval for our product candidates will severely undermine our business by leaving us without a marketable product, and therefore without any potential revenue source, until another product candidate can be developed. There is no guarantee that we will ever be able to develop or acquire another product candidate or that we will obtain FDA approval if we are able to do so.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In foreign jurisdictions, we similarly must receive approval from applicable regulatory authorities before we can commercialize any of our product candidates. Foreign regulatory approval processes generally include all of the risks associated with the FDA approval procedures described above.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable either to create sales, marketing and distribution capabilities or enter into agreements with third parties to perform these functions, we will be unable to commercialize our product candidates successfully.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently have no marketing, sales, or distribution capabilities. If, and when we become reasonably certain that we will be able to commercialize our product candidates, we anticipate allocating resources to the marketing, sales and distribution of our proposed products in North America and in certain other geographies; however, we cannot assure that we will be able to market, sell, and distribute our products successfully. Our future success also may depend, in part, on our ability to enter into and maintain collaborative relationships for such capabilities and to encourage the collaborator&#8217;s strategic interest in the product candidates under development, and such collaborator&#8217;s ability to successfully market and sell any such products. Although we intend to pursue certain collaborative arrangements regarding the sale and marketing of certain of our product candidates, there are no assurances that we will be able to establish or maintain collaborative arrangements or, if we are able to do so, whether we would be able to conduct our own sales efforts. There can also be no assurance that we will be able to establish or maintain relationships with third-party collaborators or develop in-house sales and distribution capabilities. To the extent that we depend on third parties for marketing and distribution, any revenues we receive will depend upon the efforts of such third parties, and there can be no assurance that such efforts will be successful. In addition, there can also be no assurance that we will be able to market and sell our product candidates in the United States or overseas.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are not able to partner with a third party and are not successful in recruiting sales and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty commercializing our product candidates, which would harm our business. If we rely on pharmaceutical or biotechnology companies with established distribution systems to market our products, we will need to establish and maintain partnership arrangements, and we may not be able to enter into these arrangements on acceptable terms or at all. To the extent that we enter into co-promotion or other arrangements, any revenues we receive will depend upon the efforts of third parties that may not be successful and that will be only partially in our control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If physicians and patients do not accept and use our product candidates, once approved, our ability to generate revenue from sales of our products will be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if the FDA and/or foreign equivalents thereof approve our product candidates, physicians and patients may not accept and use them. The use of engineered T cells as potential cancer treatments is a relatively recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers, third-party payors and others in the medical community. Acceptance and use of our products will depend upon a number of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The clinical indications for which our product candidates are approved;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Perceptions by members of the healthcare community, including physicians, about the safety and effectiveness of our products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The prevalence and severity of any side effects;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pharmacological benefit and cost-effectiveness of our products relative to competing products; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Availability of coverage and adequate reimbursement for our products from government or other third-party payors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effectiveness of marketing and distribution efforts by us and our licensees and distributors, if any; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The price at which we sell our products. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to generate product revenues will be diminished if our products do not obtain coverage and adequate reimbursement from payors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to commercialize our product candidates, if approved, alone or with collaborators, will depend in part on the extent to which coverage and reimbursement will be available from third-party payors, including government and health administration authorities, private health maintenance organizations and health insurers and other payors. Patients who are prescribed medicine for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Sufficient coverage and adequate reimbursement from third-party payors are critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. It is difficult to predict the coverage and reimbursement decisions that will be made by third-party payors for novel gene and cell therapy products such as ours. Even if we obtain coverage for our product candidates, the resulting reimbursement payment rates might not be adequate or may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the market for our product candidates for which we may receive regulatory approval will depend significantly on access to third-party payors&#8217; drug formularies or lists of medications for which third-party payors provide coverage and reimbursement, which might not include all of the FDA-approved drugs for a particular indication. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payors may refuse to include a particular branded drug in their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In addition, in the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that would require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that approval will be obtained. If we are unable to obtain coverage of and adequate payment levels for our product candidates, if approved, from third-party payors, physicians may limit how much or under what circumstances they will prescribe or administer our products and patients may decline to purchase them.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This in turn could affect our ability to successfully commercialize our products and materially and adversely impact our business, financial condition, results of operations, cash flows and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in many foreign countries, particularly the countries of the European Union, or EU, the pricing of prescription drugs is subject to government control. In some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. We may face competition for our product candidates from lower-priced products in foreign countries that have placed price controls on pharmaceutical products. In addition, there may be importation of foreign products that compete with our own products, which could negatively impact our profitability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cancer therapies are sometimes characterized as first line, second line or third line, and the FDA often approves new therapies initially only for third line use. When cancer is detected early enough, first line therapy is sometimes adequate to cure the cancer or prolong life without a cure. Whenever first line therapy, usually chemotherapy, hormone therapy, surgery, or a combination of these, proves unsuccessful, second line therapy may be administered. Second line therapies often consist of more chemotherapy, radiation, antibody drugs, tumor targeted small molecules, or a combination of these. Third line therapies can include bone marrow transplantation, antibody and small molecule targeted therapies, more invasive forms of surgery and new technologies. We expect to initially seek approval of our product candidates as a third line therapy for patients who have failed other approved treatments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subsequently, for those product candidates that prove to be sufficiently beneficial, if any, we would expect to seek approval as a second line therapy and potentially as a first line therapy, but there is no guarantee that our product candidates, even if approved, would be approved for second line or first line therapy. In addition, we may have to conduct additional clinical trials prior to gaining approval for second line or first line therapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our projections of both the number of people who have the cancers we targeted, as well as the subset of people with these cancers in a position to receive therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Our market opportunities may also be limited by competitor treatments that may enter the market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Healthcare legislative reform measures may have a material adverse effect on our business, financial condition, results of operations, cash flows and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory enactments in recent years that change the healthcare system in ways that could impact our future ability to sell our product candidates profitably.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, there have been and continue to be a number of initiatives at the federal and state level that seek to reduce healthcare costs. Most significantly, in March 2010, President Obama signed into law the ACA, which included measures that have significantly changed the way healthcare is financed by both governmental and private insurers. The ACA, among other things, imposed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the rebate program to individuals enrolled in Medicaid managed care organizations, added a provision to increase the Medicaid rebate for line extensions or reformulated drugs, established annual fees on manufacturers and importers of certain branded prescription drugs and biologic agents, promoted a new Medicare Part D coverage gap discount program, expanded the entities eligible for discounts under the Public Health Service Act pharmaceutical pricing program and imposed a number of substantial new compliance provisions related to pharmaceutical companies&#8217; interactions with healthcare practitioners. The ACA also expanded eligibility for Medicaid programs and introduced a new Patient Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research and a new Center for Medicare &amp; Medicaid Innovation at CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been executive, legal and political challenges to certain aspects of the ACA. For example, President Trump signed several executive orders and other directives designed to delay, circumvent or loosen certain requirements mandated by the ACA. Concurrently, Congress considered legislation to repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have been signed into law. In December 2017, Congress repealed the tax penalty, effective January 1, 2019, for an individual&#8217;s failure to maintain ACA-mandated health</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">insurance as part of the Tax Act. Further, President Biden issued an executive order that instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. Further, there have been a number of health reform initiatives by the Biden administration that have impacted the ACA. For example, on August 16, 2022, President Biden signed the IRA into law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the "donut hole" under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and implementing a newly established manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact ACA and our business. The ultimate content, timing or effect of any healthcare reform measures on the U.S. healthcare industry is unclear.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. As a result, there have been several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s proposals.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA also released a final rule, effective November 30, 2020, implementing a portion of the importation executive order providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 30, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The IRA delayed the implementation of the rule to January 1, 2032. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January 1, 2032. In addition, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate price cap, currently set at 100% of a drug's average manufacturer price for single source and innovator multiple source products, beginning on January 1, 2024. Further, in July 2021, the Biden Administration released an executive order that included multiple provisions aimed at prescription drugs. In response to President Biden's executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug price reform. The plan sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions by HHS. No legislative or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of the budget reconciliation process. Additionally, the IRA, among other things, (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions began to take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be effectuated but is likely to have a significant impact on the pharmaceutical industry. Individual states in the United States also have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we may receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or, if we receive regulatory approval, commercialize our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, we could face substantial penalties and our business, financial condition, results of operations, cash flows and prospects could be materially and adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a pharmaceutical company, even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to our business. For example, we could be subject to healthcare fraud and abuse and patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include, among others:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The federal Anti-Kickback Statute, which regulates our business activities, including our clinical research and relationships with healthcare providers or other entities as well as our future marketing practices, educational programs and pricing policies, and by prohibiting, among other things, soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual or the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Federal civil and criminal false claims laws, including the False Claims Act, which permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payors that are false or fraudulent; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HIPAA, which created new federal civil and criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">HITECH, and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on entities and individuals subject to the law including certain healthcare providers, health plans, and healthcare clearinghouses, known as covered entities, as well as individuals and entities that perform services for them which involve the use, or disclosure of, individually identifiable health information, known as business associates and their subcontractors that use, disclose or otherwise process individually identifiable health information; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Requirements under the Physician Payments Sunshine Act to report annually to CMS certain financial arrangements with prescribers and teaching hospitals, as defined in the ACA and its implementing regulations, including reporting any &#8220;transfer of value&#8221; made or distributed to teaching hospitals, and physicians, as defined by such law and reporting any ownership and investment interests held by physicians and their immediate family members during the preceding calendar year; and </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">State and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government that otherwise restricts certain payments that may be made to healthcare providers and entities; state laws that require drug manufacturers to report information related to payments and other transfer of value to physicians and other healthcare providers and entities; state laws that require the reporting of information related to drug pricing; state and local laws that require the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities, including any consulting agreements with physicians who may receive stock or stock options as compensation for their services, could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has further strengthened these laws. For example, the ACA, among other things, amended the intent requirement of the federal Anti-Kickback Statute and certain criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that any of our product candidates is ultimately sold in a foreign country, we may be subject to similar foreign laws and regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Efforts to ensure that our business arrangements comply with applicable healthcare laws involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, exclusion from participation in United States federal or state health care programs, such as Medicare and Medicaid, disgorgement, imprisonment, integrity oversight and reporting obligations, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to operate our business and our financial results. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security and fraud laws may prove costly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our immuno-oncology product candidates may face competition in the future from biosimilars and/or new technologies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, provides an abbreviated pathway for the approval of follow-on biological products. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the original branded product was approved under a BLA. However, there is a risk that the U.S. Congress could amend the BPCIA to significantly shorten this exclusivity period, potentially creating the opportunity for generic competition sooner than anticipated. Further, this data exclusivity does not prevent another company from developing a product that is highly similar to the original branded product, generating its own data and seeking approval. Data exclusivity only assures that another company cannot rely upon the data within the innovator&#8217;s application to support the biosimilar product&#8217;s approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RISKS RELATED TO OUR INTELLECTUAL PROPERTY</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we or our licensors fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of our intellectual property rights would diminish and our ability to successfully develop our product candidates may be materially impaired.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success, competitive position and future revenues will depend in part on our ability and the abilities of our licensors to obtain and maintain patent protection for our products, methods, processes and other technologies, to preserve confidential information, including trade secrets, to prevent third parties from infringing our proprietary rights, and to operate without infringing the proprietary rights of third parties. Our ability to consummate certain strategic transactions, including strategic partnerships or out-licensing opportunities, among others, may also be impaired if we are unable to adequately protect our intellectual property or if we infringe on the proprietary rights of others.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, we have exclusive rights in the field of cancer treatment to certain U.S. and foreign intellectual property with respect to certain cell therapy and related technologies from MD Anderson as well as with respect to the Precigen technology, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. Under the MD Anderson License, future patent applications require the agreement of each of MD Anderson, Precigen and us, and MD Anderson has the right to control the preparation, filing, and prosecution of such patent applications unless the parties agree that we or Precigen instead may control such activities. Although under the License Agreement MD Anderson has agreed to review and incorporate any reasonable comments that we or Precigen may have regarding licensed patents and patent applications, we cannot guarantee that our comments will be solicited or implemented. Under the Patent License with the NCI for certain TCRs, the NCI is responsible for the preparation, filing, prosecution, and maintenance of patent applications and patents licensed to us. Although under the Patent License, the NCI is required to consult with us in the preparation, filing, prosecution, and maintenance of all its patent applications and patents licensed to us, we cannot guarantee that our comments will be solicited or implemented. On October 27, 2023, we provided the NCI the requisite notice of our intent to terminate the Patent License, effective 60 days from such notice. We no longer have any rights to the technology licensed pursuant to the Patent License upon the effectiveness of the termination notice. Under our A&amp;R License Agreement Precigen has the right, but not the obligation, to prepare, file, prosecute, and maintain the patents and patent applications licensed to us and shall bear all related costs incurred by it in regard to those actions. Precigen is required to consult with us and keep us reasonably informed of the status of the patents and patent applications licensed to us, and to confer with us prior to submitting any related filings and correspondence. Although under the A&amp;R License Agreement Precigen has agreed to consider in good faith and consult with us regarding any comments we may have regarding these patents and patent applications, we cannot guarantee that our comments will be solicited or followed. Without direct control of the in-licensed patents and patent applications, we are dependent on MD Anderson or Precigen, as applicable, to keep us advised of prosecution, particularly in foreign jurisdictions where prosecution information may not be publicly available. We anticipate that we and Precigen will file additional patent applications both in the United States and in other jurisdictions. However, we cannot predict or guarantee for either our in-licensed patent portfolios or for Alaunos&#8217; patent portfolio:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When, if at all, any patents will be granted on such applications;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The scope of protection that any patents, if obtained, will afford us against competitors; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">That third parties will not find ways to invalidate and/or circumvent our patents, if obtained; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">That others will not obtain patents claiming subject matter related to or relevant to our product candidates; or </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">That we will not need to initiate litigation and/or administrative proceedings that may be costly whether we win or lose. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost, in a timely manner or at all. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. We may also require the cooperation of our licensors in order to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of other jurisdictions may not protect our rights to the same extent as the laws of the United States. For example, methods of therapeutic treatment, which are patent-eligible in the United States, may not be claimed in many other jurisdictions; some patent offices (such as the European Patent Office) may permit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the redrafting of method of treatment claims into a "medical use" format that is patent-eligible, while other patent offices (such as the Indian Patent Office) may not accept any redrafted claiming format for such claims.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in patent laws or in interpretations of patent laws in the United States and other jurisdictions may diminish the value of our intellectual property or narrow the scope of our patent protection. In September 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law, resulting in a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. In addition, the United States Supreme Court has ruled on several patent cases in recent years, narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the value of patents, once obtained, and with regard to our ability to obtain patents in the future. As the USPTO continues to implement the Leahy-Smith Act, and as the federal courts have the opportunity to interpret the Leahy-Smith Act, the laws and regulations governing patents, and the rules regarding patent procurement could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain technologies utilized in our research and development programs are already in the public domain. Moreover, a number of our competitors have developed technologies, or filed patent applications or obtained patents on technologies, compositions and methods of use that are relevant to our business and may cover or conflict with our owned or licensed patent applications, technologies or product candidates. Such conflicts could limit the scope of the patents, if any, that we may be able to obtain. Because patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, or in some cases at all, and because publications of discoveries in the scientific literature lag behind actual discoveries per se, neither we nor our licensors can be certain that others have not filed patent applications for technology used by us or covered by our pending patent applications. We cannot know with certainty whether we were the first to make and file for the inventions claimed in our owned patent portfolio, or whether our licensors were the first to make and file for the inventions claimed in our in-licensed patent portfolio. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in the issuance of patents that protect our technology or products, in whole or in part, or that effectively prevent others from commercializing competitive technologies and products. In addition, our own earlier filed patents and applications or those of MD Anderson or Precigen, to the extent not then terminated, may limit the scope of later patents we obtain, if any. If third parties file or have filed patent applications or obtained patents on technologies, compositions and methods of use that are relevant to our business and that cover or conflict with our owned or licensed patent applications, technologies or product candidates, we may be required to challenge such protection, terminate or modify our programs impacted by such protection, or obtain licenses from such third parties, which might not be available on acceptable terms, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if our owned and licensed patent applications were to be issued as patents, they may not issue in a form that would provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity due to our patents being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or even after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our confidential information, our business and competitive position would be significantly harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success also depends upon the skills, knowledge and experience of our scientific and technical personnel, our consultants and advisors, as well as our licensors and contractors. To help protect our proprietary know-how and our inventions for which patents may be unobtainable or difficult to obtain, and to maintain our competitive position, we rely on trade secret protection and confidentiality agreements. To this end, it is our general policy to require our employees, consultants, advisors and contractors to enter into agreements that prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business. These agreements may not provide adequate protection for our trade secrets, know-how, confidential information or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such information. Moreover, we may not be able to obtain adequate remedies for any breaches of these agreements. Our trade secrets or other confidential information may also be obtained by third parties by other means, such as breaches of our physical or computer security systems. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret or other confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets or other confidential information were to be lawfully obtained or independently developed by competitors, we would have no right to prevent</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets, know-how or other proprietary information is disclosed, the value of our trade secrets, know-how and other proprietary rights would be significantly impaired and our business and competitive position would suffer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third-party claims of intellectual property infringement would require us to spend significant time and money and could prevent us from developing or commercializing our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to protect or enforce patent rights, we may initiate patent infringement litigation against third parties. Similarly, we may be sued by others for patent infringement. We also may become subject to pre- and post-grant proceedings conducted in the USPTO, including interferences, derivations, post-grant review, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, or reexamination. In other jurisdictions, our patent estate may be subject to pre- and post-grant opposition, nullity, revocation proceedings and the like. Asserting and defending against intellectual property actions are costly and divert technical and management personnel away from their normal responsibilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Should we resume development in the future, our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our product candidates without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. While no such litigation has been brought against us and we have not been held by any court to have infringed a third party&#8217;s intellectual property rights, we cannot guarantee that our products or use of our products do not infringe or will not be asserted to infringe third-party patents. It is also possible that we have failed to identify relevant third-party patents or applications, or that as-yet unpublished third-party patent applications will later result in the grant of patents relevant to our business. Another possibility is for a third-party patent or patent application to first contain claims not relevant to our business but then to be reissued or amended in such a way that it does become relevant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our research, development and commercialization activities, as well as any product candidates or products resulting from these activities, may infringe or be asserted to infringe patents or patent applications under which we do not hold licenses or other rights. Owning a patent does not confer on the patentee the right to practice the claimed invention and does not protect the patentee from being sued for infringement of another owner&#8217;s patent. Our patent position cannot and does not provide any assurance that we are not infringing or will not be asserted to infringe the patent rights of another.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patent landscape in the field of immuno-oncology is particularly complex. We are aware of numerous United States and foreign patents and pending patent applications of third parties directed to compositions, methods of use and methods of manufacture of immuno-oncology products. In addition, there may be patents and patent applications in the field of which we are not aware. The technology we currently license from MD Anderson and Precigen is early-stage technology, and we were in the process of designing and developing products using this technology. Although we sought and, should we resume development activities, will seek to avoid pursuing the development of products that may infringe any third-party patent claims that we believe to be valid and enforceable, we may fail to do so. Moreover, given the breadth and number of claims in patents and pending patent applications in the field of immuno-oncology and the complexities and uncertainties associated with them, third parties may allege that we are infringing patent claims even if we do not believe such claims have merit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a claim for patent infringement is asserted, there can be no assurance that the resolution of the claim would permit us to continue marketing the relevant product on commercially reasonable terms, if at all. We may not have sufficient resources to bring these actions to a successful conclusion. If we do not successfully defend any infringement actions to which we become a party or if we are unable to have any asserted third-party patents declared invalid or unenforceable, we may have to pay substantial monetary damages, which can be tripled if the infringement is deemed willful, and/or we may be required to discontinue or significantly delay commercialization and development of the affected products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any legal action against us or our collaborators claiming damages and seeking to enjoin developmental or marketing activities relating to affected products could, in addition to subjecting us to potential liability for damages, require us or our collaborators to obtain licenses to continue to develop, manufacture or market the affected products. Such licenses may not be available to us on commercially reasonable terms, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An adverse determination in a proceeding involving our owned or licensed intellectual property may allow entry in the market of substitutes, including biosimilar or generic substitutes, for our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Annuities and other similar fees must be paid to the respective patent authority to maintain patents (or patents and patent applications) in most jurisdictions worldwide. Further, patent authorities in jurisdictions worldwide require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to submit documents with the necessary formal requirements, such as notarization and legalization. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We license rights to products and technology that are important to our business, and we expect to enter into additional licenses in the future. For instance, we have in-licensed patents and patent applications under the MD Anderson License and the License Agreement. Under these agreements, we are subject to a range of obligations pertaining to commercialization and development, sublicensing, royalty, patent prosecution and maintenance, and insurance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any failure by us to obtain a needed license, comply with any of these obligations or any other breach by us of our license agreements could give the licensor the right to terminate the license in whole, terminate the exclusive nature of the license or bring a claim against us for damages. Any such termination or claim could have a material adverse effect on our business, financial condition, results of operations, cash flows and prospects. Even if we contest any such termination or claim and are ultimately successful, such dispute could lead to delays in the development or commercialization of potential products and result in time-consuming and expensive litigation or arbitration. On termination we may be required to license to the licensor any related intellectual property that we developed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in certain cases, the rights licensed to us are rights of a third party licensed to our licensor. In such instances, if our licensors do not comply with their obligations under such licenses, our rights under our license agreements with our licensor may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the licensing or acquisition of third-party intellectual property rights is a highly competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations, cash flows and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property or claiming ownership of what we regard as our own intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many of our employees were previously employed at universities or at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OTHER RISKS RELATED TO OUR COMPANY</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our stock price has been, and may continue to be, volatile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market price for our common stock is volatile and may fluctuate significantly in response to a number of factors, most of which we cannot control, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our decision to pursue a strategic reprioritization;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Price and volume fluctuations in the overall stock market; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in operating results and performance and stock market valuations of other biopharmaceutical companies generally, or those that develop and commercialize cancer drugs in particular; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Market conditions or trends in our industry or the economy as a whole; </span></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical studies or clinical trial results, should we resume clinical development; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The commencement, enrollment or results of clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Public statements by third parties like trial participants and clinical investigators regarding clinical trials;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Public concern as to the safety of drugs developed by us or others; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The financial or operational projections we may provide to the public, any changes in these projections or our failure to meet these projections; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comments by securities analysts or changes in financial estimates or ratings by any securities analysts who follow our common stock, our failure to meet these estimates or failure of those analysts to initiate or maintain coverage of our common stock;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The public&#8217;s response to press releases or other public announcements by us or third parties, including our filings with the SEC, as well as announcements of the status of development of our products, announcements of technological innovations or new therapeutic products by us or our competitors, announcements regarding collaborative agreements and other announcements relating to product development, litigation and intellectual property impacting us or our business;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government regulation;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FDA determinations on the approval of a product candidate BLA submission; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The sustainability of an active trading market for our common stock; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future sales of our common stock by us, our executive officers, directors and significant stockholders; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Announcements of mergers or acquisition transactions; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our inclusion or removal from certain stock indices; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our delisting from Nasdaq;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Developments in patent or other proprietary rights; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in reimbursement policies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Announcements of medical innovations or new products by our competitors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Announcements of changes in our senior management or directors; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General economic, industry, political and market conditions, including, but not limited to, the ongoing impact of global economic conditions; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other events or factors, including those resulting from war, incidents of terrorism, natural disasters, pandemics or responses to these events; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in accounting principles.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the stock market in general and our stock in particular from time to time experiences significant price and volume fluctuations unrelated to the operating performance of particular companies, which has resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. Public debt and equity markets, and in particular the Nasdaq Capital Market, have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many biopharmaceutical companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock prices of many biopharmaceutical companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. In the past, stockholders have instituted securities class action litigation following periods of market volatility. If we were involved in securities litigation, we could incur substantial costs and our resources, and the attention of management could be diverted from our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Public statements made by third parties such as trial participants and clinical investigators about clinical trials without our consent may adversely impact our stock price. We may not be aware of these third-party statements when made, may not be able to respond to these third-party statements and may not be able to defend our business or the public&#8217;s legitimate interests due to restrictions on what we may say about our product candidates, which may cause the price of our stock to fluctuate. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions or incur other harm to our business.</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provisions of our amended and restated certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us, even if doing so would benefit our stockholders. These provisions authorize the issuance of &#8220;blank check&#8221; preferred stock that could be issued by our Board of Directors to increase the number of outstanding shares and hinder a takeover attempt, and limit who may call a special meeting of stockholders. In addition, Section 203 of the Delaware General Corporation Law, or Section 203, generally prohibits a publicly held Delaware corporation from engaging in a business combination with a party that owns at least 15% of its common stock unless the business combination is approved by our Board of Directors before the person acquires the 15% ownership stake or later by its Board of Directors and two-thirds of its stockholders. Section 203 could have the effect of delaying, deferring or preventing a change in control that our stockholders might consider to be in their best interests.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have begun exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. If we are approached by a third-party in connection with such process, and our Board of Directors does not believe that a transaction with such party is in the best interest of our stockholders, we may rely on the provisions described above to prevent an acquisition by such party in order to maximize stockholder value. There is no guarantee that we will be able to find a transaction that delivers superior value to our stockholders.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the exclusive forum for (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders; (iii) any action asserting a claim against us or any of our directors, officers or other employees arising pursuant to any provision of the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws; (iv) any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the amended and restated certificate of incorporation or our bylaws; (v) any claim or cause of action as to which the Delaware General Corporation Law confers jurisdiction on the Court of Chancery of the State of Delaware; or (vi) any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because we do not expect to pay dividends, you will not realize any income from an investment in our common stock unless and until you sell your shares at a profit.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never paid dividends on our common stock, and we do not anticipate that we will pay any dividends for the foreseeable future. Accordingly, any return on an investment in us will be realized, if at all, only when you sell shares of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to use net operating loss carryforwards and research tax credits to reduce future tax payments may be limited or restricted.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have generated significant net operating loss carryforwards, or NOLs, and research and development tax credits, or R&amp;D credits, as a result of our incurrence of losses and our conduct of research activities since inception. We generally are able to carry NOLs and R&amp;D credits forward to reduce our tax liability in future years. However, our ability to utilize the NOLs and R&amp;D credits is subject to the rules of Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, respectively. Those sections generally restrict the use of NOLs and R&amp;D credits after an &#8220;ownership change.&#8221; An ownership change occurs if, among other things, the stockholders (or specified groups of stockholders) who own or have owned, directly or indirectly, 5% or more of a corporation&#8217;s common stock or are otherwise treated as 5% stockholders under Section 382 of the Code and the U.S. Treasury Department regulations promulgated thereunder increase their aggregate percentage ownership of that corporation&#8217;s stock by more than 50 percentage points over the lowest percentage of the stock owned by these stockholders over the applicable testing period. In the event of an ownership change, Section 382 of the Code imposes an annual limitation on the amount of taxable income a corporation may offset with NOL carry forwards and Section 383 of the Code imposes an annual limitation on the amount of tax a corporation may offset with business credit (including R&amp;D credits) carryforwards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may have experienced an &#8220;ownership change&#8221; within the meaning of Section 382 of the Code in the past and there can be no assurance that we will not experience additional ownership changes in the future. As a result, our NOLs and business credits (including R&amp;D credits) may be subject to limitations, and we may be required to pay taxes earlier and in larger amounts than would be the case if our NOLs or R&amp;D credits were freely usable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If securities and/or industry analysts fail to continue publishing research about our business, if they change their recommendations adversely or if our business, financial condition, results of operations, cash flows or prospects do not meet their expectations, our stock price and trading volume could significantly decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of these analysts cease coverage of our Company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. In addition, it is likely that in some future period our operating results will be below the expectations of securities analysts or investors. If one or more of the analysts who cover us downgrade our stock, or if our business, financial condition, results of operations, cash flows or prospects do not meet their expectations, our stock price could significantly decline. If our common stock is delisted by Nasdaq, the impact of analysts ceasing to cover our securities may negatively impact the price of our common stock more dramatically.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business could be materially and negatively affected as a result of the actions of activist stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2021, we were engaged in a consent solicitation led by WaterMill Asset Management Corp., or WaterMill, where three new directors were added to our Board of Directors. We could experience other stockholder activism in the future, including another consent solicitation or a proxy contest. Activist stockholders may advocate for certain governance and strategic changes at our company. In the event of stockholder activism, particularly with respect to matters which our Board of Directors, in exercising their fiduciary duties, disagree with or have determined not to pursue, our business could be adversely affected because responding to actions by activist stockholders can be costly and time-consuming, disrupting our operations and diverting the attention of management, and perceived uncertainties as to our future direction may result in the loss of potential business opportunities and may make it more difficult to attract and retain qualified personnel, business partners, and customers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, if faced with a consent solicitation or proxy contest, we may not be able to respond successfully to the contest or dispute, which would be disruptive to our business. If individuals are elected to our Board of Directors with a differing agenda, our ability to effectively and timely implement our strategic plan and create additional value for our stockholders may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our Board of Directors elects to pursue a strategic alternative requiring a stockholder vote, activists may pursue a campaign against the transaction and as a result may make consummating the transaction more difficult, or impossible, despite the Board of Directors' conclusions that such transaction is in the best interest of our stockholders.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The exercise of outstanding warrants, and issuance of equity awards may have a dilutive effect on our stock, and materially and negatively impact the price of our common stock.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had warrants for 1,452,394 shares of our common stock outstanding at a weighted average exercise price of $86.33 per share. We are able to grant stock options, restricted stock, restricted stock units, stock appreciation rights, bonus stocks, and performance awards under our 2020 Equity Incentive Plan. As of December 31, 2023, under the 2020 Equity Incentive Plan and the 2012 Equity Incentive Plan, 465,895 shares were issuable upon the exercise of outstanding options at a weighted average exercise price of $25.31 per share.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our principal stockholders, executive officers and directors have substantial control over the Company, which may prevent you and other stockholders from influencing significant corporate decisions and may significantly harm the market price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our executive officers, directors and holders of five percent or more of our outstanding common stock beneficially owned, in the aggregate, 14.0% of our outstanding common stock. These stockholders may have interests that conflict with our other stockholders and, if acting together, have the ability to influence the outcome of matters submitted to our stockholders for approval, including the election and removal of directors and any merger, consolidation or sale of all or substantially all of our assets. Accordingly, this concentration of ownership may harm the market price of our common stock by:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delaying, deferring or preventing a change in control; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Impeding a merger, consolidation, takeover or other business combination involving us; or </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us. </span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, this significant concentration of stock ownership may adversely affect the trading price of our common stock should investors perceive disadvantages in owning shares of common stock in a company that has such concentrated ownership.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are considered a &#8220;smaller reporting company&#8221; under Rule 12b-2 of the Exchange Act. We are therefore entitled to rely on certain reduced disclosure requirements, such as an exemption from providing selected financial data and executive compensation information. These exemptions and reduced disclosures in our SEC filings due to our status as a smaller reporting company also mean our auditors are not required to review our internal control over financial reporting and may make it harder for investors to analyze our business, financial condition, results of operations, cash flows and prospects. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our common stock prices may be more volatile. We will remain a smaller reporting company until our public float exceeds $250 million as of the last business day of our most recently completed second quarter if our annual revenues are $100 million or more as of our most recently completed fiscal year, or until our public float exceeds $700 million as of the last business day of our most recently completed second quarter if our annual revenues are less than $100 million as of our most recently completed fiscal year.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_unregistered_sale_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2. Unregistered Sale of Equity Securities and Use of Proceeds</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_default_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 3. Defaults upon Senior Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 4. Mine Safety Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_other_information_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5. Other Information</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities Trading Plans of Directors and Executive Officers</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended March 31, 2024, none of our directors or Section 16 officers </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_92a1b3bb-ed14-465e-a889-5489b84a881c" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_a11ec5a3-4cdc-42a2-95e5-786c139d6e73" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_df9917c6-29db-4b0a-9da5-d8122f069d10" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_c1c5f3bb-b115-4459-81a0-7a960debfe53" contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> any "Rule 10b5-1 trading arrangement" or any "non-Rule 10b5-1 trading arrangement" </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(as such terms are defined in Item 408(a) of Regulation S-K).</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_exhibit_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 6. Exhibits</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:13%;"/>
    <td style="width:87%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p><p style="border-top:1pt solid #000000;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="padding-left:0.08in;vertical-align:bottom;padding-right:0.08in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p><p style="border-top:1pt solid #000000;padding-top:1pt;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:5pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001107421/000119380524000111/e619211_8k-at.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Second Amended and Restated Certificate of Incorporation of Alaunos Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, SEC File No. 001-33038, filed February 1, 2024).</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1107421/000119312520250711/d42031dex31.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Bylaws of the Registrant, dated as of September 21, 2020 (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, SEC File No. 001-33038, filed September 22, 2020).</span></a></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1&#134;</span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tcrt-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated as of January 21, 2024, by and between the Registrant and Dale Curtis Hogue</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.2&#134;</span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001107421/000095017024038868/tcrt-20231231.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Consulting Agreement, dated as of February 22, 2024, by and between the Registrant and Ferdinand Groenewald (incorporated by reference to Exhibit 10.62 to the Registrant&#8217;s Annual Report on Form 10-K, SEC File No. 001-33038, filed April 1, 2024).</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1+</span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tcrt-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Exchange Act Rule 13a-14(a) or 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1++</span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tcrt-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS+</span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH+</span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.CAL+</span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.DEF+</span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.LAB+</span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.PRE+</span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:middle;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104+</span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File&#8212;the cover page interactive data is embedded within the Inline XBRL document or included within the Exhibit 101 attachments</span></p></td>
   </tr>
   <tr style="height:6pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">+</span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Filed herewith.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">++</span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#134;</span></p></td>
    <td style="text-indent:7.2pt;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="margin-left:7.2pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Indicates management contract or compensatory plan.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signatures_"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ALAUNOS THERAPEUTICS, INC.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:53.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:12pt;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Dale Curtis Hogue, Jr.</span></p></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dale Curtis Hogue, Jr.</span></p></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:12pt;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Interim Chief Executive Officer</span></p></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:12pt;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(On Behalf of the Registrant and as Principal Executive Officer and Principal Financial Officer)</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dated: May 15, 2024</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:53.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:18pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:18pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:middle;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Ferdinand Groenewald</span></p></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:12pt;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ferdinand Groenewald</span></p></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:12pt;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vice President, Finance</span></p></td>
   </tr>
   <tr style="height:10.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:12pt;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">(Principal Accounting Officer)</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dated: May 15, 2024</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tcrt-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.1</font></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>tcrt-ex10_1.pdf
<DESCRIPTION>PDF COURTESY COPY
<TEXT>
<PDF>
begin 644 tcrt-ex10_1.pdf
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M:7[&UB:'D2M6?[= 4_:-PJQ -/S\3_:7:/K>K1\T_[AZ^#;Q&L654%2R_C1
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M@ %_R1U!.EC>8>[02,NA@31M :I8Q=T.LO(XQ"< !@'. /!H)?<$V@2P ^
M (\T$#L!0@!UM(;;Q^V#>>Z%^S40AP!6 NP X &S3T/]"AIS3W++P7MP<K=Q
M=R,]I-NYG['T,4@MD/X<ZAV0/@)EFNX9*3\(*6U_8*3^?B@;(+UO)+T7ZJV0
M[H(R3>\9*:_EUK#[5H^DO=RJ?H=3K'! NPL@#,!![F[(W0VHNYNZ4A!C[A:N
MG3VI#]("2*]-IH"NC?UN+]NCC0-&<T$OH'0CH'XC8&XC8&XCXJ%IPVB?#<D^
M>=P&Z+,!^FR /AL *V%N%3QO%?4[(18!7  <X'T5X)W61R$^#G""U=\*\4Z
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MVRP.C5[T9P0<&MM<;-%#9-<ZYV)KNGGNZ+;1(S;@7&H_JMTQ!>EO5SMC\K]
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MLH54PQZ OGP?W[K4;=:9_$!A%0O/W;,D61CC6H\?CK==*'$K+NH&M!=!B-Q
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M<MA< EJ>9C^0-+H2G4%70D0]@+D$S,\/^E-+8)@3R>2?AS)*B*0M01?>!K!
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MB.13Y_$R!-TW!Z5(DL-[I![Q+G)Q%_L%)26YHC=L?!:#X]+L=P I?VE'ICK
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M$57+:'?Y0'FJS)0UT.=E&5BI7*L7F8F-:",\FPUS.>[\XS'533K_3OQ6&\U
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M?M^A#[XS\94'O_FA/WZ@O_'Y>YZ?^_>#W[OPL1&*OOC'N0'F*4R+::I.;UA
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M\S_JS_T^"SX 02:+6JK*%FD5VSX]9G51!X8+T1!3+)& X$A1_//JHEBHM5Q
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MO#LS;]Y\O5WYXF\G7WOK-)UY+K=PLE@.WG1NC$^^(N;'AO*YW!LGBVLQ/1=
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *P?%7B'^PH(?*C26XE;A&/ 4=3Q^%;Q(4$DX Y)KR#Q+JO]KZS-<J
MQ,*_)%G^Z._XG)JHJ[$W8Z?2?'4UUJ<%O=VL,44K;"ZL?E)Z=>V:[BO#71HV
M*.I1AU!&"*]:\+:J-6T6*5F!GC_=RC_:'?\ $<TY*VPHLV****@H**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBCI0 457>_LXSA[J$'T+BD74+)SA;N$_\#%3S+N7R2[%FBD!# $$$
M'N*6J("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI_*NB^&__()NO^N__LHJVE:Y-]3L****@H**** "H+VY6RLI[IU++"A<A>I
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MYPG@7518:N;65]L%UA>>S_P_U'Y5Z=7AI#Q2$<I(C?BI%>O^'=3&K:-!=?\
M+3&R0?[0X/\ C^-5-=11?0TZ***@H**** /'?$G_ ",6H_\ 7=J]6T;_ ) M
MC_U[Q_\ H(KRGQ)_R,6H_P#7=J]6T;_D"V/_ %[Q_P#H(JY;(B.Y<HHHJ"PH
MHHH **** "BBB@!LLB0Q/+(P5$!9B>P'6O'=<U-]6U6:\<_*3MC'H@Z5VGQ
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M^@6W_?X?X4?\*[3_ *"C?]^1_C1_PKM/^@HW_?D?XTO=#W@_X6(G_0+;_O\
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M6K%6*X*VZG(S_M'O]*[<  8' HHJ&[E)6"BBBD,**** "BBB@ HHHH ****
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MBB@ HHHH **** "BBB@!"JGD@'\*Q_%JJ/"]_A1_J_3W%;-8_B[_ )%?4/\
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MUU^I?\@RZ_ZXO_(UYIX6\1C0H;A/L;7'G%3D-C&!]#ZU2U1+W/4FBC92K(K
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M^1;U#_KBU9/P[_Y%^3_KX;^2U7074ZJBBBI&<7\0=4DCCATFW8AIQNE [KG
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MFHHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF(>XCZW77#;E 'N<YR/[W!]AYO9]KLD)KH/L$[8>'\IL[#A*)=FB#[*-4(#
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MM=9M171&ZTY'])76/0_1EQR]2/X-NO$1V$;^I];]$*HGGT(V5TO^! [Z-.*
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M8P"?>FV?XF7\]'.V8RAZM ))M]GV7LYQV[O=&;9?Y:"$.]7VRYQ\VRN.;;9
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M?J([K3]NR#*^?O;^R:-3,-4[=<_4_<'YF(MZS+PXO.;F037FW&6XRUVP">L
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MD4<?FBP?NKMH:I?7I?B>G5J>E1"5D=S-KEN5H,:E94WUWS6<'AO:7WJ2OR?
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M5LIYVDS!9PV7U*3J<Q=7]&'['$/#8[@,Q^@5D(P+= S+Z!@Z.88.<E'6@#:
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MB>U_#%Z!7;8KL>&/*CHLYCU?Q4-X8SI/+EI!KR-J.!,$V2%^30J:YM'Z9JZ
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M  (1 Q$ /P#TZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *P?%7B'^PH(?*C26XE;A&/ 4=3Q^%;Q(4$DX
MY)KR#Q+JO]KZS-<JQ,*_)%G^Z._XG)JHJ[$W8Z?2?'4UUJ<%O=VL,44K;"ZL
M?E)Z=>V:[BO#71HV*.I1AU!&"*]:\+:J-6T6*5F!GC_=RC_:'?\ $<TY*VPH
MLV****@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBCI0 457>_LXSA[J$'T+BD74+)SA;N$_\#%3S
M+N7R2[%FBD!# $$$'N*6J("BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#G?&^J'3]$:&-B)[H^6I!Y _B/Y<?
MC7">%]+_ +6UJ&!ES G[R7_=';\3@4[Q7JG]JZY-(C9AB_=18/! ZG\379>
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M7M[, [&;+GT4<G_#\:]D151 B@*JC  Z 5R'P]TK[/82:E(")+CY4S_<'?\
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M<[X\_P"1HF_ZYI_*NB^&_P#R";K_ *[_ /LHK1_"0MSL****S+"BBB@ K/\
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M(HUCC0(BC"JHP *=6'I?BK2M0MT=[J.WFQ\\4K;<'V)ZUJQWMI+_ *NZA?\
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M"N^\ Z4]EI3W<RE9+HA@#V0=/SR3^5:/2)"U9U-%%%9EA1110 4444 %%%%
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MT338])TJ&S3DJ,NW]YCU-3I864;ATLX%93D,L8!'Z58IN5P2L%%%%2,****
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MAQ^50VMI<7DGEVL$DS^D:YKU:#PMH<#!DT^-F']\EOYFM6*&*!=D,21KZ(H
MHY^P<IQ?A[P1Y4B76K%6*X*VZG(S_M'O]*[<  8' HHJ&[E)6"BBBD,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&NX>60.=V.XII7$V>E?VE8?\_P!;?]_5_P :/[2L/^?ZV_[^K_C7._\ "O\
M2?\ GM=?]]+_ (4?\*_TG_GM=?\ ?2_X4] U.LZT4BC:H4= ,4M2,1B%4LQ
M Y)/:JW]I:?_ ,_UM_W]7_&EU+_D&77_ %Q?^1KSGP?X=L]<@N6N7E0PE0OE
MD#J#ZBJ2$V>C#4; G O;<G_KJO\ C5A6#*&4@@]"*Y)_A]I94A+BY5NQ)4_T
MK'M)K[PAXBBL)[@RV4I'';:3C<!V(-%D]@OW/1J***D84452UF_33-*N+MR
M8T.WW;L/SH F6\M7F\E;F%I<XV!P3GZ5/7D$=M=6-G9>(,EF>Y)_$'.<^YW5
MZU:SI=6L5Q&<I*@=?H1FJ:L).Y+1114C"JQU&P!(-[;@C@CS5_QJS7EGA[1K
M;6]>O;>Y9U5-[@QD YWX]/>FE<39Z4-1L"<"]MR?^NJ_XU85E90RD$'H17)2
M?#[2RA"7-RK=B2I_3%8]I+?^#_$$5C-.9;*8CC^$J3C<!V(/6G9/8+]ST:BB
MBI&-DD2*,R2.J(O5F. *K_VE8?\ /];?]_5_QJAXO_Y%:_\ ^N8_F*Y3POX4
ML-8TC[7<23+)YC+A" ,#\*I+2XFSNO[2L/\ G^MO^_J_XTZ.^LY9 D=W [GH
MJR DUS?_  K_ $G_ )[77_?2_P"%6=-\&Z;INH0WD,MP9(CE0S#'3'I[TM U
M.CHHHI#&3310)OFE2-,XW.P _6EC=)4#QNKHW(93D&N:^(7_ "+1_P"NR?UK
M1\*_\BSI_P#UQ%.VEQ7U-:HIKJWMR!/<11%N@=PN?SJ6O/\ XD@&_L./X&_F
M*$KL&['H%%-3_5K]!3J0QDTT4";YI4C3.-SL /UJ#^TK#_G^MO\ OZO^-1:S
MI4&LV/V2Y9UCW!\H0#D5A?\ "O\ 2?\ GM=?]]+_ (4U86IT7]I6'_/];?\
M?U?\:/[2L/\ G^MO^_J_XUYOI6@6E[XJN]+D>00PE]K*1N.T@#/%=-_PK_2?
M^>UU_P!]+_A3:2%=G5HRN@=&#*PR"#D$4M0V=LEG9PVL9)2) BD]< 8J:I*&
MNZ1H7=@JJ,EF. *2&>&=-\,J2+G&48$9_"L[Q-_R+>H?]<6K)^'7'AZ3_KX;
M^2T[:7%?4ZJBBBD,*AN;NVM%W7-Q%"/5W"_SK*\5:X-$TX-& ;F;*Q C('J3
M]*YG1O"ESK874]8N9=LOS*N<NP[')Z#VJDNK$V=C#KFDSOLBU*V9O3S!6@""
M 0<@]Q7*7/@+2I(66"2>*3LQ;</Q%9?ARYU70_$/]B7*R3P$[<*"P3/1QZ+Z
MT63V"_<[^BBBI&%5[J_L[,9NKJ&'_?<"LKQ?K+Z/I&Z XN)FV1G'W?4_@*P=
M$\&C4+==0UBXE>2<!PBM\V#T+,?Y4TNK%<ZVWUG2[EML&H6[MZ"09J]7(WO@
M'39(&%I++#-_"7;<OXBJ_@V^U:WU6?1;U)98X<@L>?*(Z<^A[4[+H%^YVU%%
M%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_%W_(KZ
MA_US_J*V*Q_%W_(KZA_US_J*:W$RGX!_Y%F/_KJ_\ZZ2N;\ _P#(LQ_]=7_G
M724/<%L%%%%(9POQ*ZZ;]9/_ &6ML>,=! '^FG_OVW^%8GQ*^]IOUD_]EKH!
MX3T$@?\ $MC_ .^F_P :O2RN3K<C_P"$QT'_ )_3_P!^V_PKEI[ZVU+XA6=U
M:2>9$SQ@-@CD#GK76_\ ")Z#_P! V/\ [Z;_ !KD[FRMM/\ B)9VUI$(H@\9
M"@D\D>]"MT!W/1J***@H#TKS'P;JMEI.IWDM[+Y:.NU3M)R=WM7IQZ5YGX*T
MVRU/5+V.]@69$3<H)(P=WM51V9+W.N_X3'0?^?T_]^V_PK1TS5K+5HY'LIO-
M6,[6.TC!_&J7_")Z#_T#8_\ OIO\:OZ=I=EIB.EE;K"KG+ $G)_&D[#U+=%%
M%(96U+_D&77_ %Q?^1KBOAU>6MK;7PN+F*$LR8\QPN>#ZUVNI?\ (,NO^N+_
M ,C7G/@_P[9Z[!<M=22J82H7RR!U!]1[52V)>YZ"^LZ7&A9M1M0!U_>K_C7"
M:S<KXG\66L6G@O$FU-^,# .6;Z5)XF\'1:9IWVRP>218S^]$A!('J,"NA\#C
M3)-'$UE;K%<#Y)SG+%A[^AZT]%J@WT.DHHHJ"@KB/B#>//+9Z/ 07D8.P]SP
MH_4UVS,%4LQ  &23VKRE];+^*I-8-K]J"N?*3)  '"GH>W-5%$R.[U31$D\)
M-I<0&Z&(%,#JR\_J?YUG?#S4?M&E26+D^9;-D _W#T_(YJA_PG]W_P! <?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
M      $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q
M!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V
M-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*
MDI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:
MXN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#TZBBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<'!P1[BI:H:)I5OHFDP:;:O(\,.[:TI!8Y8L<X [FK] !1110 4444 %%%%
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MGQ73T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5YA\1;TW&O+:@_);1@8_VFY/Z;?RKT^O(KL?VAXZ=#R)+[9^ ?'\A73AE[
MS?8Y\0_=2[GIGA^P&FZ':6N,,L8+_P"\>3^IK1HHKG;N[LW2LK!1112&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %>1:-F3QO 6;)-V23CKR37KM>1Z'_P CO!_U]-_,UTT-I>ASUMXGKE%%
M%<QT!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5Y'H?_ ".\'_7TW\S7KE>1Z'_R.\'_ %]-_,UTT-I>
MASUMXGKE%%%<QT!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYH O45DV?B?0[V3R[?4[=W]-U:P((R.10 4444 %%%% !1110 4444 %%%%
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M_(GR?]=4_G5#X/\ _(#O?^NX_E0!1^*'B6=;E=#LI"@P&F93R<]%J+1/A?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *\CT/_D=X/^OIOYFO7*\CT/\
MY'>#_KZ;^9KIH;2]#GK;Q/7****YCH"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#AO'_ (,FUV1-0T\J+I%VLAXWCM^-<I!=>/\
M3(191Q7>Q!A<Q[L#V->R44 >06/@OQ%XBU%;O6W>*,_>>0_-CT KUFSM8;&S
MBM;=-D42A5'M4U% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5YUI7AG6;?Q5%>RV>VW6<N7\Q#QD\XSFO1
M:*N%1PNEU(E!2LWT"BBBH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KSCXB_\AZ#_KV7_P!":O1Z\X^(O_(>@_Z]E_\ 0FKIPO\
M$,:WPG*4445ZAQA7H_PZ_P"0#/\ ]?+?^@K7G%>C_#K_ ) ,_P#U\M_Z"M<V
M*_AFU'XCJZ***\L[#R;Q?_R-%]_O#_T$5UWPZ_Y ,_\ U\M_Z"M<CXO_ .1H
MOO\ >'_H(KKOAU_R 9_^OEO_ $%:]&M_ 7R.6G_$9U=%%%><=04444 %%%%
M!1110 4$@#)X%%<K\2-1FT[PG.8&*23,(MPZ@'K^E #=7^(6A:9,T D>ZE7@
MB$9 /UZ5GVWQ3T:63;-:W,"_WB W\JD\ ^%=*CT"VU">WCN;FX7<6<;@HST
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MU34;;2M/EOKMBL$0RQ49/Y4FFZI8ZK!YUC<QSIWVGI]:Q_B'_P B7J'^ZO\
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M %V/\J@^)&AS:??1>)M,RCHP\[;V;LW]#6=XWUV'Q!X7TB\CP)1*5E3^ZV*
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M>&M.\.+.NG^;B<J7\Q]W3./YUIVD306<,+L&=(U4D=R!BI: "D/W32TA^Z:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ J&[M;>]MV@N8EEB;JK"IJ*-@. UOP--$6FTIO-3KY+GYA
M]#W_ ,]:YJWT?4KFZ-M%93&4'# J5V_4GI7LE%=4<5-*SU,71BWH<AH7@F"U
M*SZFRW$HY$0^X/KZ_P OK77* JA5  '  [4M%83J2F[R-(Q4=$%%%%04%%%%
M !1110 4444 %%%% !1110 44UY$C&9'5!ZL<4Q+FWD.(YXW/HK@T 2T444
M%<WJG@;P_JDS32VABD8Y9H6VYKI** .:TSP+X>TV998[0RR*<@S-NQ72]***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M##;2R@9**6Q]*\F@U;Q#X*U^"SU6X>YM)",[CN#+G&5)YR*[CQO#KEQI4?\
M84WEL&)E.X#*;3ZT 9?PZ\0:AX@N]3GOI 0NSRXU&%0'/2NYKPKP7;>);AKG
M_A'Y_*"E?.^=5SUQU_&O<H X@C$AS(%&[ZXYH ?1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4C?=/THHH ^=?$'_ "'+O_KH:7P]_P A>'ZT44 >_P"E_P#(.A_W:Y+X
MM?\ (K1_]?"_R-%% "7W_)(A_P!>BU+\*?\ D43_ -?#_P A110!H?$'_D2]
M0_W1_,5B?"#_ ) 5Y_UW_I110!SWB7_DK,'_ %WA_I7L%%% 'E<'_);)/]\_
M^BA6Y\6O^16C_P"OA?Y&BB@"_9?\DS7_ *\#_P"@FN9^#?75/^V?]:** .V\
M8?\ (HZK_P!>S_RKG?A%_P BS<?]?)_]!%%% &-H7_)8;O\ WY/_ $&O5***
M /'-,_Y*ZW_7V_\ 6O8Z** "O%OBM_R-_P#V[I_,T44 <71110!ZQ\'_ /D'
MWW^^O]:D^,/_ " ['_KY_P#93110!UWAK_D6]-_Z]T_E6%\4O^1-F_ZZ)_Z$
M*** +7@__DG]G_UP;^9K&^&'^NU;ZQ_^S444 =Y-_J7_ -TUYG\(_P#D(:O_
M ,!_F:** *\__):?^VJ_^BQ7JYZ&BB@#(T#[MQ_UT;^=>?:__P E>M/^ND5%
M% 'K%>4?%;_D9=,_ZY_^S444 =E\0?\ D2;_ /W5_F*R?A%_R+5Q_P!?)_\
M01110!?^)W_(DW7^_'_Z&*E^''_(DV/_  /_ -"-%% '3T444 %>9_&3_4Z9
M_O/_ $HHH [SP_\ \B[IG_7K%_Z *T*** ///B?_ ,?-C]#_ #%>A)]Q?I11
M0!YK\8/OZ1_O/_[+77>(?^1%O_\ KQ;_ - HHH Y/X.?\>NI?[R?UKN];_Y
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M45%145%145%145%145%145%145%145%145%145%145%145%145%1_\  $0@
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MBU_R*T?_ %\+_(U@O_R6MO\ KJO_ *+%;WQ:_P"16C_Z^%_D: +]E_R3-?\
MKP/_ *":Q/@]"BZ5?S@?.\JJ3[ ?_7K;LO\ DF:_]>!_]!-9/P@_Y 5Y_P!=
M_P"E '4>+O\ D4M6_P"O63_T$US'PB<_\([=KC[LY/\ XZ/\*Z?Q;_R*6K?]
M>LG_ *":Y?X0?\@&\_Z[_P!* ,WX?+]M\>ZQ>S89T\PKGJ"7Q_+BO4:\FM[@
M>#/B5=-=@K:7>[Y\?PL<Y_!A7I,^N:7;V9NY+^ 0@9W!P<T >=201P?&91&
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M%OMW]GA%)Q_O'?C\,5Z!93Z!;6:2VDEE' %R&0J.* /(_%^N:MKC64VH:?\
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M4*D:A5 [ 5P'Q:TR6:PL]4B4M]E8J^.RG'/Y@?G70^&/%6GZUI<4AN8X[E5
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M\*?QSQ0!9O? ^B^&]!OK^XE>YF2%A&9, ;B.,#UJY\)(&C\-3RL"!)<';GN
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M @8C!.*MT4 ,EBCGB:*5%>-QAE89!%</J7PNTBZF,EK<36@)R4 ##\,UW=%
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MCTS_ (XKL:K:C8V^I6,MG=('AE7:PH P/AU]@'A*U%F4+X/G8^]OSSFNH(#
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M[UC7_B#PEJ-H]K=ZE92Q.-I5F'Z5R7PSNTL_$VI:1;SB:S;<\3 Y!P>#^1H
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MNZY;:A/>A;>':&A8<;0<G!]Z ,&3XH7KMNM="9X>S,Q_H*W?#'CZRUV]%C+
MUK=-]U6.0Q]![UM2:OH6FP^4][:01J,;0P Q]*\OUV^TJX^(.G7>BLA7S(]Y
M1<*7W=: /5M<U6/1=)GU":-I$A )5.IYQ7+W7Q)TZ/3;>>WM99KF<$K;C&5
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M"#Z#^5=AJ5M9W&G317D<;6^P[@X& /Z5;/2O,/$GAWQK?I<L]YY]LSLRVZR
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MTE0I(BNAX(89!KS'1/B5I^FZ-:6,EA<N\$80LI7!Q^-6I_BM;O$PL]*G:;'
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MOFJ=B#)QFKO@BTN+'PC86UU"T,R*P9'&"/G8T ;M%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KS?QC_R4[P__ +\7_H=>D5%):VTL
MR326\3RI]UV0%E^AH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR+20\/C>%3C>+PJ?
M3[Q!KUVO(M8/]F>-IY2"/+NQ-^!(;^M=.'UYD<]?2S/7:* 00"#D&BN8Z HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *\X^)-@8M2M[]1\DR;&_WE_\ K$?E7H]9/B?2AK&B36RC,R_O
M(O\ >'^/(_&M:4^2:9G5CS1:&>$M1&I>'K:0MF2-?*D^J\?J,'\:V:\M\#ZS
M_96K-:7)V07)"-NXV..A_H?_ *U>I45H<DA4I\T0HHHK(U"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MSKQ]X>,$[:O:I^ZD/[]0/NM_>^A_G]:T_!7BE;R)-,OI,7*#;$['_6#T^O\
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M 'U0!9NOB+JVIW;6WAK1VF"_QR(SL1ZX7A?Q)J*;Q;XYTD"XU/1D:V'+DPD
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MZEF3>5+$$9.  !US@UV->8W(75/C(#(5^SZ>H=F8\*$3.?P=A0 __A8NO?\
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M%Q'_ +LG^(-5S47NK$\M5;,J?\+$T[_GRNO_ !W_ !H_X6)IO_/G=?\ CO\
MC5C_ (0#1?[]U_W\'^%'_" :+_?NO^_@_P *+T/,/WQ7_P"%B:;_ ,^=U_X[
M_C1_PL33?^?.Z_\ '?\ &K'_  @&B_W[K_OX/\*/^$ T7^_=?]_!_A1>AYA^
M^*__  L33?\ GSNO_'?\:/\ A8FF_P#/G=?^._XU8_X0#1?[]U_W\'^%'_"
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M[X_O<8QUXKJ?A;#)%X,B9\XDF=TSZ9Q_,&N:^$I0Z_JOVK'VXH,;OO?>._\
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M3'GC:,=6/3VSZU'XR\974E]_PCWAL-+>NWER2QC)4]U7WZY/;]1I^#/!$&A
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MO67_ %]#_P! :NH\(_\ (I:3_P!>L?\ Z"*Y?XP?\B]9?]?0_P#0&KJ/"/\
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M^QP?2O8+:XBNK:*X@</%*H=&'0@C(-<A\59+=?![),1YKS((0>N[.3^F:T?
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M^#^G2%M0U:53AL0(YZMSN;_V6@#TVBBB@ HHHH **** "BBB@ HHHH ****
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ME%X9LG,CB:^G \V1?N@#HJ^WOWKIJ* ,SQ#HMMK^D2Z?<DJ&^9' R48="/\
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MU^ZB]=H)Y//4_2NLHH R/$^@V_B/1WL9V,;9WQ2@9*..A]QV(]#7 6.G^/\
MPL'LK");JTW$IC:Z<]P"0P^G2O5J* /+[7P=XD\2ZI%>^*IS';Q_\LMPW$>@
M"\*#W/6O3HHHX84BB0)&BA551@ #@ 4ZB@#S;P3H.K:?XXOKV[L9(;:190LC
M8P<N"/TKTFBB@ K,\2V\UWX;U*WMXS)-+;NB(.I)' K3HH XGX8:1J&D:9>Q
M:A:O;N\P90^.1MKMJ** "H;RU@OK.6TN8Q)#,I1U/<&IJ* /)Y/#WBKP5J4E
MSH.^]LG/W57>6'8.@YR/4?IG%67\?>*I(_)A\.%;D\9\F1O_ !W_ .O7I]%
M'E^@^#=7US6!K/BHL$!#>3)C=)CH"!PJ^WZ5ZA110!X\ND>+=)\57VJ:9I;L
MSS2[&90059B<XS6L=8^)./\ D%*/^V2_XUZ710!Y8?"?C#Q1=1MXAN_L]LC9
MVEE./]U%XS[G]:])TS3[;2M/AL;./RX(EPH_F3[D\U:HH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH __V0IE;F1S=')E86T*96YD;V)J"C,V(# @
M;V)J"CP\"B]":71S4&5R0V]M<&]N96YT(#@*+T-O;&]R4W!A8V4@+T1E=FEC
M95)'0@HO1FEL=&5R("]$0U1$96-O9&4*+TAE:6=H=" S,#,*+TQE;F=T:" R
M-3<X-@HO4W5B='EP92 O26UA9V4*+U1Y<&4@+UA/8FIE8W0*+U=I9'1H(#$Q
M-3,*/CX*<W1R96%M"O_8_^  $$I&248  0$! &  8   _]L 0P -"0H+"@@-
M"PL+#PX-$!0A%102$A0H'1X8(3 J,C$O*BXM-#M+0#0X1SDM+D)90D=.4%15
M5#,_76-<4F)+4U11_]L 0P$.#P\4$10G%14G438N-E%145%145%145%145%1
M45%145%145%145%145%145%145%145%145%145%145%145%1_\  $0@!+P2!
M P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*"__$
M +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A""-"
ML<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U155E=8
M65IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JR
ML[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY
M^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (! @0$
M P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)R
MT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BY
MNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "
M$0,1 #\ ].HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MK#\:_P#(G:K_ -<&H W**\1\'^"/^$GTZ:[_ +2^R^5+Y>WR=^> <YW#UK?_
M .%32Q_/!KV)!T_T8K^H>@#T^BO);77/$7@;68[#6Y'N[&3D,6+_ "]-R,>>
M/[I_J#7J\,L<\*31.'CD4,K#H0>0: 'T444 %%%% !1110 4444 %%%% !5"
MXUO2+60QW&J64+C^&2=%/Y$UPGC;5M3UGQ1'X3TF8PJ<"5@Q7>2NXY(_A"]N
M_-6K;X4:2L(%SJ%[))CEHRB#\B#_ #H [NWN8+J/S+>>.9/[T;!A^8J6O)O$
M/@Z^\'Q?VUH6I3E(B!(#PZ@GKQPPZ9&/_K>@^%-:&O\ A^VORH65@4E5>@<<
M''L>OXT ;%%<OJ7A#[?XPM?$'V_R_(*'R/)SNV_[6[C\JZB@ HHHH **** "
MBBB@ HHHH **** "BBH[C_CWE_W#_*@"2BO,?@Q_S&?^V'_M2O3J "BBO+?!
MG_)5];_W[G_T:* /4J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBH+N]M;&+S+NXCA3U=@,
M_3UHW GHKE+WQ]I$!*VZS73>JKM7\SS^E94OQ'D)/E:6H';=-G^E:JC4?0R=
M:"ZGH%%>=#XBWN.;" G_ 'C1_P +%O/^@?!_WV:KZO4["]O#N>BT5YU_PL6\
M_P"@?!_WV:/^%BWG_0/@_P"^S1]7J=@]O#N>BT5YU_PL6\_Z!\'_ 'V:/^%B
MWG_0/@_[[-'U>IV#V\.YZ+6'XU_Y$[5?^N#4GA379=>M)YI8$B,;[ %).>,T
MOC7_ )$[5?\ K@U92BXNS-8M25T<Y\'_ /D7KW_KZ/\ Z M=_7 ?!_\ Y%Z]
M_P"OH_\ H"UW]2,X_P"*-C'=>#Y;@KF2UD21#WY(4_H?TJ7X:7CW?@RU#G+0
M,\.3Z Y'Z$#\*D^(\X@\$7_(R^Q!GOEQG],U4^%4;)X.1F'$D[LOTX'\P: ,
M;Q;XCU;6?$7_  C/AYVCVMLEEC;:68?>^;^%5[_0U"WPMU&.,W,.N@WV,_<9
M1G_?SG\<4GPM43>*=9N9/FE"GYC_ +3Y/\A7J5 'G7@?Q1J<6M/X:U\NURI*
MQ22<ON R5)[@CD'^>175>+]?7P[H,MZ%#3L?+A4]"YZ9]A@G\*X;QN!;?%+1
MYH?E=_L[,1W/F%>?P %6/C-(XATB('Y&:5B/<;,?S- %'3/"GB#QG;#5-6U9
MX()OFB5U+Y'J$R H]/7K4%TOB#X<ZI;,+PW>G2GA<G8X&,J0<[6]"/\ $5ZU
M8Q)#8V\48PB1JJCT &!3IK>"XV>?!'+L.Y=ZAMI]1GH: .=\;:BX\ W6HZ?<
M21%TADBEB8JP#.G0CU!I?AY=7%YX/M)[J>6>9FDS)*Y9CASW-)\2./ FH@?]
M,O\ T:E1_#+_ )$>S_WY/_0S0!+\0[JXL_!]W/:SRP3*T>)(G*L,N.XH^'EU
M<7G@^TGNIY9YF:3,DKEF.'/<U%\3?^1'O/\ ?C_]#%'PR_Y$>S_WY/\ T,T
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ML+=P%)^A! _#% &%\2/%-C?Z2VDZ7*+MF823R1?,B(ISU'OBN@^&7_(CV?\
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MHP)HSM<#TSW_ !S5'0_ 6A:+=K=Q)-<3H<H]PP;8?8  4 <S\&/^8S_VP_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110!SOC'1M7U>TMQH^I&QGB8ECYKQAU(Z$KSVK/\
M!O@C^PKM]2U"Y6[U!P0&&2J9ZG)Y)/KQWKLJ* "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y%X@
MS)XUN 6Y-RHSCZ"O7:\CUS_D=Y_^OI?YBNG#?$_0Y\1LCURBBBN8Z HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "O(]<_Y'>?\ Z^E_F*]<KR/7/^1WG_Z^E_F*Z<-N_0Y\1LCU
MRBBBN8Z HHHH **** "BBB@ HHHH ***K:A?VVF64EW=RB.&,9+&@"S17!V_
MQ N]3NGCT;0YKM$Y)+8-7(?'D$%VMKK.GW&FR-T:097\Z .PHIL<B2QK)&P=
M&&58'((IU !1110 4444 %%%% !1110 4444 %%8WB;Q)9>&[-9[K<[N<)&O
M5JM:)J]MK>F1WUH3Y;\$'JI[@T 7Z*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0OM2M-2GNYVE3SQY>XYQG)('Z5W%<C\,+7[/X0A? !FD9\^O;^E==0 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)/7;V_QJ_P#$!MG@S4#G&4 _45T$,2001PQC:D:A5'H!7.?$2*27P;>B/.5
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M.@)-=,"" 1R#7FGQASC2L?WG_I7H.E[O[*L]_P![R4S]=HH M444C,JJ68@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YUJOAG6;CQ5+
M>Q6>ZW:<.'\Q!QD<XSFO1:*TA4<'=$3@I[A1116984444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %8?C6&XN/"=_%:HSRM'PJ]
M2,\_I6Y10!Y?:R7?B7P[IWAW38)(88U'VR=UP%P>@]:]%TK3H-*TV&QMEQ%$
MN![^IJRD:1C"(JCKA1BG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%4]0U6QTSR_MMP(?,SLR"<XQGI]132;T0F[;
MERBL;_A*M"_Z""?]\M_A1_PE6A?]!!/^^6_PJO9S[,7/'N;-%8W_  E6A?\
M003_ +Y;_"C_ (2K0O\ H()_WRW^%'LY]F'/'N;-%8W_  E6A?\ 003_ +Y;
M_"C_ (2K0O\ H()_WRW^%'LY]F'/'N;-%8W_  E6A?\ 003_ +Y;_"KNGZK8
MZGYGV*X$WEXWX!&,YQU^AI.$EJT-23V9<HHHJ1A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *X;XE_\ ,-_[:_\ LE=S7#?$O_F&_P#;7_V2M\-_%1G5^!G#
M4445ZQPA7<_#3_F)?]LO_9ZX:NY^&G_,2_[9?^SUSXG^$S6E\:.YHHHKRCM/
M-/B#_P C"O\ UP7^9K2^&G_,2_[9?^SUF_$'_D85_P"N"_S-:7PT_P"8E_VR
M_P#9Z]&?^[_<<J_BG<T445YQU!1110 4444 %%%% !1161XLOY-,\,W]W"<2
MI&0A]"> : *6N>-]$T69H)9C-.O6.(9Q]3VK%A^*ND/)MDL[J-?[QP?Y54^&
MOAK3KW2VU>^B6ZN))6"[_F"X]?<YKN9M#TF>(QR:;:E3Z1 ?RH 31M<T[6[<
MS:?<K*!]Y>C+]14VJ:C;:5I\M]=L5@B&6*C)_*O//^$;U+PUXZM[C1;6>73I
M"#)M&0JDX93].M>@:RNG-I<PU7R_L6!YGF'"]>] "Z1JEIK-@E[9,S0N2 67
M!X]JNUGZ$NEIIB#1O*^QY.WRCE<]Z9K'B#2M%4&_NTB9NB=6/X4 :=%8.D^,
M="U>?R+6\ E/1)%*$_3-:-CJVGZC++%9WD4[Q'$BHV2OUH NT52NM7TZSO(K
M.YO(HKB7&R-FP6R<#%9FJ^-- TFX,%S>@R@X98U+E?KB@#H**S='U[3-:0MI
M]TDI7JO1A]16E0 45BZOXJT71I/+O;U5E')C3YF'X"F:3XOT+5YA#:7J^:W1
M)!M)^F: -VBBLUM?TA9+F,ZA!OM5+3+NY0 X.: -*BL'2?&&AZQ>?9+.[W3'
M(564KNQZ>M;U %>_O8-.L9KRY8K#"I=R!DX'M5#0O$NE>(/-&GSEVBQN5E*G
MZX-1^,_^10U3_KW;^5>,>'KZ^T"ZM];A0FW\PQ/Z-T)4_@: /H*J&LZQ9Z)8
MF\OG9(0P7*J6.3[5/87L&HV,-Y;/OBF4,IKE/BK_ ,B@W_79/YT =5I]]!J5
MC#>VS%H91N4D8./I5FL+P/\ \B=IG_7+^IJ_J>L:=I,0DO[N. 'H&/)^@H O
M45RB_$7PRTOE_:Y!_M&(@?G716&H6FI6PN+*X2>(_P 2'- %FBJ=]JNGZ=+#
M'>W<4#S<1J[8+?3\Q6?K'B[1-%F\F\O )1U1!N(^H% &Y169HWB#2];C9M/N
MEE*C++T9?J*S]2\<>'M-N#;SWNZ13AA$I?!]\4 ='15+2]6L=7MOM%A<)-'T
M.T\@^XJXQ"J68@ <DF@!:*YJ^\=^'+&8PR7V]P<'RE+@'\*U-(UW3-:0MI]V
MDQ7[RCAA]10!HT4$@#)Z50L-;TO4KA[>ROH9Y4&YD1LD#.* +]%%% '-:EXZ
MT'3+^:RNIY5GB.& B)'3/7\:K?\ "R?#/_/S-_WY:N,N;.WO_BY+:W<0EADF
M 9#T/R"O0?\ A"?#/_0(A_-O\: ':;XQT#4Y5BM[]!(WW4D^4G\ZWJX#Q/\
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ME.5(R#ZT +167J_B'2M% ^WWB1L>B=6/X50T[QQX>U&<0PWP1V. )5*9/XT
M='11UHH **** "@G )HI'^XWTH QM)\4Z3K&HRV%G+(T\0)8-&0.#@\UM5Y-
M\-?^1ZU+_<D_]#%>FZAJVGZ9Y?VZ[BM_,.$\QL;J +E%<_J/C/0--O\ [%<W
MH$P.&VJ6"GW(Z5N0317,"3PN'BD4,K#H0: )**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X;X
ME_\ ,-_[:_\ LE=S7,>/K!KK1%N$&6MGW'_=/!_I6U!VJ)LSJJ\&>:4445ZY
MPA7<_#3_ )B7_;+_ -GKAJ[GX:?\Q+_ME_[/7/B?X3-:7QH[FBBH;NYAL[62
MYN'"11C<Q->5N=IYSX_8-XBP#RL*@_J?ZUI_#3_F)?\ ;+_V>N1U2^?4M2GO
M).#*V0/0= /P&*] \ V+6NB-<.,-<ON'^Z.!_6O1JKDH<K.2'O5+HZ>BBBO.
M.L**** "BBB@ HHHH *JZI8Q:GIMQ8S9\N="A(ZC/>K59NN:Y8Z#:)=:@[I$
M[[ 50MSC/;Z4 >6I'XJ\!74J6\;363-G.W<C>_L:V[#XK19":CIKQGH6B;./
MP->A65U!J%C%=0'?!,NY21U!]JH:AX:T74E(NM.A8G^)5VG\Q0 :'XCTO7HR
MUA<AV7[T;<,/PJC\0_\ D2]0_P!U?_0A7 >)M';P/XCL;[3)G\F1LJ&/(P1E
M3Z@YKO/'SB7P->R#HR*P_$B@"EX#NTL/AV+R0X2$2.?PYKFO!V@_\)CJ-YK>
MM,TD0DP$SPQZX^@&*T='5W^#MV$Z^7*?PSS6E\)WC;PFZJ,,MR^[ZX7F@!/$
MG@#3)--DFTB#[)>0C?'L8X8CM6+\'V9[W5'<DLRJ23W.37ITQ A<DX 4UYG\
M)"&U+5V7[IP1],F@"I\4S,OBS3S;L5F$0V$=0=QQ76:5\/M$MK%5OK?[7<L,
MR22,?O'KBN<^(0!\>Z,",C"?^AUZC0!X_/IX\)_$RQ@L)&$,S(0I/\#$@K^A
MKT+QIK+Z'X;N+N(_OSB./V8\9_#K7#^/3CXE:7C^Y#_Z&U;?Q=1V\-6S+]U;
MD%OIM8?SH H^"?!-KJ%@-8UL-=2W1+JC$XQZGU)J?QCX%L(=+DU'1HS:W-J/
M,VH3A@.3^-8VC^"->O\ 2;:[M?$ CAE0,J"20;?;BK<GP\\1F-A)XC79CYMT
MLF,>] '6> M:DUOPU%-.VZXB8Q2-_>(Z'\C7G$6EG6OB1>:<SLL$MPYFVGJJ
MG=C]*]#\"^'+CPY87$$]U%<"5PZF+.!Q[URWA, _%75..AE_G0!VMAX2T33=
M0BOK*T$,T2E1@D@Y&,G/>MRBB@#$\9_\BAJG_7NW\JXWP%H\&N> K^PG'#W!
M*M_=;:,&NR\9_P#(H:I_U[M_*N?^$7_(LW'_ %\G_P!!% &1X!U>XT#6YO#.
MJ'8K.1&6Z*_M[&M_XJ_\B@W_ %V3^=5?B9X<:[M%UJR4BZM1F3;U9!W^HK"U
MGQ(OB#X<$2L/MEO+&LH[MSPWXT =[X(_Y$[3?^N7]37(GPEJFO\ C6XN=>B=
M+%2QCVMP5!PJCT]?SKK?!)"^#=-)Z"+^IKCK[Q1XC\2ZQ/I_AH>5!"2/-& 2
M!QDD\ &@#J;GP)X9DMFC_L](<C'F*Q!'ZUR/PW+Z;XRU+24F,EN X'/!*MP?
MRJP/ _BJ_8'4=>*J?O .Q/Z<5G_#RU6Q^(%Y:)+YHA62/?ZX.* +GQA9TO-&
M:,X<"0J1ZY6MS0/ NEG38[G5H/ME[<*))7D8\$\XK$^,'_']HW_;3^:5Z9!_
MJ(_]T?RH \5US2YM \;G3]'F>'[4H1,'D!^"*]"M/A]X>AL1!-:^?+CYIF8[
MB?6N8\4_\E<TG_>@_P#0S7J5 'E'@56T7XB7FCQRDPMO3![X^8?CBMCXGZQ<
MPQVFBV3%9;P_.5Z[>@'XD_I61H__ "6>;_?E_P#19J+XG6\LWC:Q02^2)841
M)">%.X\_J* .KT7X>:)96")?6RWER1EW<G&?;':N9\7:$?!FH6NNZ([10F38
M\><@'K^1Q5C_ (5[XF_Z&/\ \BR5#<_#G798PEUX@B=">%E=R,_C0!Z98W*:
MAIT%TGW)XPX'ID5E:'X3TO0;^:]LO.\V92C;WR,$@^GM5W0+&73-$M+&:19)
M(4VEUZ&M"@ HHHH \EC_ .2SM_UW_P#9!7K5>2Q_\EG;_KO_ .R"O6J "O)O
M#"FR^+=U;1\)(\P(]L%OYUZP[!$9V. HR37DW@;.J_$B\U),F-#+(&]C\H_0
MT =+\1]/US5+2VM-,A9[<DM-M;D^@QZ=:M:9\/\ P_:64<=S9+<S;1OD<GD]
M\8J'QWXMGT,P6&G1K)?7'(R,[1T''<DU@Q^'O'NJ)OO-5-L'YVF3!'X+TH S
M/'.B6GAC6+"\TB0Q%VR4#9V$$=/:O3M:D\WPO>2=-]JS?FM>1>,/#4WA]K%K
MO46N[B<G.<G &.YY[UZUJG_(H7'_ %YG_P! H Y;X0G&@WI/03_TK&6WG\?^
M-;E)YF33;,D!0?X0<<>Y-:_PF!/AN_ Z^:?_ $&N+\)>']2UFZO(;+4OL4T/
MWP78%N<=O>@#T^?P#X;EM3"M@(VQ@2*QW#WKFO!-Q=^'?&%SX7N9C) V3$3T
M!QD$?4?K3?\ A7OB;_H8_P#R+)4^A^ ]3L/$=MJ-SJ\%P\#@N,L7(].: /1Z
M1CA2?:EH(R"/6@#R;X>Q_:_B%J5S)\SQB5P3ZE\?UKUFO)O!S?V1\3KZRF^4
MS-)&,^YW#\^*]9H *  .@ HKG;;QAIUQXDDT-5E^T(^P,!E6(&3],?TH YCX
MP?=TK_?;^E>A67_'C;_]<U_E7GGQ@^[I7^^W]*]#L3FPMR/^>2_RH \V^,/_
M !^:-])/YI7<ZI_R*%Q_UYG_ - KAOC"?],T<>TG\UKN=4_Y%"X_Z\S_ .@4
M >9_#;PY;:[)<3:BK2VMKC9$3A2S=3^0_E7:ZCX$T$Z;<HD,D2;O.VH^,,%(
M'X<FLWX0 ?V'>''/GC^5=S?_ /'A<?\ 7-OY4 >/?#KPSIWB%KTW_F_N-A3R
MWV]<_P"%;GQ;010Z/&OW59E'X8IGP;ZZI_VS_P#9JF^,'W=*_P!]OZ4 :'Q%
MN[FU\#0+;E@)C''(P[+MS^N /QJKX,\.>$[[0K>21(;NZ9<R^8^"K>F,UV-Q
M8VFI:"EG?*&@DB4-DXQP.:\_U#X7W<$AGT;401U4.=K?@10!>N_ %S9>)K;4
M- D2"%"'(D;[I!Z#V(KT2O'X==\5^#KV&+5P\MJQQMD.X$=\-ZUZY;3I<VT5
MQ$<QRH'4^H(R* )*\J^,)QJ.EGKA'_FM>JUY7\7_ /D)Z5_N/_-: '0?$G5H
MH(XQH&X*H4'+<X'TJ3_A9NK_ /0O?J_^%>CV7_'C;_\ 7-?Y5/0!XKINJS:S
M\2K*^GMOLTCRH#'SQ@8[UZ)\0-:DT3PU)) VVXG811MZ$]3^0-<AJ?\ R62W
M_P"NL?\ (5J?&%2=#L6QP+CK_P !- $/@GP+8W.EQZGK$9N9KD;UC8G ![GU
M)ZTOC3P+8VNER:IHZ&VFMAYC(I."!UQZ$5VGAQE?PWIA4@C[+&./]T4_7I$B
MT&_DE("+ Y.?3% &/X"UR36/#"S7+;I[<F.1O[V!D'\OY5Q6DV+^/_%]Y=WL
MKFPMS\JJ?X<X51Z9QFM'X7QRMX6U<IQN.%^NT_XBG?!QT^RZI'C$F^,GW&&H
M V]5^'NA75@\=I:BUN /DD0GK[UQWPU2>/QQ<17+%IXXW1R3DY!Q_2O7Z\M\
M'LK_ !2U1D(*YEZ?6@"S\8/NZ5_OM_2O0K+_ (\;?_KFO\J\\^,'W=*_WV_I
M7H=B<V%N1_SR7^5 'FWQA_X_-&^DG\TKNK_45TGPN]^PSY-N& ]3C@?G7"_&
M$_Z9HX]I/YK71>.T=_AW,$ZB.(GZ KF@#F?!?A@>)WFU_77:<2.0D><;CW)]
MNV*Z#Q#\/='NM.D.FVXM+I%W(4)P2.QS7'^&/"&LZOHL=Y8ZV+>%F(\H2.-I
M!]N*U3\/?$N.?$?_ )%DH VOACK=QJ6D365XY>>S8+N;J5/3/TP:[6N,\"^$
M[KP]=74\U]!<I.@'[K)YSG)S79T %%%% !2/]QOI5674[&"[2TENXDN)" L9
M;YB3TXJT_P!QOI0!Y/\ #7_D>M2_W)/_ $,5>^,>1%I>.NY_Z52^&BD^.=4(
MZ!)"?^^Q5[XP?=TK_?;^E &GH/@32)]!AEU& SWET@EDE9CN!;GC\Z[.V@CM
M;:*WB&(XD"*/8#%,L1BPMP.!Y2_RJ>@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ILD:2Q/%
M(H9'!5E/<'K3J* /)/$>BRZ+J#1$%K=_FB?U'I]1617M&I:?;:G9O:W2;HVZ
M'NI]1[UY?K_A^[T6?YP9+9C\DP'!]CZ&O3H5U-6>YQU*?+JMC'KN?AI_S$O^
MV7_L]<-70>&/$$>A07Q,+2RS;/+4' XW9R?Q%:5XN4&D33:4DV>F7=U!96[7
M%S*L42]6:O,O$WB276IO*BW1V:'Y4/5CZM5#5M8O=7G\R[ER!]V->%7Z"K&@
M>'[O6I_D!CME/SS$<#V'J:RIT8TESS+G4<_=B)X<T676M06, K;I@ROZ#T^I
MKUF.-(HDBC4*B *JCL!TJOINGVVF6:6MJFV->I[L?4^]6JY*U7VC\C>G#D04
M445@:!1110 4444 %%%% !6/XKT4:]H-Q8@A9"-T;'LPY%;%% 'DOAOQ=>>$
MLZ-K=G+Y43$(0/F3_$5U+_$OPX(]RRSLV/N^4173WNG66H)MO+6*<=MZ@X_&
MLQ/!WAR.7S5TF /G.>3^F: .#>2^^(OB6V=+9H-,M3RS>F>>?4XKM/B" O@F
M_ & %4#\Q70P00VT0B@B2*,=%10!2RQ1SQF.:-9$/57&0?PH Y/X=0I<>!8H
M9!E)#(K#U!-<C:SZI\.M;N(7MGN--F.01T8#H0>Q'>O57B%M92)911QE5)15
M4!<_05Q&A>/[2^::R\1PPVDJ''SKE2>X(/0T 9VJ^/;SQ!:MINA:;.DDXV,[
M<D#OC%)\'U*7NJ*PY55!_,UOZIXQ\,Z3ITS:=);2SLI");*!D^^*I_";3)[?
M2[O49U(-VXV9'4#.3^)/Z4 9OQ!_Y'[1OHG_ *'7J%0RVEK-*LLMM%)(OW6=
M 2/H:FH \I\>_P#)2M,_W(?_ $-J]#\1Z1'KFB7&GN=ID7*-_=8<@_G5R6SM
M9IEFEMH9)5Z.R L/QJ>@#R/0_$NJ^"2^DZM822V\9)3'!7/H>A!J77O'5[XD
MM3I>BZ=.GG_(['EB/08KU.:W@N%VSPQRKZ.H8?K38+2VML_9[:*'/7RT"_RH
M Q_!FC3Z)H$5M=2M)<.=\F6)"D_PCZ5QOA+_ )*IJOUE_G7J%0I:6L<[3QVT
M22MU=4 8_C0!-1110!B>,_\ D4-4_P"O=OY5S_PB_P"19N/^OD_^@BNYDC26
M-HY$5T88*L,@_A38+>"V0I;PQPJ3DB-0HS^% #V4,I5AD'@@UX=X]\.OH&KN
MT 86-T=R8Z ]2OX=J]RJ*XMK>Y4+<01S*#D"1 P!_&@#%\%KO\%Z<OK"1^IK
MSG2-0OOA[KMY;W=D\MM(<;AQN /RL#TKV....*,1Q(J(O 51@#\*;/;P7"[9
MX8Y5]'4,/UH \ZN_B1=:E$;;0])G-Q)\H9^<'V K'\ )<:;\0&M=14I=2(X;
M=UW$;J];@M+:VS]GMXHL_P#/- O\J#:6IN/M!MHC,/\ EIL&[\^M 'FWQ@_X
M_M%_[:?S2O3(?]1'_NC^5,GM+6Y*FXMHIBOW3(@;'TS4PXX% 'EOBG_DKFD_
M[T'_ *&:]2J%[.UDG6=[:%IEQB1D!88Z<U-0!Y3H_P#R6>;_ 'Y?_19KIOB)
MX9FUS3XKFR7-Y:DE5_OJ>H^O%=2MG:K<?:%MH1-_ST"#=^?6IZ /,-*^)4^G
M6BVFM:=,\\0V;UX+8]0>]4-1U/6O'VJ6]K86TEM9QMNW9(Q_M$UZO/96ERVZ
M>UAE/J\8;^=210Q0($AC2-!_"B@"@".U@6RL(H S.(8PNYCDM@=36!X;\96G
MB'4[BQ@M9HGA0N6<C!P0.WUKINM0065I;R&2"UAB=A@LD84G\J )Z*** /%M
M7U./1OBC<ZA+&TB0S E5ZGY!73_\+8TS_H&W?YK_ (UW$NFV$TADEL;>1VZL
MT2DG\<4W^R=,_P"@=:?]^5_PH \TUCQKJ_B:$Z9HNFRQ+.-K-C+$>GH*['P-
MX9'AS22LV&O)\-*1V]%_"NBA@A@7;#"D8]$4#^524 >:?$S3;^WUJQ\0V<1E
M6%55L#.PJ<@D>AS4L?Q6MV@"MI4YN<<JK#;G^=>C$!@00"#U!JLNG6"2>8ME
M;J_7<(E!_/% 'B7BNZUO5WAUK4K1H+4MY<*D8 [_ -.M>M7<RW'@>2=#E9+'
M</Q2MB>W@N8]D\,<J9SM=0P_6E$,2P^2(D$6,; HVX],4 <'\(/^0#>?]=_Z
M5DZ_INJ^#O%#Z[I<)ELYF)=0,@9/*G\>17J$%M;VRE;>".%2<D1H%!_*I2 P
M((!![&@#SB3XK0FW*Q:5-]JQPK,-N?YTG@+2M8U#79O$>J-+$CY*(25WDC'3
MT KOAIU@LGF"RMP_7<(ES^>*M4 %%%% 'GGQ#\,W;WD?B'20WVF+!E5/O<=&
M%+HWQ/L6MUCUB&2WN%&&9%R&/TZBO0JR[[PYHNH,6NM-@D8]3MP3^5 '':[\
M3;0VS0:+%+-<2#"R,N I^G4FI?AOX8N;1Y=;U-&6ZFSY:O\ > /5C[FNLL?#
MFBZ<X>TTV"-AR#MR1^=:E '&?$W1+K5M$BFLXS)+:OO*CJ5QSC]*P=&^)?V'
M3(;*_P!.FDN84" I@;@!@9!KU&J[6%D\OFM9P-)_?,8)_/% 'B_B^?5]6:VU
MO4(?L]O*_E6\)ZA>N:]9U3_D4+C_ *\S_P"@5I3VMM<A1/;Q2A>0'0-C\Z>R
M(T9C9%*$8*D<8],4 <%\(/\ D!7G_7?^E=Y,N^%UQG*D4V"VM[92MO!'"I.2
M(T"@_E4M 'BOA#Q!_P (9?WUKJ%E,[2$*0O!!4GU[<UN_%B59[719E^[(2X^
MA ->C36-G<2>9-:02N/XGC!/ZTLUG:SJBS6T,H3[H= =OTS0!S'C'1KO6/"4
M"V+N+B%5D5$8C>-O(KF=$^(LND:?'8:OIT[R0#RPZ\$@<#(->I@   # ':H)
M[&SN&W3VL,I]7C#?SH \IUC4M1^(5_:V5AI[PVD;;B[]O<GZ5ZQ:6Z6EG!;1
M_<AC6-?H!BG10Q0)LAB2-?1% %/H *\K^+__ "$]*_W'_FM>J5#/9VMRRFXM
MH9BO0R(&Q^= "67_ !XV_P#US7^53T    # ':B@#RK4_P#DLEO_ -=8_P"0
MKO?%>B+K^@SV.0LA^:-CV8=*T6L[5K@7#6T)F'20H-WY]:GH \ET+Q;J?@^-
MM)UG3Y7AB)V$<%>>@)X(I=<\6:GXPB&DZ-I\L<4QPY/)8>A/0"O5)[:WN5VW
M$$<H':1 W\Z(+:"V7;!!'$OHBA?Y4 97A30DT#08K$D-(<O*P[L>O]!^%<#J
M-MJ?@3Q5+J=E;M-IUR22 .,$Y*GT(/2O6#G!QUK@;/QX(M;NM)\101VZ1LRK
M)C@X/&1Z$=Z *5Y\3);^V-KI&ES?:Y!M!;!VD^@%97PTAGM_'%Q%= B=8W$@
M/7=GFNUG\5^$M,@>XMI[1I,<+;H-S'\!6!\,K:XO]<U3Q!,A6.8LJ9[EFR<?
M0<4 :_Q-T2ZU;1(IK.,R2VK[RHZE<<X_2L'1OB7]ATR&RO\ 3II+F% @*8&X
M 8&0:]1JNUA9/+YK6<#2?WS&"?SQ0!XOXOGU?5FMM;U"'[/;ROY5O">H7KFO
M87LXM1T'[',,QS6X1OQ6K4]K;7(43V\4H7D!T#8_.I0   !@#M0!Y#INH:S\
M/=1FLKJT>XL)&W @<'_:!^G:KVK?$J;4K-K31M.G2>4;=[<E<^@'>O398HYD
MV2QK(OHPR*B@L;.W;=!:01-ZI&%/Z4 <U\.]!O-&TAY+]W^T7!#>4S$^6HZ#
MZ\U-XE\:6GAW48;*>TFF>50P9",#G'>NGKD/'%E)JUSI^EV]EO>:0/)<[!^[
MC4\\T =?1110!Y;\2;6YTOQ/8>(88RT:[<D#HRG//U_I6O<_$[1?[-9X4F:Z
M*\1%,8/UZ5V\\$5Q$T4\:R1MP589!K(3PCX>CG\Y=)@$F<YP3^F<4 <G\*-+
MN5:]UFYC*_:/DC)&-V3EC],@4WXP?=TK_?;^E>D(BQH$10J@8  P!44]K;7.
MW[1;Q3;>GF(&Q^= "67_ !XV_P#US7^59WB;Q!!X<TY;VXADF1G";4(SS]:V
M    !@#M4<]O!<ILGACE3.=KJ&'ZT 5-#U2/6M'M]2AC:-)@2%?J,$C^E7Z9
M%%'!&(X8UCC7HJ# 'X4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IDT4<\313(LD;##*PR
M"*?10!Q&N>!@Q:?26P>I@<\?\!/^/YUR/]D:E]L^R?89_/\ [FP_G]/>O9:*
MZH8J<59ZF,J,7L<1H?@8*5GU9LGJ($/'_ C_ (?G7:111PQ+%$BI&HPJJ, "
MGT5C.I*H[R-(P4=@HHHK,H**** "BBB@ HHHH **** "BBB@ HI&=47+L%'J
M3BHEN[9VVK<1,?0.#0!-1110 5A:QX0T3693-=6@$S=9(SM8UNT4 <K8_#[P
MY9RB06KS$'(\Y]PKJ418T5$4*JC 4#  I:* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(UGPUI&MD-?6BO(!@2+PW
MYUKT4 <E;?#CPW;R!S!-+_LR29%=3;P0VL"PP1+%$@PJJ, 5)10 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !575+Z+3-,N+Z;[D"%
MR/7':K58_BVQDU+PQ?VL7^L:(E><9(YQ0!YYIMAX@\?S2WUS?M:V*N5"J3CZ
M =^W)K3;X5+$I>UUF99NQ*8_4&J'P_\ &EGI%C_9.HJZ 2$QR(N>O8XKT^TO
M;>\C#V\F]3[$?SH \Y\-:]J_A_Q,OAW7)&ECD8)'(QSC/W2#W!KO/$-A<ZGH
MMQ9VEQ]GGD "R9(V\^W-+>Z%I=_?17MW91RW,6-DASD8.15/QK>W.G^%;VZM
M)3%.@&UUZCD4 3^&=-N])T6.SO;K[3,I),F2<Y/OS6M7-^!-1NM0\*0WE].T
MTQ9MSMUP#[5QMYKNO>,=?ETW19_LMK&2,[MI('\1/7\* /5J*\JNK+Q9X*B&
MHG4EO;4,/,1G)'_CW/Y5K?#;7]2UN^U(WMT\L:X:-&Q\F2?2@#OZ*\Z\?^)=
M2T/Q-8K;W,BVNP/)"N,/\W-5$T;QAXK@&IR:HMG%)\T42R$ #M]W^M 'J%9O
MB&PN=3T6XL[2X^SSR !9,D;>?;FO/?#'B'6M$\5IH&L3FXC>01<G<5)Z$'TZ
M5V_C6]N=/\*WMU:2F*= -KKU'(H G\,Z;=Z3HL=G>W7VF9229,DYR??FM:N:
M\#:A=ZCX2BN[R=IIR7R[=>#Q7 Z9XO\ $MW<W.EVUR9[NXEV0O(0!&!G./?I
M0!['17E&J>%_%VE6DNJ_VVTKQC>ZK*PP._7BNJ^'GB2?Q!I4RWG-U;,%9P,;
M@>A^O!H ZVBN)^(/BRYT;R=.TX8O+@9\PC[@Z<>]8</A#QE+"NH'6RMP1O$9
ME;_]5 'J5%>.1^,_$$NLZ?83W)ADBF$,^S&)/F'6O8Z "O,?BU=W=OJ&FI;7
M4T(9'SY;E<\CTKTZO*_B_P#\A/2O]Q_YK0 ^'P#XEEA20>(L!U#8\V3O2OX#
M\5P*9(=?\QQT7S7Y_.O2;+_CQM_^N:_RJ2:5(8S)(VU1R3C- 'F_@WQ7JUMX
M@_X1_7BSR,VQ7?[RMV'N#7I=>.RW*>(OBI;S60Q&DR?,>"0G)/Z&O6-3OHM,
MTZXOI\^7"A=L#GB@"U17DMK<>*?'EU/):7HLK.,XP'VA?3IR32WJ>*_ K0WD
MNH"\LR^UE+D@^W/- 'K-%4=&U.'6-)M]0@!5)ES@]0>A'YUY_P"(/$VM:UXG
M;0-"E^SJC%"^<%B.O)[4 >G45Y=-X'\6P1M<Q:Z9)E&=@F<9_/BM/X<>)[_4
MKFYTG4V\V:!2RR'KP<$'\Z .^HKAOB'XFO=,DMM*TP[+JY&3)_=&<#'O63_P
MA'B]D^U'7L3XSL\UNOIZ4 >GT5YWX \3ZG/K$VA:N_FRH&V/W!7J"1UK<\=>
M*&\-Z:A@0/=W!*Q[A\J^I- '445Y18^'/%_B*U34IM9, D&Y%,I&1]%Z4ZR\
M2:[X1UQ-,UV7[5;-CYL[BH/<'^E 'JM%4=9G>'0[RX@<JZ0,Z,.QQP:\LT/Q
M+XIUZ :/9W1:Z=R[W,A *I@<#]: /8:*\BUG1/%GA>V.JC66F56&_;(3C/LW
M6N_\%ZZ_B#P_'>2J%G5C'+CH6&.1^!% &]17(^++3Q;/JD#Z%<>7:A!Y@WJ,
MG/O[5UU !7%_%.XGMO#,;V\TD3^>HW(Q4]#Z5VE</\6O^16C_P"OA?Y&@#7\
M!2R3^"].DFD:1V5\LYR3\[=ZZ&N;^'G_ "(^F?[K_P#H;5TE !16%XQU_P#X
M1W0WNU3?,S".)3TW'UKA-.T?Q?XLM!J,FL_9X9"2@WD?HO2@#UBBO'M0D\5>
M!KNWDGU W-L[8 +[E?U!!Y%>KVMV+S28KV,%1-") /3(S0!:HKQ?1_%_B;4(
MY-*@NFGO+IU6.5R!Y8YSCZ\?E6CJ'AGQ?HEL^J1ZT9FC&]U$IX'T;B@#U>BN
M6\!^*&\1Z;(+A=MW;D"0@<,#T/Z5SWCOQ1J>A^,;5(+EQ:+%')) ,8?YFS^8
M% 'I5%>61:%XO\3P?VK)JHM5E^:*)9"!CM]W^M2>&/$^KZ/XC'A_79#.'<1J
M^=Q0GIR.HH ]/HK"\:WMSI_A6]NK24Q3H!M=>HY%>?Z3-XI\;VJ6\.I>1%:K
MB64MM,CDDC..>G'X4 >NT5R>F2W_ (6\)75QKEPUU+ S%<'=E> HS[GUKC[$
M^+/'4LT\5^+2U1L85RH7T'')H ]<HKR2]/BOP+)#<37XO+1FP0SE@?;GFO0[
M74#K_A?[;82/;R3Q-L;NC=/T- &Q17"?#3Q#?:J+ZRU.=IKB$AE9@.G0CCWQ
M^==M=3K;6LL[_=C0L?P% $M%<!\.-7U?7;_4;R]O'>VCX2$XPI8Y'Y 8J3Q]
MXONM,NH]'TL8O)0"TA'W0> !GO0!W=%>7KX+\82(+M]<VW&,^7YK=?Y5H^!_
M%=]-JDGA_6OGNXRP24<Y(Z@X_G0!W]%%1SB0P2"(XD*G;]: .%\5>)=1MO&N
MG:-;N(K=WB:0@?,^6QCZ<5U^O,R:#?NC%6$#D$'!'%>*ZQ;>(H_%5M#J$^[5
M3L\I]RG'/R\CCK7I-A;Z_;^$-67Q!-YLYC<H=P;Y=OM0!5^$]S<7.B7;7$\D
MS"; ,C%B./>NZKQ#P??ZW/:OH6B,L,L\GF23$@%5QCBM+6-#\6>%[4ZJ-9:9
M48;]LC'&3Z-UH ]=KEY?#NIOXT36%U+%D",VVYN>,=.E6_!FN/K_ (?BO95"
MS!C')CH6'<?@17.7.N:HGQ2CTM;QQ9$KF'C'W<T >@45PWQ#\37NF26VE:8=
MEU<C)D_NC.!CWK)_X0CQ>R?:CKV)\9V>:W7T]* /3Z*\[\ >)]3GUB;0M7?S
M94#;'[@KU!(ZUZ)0 445YCXE\2ZQK/B0^']"D, 1MC/G:7/?D] * /3J\S\#
MWEU-\0]8AEN9I(E,VU&<D#]YV%1OH/B_PS$VJ1:LMTL8WRQ-(2"!U^]_2JOP
MRN?MOC?4;O;M\^.23;Z9<''ZT >M45R_CKQ0WAO34,"![NX)6/</E7U)KD+'
MPYXO\16J:E-K)@$@W(IE(R/HO2@#U>BO*K+Q)KOA'7$TS79?M5LV/FSN*@]P
M?Z5ZA/<1P6KW#G]VB%R<=L9H EHKR5=7\2^.=4F@TRY%G9Q]@VW"]B>Y/TIF
MJ67BSP4D=_\ VK]I@W8;+EAGT(;F@#UVBN>M==;5?!,NK09AF\ASQ_"X!Z5G
M?#/5K_5](NIM0N7N)$FVJS8X&/:@#LJ*S?$EQ-:>&]2N;=S'-%;NZ,.H(!P:
MY_X9ZM?ZOI%U-J%R]Q(DVU6;' Q[4 =E17EFO>,=5T?QQJ%LDS36Z@)% <;0
MQ08/YG-.NO"OC.ZMVU*;6<3A?,$*RD>^..* /4:*\CT7QUK<^G#1X\3:I)((
MX9GP, ]<^XJ36/#7B[2[.35Y-;:5XAO=5E88'?CH: /6**Y?P!K\^OZ"9+HY
MN8'\MV QN]#69X^\7W6F74>CZ6,7DH!:0C[H/  SWH [NBO+U\%^,)$%V^N;
M;C&?+\UNO\JT? _BN^FU23P_K7SW<98)*.<D=0<?SH [^BN2^)&IWVD^'DN+
M"X:"4S*I9<=,'UKF+&X\5>-K=4M+T6=I BI)(6PTCXY)QS0!ZI0>!7CM[<>)
M_ FI6_VB_-U!)SAG+*X'4<\BO1-<?4]3\+I/H$ABNIU22,D@84X)Z^U &!X6
M\2:CK/CF_M;B0+;6Z2*D2CCA@,GWKO:\&\/6WB.;Q#=QZ3/LU%=_G-N49^;Y
MN3QUKVW2$O(])MDU!MUV(P)3D'+=^E %RBBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH __]D*96YD<W1R96%M"F5N9&]B:@HS-R P(&]B:@H\/ HO
M0FET<U!E<D-O;7!O;F5N=" X"B]#;VQO<E-P86-E("]$979I8V521T(*+T9I
M;'1E<B O1$-41&5C;V1E"B](96EG:'0@,3@V"B],96YG=&@@,S S,3,*+U-U
M8G1Y<&4@+TEM86=E"B]4>7!E("]83V)J96-T"B]7:61T:" Q,34S"CX^"G-T
M<F5A;0K_V/_@ !!*1DE&  $! 0!@ &   /_; $, #0D*"PH(#0L+"P\.#1 4
M(144$A(4*!T>&"$P*C(Q+RHN+30[2T T.$<Y+2Y"64)'3E!4550S/UUC7%)B
M2U-44?_; $,!#@\/%!$4)Q45)U$V+C9145%145%145%145%145%145%145%1
M45%145%145%145%145%145%145%145%145%14?_  !$( +H$@0,!(@ "$0$#
M$0'_Q  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,#
M @0#!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S
M8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 #
M 0$! 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  !
M G<  0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q
M%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(
MR<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /3J
M*** "BBB@ KAM2\9:E:>(Y-.C@M3"LPC!96W8./]JNYKR/7/^1WG_P"OI?YB
MNBA%2;N85I.*5CURBBBN<W"BBB@ HHHH **** "BBB@ HHHH *1E#*58 @\$
M&EKG/'6K:CHNA?;M-$>]) )-Z[AM/'\\4 <]KWPQBN+E[K2+H6SL=WE/]T'V
M(Z5B-IOC[P_\T$L\T2G^!_,&/I7H_A765UW0;>\+*9B,2JO\+#KQ6Q0!YYX3
M^(,MW?IIFMPK#.YVI*!M&[T([5O_ !#_ .1+U#_=7_T(5Q_Q7M[9-:TR2V 6
M\DSO"=2 1@G]:ZWQYO\ ^$$O/,^_Y:;OKD9H Q_"]ZVG_"J:[3AXTE*_7M3?
MA)IL2Z3<ZHZ;KB64QAFZA0 >/J3^E+X:LWO_ (43VL8S)(DH4>_:CX2:C$^C
M7&G,^)X92X4]=I Z?B/UH [/6=/M]4TNXL[E T<B$?0]B*\[^#Z&.^U1#U55
M!_,UZ-JM[!I^FW%W<.$CC0DDUYS\(',E]JKD8+*I_4T 0_$^#[5XPTVW_P">
MD:K^;5ZE:V\5I;1V\"!(HU"JH["O-/B#_P C]HWT3_T.O4* /*/&:1VWQ2TR
M1%"[O)D8CN=Y&?T%=G\0_P#D2]0_W5_]"%<;X]_Y*5IG^Y#_ .AM79?$/_D2
M]0_W5_\ 0A0!5^&__(CP_63^=<G\+M/BN?$]_=RH&-N#LSV8MU_+-=9\-_\
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M4_@S0O"^M^';:X;38)+A!LFR3G<.YY[]:T-8\.^$-'TV:^NM*A$<8SC)RQ[
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MSV(&0:YWX1/GPW<IG[MP3^:C_"NE\6_\BEJW_7K)_P"@FN7^$'_("O/^N_\
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M [%_%VP3^@KT^WMXK6WC@@C6.*,;551P!7F'C_=I?C[2M6D!, \ML_[C9/\
M,5ZA!-'<0I-"X>-QN5@<@B@#S_XMZ7$VF6^JQHJSQ2!&8=2I_P#KXJ_JVL3?
M\*K^W[CYLMLL9;ODD*35'XMZE$FDV^FHX:>64.5'4*/_ *^*N:MI,W_"J!9;
M2)8[9)2O?((<B@ ^%FF06WAH7P0&>Z<EG[[0< ?SKI=>T>WUW2I;"YX5^0P&
M2I'0BN=^%NH0W/A9;16'FVSLK+WP3D']372:WJ<6CZ1<7\V,1(2%)QN/8?C0
M!EMHL&@^"[^QMI)'C$,C9D.3DK_*L/X0?\@*\_Z[_P!*U+'7CXG\':C<I:O
M1&\8!.0QV]OSK&^#T\;:7?V^X>8LH;'L1_\ 6H ZWQ;_ ,BEJW_7K)_Z":Y?
MX0?\@*\_Z[_TKH?&]W#:>$=2,SA?,@:-03U9A@5SWP@_Y 5Y_P!=_P"E &#?
M6,6H_&.2VF7=&9D9E/<"-3C]*];95,97 VXQBO+X_P#DMLG^]_[2%>HG[IH
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M7E'Q:XU[3/\ </\ Z$*]7H **** "D?[C?2EI'^XWTH \G^&O_(]:E_N2?\
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M//I?AF^U"^R^HWD+/(S=5!&<?U- &9\&O^/?5O\ >B_DU>EUYI\&O^/?5O\
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MPQ#$<:A%'H ,"@!]<C\4/^1+N/\ KI'_ .A"NNKD?BA_R)=Q_P!=(_\ T(4
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M;%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>1ZY_R.\_\
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ME7;>'_\ D7=,_P"O6+_T 5Q/QB_Y!VG_ /75OY5VWA__ )%W3/\ KUB_] %
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MK)_Z":Y;X0D_V!>X_P">_'Y5U/BW_D4M6_Z]9/\ T$UR_P (/^0%>?\ 7?\
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M2-H/;.>P["@#J] \,:AXIU%==\1LWD$YC@/&X=ACL/YUZ:JI%$$10J(,!0,
M 5Y^/BOI@&!IET!]5_QK:\+^-;/Q-?2VEO:30M''YA,A&",@8X^M 'G=UXGM
MY_&\FIZQ;RSPVK%8((R,#:>,Y_.NCO?BEIUS93P+IUT#(A4$E>,CZUWQTK36
M8LVGVI)Y),*\_I5/5=+TY=*NV73[4$1,01"O''TH \I\!^+;7PRMY'<6TLQN
M63;Y9'&,]<_6O:H9!+"D@& ZAL?6O,?A#:6MU!JAN+:*8JT6WS$#8X;IFO40
M   !@#M0 5YO\7?O:1_UT;^E>D5YO\7?O:1_UT;^E 'I%%%% !6!XZ_Y$[4O
M^N1K?K \=?\ (G:E_P!<C0!C_"3_ )%*7_KZ?_T%:V_&EY+8^$]0G@8K((]H
M8=1GC/ZUB?"3_D4I?^OI_P#T%:ZO5]/CU72[FPEX29"F?3WH X[X6:/9IH?]
MIM&LEU-(PWL,E0.PKJ?$&CV>LZ7/;W42ME#M?'S(>Q!KS72-8UCP!<S:=J%B
M\UF7+ KT_P!Y3[\5=U?XBW.KV;6.B:=.DTWR;VY(SZ8[T 6_@_>S2V-_9NQ:
M*%E= ?X<YS_(5Z-7*_#_ ,-R>']'<W(Q=W)#2#^Z!T'ZFG^)?&EIX=U&&RGM
M)IGE4,&0C YQWH I?$_6;C2]!2"V.UKMC&S@\JN.<5S/A?QUHOA[1X[.+3;I
MI/O2R K\[?GTKU6XM;>Z %Q;Q3 <@2(&Q^=0?V3IG_0.M/\ ORO^% 'B_C3Q
M/;^(]2M+JWMY85@7!#D9/.>U>H^%?%]KXGDN$M[6:$P@$^81SGZ5PWQ3M;>V
MUS35@MXHE9#D(@4'YAZ5ZM;V=K:DFWMH82W7RT"Y_*@":O.?C%_R#M/_ .NK
M?RKT:O.?C%_R#M/_ .NK?RH [;P__P B[IG_ %ZQ?^@"M"L_P_\ \B[IG_7K
M%_Z *77-5CT729]0FC:1(0"53J><4 7ZHZQJUGHU@]Y>RA(UZ#NQ]!5;PSX@
M@\1Z6U_!#)"BR&/;(1G( .>/K7DWBSQ!'K/BL_;O.;3;60HL41&2 >3SW/\
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M7+8[-+Q_*I?AE_R)EM_OO_.NLH HZ7H^GZ1"8K"U2!3U*CD_4U6UWQ)IN@-
MNH22)Y^=FU"W3'I]:UZYCQ]X>D\0:'MMP/M4#>9$/[WJ* .D!CGA5L!XW (R
M,@@UCZEX2T+4E/GZ?$K'^.,;2/RKB?#?C]]'MTTK7K696@&Q9 OS #L16]/\
M3/#T<1:)IY7QP@C(S^)H Y)+.;P3\0K6VMIG>UN"O!_B1C@@^XKV"O+=!M[_
M ,9^,4U^[MS#8VQ&P'OCE0/7DY->I4 8'CK_ )$[4O\ KD:Q_A)_R*4O_7T_
M_H*UL>.O^1.U+_KD:Q_A)_R*4O\ U]/_ .@K0!V]%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>1ZY_P CO/\ ]?2_S%>N5Y'KG_([S_\
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M_H'6G_?E?\*N44 1P6\%M'Y=O#'$F<[8U"C/X5)110!!/9VMRP:>VAE9>A=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5Y]\3+(K<6=^J\.IB8^XY'\S^5>@UE>)M+_M?0[BU4?O0-\7^\.GY]/Q
MK2E+EFF9U8\T6BMX)OA>^&K89R\'[EO;'3],5O5Y=X#U?^SM8:SG;;#=83G^
M%QT_J/RKU&JK0Y9L5*7-$****Q-0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG_[\FC_A97AG_GO/_P!^37/_  PT+2M4T2ZFO["&XD6X*JSKD@;5./UKL_\
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MMAF"(6/0#)KQ3P3:7-C\2[.VO<_:5,ADR<G<8F)R?7FO:R RD$9!X- '(_\
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MK+A0.@KDM.\46]GXZG\0-;2-#(\C"($;AN!% 'NE>>>-=2N?$&M1>$-)?[S
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MF_\ 0,NO^^EKM=,O8M9T:"\$16*ZCW;&ZX/8U-]@LO\ GT@_[]C_  J=$6-
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M?7J?Q%>NHZR1K(C!D8 @CH139;>"?!FACDQTWJ#BGJH50J@!0, #M0 M%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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%)45/1@H!

end
</PDF>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>tcrt-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Dale Curtis Hogue, Jr.., certify that:</font></p>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Quarterly Report on Form 10-Q of Alaunos Therapeutics, Inc.&#x37e;</font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#x37e;</font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#x37e;</font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">4)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#x37e;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#x37e;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#x37e; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting&#x37e; and</font></div></div>
  <div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:6.667%;display:inline-flex;justify-content:flex-start;">5)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information&#x37e; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:7.14323979728499%;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date: May 15, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Dale Curtis Hogue, Jr..</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">      	 </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dale Curtis Hogue, Jr.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interim Chief Executive Officer and Director</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principal Executive Officer and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principal Financial Officer</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>tcrt-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Quarterly Report of Alaunos Therapeutics, Inc. (the &#x201c;Company&#x201d;) on Form 10-Q for the period ended March 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Dale Curtis Hogue, Jr.., Interim Chief Executive Officer and Director (and Principal Executive Officer and Principal Financial Officer) of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#x37e; and</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/s/ Dale Curtis Hogue, Jr.      	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dale Curtis Hogue, Jr.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interim Chief Executive Officer and Director</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principal Executive Officer and</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principal Financial Officer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">May 15, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>tcrt-20240331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-05-15T07:52:07.7404+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://alaunos.com/20240331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:tcrt="http://alaunos.com/20240331" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" namespace="http://xbrl.sec.gov/ecd/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/CoverPage" id="CoverPage">
        <link:definition>100000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets" id="StatementCondensedBalanceSheets">
        <link:definition>100010 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" id="StatementCondensedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations" id="StatementCondensedStatementsOfOperations">
        <link:definition>100030 - Statement - CONDENSED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquity" id="StatementCondensedStatementsOfChangesInStockholdersEquity">
        <link:definition>100040 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows" id="StatementCondensedStatementsOfCashFlows">
        <link:definition>100050 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureOrganization" id="DisclosureOrganization">
        <link:definition>995455 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/Financings" id="Financings">
        <link:definition>995465 - Disclosure - Financings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>995475 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>995485 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/FairValueMeasurements" id="FairValueMeasurements">
        <link:definition>995495 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/NetLossPerShare" id="NetLossPerShare">
        <link:definition>995505 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>995515 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>995525 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/StockBasedCompensation" id="StockBasedCompensation">
        <link:definition>995535 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/Warrants" id="Warrants">
        <link:definition>995545 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/JointVenture" id="JointVenture">
        <link:definition>995555 - Disclosure - Joint Venture</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>995565 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationPolicies" id="DisclosureOrganizationPolicies">
        <link:definition>995575 - Disclosure - Organization (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
        <link:definition>995585 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/NetLossPerShareTables" id="NetLossPerShareTables">
        <link:definition>995595 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
        <link:definition>995605 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" id="DisclosureOrganizationAdditionalInformationDetails">
        <link:definition>995615 - Disclosure - Organization - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails" id="DisclosureFinancingsAdditionalInformationDetails">
        <link:definition>995625 - Disclosure - Financings - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails" id="DisclosureDebtAdditionalInformationDetails">
        <link:definition>995635 - Disclosure - Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>995645 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>995655 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" id="DisclosureNetLossPerSharePotentiallyDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails">
        <link:definition>995665 - Disclosure - Net Loss Per Share - Potentially Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>995675 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>995685 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails" id="DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails">
        <link:definition>995695 - Disclosure - Stock-Based Compensation Expense Included in Statement of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" id="DisclosureStockbasedCompensationAdditionalInformationDetails">
        <link:definition>995705 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails" id="DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails">
        <link:definition>995715 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails" id="DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails">
        <link:definition>995725 - Disclosure - Stock-Based Compensation - Stock Option Activity Under Stock Option Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" id="DisclosureWarrantsAdditionalInformationDetails">
        <link:definition>995735 - Disclosure - Warrants - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails" id="DisclosureJointVentureAdditionalInformationDetails">
        <link:definition>995745 - Disclosure - Joint Venture - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets" xlink:href="tcrt-20240331.xsd#StatementCondensedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquity" xlink:href="tcrt-20240331.xsd#StatementCondensedStatementsOfChangesInStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows" xlink:href="tcrt-20240331.xsd#StatementCondensedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" xlink:href="tcrt-20240331.xsd#DisclosureOrganizationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails" xlink:href="tcrt-20240331.xsd#DisclosureFinancingsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:href="tcrt-20240331.xsd#DisclosureDebtAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="tcrt-20240331.xsd#DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsDetails" xlink:href="tcrt-20240331.xsd#DisclosureFairValueMeasurementsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="tcrt-20240331.xsd#DisclosureNetLossPerSharePotentiallyDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="tcrt-20240331.xsd#DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="tcrt-20240331.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails" xlink:href="tcrt-20240331.xsd#DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:href="tcrt-20240331.xsd#DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails" xlink:href="tcrt-20240331.xsd#DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" xlink:href="tcrt-20240331.xsd#DisclosureWarrantsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails" xlink:href="tcrt-20240331.xsd#DisclosureJointVentureAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations" xlink:href="tcrt-20240331.xsd#StatementCondensedStatementsOfOperations" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/CoverPage" xlink:href="tcrt-20240331.xsd#CoverPage" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" xlink:href="tcrt-20240331.xsd#StatementCondensedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureOrganization" xlink:href="tcrt-20240331.xsd#DisclosureOrganization" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/Financings" xlink:href="tcrt-20240331.xsd#Financings" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/SummaryOfSignificantAccountingPolicies" xlink:href="tcrt-20240331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureDebt" xlink:href="tcrt-20240331.xsd#DisclosureDebt" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/FairValueMeasurements" xlink:href="tcrt-20240331.xsd#FairValueMeasurements" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/NetLossPerShare" xlink:href="tcrt-20240331.xsd#NetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/RelatedPartyTransactions" xlink:href="tcrt-20240331.xsd#RelatedPartyTransactions" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/CommitmentsAndContingencies" xlink:href="tcrt-20240331.xsd#CommitmentsAndContingencies" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/StockBasedCompensation" xlink:href="tcrt-20240331.xsd#StockBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/Warrants" xlink:href="tcrt-20240331.xsd#Warrants" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/JointVenture" xlink:href="tcrt-20240331.xsd#JointVenture" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/SubsequentEvents" xlink:href="tcrt-20240331.xsd#SubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationPolicies" xlink:href="tcrt-20240331.xsd#DisclosureOrganizationPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/FairValueMeasurementsTables" xlink:href="tcrt-20240331.xsd#FairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/NetLossPerShareTables" xlink:href="tcrt-20240331.xsd#NetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/StockBasedCompensationTables" xlink:href="tcrt-20240331.xsd#StockBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails" xlink:href="tcrt-20240331.xsd#DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AdditionalLoansCommitted" xlink:label="tcrt_AdditionalLoansCommitted"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ClinicalExpenses" xlink:label="tcrt_ClinicalExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember" xlink:label="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AnnualLicenseFees" xlink:label="tcrt_AnnualLicenseFees"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_FullyDrawnAmount" xlink:label="tcrt_FullyDrawnAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AtTheMarketOfferingMember" xlink:label="tcrt_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_LicensedProductsMember" xlink:label="tcrt_LicensedProductsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ReverseStockSplitPolicyTextBlock" xlink:label="tcrt_ReverseStockSplitPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MaximumAmountOfRoyaltyPayable" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_SiliconValleyBankMember" xlink:label="tcrt_SiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TcellReceptorMember" xlink:label="tcrt_TcellReceptorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_WatermillAndRobertWPostmaMember" xlink:label="tcrt_WatermillAndRobertWPostmaMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AggregateAmountPotentiallyReimburseableAmount" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MaximumAmountOfAdditionalMilestonesPayable" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AgreementTypeAxisAxis" xlink:label="tcrt_AgreementTypeAxisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PreStockSplitSharesAuthorized" xlink:label="tcrt_PreStockSplitSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TenthScheduledPaymentMember" xlink:label="tcrt_TenthScheduledPaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_FinancingArrangementsDisclosureTextBlock" xlink:label="tcrt_FinancingArrangementsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AccrualsPriorToFirstMarketingApproval" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_EdenBiocellMember" xlink:label="tcrt_EdenBiocellMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ShareSubscriptionAgreementMember" xlink:label="tcrt_ShareSubscriptionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_NonVestedStockMember" xlink:label="tcrt_NonVestedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PaymentTypeAxis" xlink:label="tcrt_PaymentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PaymentTypeDomain" xlink:label="tcrt_PaymentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_IntrexonCorporationMember" xlink:label="tcrt_IntrexonCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TermBTrancheMember" xlink:label="tcrt_TermBTrancheMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_NumberOfEmployeesExpectedToRemain" xlink:label="tcrt_NumberOfEmployeesExpectedToRemain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_SecuritiesPurchaseAgreementMember" xlink:label="tcrt_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_StockOptionsAndRestrictedStockAwardsTextBlock" xlink:label="tcrt_StockOptionsAndRestrictedStockAwardsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankingAndThriftInterestAbstract" xlink:label="us-gaap_BankingAndThriftInterestAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_SvbWarrantsMember" xlink:label="tcrt_SvbWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_DueDateDomain" xlink:label="tcrt_DueDateDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_EightScheduledPaymentMember" xlink:label="tcrt_EightScheduledPaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MaximumRoyaltyAmount" xlink:label="tcrt_MaximumRoyaltyAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" xlink:label="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MdAndersonAgreementAndWorldwideLicenseMember" xlink:label="tcrt_MdAndersonAgreementAndWorldwideLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_WarrantsDisclosureAbstract" xlink:label="tcrt_WarrantsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TriArmMember" xlink:label="tcrt_TriArmMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_NonOperatingIncomeExpenseInducementOfWarrants" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PercentageOfPrepaymentPremium" xlink:label="tcrt_PercentageOfPrepaymentPremium"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_OneTimeBenchmarkPaymentsMember" xlink:label="tcrt_OneTimeBenchmarkPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PocketExpenses" xlink:label="tcrt_PocketExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AgreementTerminationDate" xlink:label="tcrt_AgreementTerminationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_DuneLakeCapitalMember" xlink:label="tcrt_DuneLakeCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_StrategicAdvisorName" xlink:label="tcrt_StrategicAdvisorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MilestonePaymentsMaximumAmount" xlink:label="tcrt_MilestonePaymentsMaximumAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TermBMilestoneMember" xlink:label="tcrt_TermBMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_StockOfferedDuringPeriodShares" xlink:label="tcrt_StockOfferedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ClassOfWarrantOrRightAxisAxis" xlink:label="tcrt_ClassOfWarrantOrRightAxisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PaymentUnderLicenseAgreement" xlink:label="tcrt_PaymentUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" xlink:label="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AdditionalPaidInCapitalCommonStockMember" xlink:label="tcrt_AdditionalPaidInCapitalCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AmountOfPrepaymentsPremium" xlink:label="tcrt_AmountOfPrepaymentsPremium"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AggregatePotentialBenchmarkPayments" xlink:label="tcrt_AggregatePotentialBenchmarkPayments"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" xlink:label="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_RelatedPartyTransactionReimbursedAmount" xlink:label="tcrt_RelatedPartyTransactionReimbursedAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_VinetiIncMember" xlink:label="tcrt_VinetiIncMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment" xlink:label="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_DebtInstrumentPrepaymentPremium" xlink:label="tcrt_DebtInstrumentPrepaymentPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TwoThousandAndThreeEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandAndThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_EquityDistributionAgreementMember" xlink:label="tcrt_EquityDistributionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_GainLossOnOperatingLeaseModification" xlink:label="tcrt_GainLossOnOperatingLeaseModification"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TermATrancheMember" xlink:label="tcrt_TermATrancheMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_EdenBioCellMember" xlink:label="tcrt_EdenBioCellMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_FairValueOfWarrants" xlink:label="tcrt_FairValueOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MdAndersonWarrantMember" xlink:label="tcrt_MdAndersonWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ClassOfWarrantOrRightWarrantsExercised" xlink:label="tcrt_ClassOfWarrantOrRightWarrantsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AgreementTypeAxis" xlink:label="tcrt_AgreementTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ZiopharmMember" xlink:label="tcrt_ZiopharmMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_IntendedPercentageOfResductionInWorkforce" xlink:label="tcrt_IntendedPercentageOfResductionInWorkforce"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_EquityMilestoneMember" xlink:label="tcrt_EquityMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PercentageOfPrepaymentsPremium" xlink:label="tcrt_PercentageOfPrepaymentsPremium"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PostStockSplitSharesAuthorized" xlink:label="tcrt_PostStockSplitSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_NewWarrantsMember" xlink:label="tcrt_NewWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ZeroMilestoneMember" xlink:label="tcrt_ZeroMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_OutsideTwoThousandTwelvePlanMember" xlink:label="tcrt_OutsideTwoThousandTwelvePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AnnualExpenseIncurred" xlink:label="tcrt_AnnualExpenseIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_CantorMember" xlink:label="tcrt_CantorMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TermLoanMember" xlink:label="tcrt_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_UnderwriterParOrStatedValuePerShare" xlink:label="tcrt_UnderwriterParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_IncreaseDecreaseInRightOfUseAsset" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TwoThousandAndTwelveEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_NonVestedRestrictedStockMember" xlink:label="tcrt_NonVestedRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNameOfPlaintiff" xlink:label="us-gaap_LossContingencyNameOfPlaintiff"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PerformanceBasedPaymentsMemberMember" xlink:label="tcrt_PerformanceBasedPaymentsMemberMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PostMarketingApprovalMember" xlink:label="tcrt_PostMarketingApprovalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_LicenseAgreementCommencingDate" xlink:label="tcrt_LicenseAgreementCommencingDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AdditionalNumberOfWarrantsIssued" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_LaboratoryEquipmentMember" xlink:label="tcrt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_IncreaseDecreaseInLeaseLiabilities" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCallOrExerciseFeatures" xlink:label="us-gaap_CommonStockCallOrExerciseFeatures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ReversalOfAccruedExpenses" xlink:label="tcrt_ReversalOfAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_QuarterlyExpenseIncurred" xlink:label="tcrt_QuarterlyExpenseIncurred"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_InterestExpenseAmortizedDate" xlink:label="tcrt_InterestExpenseAmortizedDate"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_DueDateAxis" xlink:label="tcrt_DueDateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" xlink:label="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_WarrantsExpirationDate" xlink:label="tcrt_WarrantsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_BlackScholesModelMember" xlink:label="tcrt_BlackScholesModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel12And3Member" xlink:label="us-gaap_FairValueInputsLevel12And3Member"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PlacementAgentFeesAndOtherRelatedExpenses" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_CRADAAgreementMember" xlink:label="tcrt_CRADAAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_WarrantTextBlock" xlink:label="tcrt_WarrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ClassOfWarrantOrRightDomainDomain" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_LicenseExpense" xlink:label="tcrt_LicenseExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalLoansCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Loans Committed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalLoansCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Loans Committed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalLoansCommitted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional loans committed.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arrangements and Non-arrangement Transactions [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">M D Anderson License and the Two Thousand Fifteen Research and Development Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">M D Anderson License and the Two Thousand Fifteen Research and Development Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">M D Anderson license and the two thousand fifteen research and development agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual License Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual License Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty equity incentive plan [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FullyDrawnAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fully drawn amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FullyDrawnAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fully Drawn Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FullyDrawnAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fully drawn amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">At The Market Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At The Market Offering Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Market Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicensedProductsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Licensed Products Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicensedProductsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">licensed products [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ReverseStockSplitPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ReverseStockSplitPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reverse Stock Split [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ReverseStockSplitPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reverse stock split policy text block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments and Joint Ventures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum royalty amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount of Royalty Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of royalty payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Silicon Valley Bank [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Silicon valley bank.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Silicon Valley Bank [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Relationship to Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TcellReceptorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">T-cell receptor [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TcellReceptorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tcell Receptor Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TcellReceptorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tcell receptor [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WatermillAndRobertWPostmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Watermill And Robert W Postma.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WatermillAndRobertWPostmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Watermill And Robert W Postma [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WatermillAndRobertWPostmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WatermillAndRobertWPostmaMember</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Portion of income payable to related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Sub licensing Income Payable to Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of sub licensing income, attributable to related party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Subscribed but Unissued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Reimbursement of historical costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Amount Potentially Reimburseable Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate Amount Potentially Reimburseable Amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to Fund Long-term Loans to Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Fund Long-Term Loans to Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected additional milestones payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount of Additional Milestones Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of additional milestones payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, net of expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate offering price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock option, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding options issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Costs and Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTypeAxisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement Type Axis Axis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTypeAxisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Type Axis [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Interest Rate During Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term B Tranche [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Chief Executive Officer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Chief Executive Officer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lender Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of payment terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Frequency of Payment and Payment Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PreStockSplitSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Stock Split Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PreStockSplitSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Stock Split Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PreStockSplitSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre Stock Split Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restructuring Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TenthScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenth Scheduled Payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TenthScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenth Scheduled Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TenthScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenth Scheduled Payment Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of securities into which the class of warrant converted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FinancingArrangementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FinancingArrangementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Arrangements Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FinancingArrangementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Includes disclosures related to financing receivables and financing guarantees in which the company is the guarantor.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments due prior to the first marketing approval for TCR products.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accruals Prior to First Marketing Approval</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments due prior to the first marketing approval</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EdenBiocellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eden Biocell [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EdenBiocellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eden Biocell.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Issuance Costs, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash proceeds from sale of equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplementary disclosure of cash flow information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Forecast[Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term A Tranche [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareSubscriptionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Subscription Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareSubscriptionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Subscription Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Vested Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Vested Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit facility, interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Basis Spread on Variable Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options available for future grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock $0.001 par value; 34,666,667 shares authorized, 16,012,522 shares issued and outstanding at March 31, 2024 and at December 31, 2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Repayments of Long-Term Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment Type Axis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the disposal of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale of Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Laboratory equipment, gross proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment Type Domain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IntrexonCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intrexon Corporation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IntrexonCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intrexon Corporation Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IntrexonCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intrexon Corporation/Precigen [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermBTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term B Tranche [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermBTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term B Tranche [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermBTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term B Tranche.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Assumptions Expected volatility Rate Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NumberOfEmployeesExpectedToRemain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of employees expected to remain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NumberOfEmployeesExpectedToRemain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Employees Expected To Remain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NumberOfEmployeesExpectedToRemain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number Of Employees Expected To Remain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SecuritiesPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities Purchase Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options, granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOptionsAndRestrictedStockAwardsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOptionsAndRestrictedStockAwardsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options and Restricted Stock Awards [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOptionsAndRestrictedStockAwardsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Options and Restricted Stock Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding, at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs and Expenses, Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fees and Expenses, Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BankingAndThriftInterestAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Banking and Thrift, Interest [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SvbWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SVB Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SvbWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Svb Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SvbWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Svb Warrants [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DueDateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Due Date Domain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DueDateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due date [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EightScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eighth Scheduled Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EightScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eighth Scheduled Payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EightScheduledPaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Eighth Scheduled Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Secured Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecuredDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Secured Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum borrowing capacity under the credit facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additonal tranche facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumRoyaltyAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of royalty.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumRoyaltyAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Royalty Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MaximumRoyaltyAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum royalty amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date Range, Start</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, initial maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Expenses From Transactions With Related Party Advisory Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction expenses from transactions with related party advisory fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sale of stock consideration received on transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with a public offering, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonAgreementAndWorldwideLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MD Anderson Agreement and Worldwide License.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonAgreementAndWorldwideLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MD Anderson Agreement and Worldwide License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings per share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commitments and contingencies (Note 8)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants Disclosure Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from collateral account</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument Redemption Period Two Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings per share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TriArmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TriArm [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TriArmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tri Arm [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TriArmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tri Arm</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash inducement warrant expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Operating Income Expense Inducement Of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Operating Income Expense Inducement Of Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfPrepaymentPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of prepayment premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfPrepaymentPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of prepayment premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfPrepaymentPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment premium percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OneTimeBenchmarkPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">One Time Benchmark Payments Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OneTimeBenchmarkPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One Time Benchmark Payments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PocketExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pocket expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PocketExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pocket Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PocketExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pocket expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Agreement termination date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Termination Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTerminationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Termination Date of CRADA Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of employee stock options (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DuneLakeCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dune Lake Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DuneLakeCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dune Lake Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Term (Years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Warrants or Options Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TextBlockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Text Block [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales commission as a percentage of gross proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Commission On Gross Proceeds From Sale Of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of commission on gross proceeds from sale of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StrategicAdvisorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strategic advisor name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StrategicAdvisorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Strategic Advisor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StrategicAdvisorName_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Strategic advisor name.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise price of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePaymentsMaximumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone maximum payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePaymentsMaximumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments, Maximum Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MilestonePaymentsMaximumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments maximum amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermBMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term B Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermBMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term B Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOfferedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued during period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOfferedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Offered During Period Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOfferedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock offered during period shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_StockOfferedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock during period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightAxisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Axis [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightAxisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class Of Warrant Or Right Axis.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected recognition period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ziop License Agreement With The National Cancer Institute [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ziop License Agreement With The National Cancer Institute [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ZiopLicenseAgreementWithTheNationalCancerInstituteMember</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from private placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The University of Texas MD Anderson Cancer Center and The Texas A &amp; M University System [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">The University Of Texas M D Anderson Cancer Center And The Texas A And M University System [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The University Of Texas M D Anderson Cancer Center And The Texas A And M University System</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Dividends_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment under license agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Under License Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PaymentUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment under license agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Threshold period for exercise or conversion of stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Threshold Commitment Period for Exercise of Rights to Participate in Future Offerings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Threshold commitment period for exercise of rights to participate in future offerings.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and Administrative [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalPaidInCapitalCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalPaidInCapitalCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalPaidInCapitalCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Potentially Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AmountOfPrepaymentsPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of prepayments premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AmountOfPrepaymentsPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Of Prepayments Premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AmountOfPrepaymentsPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount Of Prepayments Premium.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregatePotentialBenchmarkPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate potential benchmark payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregatePotentialBenchmarkPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate potential benchmark payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AggregatePotentialBenchmarkPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate potential benchmark payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">MD Anderson License and the Research and Development Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MD Anderson License and the Research and Development Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RelatedPartyTransactionReimbursedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party transaction, reimbursed amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RelatedPartyTransactionReimbursedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Reimbursed Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_RelatedPartyTransactionReimbursedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Related Party Transaction Reimbursed Amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_VinetiIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vineti Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_VinetiIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vineti Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Property and equipment and right of use assets impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property And Equipment And Right Of Use Assets Impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment and right-of-use assets impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DebtInstrumentPrepaymentPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument prepayment premium.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DebtInstrumentPrepaymentPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Prepayment Premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DebtInstrumentPrepaymentPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandAndThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2003 Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandAndThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Three Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandAndThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand And Three Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityDistributionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Distribution Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityDistributionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity distribution agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityDistributionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Distribution Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnOperatingLeaseModification_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on lease modification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnOperatingLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on lease modification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnOperatingLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) On Operating Lease Modification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_GainLossOnOperatingLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain (loss) on operating lease modification.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Activity under Stock Option Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of assets (liabilities)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Net Asset (Liability)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Net Asset (Liability), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermATrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term A Tranche [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermATrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term A Tranche [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermATrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term A Tranche [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EdenBioCellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Eden Bio Cell</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EdenBioCellMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Eden Bio Cell [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and Contingencies Disclosure [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_FairValueOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Damages Sought, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unspecified monetary damages</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant expiry date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement with Solasia Pharma KK [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement With Solasia Pharma KK [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement with solasia pharma K.K.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee Benefit and Share-based Payment Arrangement, Noncash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Benefit and Share-Based Payment Arrangement, Noncash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-Based Compensation Expense on All Employee and Non-Employee Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Md Anderson Warrant Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">MD Anderson Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MD Anderson Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_MdAndersonWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Md Anderson Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right warrants exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Warrants Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightWarrantsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Settlement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement Type Axis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extinguishment of debt, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extinguishment of Debt, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZiopharmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ziopharm [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZiopharmMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ziopharm [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IntendedPercentageOfResductionInWorkforce_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intended percentage of resduction in workforce</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IntendedPercentageOfResductionInWorkforce_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intended percentage of resduction in workforce</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IntendedPercentageOfResductionInWorkforce_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intended percentage of reduction in workforce</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants fully vested upon issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_EquityMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfPrepaymentsPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of prepayments premium.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfPrepaymentsPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Prepayments Premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfPrepaymentsPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of prepayments premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PostStockSplitSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Post Stock Split Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PostStockSplitSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Post Stock Split Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PostStockSplitSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Post Stock Split Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity interest in affilated entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NewWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NewWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New Warrants Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NewWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZeroMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Zero Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ZeroMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Zero Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OutsideTwoThousandTwelvePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outside 2012 Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OutsideTwoThousandTwelvePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Outside Two Thousand Twelve Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_OutsideTwoThousandTwelvePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Outside two thousand twelve plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Silicon Valley Bank Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Silicon Valley Bank Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_SiliconValleyBankLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Silicon Valley Bank loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualExpenseIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual expense incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualExpenseIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Expense Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AnnualExpenseIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual expense incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CantorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cantor [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CantorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cantor [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CantorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cantor.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Excluding Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UnderwriterParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriter par or stated value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UnderwriterParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriter Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_UnderwriterParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriter par or stated value per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Decrease in the carrying amount of right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Right Of Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The increase (decrease) during the period in the carrying value of right of use asset reported as assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Periodic Payment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, periodic payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Periodic Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Assumptions Expected Term1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life in years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2012 Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twelve Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand And Twelve Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">(Increase) decrease in:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Unvested Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant exercise per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non Vested Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Vested Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NonVestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Vested Restricted Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation costs related to unvested restricted stock outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash related to the Company's debt agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyNameOfPlaintiff_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss contingency, name of plaintiff</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyNameOfPlaintiff_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency, Name of Plaintiff</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyNameOfPlaintiff_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of Plaintiff</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PerformanceBasedPaymentsMemberMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance Based Payments Member Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PerformanceBasedPaymentsMemberMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Payments Member [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Assumptions Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Lender [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement With The National Cancer Institute Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement with the National Cancer Institute [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement Type Domain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AgreementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Subsidiary or Equity Method Investee [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PostMarketingApprovalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Post Marketing Approval Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PostMarketingApprovalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Post Marketing Approval [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses and Other Current Assets [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of financing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance of Long-term Debt and Capital Securities, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Long-Term Debt and Capital Securities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementCommencingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement commencing date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementCommencingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Commencing Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseAgreementCommencingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement commencing date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional number warrants issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Number Of Warrants Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional number of warrants issued.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Terms [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The increase (decrease) during the period in the carrying value of lease liabilities reported as liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and Contingencies Disclosure [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan and Security Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Current Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCallOrExerciseFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCallOrExerciseFeatures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Call or Exercise Features</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ReversalOfAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reversal of accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ReversalOfAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reversal Of Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ReversalOfAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reversal of accrued expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss applicable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_QuarterlyExpenseIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Quarterly expense incurred.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_QuarterlyExpenseIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Expense Incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_QuarterlyExpenseIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quarterly expense incurred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Joint Venture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InterestExpenseAmortizedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense amortized date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InterestExpenseAmortizedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense Amortized Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_InterestExpenseAmortizedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest expense amortized date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DueDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Due Date Axis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_DueDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due date [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other income (expense), net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument Redemption Period Three Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts included in accrued expenses and accounts payable related to property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument description of variable rate basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Description of Variable Rate Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional option available to the underwriter to purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Additional Option Available To The Underwriter To Purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of additional option available to the underwriter to purchase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_BlackScholesModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Black-Scholes Model [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_BlackScholesModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Black Scholes Model [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_BlackScholesModelMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Black-Scholes Model [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Receivables, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income and Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel12And3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 2, and Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel12And3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of original principal due as a final payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Original Principal Due as a Final Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of original principal due as a final payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Placement agent fees and other expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Placement Agent Fees And Other Related Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Placement agent fees and other related expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CRADAAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CRADA Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_CRADAAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CRADA Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Receivables, Net, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables, Net, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument Redemption Period One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure pertaining to the warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_WarrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Hierarchy [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consulting service amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Professional and Contract Services Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Domain [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class Of Warrant Or Right.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of expense related to License payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tcrt_LicenseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, net of expenses, (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Axis]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AdditionalLoansCommitted" xlink:to="tcrt_AdditionalLoansCommitted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ClinicalExpenses" xlink:to="tcrt_ClinicalExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember" xlink:to="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AnnualLicenseFees" xlink:to="tcrt_AnnualLicenseFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:to="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_FullyDrawnAmount" xlink:to="tcrt_FullyDrawnAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AtTheMarketOfferingMember" xlink:to="tcrt_AtTheMarketOfferingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LicensedProductsMember" xlink:to="tcrt_LicensedProductsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ReverseStockSplitPolicyTextBlock" xlink:to="tcrt_ReverseStockSplitPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MaximumAmountOfRoyaltyPayable" xlink:to="tcrt_MaximumAmountOfRoyaltyPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SiliconValleyBankMember" xlink:to="tcrt_SiliconValleyBankMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TcellReceptorMember" xlink:to="tcrt_TcellReceptorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_WatermillAndRobertWPostmaMember" xlink:to="tcrt_WatermillAndRobertWPostmaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" xlink:to="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AggregateAmountPotentiallyReimburseableAmount" xlink:to="tcrt_AggregateAmountPotentiallyReimburseableAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MaximumAmountOfAdditionalMilestonesPayable" xlink:to="tcrt_MaximumAmountOfAdditionalMilestonesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AgreementTypeAxisAxis" xlink:to="tcrt_AgreementTypeAxisAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PreStockSplitSharesAuthorized" xlink:to="tcrt_PreStockSplitSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TenthScheduledPaymentMember" xlink:to="tcrt_TenthScheduledPaymentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_FinancingArrangementsDisclosureTextBlock" xlink:to="tcrt_FinancingArrangementsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AccrualsPriorToFirstMarketingApproval" xlink:to="tcrt_AccrualsPriorToFirstMarketingApproval_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EdenBiocellMember" xlink:to="tcrt_EdenBiocellMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ShareSubscriptionAgreementMember" xlink:to="tcrt_ShareSubscriptionAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NonVestedStockMember" xlink:to="tcrt_NonVestedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PaymentTypeAxis" xlink:to="tcrt_PaymentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PaymentTypeDomain" xlink:to="tcrt_PaymentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IntrexonCorporationMember" xlink:to="tcrt_IntrexonCorporationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TermBTrancheMember" xlink:to="tcrt_TermBTrancheMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NumberOfEmployeesExpectedToRemain" xlink:to="tcrt_NumberOfEmployeesExpectedToRemain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SecuritiesPurchaseAgreementMember" xlink:to="tcrt_SecuritiesPurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_StockOptionsAndRestrictedStockAwardsTextBlock" xlink:to="tcrt_StockOptionsAndRestrictedStockAwardsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BankingAndThriftInterestAbstract" xlink:to="us-gaap_BankingAndThriftInterestAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SvbWarrantsMember" xlink:to="tcrt_SvbWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DueDateDomain" xlink:to="tcrt_DueDateDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EightScheduledPaymentMember" xlink:to="tcrt_EightScheduledPaymentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtMember" xlink:to="us-gaap_SecuredDebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MaximumRoyaltyAmount" xlink:to="tcrt_MaximumRoyaltyAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeStart1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" xlink:to="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MdAndersonAgreementAndWorldwideLicenseMember" xlink:to="tcrt_MdAndersonAgreementAndWorldwideLicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_WarrantsDisclosureAbstract" xlink:to="tcrt_WarrantsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TriArmMember" xlink:to="tcrt_TriArmMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NonOperatingIncomeExpenseInducementOfWarrants" xlink:to="tcrt_NonOperatingIncomeExpenseInducementOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PercentageOfPrepaymentPremium" xlink:to="tcrt_PercentageOfPrepaymentPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OneTimeBenchmarkPaymentsMember" xlink:to="tcrt_OneTimeBenchmarkPaymentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PocketExpenses" xlink:to="tcrt_PocketExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AgreementTerminationDate" xlink:to="tcrt_AgreementTerminationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DuneLakeCapitalMember" xlink:to="tcrt_DuneLakeCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xlink:to="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_StrategicAdvisorName" xlink:to="tcrt_StrategicAdvisorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MilestonePaymentsMaximumAmount" xlink:to="tcrt_MilestonePaymentsMaximumAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TermBMilestoneMember" xlink:to="tcrt_TermBMilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_StockOfferedDuringPeriodShares" xlink:to="tcrt_StockOfferedDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ClassOfWarrantOrRightAxisAxis" xlink:to="tcrt_ClassOfWarrantOrRightAxisAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" xlink:to="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" xlink:to="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PaymentUnderLicenseAgreement" xlink:to="tcrt_PaymentUnderLicenseAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" xlink:to="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AdditionalPaidInCapitalCommonStockMember" xlink:to="tcrt_AdditionalPaidInCapitalCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AmountOfPrepaymentsPremium" xlink:to="tcrt_AmountOfPrepaymentsPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AggregatePotentialBenchmarkPayments" xlink:to="tcrt_AggregatePotentialBenchmarkPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" xlink:to="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_RelatedPartyTransactionReimbursedAmount" xlink:to="tcrt_RelatedPartyTransactionReimbursedAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_VinetiIncMember" xlink:to="tcrt_VinetiIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment" xlink:to="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DebtInstrumentPrepaymentPremium" xlink:to="tcrt_DebtInstrumentPrepaymentPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TwoThousandAndThreeEquityIncentivePlanMember" xlink:to="tcrt_TwoThousandAndThreeEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EquityDistributionAgreementMember" xlink:to="tcrt_EquityDistributionAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_GainLossOnOperatingLeaseModification" xlink:to="tcrt_GainLossOnOperatingLeaseModification_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TermATrancheMember" xlink:to="tcrt_TermATrancheMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EdenBioCellMember" xlink:to="tcrt_EdenBioCellMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_CommitmentsAndContingenciesDisclosureTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_FairValueOfWarrants" xlink:to="tcrt_FairValueOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" xlink:to="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_MdAndersonWarrantMember" xlink:to="tcrt_MdAndersonWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ClassOfWarrantOrRightWarrantsExercised" xlink:to="tcrt_ClassOfWarrantOrRightWarrantsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ZiopharmMember" xlink:to="tcrt_ZiopharmMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IntendedPercentageOfResductionInWorkforce" xlink:to="tcrt_IntendedPercentageOfResductionInWorkforce_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_EquityMilestoneMember" xlink:to="tcrt_EquityMilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PercentageOfPrepaymentsPremium" xlink:to="tcrt_PercentageOfPrepaymentsPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PostStockSplitSharesAuthorized" xlink:to="tcrt_PostStockSplitSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NewWarrantsMember" xlink:to="tcrt_NewWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ZeroMilestoneMember" xlink:to="tcrt_ZeroMilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_OutsideTwoThousandTwelvePlanMember" xlink:to="tcrt_OutsideTwoThousandTwelvePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_SiliconValleyBankLoanMember" xlink:to="tcrt_SiliconValleyBankLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AnnualExpenseIncurred" xlink:to="tcrt_AnnualExpenseIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CantorMember" xlink:to="tcrt_CantorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TermLoanMember" xlink:to="tcrt_TermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_UnderwriterParOrStatedValuePerShare" xlink:to="tcrt_UnderwriterParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IncreaseDecreaseInRightOfUseAsset" xlink:to="tcrt_IncreaseDecreaseInRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember" xlink:to="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NonVestedRestrictedStockMember" xlink:to="tcrt_NonVestedRestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNameOfPlaintiff" xlink:to="us-gaap_LossContingencyNameOfPlaintiff_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PerformanceBasedPaymentsMemberMember" xlink:to="tcrt_PerformanceBasedPaymentsMemberMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" xlink:to="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_AgreementTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PostMarketingApprovalMember" xlink:to="tcrt_PostMarketingApprovalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LicenseAgreementCommencingDate" xlink:to="tcrt_LicenseAgreementCommencingDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_AdditionalNumberOfWarrantsIssued" xlink:to="tcrt_AdditionalNumberOfWarrantsIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LaboratoryEquipmentMember" xlink:to="tcrt_LaboratoryEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_IncreaseDecreaseInLeaseLiabilities" xlink:to="tcrt_IncreaseDecreaseInLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_CommitmentsAndContingenciesDisclosureLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCallOrExerciseFeatures" xlink:to="us-gaap_CommonStockCallOrExerciseFeatures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ReversalOfAccruedExpenses" xlink:to="tcrt_ReversalOfAccruedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_QuarterlyExpenseIncurred" xlink:to="tcrt_QuarterlyExpenseIncurred_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_InterestExpenseAmortizedDate" xlink:to="tcrt_InterestExpenseAmortizedDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_DueDateAxis" xlink:to="tcrt_DueDateAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" xlink:to="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_WarrantsExpirationDate" xlink:to="tcrt_WarrantsExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_BlackScholesModelMember" xlink:to="tcrt_BlackScholesModelMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel12And3Member" xlink:to="us-gaap_FairValueInputsLevel12And3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" xlink:to="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_PlacementAgentFeesAndOtherRelatedExpenses" xlink:to="tcrt_PlacementAgentFeesAndOtherRelatedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_CRADAAgreementMember" xlink:to="tcrt_CRADAAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_WarrantTextBlock" xlink:to="tcrt_WarrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_ClassOfWarrantOrRightDomainDomain" xlink:to="tcrt_ClassOfWarrantOrRightDomainDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tcrt_LicenseExpense" xlink:to="tcrt_LicenseExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/CoverPage" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_GainLossOnOperatingLeaseModification" xlink:label="tcrt_GainLossOnOperatingLeaseModification"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment" xlink:label="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="tcrt_GainLossOnOperatingLeaseModification" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_RestructuringCharges" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AdditionalPaidInCapitalCommonStockMember" xlink:label="tcrt_AdditionalPaidInCapitalCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_7"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tcrt_AdditionalPaidInCapitalCommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_IncreaseDecreaseInLeaseLiabilities" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_IncreaseDecreaseInRightOfUseAsset" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="tcrt_IncreaseDecreaseInLeaseLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tcrt_IncreaseDecreaseInRightOfUseAsset" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureOrganization" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/Financings" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_FinancingArrangementsDisclosureTextBlock" xlink:label="tcrt_FinancingArrangementsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="tcrt_FinancingArrangementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/SummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureDebt" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/FairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/NetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/RelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/CommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/StockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_StockOptionsAndRestrictedStockAwardsTextBlock" xlink:label="tcrt_StockOptionsAndRestrictedStockAwardsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="tcrt_StockOptionsAndRestrictedStockAwardsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/Warrants" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_WarrantsDisclosureAbstract" xlink:label="tcrt_WarrantsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_WarrantTextBlock" xlink:label="tcrt_WarrantTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_WarrantsDisclosureAbstract" xlink:to="tcrt_WarrantTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/JointVenture" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/SubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ReverseStockSplitPolicyTextBlock" xlink:label="tcrt_ReverseStockSplitPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tcrt_ReverseStockSplitPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/FairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/NetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/StockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PaymentTypeAxis" xlink:label="tcrt_PaymentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PaymentTypeDomain" xlink:label="tcrt_PaymentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_IntendedPercentageOfResductionInWorkforce" xlink:label="tcrt_IntendedPercentageOfResductionInWorkforce"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_NumberOfEmployeesExpectedToRemain" xlink:label="tcrt_NumberOfEmployeesExpectedToRemain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ReversalOfAccruedExpenses" xlink:label="tcrt_ReversalOfAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_StrategicAdvisorName" xlink:label="tcrt_StrategicAdvisorName"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PreStockSplitSharesAuthorized" xlink:label="tcrt_PreStockSplitSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PostStockSplitSharesAuthorized" xlink:label="tcrt_PostStockSplitSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_PaymentTypeAxis" xlink:to="tcrt_PaymentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_IntendedPercentageOfResductionInWorkforce" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_NumberOfEmployeesExpectedToRemain" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCash" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="tcrt_PaymentTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_ReversalOfAccruedExpenses" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_StrategicAdvisorName" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_PreStockSplitSharesAuthorized" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_PostStockSplitSharesAuthorized" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AgreementTypeAxisAxis" xlink:label="tcrt_AgreementTypeAxisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankingAndThriftInterestAbstract" xlink:label="us-gaap_BankingAndThriftInterestAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_SiliconValleyBankMember" xlink:label="tcrt_SiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_StockOfferedDuringPeriodShares" xlink:label="tcrt_StockOfferedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AtTheMarketOfferingMember" xlink:label="tcrt_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_CantorMember" xlink:label="tcrt_CantorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_UnderwriterParOrStatedValuePerShare" xlink:label="tcrt_UnderwriterParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_EquityDistributionAgreementMember" xlink:label="tcrt_EquityDistributionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" xlink:label="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" xlink:label="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="tcrt_AgreementTypeAxisAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeAxisAxis" xlink:to="tcrt_AgreementTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BankingAndThriftInterestAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="tcrt_SiliconValleyBankMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_StockOfferedDuringPeriodShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tcrt_AtTheMarketOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_StockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_CantorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_UnderwriterParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_EquityDistributionAgreementMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TermLoanMember" xlink:label="tcrt_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_FullyDrawnAmount" xlink:label="tcrt_FullyDrawnAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TermATrancheMember" xlink:label="tcrt_TermATrancheMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_EquityMilestoneMember" xlink:label="tcrt_EquityMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TermBMilestoneMember" xlink:label="tcrt_TermBMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TermBTrancheMember" xlink:label="tcrt_TermBTrancheMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ZeroMilestoneMember" xlink:label="tcrt_ZeroMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_WarrantsExpirationDate" xlink:label="tcrt_WarrantsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TenthScheduledPaymentMember" xlink:label="tcrt_TenthScheduledPaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_EightScheduledPaymentMember" xlink:label="tcrt_EightScheduledPaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PercentageOfPrepaymentsPremium" xlink:label="tcrt_PercentageOfPrepaymentsPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AmountOfPrepaymentsPremium" xlink:label="tcrt_AmountOfPrepaymentsPremium"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_DebtInstrumentPrepaymentPremium" xlink:label="tcrt_DebtInstrumentPrepaymentPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AdditionalNumberOfWarrantsIssued" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_InterestExpenseAmortizedDate" xlink:label="tcrt_InterestExpenseAmortizedDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PercentageOfPrepaymentPremium" xlink:label="tcrt_PercentageOfPrepaymentPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcrt_TermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_FullyDrawnAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="tcrt_TermATrancheMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_EquityMilestoneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcrt_TermBMilestoneMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="tcrt_TermBTrancheMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_ZeroMilestoneMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_SecuredDebtMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_WarrantsExpirationDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_TenthScheduledPaymentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_EightScheduledPaymentMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_PercentageOfPrepaymentsPremium" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_AmountOfPrepaymentsPremium" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_DebtInstrumentPrepaymentPremium" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_AdditionalNumberOfWarrantsIssued" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_InterestExpenseAmortizedDate" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeStart1" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_PercentageOfPrepaymentPremium" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RestrictedCash" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel12And3Member" xlink:label="us-gaap_FairValueInputsLevel12And3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_LaboratoryEquipmentMember" xlink:label="tcrt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel12And3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" xlink:label="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_VinetiIncMember" xlink:label="tcrt_VinetiIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PocketExpenses" xlink:label="tcrt_PocketExpenses"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_EdenBiocellMember" xlink:label="tcrt_EdenBiocellMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_WatermillAndRobertWPostmaMember" xlink:label="tcrt_WatermillAndRobertWPostmaMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_RelatedPartyTransactionReimbursedAmount" xlink:label="tcrt_RelatedPartyTransactionReimbursedAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_DuneLakeCapitalMember" xlink:label="tcrt_DuneLakeCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AdditionalLoansCommitted" xlink:label="tcrt_AdditionalLoansCommitted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_VinetiIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_PocketExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_EdenBiocellMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CostsAndExpensesRelatedParty" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_WatermillAndRobertWPostmaMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_RelatedPartyTransactionReimbursedAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_DuneLakeCapitalMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_AdditionalLoansCommitted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_IntrexonCorporationMember" xlink:label="tcrt_IntrexonCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PaymentTypeAxis" xlink:label="tcrt_PaymentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PaymentTypeDomain" xlink:label="tcrt_PaymentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PerformanceBasedPaymentsMemberMember" xlink:label="tcrt_PerformanceBasedPaymentsMemberMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_DueDateDomain" xlink:label="tcrt_DueDateDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PostMarketingApprovalMember" xlink:label="tcrt_PostMarketingApprovalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TcellReceptorMember" xlink:label="tcrt_TcellReceptorMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ClassOfWarrantOrRightAxisAxis" xlink:label="tcrt_ClassOfWarrantOrRightAxisAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ClassOfWarrantOrRightDomainDomain" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MdAndersonAgreementAndWorldwideLicenseMember" xlink:label="tcrt_MdAndersonAgreementAndWorldwideLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_DueDateAxis" xlink:label="tcrt_DueDateAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MdAndersonWarrantMember" xlink:label="tcrt_MdAndersonWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_OneTimeBenchmarkPaymentsMember" xlink:label="tcrt_OneTimeBenchmarkPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_LicensedProductsMember" xlink:label="tcrt_LicensedProductsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" xlink:label="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ClinicalExpenses" xlink:label="tcrt_ClinicalExpenses"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_CRADAAgreementMember" xlink:label="tcrt_CRADAAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MilestonePaymentsMaximumAmount" xlink:label="tcrt_MilestonePaymentsMaximumAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember" xlink:label="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_LicenseAgreementCommencingDate" xlink:label="tcrt_LicenseAgreementCommencingDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AnnualLicenseFees" xlink:label="tcrt_AnnualLicenseFees"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AggregateAmountPotentiallyReimburseableAmount" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MaximumAmountOfAdditionalMilestonesPayable" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MaximumAmountOfRoyaltyPayable" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MaximumRoyaltyAmount" xlink:label="tcrt_MaximumRoyaltyAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_QuarterlyExpenseIncurred" xlink:label="tcrt_QuarterlyExpenseIncurred"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AgreementTerminationDate" xlink:label="tcrt_AgreementTerminationDate"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AnnualExpenseIncurred" xlink:label="tcrt_AnnualExpenseIncurred"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AggregatePotentialBenchmarkPayments" xlink:label="tcrt_AggregatePotentialBenchmarkPayments"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AccrualsPriorToFirstMarketingApproval" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_LicenseExpense" xlink:label="tcrt_LicenseExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PaymentUnderLicenseAgreement" xlink:label="tcrt_PaymentUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNameOfPlaintiff" xlink:label="us-gaap_LossContingencyNameOfPlaintiff"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_IntrexonCorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_PaymentTypeAxis" xlink:to="tcrt_PaymentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_PaymentTypeDomain" xlink:to="tcrt_PerformanceBasedPaymentsMemberMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_DueDateDomain" xlink:to="tcrt_PostMarketingApprovalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="tcrt_CommitmentsAndContingenciesDisclosureTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_TcellReceptorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ClassOfWarrantOrRightAxisAxis" xlink:to="tcrt_ClassOfWarrantOrRightDomainDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MdAndersonAgreementAndWorldwideLicenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_DueDateAxis" xlink:to="tcrt_DueDateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ClassOfWarrantOrRightDomainDomain" xlink:to="tcrt_MdAndersonWarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_PaymentTypeDomain" xlink:to="tcrt_OneTimeBenchmarkPaymentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_LicensedProductsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ClinicalExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_CRADAAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MilestonePaymentsMaximumAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="dei_LegalEntityAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_LicenseAgreementCommencingDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_ProductOrServiceAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RoyaltyExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AnnualLicenseFees" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_DueDateAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregateAmountPotentiallyReimburseableAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_PaymentTypeAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumAmountOfAdditionalMilestonesPayable" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_ClassOfWarrantOrRightAxisAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumAmountOfRoyaltyPayable" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_CommitmentsAndContingenciesDisclosureLineItems" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumRoyaltyAmount" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_QuarterlyExpenseIncurred" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AgreementTerminationDate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AnnualExpenseIncurred" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregatePotentialBenchmarkPayments" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AccrualsPriorToFirstMarketingApproval" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_LicenseExpense" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PaymentUnderLicenseAgreement" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LossContingencyDamagesSoughtValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LossContingencyNameOfPlaintiff" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LitigationSettlementExpense" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_OutsideTwoThousandTwelvePlanMember" xlink:label="tcrt_OutsideTwoThousandTwelvePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TwoThousandAndTwelveEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TwoThousandAndThreeEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandAndThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_NonVestedStockMember" xlink:label="tcrt_NonVestedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_NonVestedRestrictedStockMember" xlink:label="tcrt_NonVestedRestrictedStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_OutsideTwoThousandTwelvePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandAndThreeEquityIncentivePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedStockMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedRestrictedStockMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_BlackScholesModelMember" xlink:label="tcrt_BlackScholesModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_WarrantsDisclosureAbstract" xlink:label="tcrt_WarrantsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AgreementTypeAxis" xlink:label="tcrt_AgreementTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_NewWarrantsMember" xlink:label="tcrt_NewWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_SecuritiesPurchaseAgreementMember" xlink:label="tcrt_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MdAndersonWarrantMember" xlink:label="tcrt_MdAndersonWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_FairValueOfWarrants" xlink:label="tcrt_FairValueOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_SvbWarrantsMember" xlink:label="tcrt_SvbWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PlacementAgentFeesAndOtherRelatedExpenses" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_NonOperatingIncomeExpenseInducementOfWarrants" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCallOrExerciseFeatures" xlink:label="us-gaap_CommonStockCallOrExerciseFeatures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ClassOfWarrantOrRightWarrantsExercised" xlink:label="tcrt_ClassOfWarrantOrRightWarrantsExercised"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_BlackScholesModelMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_WarrantsDisclosureAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_NewWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_SecuritiesPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="tcrt_AgreementTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_MdAndersonWarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_FairValueOfWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_SvbWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_PlacementAgentFeesAndOtherRelatedExpenses" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_NonOperatingIncomeExpenseInducementOfWarrants" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCallOrExerciseFeatures" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Dividends" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_ClassOfWarrantOrRightWarrantsExercised" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ZiopharmMember" xlink:label="tcrt_ZiopharmMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ShareSubscriptionAgreementMember" xlink:label="tcrt_ShareSubscriptionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TriArmMember" xlink:label="tcrt_TriArmMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_EdenBioCellMember" xlink:label="tcrt_EdenBioCellMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="tcrt_ZiopharmMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="tcrt_ShareSubscriptionAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_TriArmMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="tcrt_EdenBioCellMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AdditionalPaidInCapitalCommonStockMember" xlink:label="tcrt_AdditionalPaidInCapitalCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tcrt_AdditionalPaidInCapitalCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_IncreaseDecreaseInLeaseLiabilities" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_IncreaseDecreaseInRightOfUseAsset" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="tcrt_IncreaseDecreaseInLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tcrt_IncreaseDecreaseInRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PaymentTypeAxis" xlink:label="tcrt_PaymentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PaymentTypeDomain" xlink:label="tcrt_PaymentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PaymentTypeDomain" xlink:label="tcrt_PaymentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_IntendedPercentageOfResductionInWorkforce" xlink:label="tcrt_IntendedPercentageOfResductionInWorkforce"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_NumberOfEmployeesExpectedToRemain" xlink:label="tcrt_NumberOfEmployeesExpectedToRemain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ReversalOfAccruedExpenses" xlink:label="tcrt_ReversalOfAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_StrategicAdvisorName" xlink:label="tcrt_StrategicAdvisorName"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PreStockSplitSharesAuthorized" xlink:label="tcrt_PreStockSplitSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PostStockSplitSharesAuthorized" xlink:label="tcrt_PostStockSplitSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_PaymentTypeAxis" xlink:to="tcrt_PaymentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tcrt_PaymentTypeAxis" xlink:to="tcrt_PaymentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_IntendedPercentageOfResductionInWorkforce" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_NumberOfEmployeesExpectedToRemain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="tcrt_PaymentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_ReversalOfAccruedExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_StrategicAdvisorName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_PreStockSplitSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_PostStockSplitSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AgreementTypeAxisAxis" xlink:label="tcrt_AgreementTypeAxisAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_SiliconValleyBankMember" xlink:label="tcrt_SiliconValleyBankMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_EquityDistributionAgreementMember" xlink:label="tcrt_EquityDistributionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_StockOfferedDuringPeriodShares" xlink:label="tcrt_StockOfferedDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AtTheMarketOfferingMember" xlink:label="tcrt_AtTheMarketOfferingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_CantorMember" xlink:label="tcrt_CantorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_UnderwriterParOrStatedValuePerShare" xlink:label="tcrt_UnderwriterParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" xlink:label="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" xlink:label="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" xlink:label="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="tcrt_AgreementTypeAxisAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_AgreementTypeAxisAxis" xlink:to="tcrt_AgreementTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tcrt_AgreementTypeAxisAxis" xlink:to="tcrt_AgreementTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="tcrt_SiliconValleyBankMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_EquityDistributionAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_StockOfferedDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tcrt_AtTheMarketOfferingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_StockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_CantorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_UnderwriterParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TermLoanMember" xlink:label="tcrt_TermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_FullyDrawnAmount" xlink:label="tcrt_FullyDrawnAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TermATrancheMember" xlink:label="tcrt_TermATrancheMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_EquityMilestoneMember" xlink:label="tcrt_EquityMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TermBMilestoneMember" xlink:label="tcrt_TermBMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TermBTrancheMember" xlink:label="tcrt_TermBTrancheMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ZeroMilestoneMember" xlink:label="tcrt_ZeroMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_WarrantsExpirationDate" xlink:label="tcrt_WarrantsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TenthScheduledPaymentMember" xlink:label="tcrt_TenthScheduledPaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" xlink:label="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_EightScheduledPaymentMember" xlink:label="tcrt_EightScheduledPaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" xlink:label="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PercentageOfPrepaymentsPremium" xlink:label="tcrt_PercentageOfPrepaymentsPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AmountOfPrepaymentsPremium" xlink:label="tcrt_AmountOfPrepaymentsPremium"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_DebtInstrumentPrepaymentPremium" xlink:label="tcrt_DebtInstrumentPrepaymentPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AdditionalNumberOfWarrantsIssued" xlink:label="tcrt_AdditionalNumberOfWarrantsIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_InterestExpenseAmortizedDate" xlink:label="tcrt_InterestExpenseAmortizedDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PercentageOfPrepaymentPremium" xlink:label="tcrt_PercentageOfPrepaymentPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcrt_TermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_FullyDrawnAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="tcrt_TermATrancheMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_EquityMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="tcrt_TermBMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="tcrt_TermBTrancheMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_ZeroMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_SecuredDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_WarrantsExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_TenthScheduledPaymentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="tcrt_EightScheduledPaymentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_PercentageOfPrepaymentsPremium" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_AmountOfPrepaymentsPremium" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_DebtInstrumentPrepaymentPremium" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_AdditionalNumberOfWarrantsIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_InterestExpenseAmortizedDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeStart1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="tcrt_PercentageOfPrepaymentPremium" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel12And3Member" xlink:label="us-gaap_FairValueInputsLevel12And3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_LaboratoryEquipmentMember" xlink:label="tcrt_LaboratoryEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel12And3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tcrt_LaboratoryEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" xlink:label="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_VinetiIncMember" xlink:label="tcrt_VinetiIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PocketExpenses" xlink:label="tcrt_PocketExpenses"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_EdenBiocellMember" xlink:label="tcrt_EdenBiocellMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="us-gaap_CostsAndExpensesRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_WatermillAndRobertWPostmaMember" xlink:label="tcrt_WatermillAndRobertWPostmaMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_RelatedPartyTransactionReimbursedAmount" xlink:label="tcrt_RelatedPartyTransactionReimbursedAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_DuneLakeCapitalMember" xlink:label="tcrt_DuneLakeCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AdditionalLoansCommitted" xlink:label="tcrt_AdditionalLoansCommitted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_VinetiIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_PocketExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_EdenBiocellMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CostsAndExpensesRelatedParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_WatermillAndRobertWPostmaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_RelatedPartyTransactionReimbursedAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_DuneLakeCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="tcrt_AdditionalLoansCommitted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:label="tcrt_CommitmentsAndContingenciesDisclosureTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_IntrexonCorporationMember" xlink:label="tcrt_IntrexonCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PaymentTypeAxis" xlink:label="tcrt_PaymentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PaymentTypeDomain" xlink:label="tcrt_PaymentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PerformanceBasedPaymentsMemberMember" xlink:label="tcrt_PerformanceBasedPaymentsMemberMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_DueDateDomain" xlink:label="tcrt_DueDateDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PostMarketingApprovalMember" xlink:label="tcrt_PostMarketingApprovalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" xlink:label="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TcellReceptorMember" xlink:label="tcrt_TcellReceptorMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ClassOfWarrantOrRightAxisAxis" xlink:label="tcrt_ClassOfWarrantOrRightAxisAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ClassOfWarrantOrRightDomainDomain" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ClassOfWarrantOrRightDomainDomain" xlink:label="tcrt_ClassOfWarrantOrRightDomainDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MdAndersonAgreementAndWorldwideLicenseMember" xlink:label="tcrt_MdAndersonAgreementAndWorldwideLicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_DueDateAxis" xlink:label="tcrt_DueDateAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_DueDateDomain" xlink:label="tcrt_DueDateDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MdAndersonWarrantMember" xlink:label="tcrt_MdAndersonWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" xlink:label="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_OneTimeBenchmarkPaymentsMember" xlink:label="tcrt_OneTimeBenchmarkPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_LicensedProductsMember" xlink:label="tcrt_LicensedProductsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" xlink:label="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ClinicalExpenses" xlink:label="tcrt_ClinicalExpenses"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" xlink:label="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_CRADAAgreementMember" xlink:label="tcrt_CRADAAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MilestonePaymentsMaximumAmount" xlink:label="tcrt_MilestonePaymentsMaximumAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember" xlink:label="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_LicenseAgreementCommencingDate" xlink:label="tcrt_LicenseAgreementCommencingDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AnnualLicenseFees" xlink:label="tcrt_AnnualLicenseFees"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AggregateAmountPotentiallyReimburseableAmount" xlink:label="tcrt_AggregateAmountPotentiallyReimburseableAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MaximumAmountOfAdditionalMilestonesPayable" xlink:label="tcrt_MaximumAmountOfAdditionalMilestonesPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MaximumAmountOfRoyaltyPayable" xlink:label="tcrt_MaximumAmountOfRoyaltyPayable"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" xlink:label="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MaximumRoyaltyAmount" xlink:label="tcrt_MaximumRoyaltyAmount"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_QuarterlyExpenseIncurred" xlink:label="tcrt_QuarterlyExpenseIncurred"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AgreementTerminationDate" xlink:label="tcrt_AgreementTerminationDate"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AnnualExpenseIncurred" xlink:label="tcrt_AnnualExpenseIncurred"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AggregatePotentialBenchmarkPayments" xlink:label="tcrt_AggregatePotentialBenchmarkPayments"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AccrualsPriorToFirstMarketingApproval" xlink:label="tcrt_AccrualsPriorToFirstMarketingApproval"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_LicenseExpense" xlink:label="tcrt_LicenseExpense"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PaymentUnderLicenseAgreement" xlink:label="tcrt_PaymentUnderLicenseAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNameOfPlaintiff" xlink:label="us-gaap_LossContingencyNameOfPlaintiff"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_CommitmentsAndContingenciesDisclosureTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_IntrexonCorporationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_PaymentTypeAxis" xlink:to="tcrt_PaymentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_PaymentTypeDomain" xlink:to="tcrt_PerformanceBasedPaymentsMemberMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_DueDateDomain" xlink:to="tcrt_PostMarketingApprovalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_TcellReceptorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_ClassOfWarrantOrRightAxisAxis" xlink:to="tcrt_ClassOfWarrantOrRightDomainDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tcrt_ClassOfWarrantOrRightAxisAxis" xlink:to="tcrt_ClassOfWarrantOrRightDomainDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MdAndersonAgreementAndWorldwideLicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_DueDateAxis" xlink:to="tcrt_DueDateDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tcrt_DueDateAxis" xlink:to="tcrt_DueDateDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_ClassOfWarrantOrRightDomainDomain" xlink:to="tcrt_MdAndersonWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_PaymentTypeDomain" xlink:to="tcrt_OneTimeBenchmarkPaymentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tcrt_LicensedProductsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_ClinicalExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="tcrt_CRADAAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MilestonePaymentsMaximumAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_LicenseAgreementCommencingDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AnnualLicenseFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_DueDateAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregateAmountPotentiallyReimburseableAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_PaymentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumAmountOfAdditionalMilestonesPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="tcrt_ClassOfWarrantOrRightAxisAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumAmountOfRoyaltyPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_MaximumRoyaltyAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_QuarterlyExpenseIncurred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AgreementTerminationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AnnualExpenseIncurred" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AggregatePotentialBenchmarkPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_AccrualsPriorToFirstMarketingApproval" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_LicenseExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="tcrt_PaymentUnderLicenseAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LossContingencyDamagesSoughtValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LossContingencyNameOfPlaintiff" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_LitigationSettlementExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_OutsideTwoThousandTwelvePlanMember" xlink:label="tcrt_OutsideTwoThousandTwelvePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_NonVestedStockMember" xlink:label="tcrt_NonVestedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TwoThousandAndTwentyEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_NonVestedRestrictedStockMember" xlink:label="tcrt_NonVestedRestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TwoThousandAndTwelveEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TwoThousandAndThreeEquityIncentivePlanMember" xlink:label="tcrt_TwoThousandAndThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_OutsideTwoThousandTwelvePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tcrt_NonVestedRestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tcrt_TwoThousandAndThreeEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_BlackScholesModelMember" xlink:label="tcrt_BlackScholesModelMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_SiliconValleyBankLoanMember" xlink:label="tcrt_SiliconValleyBankLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AgreementTypeAxis" xlink:label="tcrt_AgreementTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_AgreementTypeDomain" xlink:label="tcrt_AgreementTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_NewWarrantsMember" xlink:label="tcrt_NewWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_SecuritiesPurchaseAgreementMember" xlink:label="tcrt_SecuritiesPurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_MdAndersonWarrantMember" xlink:label="tcrt_MdAndersonWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_FairValueOfWarrants" xlink:label="tcrt_FairValueOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_SvbWarrantsMember" xlink:label="tcrt_SvbWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PlacementAgentFeesAndOtherRelatedExpenses" xlink:label="tcrt_PlacementAgentFeesAndOtherRelatedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_NonOperatingIncomeExpenseInducementOfWarrants" xlink:label="tcrt_NonOperatingIncomeExpenseInducementOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCallOrExerciseFeatures" xlink:label="us-gaap_CommonStockCallOrExerciseFeatures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ClassOfWarrantOrRightWarrantsExercised" xlink:label="tcrt_ClassOfWarrantOrRightWarrantsExercised"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_BlackScholesModelMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="tcrt_SiliconValleyBankLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tcrt_AgreementTypeAxis" xlink:to="tcrt_AgreementTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_NewWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tcrt_AgreementTypeDomain" xlink:to="tcrt_SecuritiesPurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="tcrt_AgreementTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_MdAndersonWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_FairValueOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="tcrt_SvbWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_PlacementAgentFeesAndOtherRelatedExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_NonOperatingIncomeExpenseInducementOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCallOrExerciseFeatures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Dividends" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tcrt_ClassOfWarrantOrRightWarrantsExercised" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:label="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ZiopharmMember" xlink:label="tcrt_ZiopharmMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_ShareSubscriptionAgreementMember" xlink:label="tcrt_ShareSubscriptionAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_TriArmMember" xlink:label="tcrt_TriArmMember"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_EdenBioCellMember" xlink:label="tcrt_EdenBioCellMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_default"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="tcrt_ZiopharmMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="tcrt_ShareSubscriptionAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tcrt_TriArmMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="tcrt_EdenBioCellMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ReceivablesNetCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="tcrt_GainLossOnOperatingLeaseModification" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RestructuringCharges" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_GainLossOnOperatingLeaseModification" xlink:label="tcrt_GainLossOnOperatingLeaseModification"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment" xlink:label="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tcrt_IncreaseDecreaseInRightOfUseAsset" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tcrt_IncreaseDecreaseInLeaseLiabilities" order="14" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_IncreaseDecreaseInRightOfUseAsset" xlink:label="tcrt_IncreaseDecreaseInRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="tcrt-20240331.xsd#tcrt_IncreaseDecreaseInLeaseLiabilities" xlink:label="tcrt_IncreaseDecreaseInLeaseLiabilities"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="tcrt_DebtInstrumentPrepaymentPremium" name="DebtInstrumentPrepaymentPremium" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_StrategicAdvisorName" name="StrategicAdvisorName" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PercentageOfPrepaymentPremium" name="PercentageOfPrepaymentPremium" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_AdditionalLoansCommitted" name="AdditionalLoansCommitted" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_AgreementTypeAxis" name="AgreementTypeAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MdAndersonAgreementAndWorldwideLicenseMember" name="MdAndersonAgreementAndWorldwideLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AggregatePotentialBenchmarkPayments" name="AggregatePotentialBenchmarkPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_PerformanceBasedPaymentsMemberMember" name="PerformanceBasedPaymentsMemberMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember" name="ZiopLicenseAgreementWithTheNationalCancerInstituteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_LicenseExpense" name="LicenseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_FairValueOfWarrants" name="FairValueOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_TenthScheduledPaymentMember" name="TenthScheduledPaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_WarrantsExpirationDate" name="WarrantsExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_TermLoanMember" name="TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PercentageOfPrepaymentsPremium" name="PercentageOfPrepaymentsPremium" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_VinetiIncMember" name="VinetiIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TermBMilestoneMember" name="TermBMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_LicensedProductsMember" name="LicensedProductsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_DueDateAxis" name="DueDateAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_InterestExpenseAmortizedDate" name="InterestExpenseAmortizedDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_LicenseAgreementWithTheNationalCancerInstituteMember" name="LicenseAgreementWithTheNationalCancerInstituteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_IncreaseDecreaseInLeaseLiabilities" name="IncreaseDecreaseInLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_OneTimeBenchmarkPaymentsMember" name="OneTimeBenchmarkPaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" name="MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PaymentTypeDomain" name="PaymentTypeDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_NewWarrantsMember" name="NewWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PlacementAgentFeesAndOtherRelatedExpenses" name="PlacementAgentFeesAndOtherRelatedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_TwoThousandAndThreeEquityIncentivePlanMember" name="TwoThousandAndThreeEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ClassOfWarrantOrRightDomainDomain" name="ClassOfWarrantOrRightDomainDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_SiliconValleyBankLoanMember" name="SiliconValleyBankLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_CommitmentsAndContingenciesDisclosureTable" name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EdenBioCellMember" name="EdenBioCellMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_UnderwriterParOrStatedValuePerShare" name="UnderwriterParOrStatedValuePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_AgreementTypeDomain" name="AgreementTypeDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_CRADAAgreementMember" name="CRADAAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_NonOperatingIncomeExpenseInducementOfWarrants" name="NonOperatingIncomeExpenseInducementOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_WarrantsDisclosureAbstract" name="WarrantsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" name="RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_SiliconValleyBankMember" name="SiliconValleyBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_CantorMember" name="CantorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ZeroMilestoneMember" name="ZeroMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ReverseStockSplitPolicyTextBlock" name="ReverseStockSplitPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_AdditionalNumberOfWarrantsIssued" name="AdditionalNumberOfWarrantsIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_RelatedPartyTransactionReimbursedAmount" name="RelatedPartyTransactionReimbursedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_OutsideTwoThousandTwelvePlanMember" name="OutsideTwoThousandTwelvePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TermATrancheMember" name="TermATrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PocketExpenses" name="PocketExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_TermBTrancheMember" name="TermBTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_StockOfferedDuringPeriodShares" name="StockOfferedDuringPeriodShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" name="ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_GainLossOnOperatingLeaseModification" name="GainLossOnOperatingLeaseModification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_DuneLakeCapitalMember" name="DuneLakeCapitalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_PostMarketingApprovalMember" name="PostMarketingApprovalMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_DueDateDomain" name="DueDateDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TwoThousandAndTwelveEquityIncentivePlanMember" name="TwoThousandAndTwelveEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_NumberOfEmployeesExpectedToRemain" name="NumberOfEmployeesExpectedToRemain" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PaymentUnderLicenseAgreement" name="PaymentUnderLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_QuarterlyExpenseIncurred" name="QuarterlyExpenseIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" name="NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PaymentTypeAxis" name="PaymentTypeAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_SvbWarrantsMember" name="SvbWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AgreementTerminationDate" name="AgreementTerminationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PostStockSplitSharesAuthorized" name="PostStockSplitSharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PreStockSplitSharesAuthorized" name="PreStockSplitSharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_FinancingArrangementsDisclosureTextBlock" name="FinancingArrangementsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_WatermillAndRobertWPostmaMember" name="WatermillAndRobertWPostmaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_IntendedPercentageOfResductionInWorkforce" name="IntendedPercentageOfResductionInWorkforce" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember" name="MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_CollaborationAgreementWithSolasiaPharmaKkMember" name="CollaborationAgreementWithSolasiaPharmaKkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_WarrantTextBlock" name="WarrantTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty" name="PercentageOfSubLicensingIncomePayableToRelatedParty" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_LicenseAgreementCommencingDate" name="LicenseAgreementCommencingDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_MilestonePaymentsMaximumAmount" name="MilestonePaymentsMaximumAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_IntrexonCorporationMember" name="IntrexonCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AggregateAmountPotentiallyReimburseableAmount" name="AggregateAmountPotentiallyReimburseableAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_EdenBiocellMember" name="EdenBiocellMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_IncreaseDecreaseInRightOfUseAsset" name="IncreaseDecreaseInRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" name="TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AnnualExpenseIncurred" name="AnnualExpenseIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment" name="PercentageOfOriginalPrincipalDueAsAFinalPayment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_ClassOfWarrantOrRightAxisAxis" name="ClassOfWarrantOrRightAxisAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_ReversalOfAccruedExpenses" name="ReversalOfAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_NonVestedStockMember" name="NonVestedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_FullyDrawnAmount" name="FullyDrawnAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_ShareSubscriptionAgreementMember" name="ShareSubscriptionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_EightScheduledPaymentMember" name="EightScheduledPaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TriArmMember" name="TriArmMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MaximumRoyaltyAmount" name="MaximumRoyaltyAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment" name="PropertyAndEquipmentAndRightOfUseAssetsImpairment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_StockOptionsAndRestrictedStockAwardsTextBlock" name="StockOptionsAndRestrictedStockAwardsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_ClassOfWarrantOrRightWarrantsExercised" name="ClassOfWarrantOrRightWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_ClinicalExpenses" name="ClinicalExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_AmountOfPrepaymentsPremium" name="AmountOfPrepaymentsPremium" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_ZiopharmMember" name="ZiopharmMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MdAndersonWarrantMember" name="MdAndersonWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AnnualLicenseFees" name="AnnualLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_EquityMilestoneMember" name="EquityMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MaximumAmountOfAdditionalMilestonesPayable" name="MaximumAmountOfAdditionalMilestonesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_AgreementTypeAxisAxis" name="AgreementTypeAxisAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AccrualsPriorToFirstMarketingApproval" name="AccrualsPriorToFirstMarketingApproval" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tcrt_EquityDistributionAgreementMember" name="EquityDistributionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TwoThousandAndTwentyEquityIncentivePlanMember" name="TwoThousandAndTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_MaximumAmountOfRoyaltyPayable" name="MaximumAmountOfRoyaltyPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" name="PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tcrt_NonVestedRestrictedStockMember" name="NonVestedRestrictedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_AdditionalPaidInCapitalCommonStockMember" name="AdditionalPaidInCapitalCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_TcellReceptorMember" name="TcellReceptorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tcrt_BlackScholesModelMember" name="BlackScholesModelMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911601740384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>May 12, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Alaunos Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001107421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TCRT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,012,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-1475642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2617 Bissonnet Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">355-4099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911601401696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,145<span></span>
</td>
<td class="nump">$ 6,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,891<span></span>
</td>
<td class="nump">2,198<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,037<span></span>
</td>
<td class="nump">8,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">6,037<span></span>
</td>
<td class="nump">8,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">597<span></span>
</td>
<td class="nump">616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">643<span></span>
</td>
<td class="nump">1,340<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,240<span></span>
</td>
<td class="nump">1,956<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,240<span></span>
</td>
<td class="nump">1,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock $0.001 par value; 34,666,667 shares authorized, 16,012,522 shares issued and outstanding at March 31, 2024 and at December 31, 2023</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">922,230<span></span>
</td>
<td class="nump">922,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(917,449)<span></span>
</td>
<td class="num">(915,767)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">4,797<span></span>
</td>
<td class="nump">6,307<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 6,037<span></span>
</td>
<td class="nump">$ 8,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911685635344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">34,666,667<span></span>
</td>
<td class="nump">34,666,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">16,012,522<span></span>
</td>
<td class="nump">16,012,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">16,012,522<span></span>
</td>
<td class="nump">16,012,522<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911601631552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">6,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,617<span></span>
</td>
<td class="nump">3,168<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,743<span></span>
</td>
<td class="nump">9,672<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,742)<span></span>
</td>
<td class="num">(9,672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(853)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">477<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">60<span></span>
</td>
<td class="num">(376)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,682)<span></span>
</td>
<td class="num">$ (10,048)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, Basic</a></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, Diluted</a></td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="nump">16,012,522<span></span>
</td>
<td class="nump">15,978,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">16,012,522<span></span>
</td>
<td class="nump">15,978,623<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911601723856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 38,555<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 919,166<span></span>
</td>
<td class="num">$ (880,627)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,027,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of expenses</a></td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of expenses, (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(10,048)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,048)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">29,509<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">920,168<span></span>
</td>
<td class="num">(890,675)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,041,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">6,307<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">922,058<span></span>
</td>
<td class="num">(915,767)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,012,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,682)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,682)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 4,797<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 922,230<span></span>
</td>
<td class="num">$ (917,449)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,012,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911689381312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,682)<span></span>
</td>
<td class="num">$ (10,048)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of financing costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash', window );">Stock-based compensation</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IncreaseDecreaseInRightOfUseAsset', window );">Decrease in the carrying amount of right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase) decrease in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">307<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase (decrease) in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(697)<span></span>
</td>
<td class="num">(1,334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,917)<span></span>
</td>
<td class="num">(9,381)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the disposal of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,250)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,158)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(1,917)<span></span>
</td>
<td class="num">(15,562)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">6,062<span></span>
</td>
<td class="nump">52,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">4,145<span></span>
</td>
<td class="nump">37,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Amounts included in accrued expenses and accounts payable related to property and equipment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of lease liabilities reported as liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_IncreaseDecreaseInRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of right of use asset reported as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_IncreaseDecreaseInRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911690757408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (1,682)<span></span>
</td>
<td class="num">$ (10,048)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911687911760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911595884704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization</a></td>
<td class="text"><div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Organization</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Alaunos Therapeutics, Inc., which is referred to herein as &#8220;Alaunos,&#8221; or the &#8220;Company,&#8221; is a clinical-stage oncology-focused cell therapy company that was historically involved in the development of adoptive TCR therapies, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. The Company is leveraging its proprietary, non-viral </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">gene transfer platform and its novel cancer mutation hotspot TCR library to design and manufacture personalized cell therapies that target neoantigens arising from common tumor-related mutations in key oncogenic genes, including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS, TP53 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s operations to date have consisted primarily of conducting research and development and raising capital to fund those efforts.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of March 31, 2024, there were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16,012,522</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shares of common stock outstanding and an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,714,489</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shares of common stock reserved for issuance pursuant to outstanding stock options and warrants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2023, the Company announced a strategic reprioritization of its business and wind down of its TCR-T Library Phase 1/2 Trial. In connection with the reprioritization, the Company has significantly reduced its workforce and continues working to reduce costs in order to extend its cash runway. The Company continues to explore strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. The Company has engaged Cantor Fitzgerald &amp; Co., or </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cantor</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to act as strategic advisor for this process.  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company follows the guidance of Accounting Standards Codification, or ASC, Topic 205-40, Presentation of Financial Statements - Going Concern, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its condensed financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management's plans that have not been fully implemented as of the date the condensed financial statements are issued. When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the condensed financial statements are issued and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the condensed financial statements are issued.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has operated at a loss since its inception in 2003 and has no recurring revenue from operations.&#8239;The Company anticipates that losses will continue for the foreseeable future. As of March 31, 2024, the Company had approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of cash and cash equivalents. The Company&#8217;s accumulated deficit at March 31, 2024 was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">917.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.&#8239;Given its current development plans and cash management efforts, the Company anticipates cash resources will be sufficient to fund operations into the third quarter of 2024.&#8239;The Company&#8217;s ability to continue operations after its current cash resources are exhausted depends on future events outside of the Company's control, including its ability to obtain additional financing or to achieve profitable results, as to which no assurances can be given. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If adequate additional funds are not available when required, or if the Company is unsuccessful in entering into partnership agreements for further development of its product candidates, management may need to curtail its development efforts and planned operations to conserve cash until sufficient additional capital is raised. There can be no assurances that such a plan would be successful.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on the current cash forecast and the Company's dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the condensed financial statements, and substantial doubt as to the Company's ability to continue as a going concern exists. This forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited interim condensed financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information and note disclosures required by generally accepted accounting principles in the United States, or GAAP, have been condensed or omitted pursuant to such rules and regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is management&#8217;s opinion that the accompanying unaudited interim condensed financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair presentation of the financial position of the Company and its results of operations and cash flows for the periods presented. The unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2023, included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on April 1, 2024, or the Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results disclosed in the statements of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full fiscal year 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Stock Split</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 31, 2024, the Company filed a Second Amended and Restated Certificate of Incorporation (the &#8220;Charter Amendment&#8221;) with the Secretary of State of the State of Delaware in order to effect a reverse stock split of the Company&#8217;s common stock at a ratio of 1-for-15 (the &#8220;Reverse Split&#8221;). The Charter Amendment decreased the number of authorized shares of common stock from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">520,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">34,666,667</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Charter Amendment does not affect the par value of the Company&#8217;s common stock or change the number of authorized shares or par value of the Company&#8217;s preferred stock. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Charter Amendment became effective on January 31, 2024 at 5:00 p.m. Eastern Time, at which time every 15 shares of the Company&#8217;s issued and outstanding common stock automatically combined and converted into 1 share of common stock.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No fractional shares were issued in connection with the Reverse Split. Stockholders of record who would otherwise have been entitled to receive fractional shares as a result of the Reverse Split received a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing sales price per share of the common stock (as adjusted for the Reverse Split) on The Nasdaq Capital Market on January 31, 2024.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All share and per share amounts of common stock, options, warrants, and restricted stock in the accompanying financial statements and notes thereto have been retroactively adjusted for all periods presented to reflect the Reverse Split as if it had occurred at the beginning of the earliest period presented.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911595908352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financings<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_FinancingArrangementsDisclosureTextBlock', window );">Financings</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financings</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2021 Loan and Security Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 6, 2021, the Company entered into a Loan and Security Agreement, or the Loan and Security Agreement, with Silicon Valley Bank and affiliates of Silicon Valley Bank, or collectively, SVB. The Loan and Security Agreement provided for an initial term loan of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million funded at the closing, or the Term A Tranche, with an additional tranche of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million available if certain funding and clinical milestones were met by August 31, 2022, or the Term B Tranche.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Effective December 28, 2021, the Company, entered into an amendment to the Loan and Security Agreement, or the First Amendment. The First Amendment extended the interest-only period through August 31, 2022. The First Amendment also eliminated the Term B Tranche, which remained unfunded, leaving only the Term A Tranche, or the SVB Facility. Under the amended Loan and Security Agreement, the SVB Facility was to mature on August 1, 2023. On May 1, 2023, the Company repaid its outstanding debt obligations under the amended Loan and Security Agreement in their entirety.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Refer to Note 4, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for further discussion of the Loan and Security Agreement and the First Amendment.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2022 Equity Distribution Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 12, 2022, the Company entered into an Equity Distribution Agreement, or the Equity Distribution Agreement, with Piper Sandler &amp; Co., or Piper Sandler, pursuant to which the Company can offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million through Piper Sandler as its sales agent in an "at the market offering." Piper Sandler will receive a commission of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the gross proceeds of any common stock sold under the Equity Distribution</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Agreement. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended March 31, 2024 and 2023, there have been </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> sales of the Company's common stock under the Equity Distribution Agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2022 Public Offering</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 29, 2022, the Company entered into an underwriting agreement, or the Underwriting Agreement, with Cantor as the sole underwriter, relating to the issuance and sale in an underwritten offering, or the Offering, of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,615,248</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares, or the Firm Shares, of the Company&#8217;s common stock to Cantor at a price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.2865</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The net proceeds to the Company from the Offering were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (before accounting for the partial exercise of Cantor's option as described below) after deducting underwriting discounts and commissions and offering expenses payable by the Company.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Underwriting Agreement, the Company granted Cantor an option, exercisable for </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30 days</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, to purchase up to an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">242,287</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, which we refer to, together with the Firm Shares, as the Shares, at the same price per share as the Firm Shares. On January 5, 2023, Cantor partially exercised its option to purchase an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14,420</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_FinancingArrangementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Includes disclosures related to financing receivables and financing guarantees in which the company is the guarantor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_FinancingArrangementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911595872512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Summary of Significant Accounting Policies</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s significant accounting policies were identified in the Company&#8217;s Annual Report. There have been no material changes in those policies since the filing of its Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911688710528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Debt</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> debt obligations outstanding at March 31, 2024 and December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 6, 2021, the Company entered into the Loan and Security Agreement with SVB. The Loan and Security Agreement provided for the funding of the Term A Tranche at the closing, with the Term B Tranche available if certain funding and clinical milestones were met by August 31, 2022. The SVB Facility and related obligations under the Loan and Security Agreement were secured by substantially all of the Company's properties, rights and assets, except for its intellectual property (which was subject to a negative pledge under the Loan and Security Agreement). In addition, the Loan and Security Agreement contained customary representations, warranties, events of default and covenants.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 28, 2021, the Company entered into the First Amendment to the Loan and Security Agreement. The First Amendment eliminated the unfunded Term B Tranche, among other things. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The SVB Facility bore interest at a floating rate per annum on outstanding loans, payable monthly, at the greater of (a) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and (b) the current published U.S. prime rate, plus a margin of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All outstanding obligations under the amended Loan and Security Agreement were due and payable on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 1, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In connection with the payment of all of the Company's outstanding obligations, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the Company also owed SVB </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the original principal amounts borrowed as a final payment, or the Final Payment. Effective March 30, 2023, the Company entered into a Third Amendment to the Loan and Security Agreement, or the Third Amendment. Under the terms of the Third Amendment, the Company was no longer required to maintain all of its operating accounts, depository accounts and excess cash with SVB or one of its affiliates, and was instead only required to maintain a single operating or depository account at Silicon Valley Bank. The Third Amendment also modified the cash collateralization requirement, such that the Company was required to cash collateralize the entire sum of the outstanding principal amount of the SVB Facility, plus an amount equal to the Final Payment, which amount was to be reduced commensurate with each regularly scheduled monthly payment of principal and interest on the SVB Facility.</span></span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 1, 2023, the Company paid SVB an amount equal to the entire outstanding principal amount under the SVB Facility, all accrued and unpaid interest and the Final Payment. In accordance with the First Amendment, the payment was subject to a prepayment premium of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%. During the second quarter of 2023, the Company recorded the remaining amounts associated with the Final Payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and the prepayment premium of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as interest expense within the condensed statement of operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with its entry into the Loan and Security Agreement in August 2021, the Company issued to SVB warrants to purchase (i) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,856</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock, in the aggregate, and (ii) up to an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,856</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, in the aggregate, in the event the Company achieved certain clinical milestones, in each case at an exercise price per share of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33.30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with its entry into the First Amendment in December 2021, the Company amended and restated the warrants issued to SVB. As amended and restated, the warrants are for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">43,308</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, in the aggregate, with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.40</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, or the SVB Warrants. The SVB Warrants expire on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">August 6, 2031</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The issuance costs for the Loan and Security Agreement, including the First Amendment, were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and primarily related to the issuance of the SVB Warrants, which were amortized into interest expense over the term of the loan. Interest expense,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the amortization of issuance costs, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for the three months ended March 31, 2024, compared to $0</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the three months ended March 31, 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911691173136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair Value Measurements</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</span></p><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3&#8212;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of March 31, 2024 and December 31, 2023 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.603000000000002%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.542%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.302%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.302%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance as of<br/>March 31,<br/>2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,832</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,832</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.203999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.924999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.303999999999998%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.303999999999998%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance as of<br/>December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,744</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,744</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The cash equivalents represent demand deposit accounts and deposits in a short-term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been no changes to the valuation methods during the three months ended March 31, 2024. We had </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> financial assets or liabilities that were classified as Level 2 or Level 3 during the three months ended March 31, 2024.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911690823120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net loss per share</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">net loss per share of common stock is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period, plus the dilutive effect of outstanding options and warrants, using the treasury stock method and the average market price of the Company's common stock during the applicable period, unless their effect on net loss per share is antidilutive. The effect of computing diluted net loss per common share was antidilutive for any potentially issuable shares of common stock from the conversion of stock options, unvested restricted stock and warrants and, as</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">have been excluded from the calculation. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such potentially dilutive shares of common stock consisted of the following as of March 31, 2024 and 2023:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">251,457</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">887,549</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59,875</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,452,399</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,528,156</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,703,856</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,475,580</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911601745584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Related Party Transactions</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Joint Venture with TriArm Therapeutics/Eden BioCell</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 18, 2018, the Company and TriArm Therapeutics, Ltd., or TriArm, launched Eden BioCell, Ltd., or Eden BioCell, as a joint venture to lead commercialization of the Company&#8217;s </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-generated CAR-T therapies in the People&#8217;s Republic of China (including Macau and Hong Kong), Taiwan and Korea. The Company licensed to Eden BioCell the rights in Greater China for its third-generation </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-generated CAR-T therapies targeting the CD19 antigen. Eden BioCell is owned equally by the Company and TriArm and the parties share decision-making authority. TriArm contributed $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to Eden BioCell and has committed up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to this joint venture. TriArm also managed all clinical development in the territory pursuant to a master services agreement between TriArm and Eden BioCell. James Huang was the founder and serves as managing partner of Panacea Venture, which is an investor in TriArm. Mr. Huang was the Chair of the Company's board of directors until September 22, 2023 and had been a director since July 2020. He also serves as a member of Eden BioCell&#8217;s board of directors.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, TriArm and Alaunos mutually agreed to dissolve the Eden BioCell joint venture. The joint venture agreement has been terminated and the Eden BioCell entity has been dissolved as of July 2023. Refer to Note 13, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Joint Venture</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, for further details.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration with Dune Lake Capital</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2023, the Company entered into a consulting agreement with Dune Lake Capital, LLC, or Dune Lake Capital, which was founded by Dale Curtis Hogue, Jr., the Company's interim Chief Executive Officer. During the three months ended March 31, 2024 and 2023, the Company recorded expenses of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand, respectively, for consulting services performed by Dune Lake Capital.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911601102272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commitments and Contingencies</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">License Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exclusive License Agreement with Precigen</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 5, 2018, the Company entered into an exclusive license agreement, or License Agreement, with PGEN Therapeutics, or PGEN, a wholly owned subsidiary of Precigen Inc., or Precigen, which was formerly known as Intrexon Corporation. Except where the context otherwise requires, the Company refers to PGEN and Precigen together as Precigen. Pursuant to the terms of the License Agreement, the Company had exclusive, worldwide rights to research, develop and commercialize (i) TCR products designed for neoantigens for the treatment of cancer, (ii) products utilizing Precigen&#8217;s RheoSwitch&#174; gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products and (iii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) BCMA for the treatment of cancer, subject to certain obligations to pursue such target under the License and Collaboration Agreement effective March 27, 2015 between the Company, Precigen and ARES TRADING S.A., a subsidiary of Merck KGaA, as assigned by Precigen to PGEN. Under the License Agreement, the Company also had exclusive, worldwide rights for certain patents relating to the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company was responsible for all aspects of the research, development and commercialization and was required to use commercially reasonable efforts to develop certain products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In consideration of the licenses and other rights granted by Precigen, the Company was required to pay Precigen an annual license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, reimburse Precigen for certain historical costs, pay Precigen milestones up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">52.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for each exclusively licensed program upon the achievement of certain milestones, and pay Precigen tiered royalties up to a maximum royalty amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the aggregate. The Company was also obligated to pay Precigen </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of any sublicensing</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">income </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">received by us relating to the licensed products. The Company was responsible for all development costs associated with each of the licensed products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Precigen was obligated to pay the Company royalties up to a maximum royalty amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> royalty amounts were incurred during the three months ended March 31, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 3, 2023, the Company entered into the Amended and Restated Exclusive License Agreement with Precigen, or the A&amp;R License Agreement, which restated and amended the License Agreement in full. Under the A&amp;R License Agreement, the Company still has exclusive, worldwide rights to research, develop and commercialize TCR products designed for neoantigens or driver mutations for the treatment of cancer and non-exclusive rights to use non-driver mutation TCRs. The Company further maintains its exclusive, worldwide rights for certain patents relating to the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company remains solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. The (i) products utilizing Precigen&#8217;s RheoSwitch&#174; gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products and (ii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) BCMA for the treatment of cancer, subject to certain obligations to pursue such target under the License and Collaboration Agreement effective March 27, 2015 between the Company, Precigen and ARES TRADING S.A., a subsidiary of Merck KGaA, as assigned by Precigen to PGEN are no longer exclusively licensed to the Company. The Company is no longer obligated to use commercially reasonable efforts for the exclusively licensed products. The A&amp;R License Agreement further eliminates any royalty or milestone obligations to Precigen, with an annual license fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand due on the anniversary of the A&amp;R License Agreement effective date. Precigen is no longer obligated to pay the Company royalties on the net sales derived from the sale of Precigen's CAR products.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreement and 2015 Research and Development Agreement &#8212;The University of Texas MD Anderson Cancer Center</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 13, 2015</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company, together with Precigen, entered into a license agreement, or the MD Anderson License with MD Anderson (which Precigen subsequently assigned to PGEN). Pursuant to the MD Anderson License, the Company, together with Precigen, holds an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR T-cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer, or NK Cells, and TCRs.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 17, 2015, the Company, Precigen and MD Anderson entered into the 2015 R&amp;D Agreement to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the MD Anderson License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs. The rights and obligations of Precigen under the 2015 R&amp;D Agreement were assigned to the Company pursuant to the Fourth Amendment to 2015 R&amp;D Agreement which was entered into on September 19, 2019 (the &#8220;Fourth Amendment&#8221;) with an effective date of October 5, 2018. The activities under the 2015 R&amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As provided under the MD Anderson License, the Company provided funding for research and development activities in support of the research programs under the 2015 R&amp;D Agreement for a period of three years and in an amount of no less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and no greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million per year. On November 14, 2017, the Company entered into an amendment to the 2015 R&amp;D Agreement, extending its term until April 15, 2021. In connection with the execution of the 2019 R&amp;D Agreement described below, on October 22, 2019, the Company amended the 2015 R&amp;D Agreement to extend the term of the 2015 R&amp;D Agreement until December 31, 2026 and to allow cash resources on hand at MD Anderson under the 2015 R&amp;D Agreement to be used for development costs under the 2019 Research and Development Agreement, or the 2019 R&amp;D Agreement, which the Company entered into on October 22, 2019, with MD Anderson, pursuant to which the Company agreed to collaborate with respect to the TCR program. The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t incur clinical costs from MD Anderson related to the 2015 R&amp;D Agreement for the three months ended March 31, 2024 and 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term of the MD Anderson License, the Company, together with Precigen, shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the MD Anderson License and subject to a 90-day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if the Company and Precigen are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third-party contract if the Company and Precigen are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by the Company and Precigen, if</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both the Company and Precigen and may be terminated by the mutual written agreement of the Company, Precigen, and MD Anderson.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2019 Research and Development Agreement&#8212;The University of Texas MD Anderson Cancer Center</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the 2019 R&amp;D Agreement, the Company and MD Anderson will, among other things, collaborate on programs to expand the Company's TCR library and conduct clinical trials. The activities under the 2019 R&amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company will own all inventions and intellectual property developed under the 2019 R&amp;D Agreement and the Company will retain all rights to all intellectual property, patentable or not, for oncology products manufactured using non-viral gene transfer technologies under the 2019 R&amp;D Agreement, including the Company's</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology. The Company has granted MD Anderson an exclusive license for such intellectual property to develop and commercialize autologous TCR products manufactured using viral gene transfer technologies and any products outside the field of oncology and a non-exclusive license for allogenic TCR products manufactured using viral-based technologies.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the 2019 R&amp;D Agreement, the Company agreed, beginning on January 1, 2021, to reimburse MD Anderson up to a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for development costs under the 2019 R&amp;D Agreement, after the funds from the 2015 R&amp;D Agreement are exhausted. In addition, the Company will pay MD Anderson royalties on net sales of its TCR products. The Company is required to make performance-based payments upon the successful completion of clinical and regulatory benchmarks relating to its TCR products. The aggregate potential benchmark payments are $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">36.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, of which only $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million will be due prior to the first marketing approval of the Company's TCR products. The royalty rates and benchmark payments owed to MD Anderson may be reduced upon the occurrence of certain events. The Company also agreed to sell its TCR products to MD Anderson at preferential prices and will sell the Company's TCR products in Texas exclusively to MD Anderson for a limited period of time following the first commercial sale of the Company's TCR products. For the three months ended March 31, 2024 the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t incur clinical expenses from MD Anderson related to the 2019 R&amp;D Agreement, compared to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the three months ended March 31, 2023.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2019 R&amp;D Agreement will terminate on December 31, 2026 and either party may terminate the 2019 R&amp;D Agreement following written notice of a material breach. The 2019 R&amp;D Agreement also contains customary provisions related to indemnification obligations, confidentiality and other matters.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the execution of the 2019 R&amp;D Agreement, on October 22, 2019, the Company issued MD Anderson a warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">222,222</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company's common stock, which is referred to as the MD Anderson Warrant. The MD Anderson Warrant has an initial exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.015</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, and vests upon the occurrence of certain clinical milestones. As of March 31, 2024, the milestones have not been met.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Agreement with the NCI</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 28, 2019, the Company entered into a patent license agreement, or the Patent License, with the NCI. Pursuant to the Patent License, the Company held an exclusive, worldwide license to certain intellectual property to develop and commercialize patient-derived (autologous), peripheral blood T-cell therapy products engineered by transposon-mediated gene transfer to express TCRs reactive to mutated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS, TP53</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EGFR </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">neoantigens. In addition, pursuant to the Patent License, the Company held an exclusive, worldwide license to certain intellectual property for manufacturing technologies to develop and commercialize autologous, peripheral blood T-cell therapy products engineered by non-viral gene transfer to express TCRs, as well as a non-exclusive, worldwide license to certain additional manufacturing technologies. On May 29, 2019, January 8, 2020, September 28, 2020, April 16, 2021, May 4, 2021 and August 13, 2021 the Company amended the Patent License to expand its TCR library to include additional TCRs reactive to mutated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TP53 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">neoantigens licensed from the NCI.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 27, 2023, the Company provided the NCI the requisite notice of its intent to terminate the Patent License, effective December 26, 2023. The Company discovered multiple proprietary TCRs targeting driver mutations through its hunTR TCR discovery platform, including many of the same </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KRAS </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TP53 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">mutations licensed from the NCI.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the three months ended March 31, 2024, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t incur expenses to the NCI under this agreement, compared to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the three months ended March 31, 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cooperative Research and Development Agreement (CRADA) with the NCI</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 9, 2017, the Company entered into a Cooperative Research and Development Agreement, or the CRADA, with the NCI. The purpose of this collaboration was to advance a personalized TCR-T approach for the treatment of solid tumors. Using the Company's</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology, the NCI would analyze a patient&#8217;s own cancer cells, identify their unique neoantigens and TCRs reactive against those neoantigens and then use the Company's </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> technology to transpose one or more TCRs into T cells for re-infusion. Research conducted under the CRADA was under the direction of Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI, in collaboration with the Company's researchers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 14, 2023, the Company announced that it had provided the requisite notice to terminate the CRADA, pursuant to its terms, effective </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">October 13, 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, in light of the Company&#8217;s exploration of strategic alternatives.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t record expenses under the CRADA for the three months ended March 31, 2024, compared to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the three months ended March 31, 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent and Technology License Agreement&#8212;The University of Texas MD Anderson Cancer Center and the Texas A&amp;M University System</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 24, 2004, the Company entered into a patent and technology license agreement with MD Anderson and the Texas A&amp;M University System, which the Company refers to, collectively, as the Licensors. Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) for the manufacture and commercialization of two classes of organic arsenicals (water- and lipid-based) for human and animal use. The class of water-based organic arsenicals includes darinaparsin.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the agreement, the Company may be required to make additional payments to the Licensors upon achievement of certain milestones in varying amounts which, on a cumulative basis could total up to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. In addition, the Licensors are entitled to receive royalty payments on sales from a licensed product and will also be entitled to receive a portion of any fees that the Company may receive from a possible sublicense under certain circumstances. During the three months ended March 31, 2024 and 2023, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t incur any milestone expenses or royalty expenses on sales under this agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Agreement with Solasia Pharma K.K.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 7, 2011, the Company entered into a License and Collaboration Agreement with Solasia Pharma K. K., or Solasia, which was amended on July 31, 2014 to include an exclusive worldwide license and amended on October 14, 2021 to revise certain payment schedule details, or, as so amended, the Solasia License and Collaboration Agreement. Pursuant to the Solasia License and Collaboration Agreement, the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both intravenous and oral forms and related organic arsenic molecules, in all indications for human use.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As consideration for the license, the Company is eligible to receive from Solasia development- and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenue generated by Solasia. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The Company&#8217;s licensors, as defined in the Solasia License and Collaboration Agreement, will receive a portion of all milestone and royalty payments made by Solasia to the Company in accordance with the terms of the Solasia License and Collaboration Agreement with the licensors, as described above.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, Solasia announced that darinaparsin had been approved from relapsed or refractory Peripheral T-Cell Lymphoma by the Minis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">try of Health, Labor and Welfare in Japan. During the three months ended March 31, 2024 and 2023, the Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t earn collaboration revenue and earned royalty revenues of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> thousand and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, of royalty revenues on net sales under the Solasia License and Collaboration Agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">KBI Biopharma Litigation</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 17, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">KBI Biopharma</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Inc., or KBI, filed a complaint against the Company in the District Court of Harris County, Texas, 165th Judicial District, asserting breach of an Amended and Restated Master Services Agreement between the Company and KBI relating to the development of an autologous gene modified T-cell therapy product, or the KBI Agreement. KBI was primarily seeking unspecified monetary damages in excess of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. On May 1, 2023, the Company filed an answer generally denying all of KBI&#8217;s allegations and asserting affirmative and other defenses as well as counterclaims for breach of the KBI Agreement and conversion. On October 20, 2023, the Company entered into an agreement with KBI to settle all claims asserted by KBI against the Company and the Company's counterclaims against KBI at issue in the litigation for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911601076224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_StockOptionsAndRestrictedStockAwardsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-Based Compensation</span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized stock-based compensation expense on all employee and non-employee awards as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:63.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.713%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.643%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.523%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">175</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">161</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">735</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">172</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">910</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company granted an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options during the three months ended March 31, 2024, with a weighted-average grant date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, and granted an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">204,344</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> stock options during the three months ended March 31, 2023, with a weighted-average grant date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the three months ended March 31, 2024 and 2023, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions:</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:79.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.173%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:13.443%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:16.143%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.09</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.58</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.87</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected life in years</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.27</span></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.06</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">114.65</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89.69</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95.63</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.528%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:4.743198935713313%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option activity under the Company&#8217;s stock option plans for the three months ended March 31, 2024 was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted- Average Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted- Average Contractual Term (Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">465,898</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26.85</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.80</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">254,441</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19.61</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">251,457</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.92</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercisable, March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">161,844</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28.28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.53</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options available for future grant, March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,514,087</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At March 31, 2024, total unrecognized compensation costs related to unvested stock options outstanding amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The cost is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.28</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_StockOptionsAndRestrictedStockAwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Options and Restricted Stock Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_StockOptionsAndRestrictedStockAwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911598519824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_WarrantsDisclosureAbstract', window );"><strong>Warrants Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_WarrantTextBlock', window );">Warrants</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warrants</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Company&#8217;s November 2018 private placement that provided net proceeds of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">47.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, the Company issued warrants to purchase an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,262,626</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, which became exercisable six months after the closing of the private placement, or the November 2018 Warrants. The November 2018 Warrants had an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">45.15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and have a five-year term. The fair value of the November 2018 Warrants was estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million using a Black-Scholes model with the following assumptions: expected volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">71</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, risk free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.99</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, expected life of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 26, 2019 and September 12, 2019, the Company entered into agreements with existing investors whereby the investors exercised the November 2018 Warrants for an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,186,869</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">45.15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. Proceeds from the warrant exercise after deducting placement agent fees and other related expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million were approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">52.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company issued participating investors new warrants to purchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,186,869</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> additional </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">shares of common stock (the "2019 Warrants") as consideration for the warrant holders to exercise their November 2018 Warrants. The 2019 Warrants will expire on the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fifth </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">anniversary of the initial exercise date and have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">105.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The 2019 Warrants were valued using a Black-Scholes valuation model and resulted in a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">60.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million non-cash charge in the Company&#8217;s statement of operations in 2019.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 22, 2019, the Company entered into the 2019 R&amp;D Agreement with MD Anderson. In connection with the execution of the 2019 R&amp;D Agreement, the Company issued the MD Anderson Warrant to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">222,222</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The MD Anderson Warrant has an initial exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.015</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and grant date fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The MD Anderson Warrant expires on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2026 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and vests upon the occurrence of certain clinical milestones. The Company will recognize expense on the MD Anderson Warrant in the same manner as if the Company paid cash for services to be rendered. For the three months ended March 31, 2024 and 2023, the Company did not recognize any expense related to the MD Anderson Warrant as the clinical milestones had not been achieved.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On August 6, 2021, the Company entered into the Loan and Security Agreement with SVB. Refer to Note 4, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. In connection with the Loan and Security Agreement, the Company issued SVB warrants to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28,856</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock with an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33.30</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. The warrants have a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> life and were fully vested upon issuance. The fair value of the warrants was estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million using a Black-Scholes model with the following assumptions: expected volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">79</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, risk free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, expected life of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> dividends. On December 28, 2021, the Company entered into the First Amendment, as described in Note 4, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in connection with which, the original warrants issued to SVB were amended and restated. As amended and restated, the SVB Warrants are for up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">43,308</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock, in the aggregate, with an exercise price of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$17.40 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">per share. The SVB Warrants expire on August 6, 2031 and were fully vested upon issuance. As of March 31, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">none</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the SVB Warrants have been exercised.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_WarrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to the warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_WarrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_WarrantsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Disclosure Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_WarrantsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911597531456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Joint Venture<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Joint Venture</a></td>
<td class="text"><div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Joint Venture</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 18, 2018, the Company entered into a Framework Agreement with TriArm whereby the parties agreed to launch Eden BioCell, to lead clinical development and commercialization of certain </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-generated CAR-T therapies as set forth in a separate license agreement.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 3, 2019, Eden BioCell was incorporated in Hong Kong as a private company. Eden BioCell, the Company and TriArm entered into a Share Subscription Agreement on January 23, 2019, where the Company and TriArm agreed to contribute certain intellectual property, services and cash (only with respect to TriArm) to Eden BioCell to subscribe for a certain number of newly issued ordinary shares in the share capital of Eden BioCell.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The closing of the transaction occurred on July 5, 2019. The Framework Agreement and Share Subscription Agreements were each respectively amended to be effective as of this date. Upon consummation of the joint venture, Eden BioCell and the Company also entered into a license agreement, pursuant to which the Company licensed the rights to Eden BioCell for third generation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Sleeping Beauty</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-generated CAR-T therapies targeting the CD19 antigen for the territory of China (including Macau and Hong Kong), Taiwan and Korea. TriArm and the Company each received a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% equity interest in the joint venture in exchange for their contributions to Eden BioCell.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined that Eden BioCell was considered a variable interest entity, or VIE, and concluded that it was not the primary beneficiary of the VIE as it did not have the power to direct the activities of the VIE. As a result, the Company accounted for the equity interest in Eden BioCell under the equity method of accounting as it had the ability to exercise significant influence.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2021, TriArm and the Company mutually agreed to dissolve the joint venture, which has now been terminated. The Eden BioCell entity has been dissolved as of July 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 323<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481543/323-740-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 323<br> -Publisher FASB<br> -URI https://asc.fasb.org//323/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911595175536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Subsequent Events</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has evaluated subsequent events from the balance sheet date through the date on which these condensed financial statements were issued. Other than as described in the notes above, the Company did not have any material subsequent events that impacted its condensed financial statements or disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911595930336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited interim condensed financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information and note disclosures required by generally accepted accounting principles in the United States, or GAAP, have been condensed or omitted pursuant to such rules and regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is management&#8217;s opinion that the accompanying unaudited interim condensed financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair presentation of the financial position of the Company and its results of operations and cash flows for the periods presented. The unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2023, included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on April 1, 2024, or the Annual Report.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The results disclosed in the statements of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full fiscal year 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Stock Split</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 31, 2024, the Company filed a Second Amended and Restated Certificate of Incorporation (the &#8220;Charter Amendment&#8221;) with the Secretary of State of the State of Delaware in order to effect a reverse stock split of the Company&#8217;s common stock at a ratio of 1-for-15 (the &#8220;Reverse Split&#8221;). The Charter Amendment decreased the number of authorized shares of common stock from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">520,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">34,666,667</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Charter Amendment does not affect the par value of the Company&#8217;s common stock or change the number of authorized shares or par value of the Company&#8217;s preferred stock. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Charter Amendment became effective on January 31, 2024 at 5:00 p.m. Eastern Time, at which time every 15 shares of the Company&#8217;s issued and outstanding common stock automatically combined and converted into 1 share of common stock.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No fractional shares were issued in connection with the Reverse Split. Stockholders of record who would otherwise have been entitled to receive fractional shares as a result of the Reverse Split received a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing sales price per share of the common stock (as adjusted for the Reverse Split) on The Nasdaq Capital Market on January 31, 2024.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All share and per share amounts of common stock, options, warrants, and restricted stock in the accompanying financial statements and notes thereto have been retroactively adjusted for all periods presented to reflect the Reverse Split as if it had occurred at the beginning of the earliest period presented.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse stock split policy text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911597552016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of March 31, 2024 and December 31, 2023 are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.01%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.603000000000002%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.542%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.302%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.302%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance as of<br/>March 31,<br/>2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,832</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,832</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:10.203999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.924999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.303999999999998%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.303999999999998%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">($ in thousands)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value Measurements at Reporting Date Using</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance as of<br/>December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Quoted Prices in<br/>Active Markets<br/>for Identical<br/>Assets/Liabilities<br/>(Level 1)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,744</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,744</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911685748272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potentially Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such potentially dilutive shares of common stock consisted of the following as of March 31, 2024 and 2023:</span><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">251,457</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">887,549</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested restricted stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59,875</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Warrants</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,452,399</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,528,156</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,703,856</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,475,580</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911601738160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Stock-Based Compensation Expense on All Employee and Non-Employee Awards</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized stock-based compensation expense on all employee and non-employee awards as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:63.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.713%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.643%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.56%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.523%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">175</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">161</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">735</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">172</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">910</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the three months ended March 31, 2024 and 2023, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions:</span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:79.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.173%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:13.443%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:16.143%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.09</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.58</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.87</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected life in years</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.27</span></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.06</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.25</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">114.65</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89.69</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#8211; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95.63</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity under Stock Option Plan</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock option activity under the Company&#8217;s stock option plans for the three months ended March 31, 2024 was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.11%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.942%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.662%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.22%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.182%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">(in thousands, except share and per share data)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of Shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted- Average Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted- Average Contractual Term (Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate Intrinsic Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">465,898</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26.85</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,000</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.80</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cancelled</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">254,441</span></p></td>
        <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19.61</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">251,457</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.15</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.92</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercisable, March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">161,844</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28.28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.53</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options available for future grant, March 31, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,514,087</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911704222288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Aug. 14, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,145<span></span>
</td>
<td class="nump">$ 6,062<span></span>
</td>
<td class="nump">$ 37,434<span></span>
</td>
<td class="nump">$ 52,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 917,449<span></span>
</td>
<td class="nump">$ 915,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,666,667<span></span>
</td>
<td class="nump">34,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,012,522<span></span>
</td>
<td class="nump">16,012,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_StrategicAdvisorName', window );">Strategic advisor name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Cantor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PreStockSplitSharesAuthorized', window );">Pre Stock Split Shares Authorized</a></td>
<td class="nump">520,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PostStockSplitSharesAuthorized', window );">Post Stock Split Shares Authorized</a></td>
<td class="nump">34,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">The Charter Amendment became effective on January 31, 2024 at 5:00 p.m. Eastern Time, at which time every 15 shares of the Company&#8217;s issued and outstanding common stock automatically combined and converted into 1 share of common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,012,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,714,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PostStockSplitSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Post Stock Split Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PostStockSplitSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PreStockSplitSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre Stock Split Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PreStockSplitSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_StrategicAdvisorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strategic advisor name.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_StrategicAdvisorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911601611840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financings - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 05, 2023</div></th>
<th class="th"><div>Nov. 29, 2022</div></th>
<th class="th"><div>Aug. 12, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Aug. 06, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tcrt_AtTheMarketOfferingMember', window );">At The Market Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase', window );">Number of additional option available to the underwriter to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Term A Tranche [Member] | Silicon Valley Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Loan and Security Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Term B Tranche [Member] | Silicon Valley Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Additonal tranche facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tcrt_EquityDistributionAgreementMember', window );">Equity Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_StockOfferedDuringPeriodShares', window );">Stock issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock', window );">Percentage Of Commission On Gross Proceeds From Sale Of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AgreementTypeAxisAxis=tcrt_CantorMember', window );">Cantor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,615,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_UnderwriterParOrStatedValuePerShare', window );">Underwriter par or stated value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.2865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings', window );">Threshold period for exercise or conversion of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AgreementTypeAxisAxis=tcrt_CantorMember', window );">Cantor [Member] | Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_StockOfferedDuringPeriodShares', window );">Stock issued during period</a></td>
<td class="nump">14,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional option available to the underwriter to purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on gross proceeds from sale of common stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_StockOfferedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock offered during period shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_StockOfferedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold commitment period for exercise of rights to participate in future offerings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_UnderwriterParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriter par or stated value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_UnderwriterParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tcrt_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tcrt_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tcrt_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tcrt_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcrt_EquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcrt_EquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AgreementTypeAxisAxis=tcrt_CantorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AgreementTypeAxisAxis=tcrt_CantorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911685832048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2021</div></th>
<th class="th"><div>Aug. 06, 2021</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Line of credit facility, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=tcrt_TermLoanMember', window );">Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment', window );">Percentage of original principal due as a final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Line of credit facility, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Warrants issued</a></td>
<td class="nump">43,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_WarrantsExpirationDate', window );">Warrants expiration date</a></td>
<td class="text">Aug.  06,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms', window );">Description of payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company also owed SVB 5.75% of the original principal amounts borrowed as a final payment, or the Final Payment. Effective March 30, 2023, the Company entered into a Third Amendment to the Loan and Security Agreement, or the Third Amendment. Under the terms of the Third Amendment, the Company was no longer required to maintain all of its operating accounts, depository accounts and excess cash with SVB or one of its affiliates, and was instead only required to maintain a single operating or depository account at Silicon Valley Bank. The Third Amendment also modified the cash collateralization requirement, such that the Company was required to cash collateralize the entire sum of the outstanding principal amount of the SVB Facility, plus an amount equal to the Final Payment, which amount was to be reduced commensurate with each regularly scheduled monthly payment of principal and interest on the SVB Facility.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt instrument description of variable rate basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The SVB Facility bore interest at a floating rate per annum on outstanding loans, payable monthly, at the greater of (a) 7.75% and (b) the current published U.S. prime rate, plus a margin of 4.5%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AmountOfPrepaymentsPremium', window );">Amount of prepayments premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise per share</a></td>
<td class="nump">$ 17.4<span></span>
</td>
<td class="nump">$ 33.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AdditionalNumberOfWarrantsIssued', window );">Additional number warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeStart1', window );">Debt instrument, initial maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member] | Debt Instrument Redemption Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PercentageOfPrepaymentsPremium', window );">Percentage of prepayments premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Issuance costs</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AdditionalNumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AdditionalNumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AmountOfPrepaymentsPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount Of Prepayments Premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AmountOfPrepaymentsPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of original principal due as a final payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PercentageOfPrepaymentsPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of prepayments premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PercentageOfPrepaymentsPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_WarrantsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Expiration Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_WarrantsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reference rate used for variable rate of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateRangeStart1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateRangeStart1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of the required periodic payments of interest, principal, or both, and the amount, if set, or a description of a formula upon which payment is based.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=tcrt_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=tcrt_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911601389216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 3,832<span></span>
</td>
<td class="nump">$ 5,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 3,832<span></span>
</td>
<td class="nump">$ 5,744<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911595921984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member', window );">Fair Value, Inputs, Level 2, and Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value of assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel12And3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911685762784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Potentially Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">1,703,856<span></span>
</td>
<td class="nump">2,475,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">1,452,399<span></span>
</td>
<td class="nump">1,528,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">251,457<span></span>
</td>
<td class="nump">887,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">59,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911685822032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 18, 2018</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_EdenBiocellMember', window );">Eden Biocell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties', window );">Payments to Fund Long-term Loans to Related Parties</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AdditionalLoansCommitted', window );">Additional Loans Committed</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_DuneLakeCapitalMember', window );">Dune Lake Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Consulting service amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AdditionalLoansCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional loans committed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AdditionalLoansCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToFundLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_EdenBiocellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_EdenBiocellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_DuneLakeCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_DuneLakeCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911590110064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 20, 2023</div></th>
<th class="th"><div>Aug. 14, 2023</div></th>
<th class="th"><div>Mar. 17, 2023</div></th>
<th class="th"><div>Aug. 17, 2015</div></th>
<th class="th"><div>Jan. 13, 2015</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 03, 2023</div></th>
<th class="th"><div>Oct. 22, 2019</div></th>
<th class="th"><div>Oct. 05, 2018</div></th>
<th class="th"><div>Aug. 24, 2004</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 126,000<span></span>
</td>
<td class="nump">$ 6,504,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MaximumRoyaltyAmount', window );">Maximum royalty amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Unspecified monetary damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNameOfPlaintiff', window );">Loss contingency, name of plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">KBI Biopharma<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ClassOfWarrantOrRightAxisAxis=tcrt_MdAndersonWarrantMember', window );">MD Anderson Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonAgreementAndWorldwideLicenseMember', window );">MD Anderson Agreement and Worldwide License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_LicenseAgreementCommencingDate', window );">License agreement commencing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 13,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember', window );">MD Anderson License and the Research and Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AggregateAmountPotentiallyReimburseableAmount', window );">Reimbursement of historical costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_QuarterlyExpenseIncurred', window );">Quarterly expense incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AggregatePotentialBenchmarkPayments', window );">Aggregate potential benchmark payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AccrualsPriorToFirstMarketingApproval', window );">Payments due prior to the first marketing approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_CRADAAgreementMember', window );">CRADA Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AgreementTerminationDate', window );">Agreement termination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 13,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AnnualExpenseIncurred', window );">Annual expense incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember', window );">The University of Texas MD Anderson Cancer Center and The Texas A &amp; M University System [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MilestonePaymentsMaximumAmount', window );">Milestone maximum payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember', window );">The University of Texas MD Anderson Cancer Center and The Texas A &amp; M University System [Member] | Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PaymentUnderLicenseAgreement', window );">Payment under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_LicenseAgreementWithTheNationalCancerInstituteMember', window );">License Agreement with the National Cancer Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_LicenseExpense', window );">License expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_CollaborationAgreementWithSolasiaPharmaKkMember', window );">Collaboration Agreement with Solasia Pharma KK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_CollaborationAgreementWithSolasiaPharmaKkMember', window );">Collaboration Agreement with Solasia Pharma KK [Member] | Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember', window );">M D Anderson License and the Two Thousand Fifteen Research and Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ClinicalExpenses', window );">Clinical expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_IntrexonCorporationMember', window );">Intrexon Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AnnualLicenseFees', window );">Annual license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MaximumAmountOfAdditionalMilestonesPayable', window );">Expected additional milestones payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_IntrexonCorporationMember', window );">Intrexon Corporation [Member] | T-cell receptor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_MaximumAmountOfRoyaltyPayable', window );">Maximum royalty amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty', window );">Portion of income payable to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | MD Anderson License and the Research and Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | MD Anderson License and the Research and Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Accrued Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AccrualsPriorToFirstMarketingApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments due prior to the first marketing approval for TCR products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AccrualsPriorToFirstMarketingApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AggregateAmountPotentiallyReimburseableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Amount Potentially Reimburseable Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AggregateAmountPotentiallyReimburseableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AggregatePotentialBenchmarkPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential benchmark payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AggregatePotentialBenchmarkPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AgreementTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination Date of CRADA Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AgreementTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AnnualExpenseIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual expense incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AnnualExpenseIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AnnualLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual License Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AnnualLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ClinicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ClinicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_LicenseAgreementCommencingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement commencing date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_LicenseAgreementCommencingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_LicenseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to License payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_LicenseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MaximumAmountOfAdditionalMilestonesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of additional milestones payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MaximumAmountOfAdditionalMilestonesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MaximumAmountOfRoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of royalty payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MaximumAmountOfRoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MaximumRoyaltyAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of royalty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MaximumRoyaltyAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_MilestonePaymentsMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments maximum amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_MilestonePaymentsMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PaymentUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment under license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PaymentUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of sub licensing income, attributable to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_QuarterlyExpenseIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Quarterly expense incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_QuarterlyExpenseIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNameOfPlaintiff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identifies the plaintiff in the lawsuit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNameOfPlaintiff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ClassOfWarrantOrRightAxisAxis=tcrt_MdAndersonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ClassOfWarrantOrRightAxisAxis=tcrt_MdAndersonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonAgreementAndWorldwideLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonAgreementAndWorldwideLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_CRADAAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=tcrt_CRADAAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tcrt_LicenseAgreementWithTheNationalCancerInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tcrt_LicenseAgreementWithTheNationalCancerInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tcrt_CollaborationAgreementWithSolasiaPharmaKkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tcrt_CollaborationAgreementWithSolasiaPharmaKkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_IntrexonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_IntrexonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tcrt_TcellReceptorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tcrt_TcellReceptorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911685520272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Expense Included in Statement of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">$ 910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 161<span></span>
</td>
<td class="nump">$ 735<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911691160464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options, granted</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">204,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 5.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tcrt_NonVestedStockMember', window );">Unvested Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs related to unvested restricted stock outstanding</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected recognition period</a></td>
<td class="text">1 year 3 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tcrt_NonVestedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tcrt_NonVestedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911691378208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.58%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.87%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">114.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.69%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.63%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 21 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911601580640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity Under Stock Option Plan (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance</a></td>
<td class="nump">465,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">204,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled</a></td>
<td class="num">(254,441)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance</a></td>
<td class="nump">251,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, at end of period</a></td>
<td class="nump">161,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options available for future grant</a></td>
<td class="nump">1,514,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance</a></td>
<td class="nump">$ 26.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled</a></td>
<td class="nump">19.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance</a></td>
<td class="nump">21.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, at end of period</a></td>
<td class="nump">$ 28.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, at end of period</a></td>
<td class="text">6 years 11 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, at end of period</a></td>
<td class="text">5 years 6 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, at end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, at end of period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911592382256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 28, 2021</div></th>
<th class="th"><div>Aug. 06, 2021</div></th>
<th class="th"><div>Oct. 22, 2019</div></th>
<th class="th"><div>Sep. 12, 2019</div></th>
<th class="th"><div>Nov. 11, 2018</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Fair Value Assumptions Expected volatility Rate Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.63%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Fair Value Assumptions Risk Free Interest Rate Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.87%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair Value Assumptions Expected Term1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember', window );">Silicon Valley Bank Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise per share</a></td>
<td class="nump">$ 17.4<span></span>
</td>
<td class="nump">$ 33.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tcrt_MdAndersonWarrantMember', window );">MD Anderson Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities into which the class of warrant converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_FairValueOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=tcrt_SvbWarrantsMember', window );">SVB Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCallOrExerciseFeatures', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">33.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants fully vested upon issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_ClassOfWarrantOrRightWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_BlackScholesModelMember', window );">Black-Scholes Model [Member] | Silicon Valley Bank Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCallOrExerciseFeatures', window );">Exercise price</a></td>
<td class="text">$17.40 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="nump">43,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_BlackScholesModelMember', window );">Black-Scholes Model [Member] | SVB Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_FairValueOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair Value Assumptions Expected Term1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.31%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_AgreementTypeAxis=tcrt_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities into which the class of warrant converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,186,869<span></span>
</td>
<td class="nump">1,262,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.15<span></span>
</td>
<td class="nump">$ 45.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_FairValueOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Fair Value Assumptions Expected volatility Rate Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Fair Value Assumptions Risk Free Interest Rate Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair Value Assumptions Expected Term1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_PlacementAgentFeesAndOtherRelatedExpenses', window );">Placement agent fees and other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | New Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of securities into which the class of warrant converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,186,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tcrt_NonOperatingIncomeExpenseInducementOfWarrants', window );">Non-cash inducement warrant expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_ClassOfWarrantOrRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_ClassOfWarrantOrRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_FairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_FairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_NonOperatingIncomeExpenseInducementOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Operating Income Expense Inducement Of Warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_NonOperatingIncomeExpenseInducementOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_PlacementAgentFeesAndOtherRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Placement agent fees and other related expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_PlacementAgentFeesAndOtherRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tcrt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCallOrExerciseFeatures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describe the call and/or exercise rights, prices and dates of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCallOrExerciseFeatures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=tcrt_SiliconValleyBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tcrt_MdAndersonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tcrt_MdAndersonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tcrt_SvbWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tcrt_SvbWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_BlackScholesModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tcrt_BlackScholesModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tcrt_AgreementTypeAxis=tcrt_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tcrt_AgreementTypeAxis=tcrt_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=tcrt_NewWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=tcrt_NewWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139911595919376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Joint Venture - Additional Information (Details)<br></strong></div></th>
<th class="th"><div>Jul. 05, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=tcrt_ZiopharmMember', window );">Ziopharm [Member] | Eden Bio Cell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems', window );"><strong>Subsidiary or Equity Method Investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity interest in affilated entity</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=tcrt_ZiopharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=tcrt_ZiopharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=tcrt_EdenBioCellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=tcrt_EdenBioCellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>46
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MX/T#AWI>W^@S=O.?ROQ?4$L#!!0    ( "Y'KU@]+!R/D (  "@'   8
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&ULK55K;],P%/TK5D (I-&\F@R--%*7
M=MHD&-7*XP/B@YO<-M8<.]A.._CUV$X6M2,;G40_-'[<<^XYSLUULN/B5I8
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M_(?Y+\#_\W&Z^ <,P./< Y\_?0&?0)2"Q8IN&$Y#-E2Y\$IBJT'AP<W. W3
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M%!#OEY3R]QMY"%<>ZX[_ U!+ P04    "  N1Z]81M6;814&  !]&@  &
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M"[ @SS3+='+TT"6<LMCJ4I.Z0R\\/'):I/IHU': 1S7!(_?1V PN#?_0IPM
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MKS?^N5I =E_\H;';2SV/':$"E;!5E-[HHQI?;C>"-22KS5!MF%0C:HZ%6J+
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MQ]:267&,.J(2?(ACZ11&$7B*6SOS9Q#4)1,MN8/[L0;W0#Y+I2$B+.P8CPI
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M J7N9FS,]@>/HJK)'T39M.45KI&^MBOC=M% *42#R@JMP& Y8_/QW6+BXT/
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MX]'-%0/33XY^0[H-W;K1Y'H_+&LW;-'X />^U)KV&Y]@&-_9;U!+ P04
M"  N1Z]8UA18VH$'   -%   &0   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6R56-MNVS@0_17"VRM@R([M7+9- B1M@RVPQ19-+P^+?: EVN:6$E62BN-^
M_9X92K)\B=-]22R2,YS+F3,CG2^M^^X72@5QGYO"7_06(92O!@.?+E0N?6)+
M56!G9ETN Q[=?.!+IV3&0KD9C(;#DT$N==&[/.>UC^[RW%;!Z$)]=,)7>2[=
MZEH9N[SH'?6:A4]ZO@BT,+@\+^5<W:KPI?SH\#1HM60Z5X77MA!.S2YZ5T>O
MKB=TG@]\U6KI.[\%>3*U]CL]O,\N>D,R2!F5!M(@\>].O5'&D"*8\:/6V6NO
M),'N[T;[#?L.7Z;2JS?6?--96%STSGHB4S-9F?#)+O]0M3_'I"^UQO-?L8QG
M1Z<]D58^V+P6A@6Y+N)_>5_'H2-P-GQ 8%0+C-CN>!%;^58&>7GN[%(X.@UM
M](-=96D8IPM*RFUPV-60"Y=OU32<#P(TT?,@K:6NH]3H :FQ^&"+L/#B79&I
M;%-^  M:,T:-&=>C@PH_2)>(\5%?C(:CR0%]X]:M,>L;'W!+O-4^-=973HF_
MKZ8^.$#@GWW.1EV3_;JH+%[Y4J;JH@?<>^7N5._RV6]')\/7!RR=M)9.#FE_
M, &'I2:)8!<_+Q2\6]*?P@*-6+)3H^>2(.\%JM '662ZF L9!**<+MHP"VQ
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M;V^WT[PEZT5T51H1IRYBX$R?!1Y2]G(!YS.'(EPM1$'[/\/D?U!+ P04
M"  N1Z]8^ 'X[Z$6  !!3@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6SM7&USVT:2_BM3VFPB5U&42$E^B5^J9"G).HY]+DG>?+BZ#T-P2,X:;\$
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MM2;41_E,PE];-?5/<),])<15.:T+E+X31A\A;#M"?_G^9"L>NK,G7'ZE=Q(
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M\T__H2Y*_I$P<)FZR/C/E4)\J>@&?+\HBMI_H G"K\:]^6]02P,$%     @
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M_"D-D:H=,]N%D;4;[1;2T*#H7@N:S%%9 ?J^E-)L%]9 /^O/_P502P,$%
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MP/;5H]>Q6^T*EIW*-%K= #CCY6*\7%P<!2<J\G6(B-C'CDNYT97WI"7(3CS
M&.1K4A_8CIIHE?C-A0BIU1 W:(^EAP450MG@'O"QHR7;"L+B$^*>)=%9MR/
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MCQ9!$G583N K0RSC!'<G<2]1867.2*D#O38."41N-G@4 CO]I2Q]DGUL$'R
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M]X94.E73VC43(RO73LVDH>;,#7/JAE%9 WH_E])L)C9 VU]/_@=02P,$%
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M9(5:7Y+KCI&+XIZ92D.W5M%,Z+\"E0V@[S-)^Z3LV*NK^E,)?P%02P,$%
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MW' SA/%H $F<3.!^?@&'!T=_TT1.=*\\Z94G@7?RKO(!7*FZL32 :URCA&0
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M.>8 B&02. B).)90%ZA"R"^65)_3^<!K>)'7[;GS;0#K"_7]<"5R'$/?41>
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M)E$T4VRUI6_3GO[3MSNV/[^,/#2 VOI0F@^E!5 :A]($E"91-%-[=0O IGL
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M46WK>[2M?]Y[97^R+^KELI,7Z22MU08U_*&T $KC4)J TB2*9@KSX!8!=%,
M[\G2"5N+%-HX@-*"BO:Q)PM-*Z TB:*9^JM[ AYR92$:UEI;4+\?2@LJFC%S
MLXYM6VA* :5)%,W45=T0\.B&P)<T^30)\X6N9=-UM<M]J9>$*8\-&@4&[0Q
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M1AS!'( '#(DB\Q[<>1\%J_=4L/X/[O 94$L#!!0    ( "Y'KUB7BKL<P
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MG[A=DUJ5S<&?=3_C9U]02P$"% ,4    "  N1Z]8!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( "Y'
MKUC\ 6%5[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( "Y'KUB97)PC$ 8  )PG   3              "
M <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ +D>O6)19$S7:
M!0  HQ\  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( "Y'KU@[G$_-B@0  %\1   8              "
M@1X.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  N1Z]8
M/2P<CY "   H!P  &               @('>$@  >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ +D>O6(4=8O$P!   CP\  !@
M     ("!I!4  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M "Y'KUB!--LC9@0  .(5   8              " @0H:  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    "  N1Z]81M6;814&  !]&@  &
M            @(&F'@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ +D>O6*B>6$9' @  H@4  !@              ("!\20  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( "Y'KU@FVB\.1 (  (H&
M   8              " @6XG  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    "  N1Z]8.?RYX:8.  "U)@  &               @('H*0
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ +D>O6/0C2&E+
M!@  "!   !D              ("!Q#@  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    "  N1Z]8:L3"BF8"  #*!0  &0
M@(%&/P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( "Y'
MKUC6%%C:@0<   T4   9              " @>-!  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ +D>O6#7PDDF2!   Q@L  !D
M         ("!FTD  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    "  N1Z]8V",F*+(#  #J"   &0              @(%D3@  >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( "Y'KU@>#"GT6 4  #\,
M   9              " @4U2  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ +D>O6/@!^.^A%@  04X  !D              ("!W%<
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  N1Z]8?4[.
M:!(%  #W"P  &0              @(&T;@  >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( "Y'KUAQO:39L@8  !$2   9
M  " @?US  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
M+D>O6+;64Q!.!0  3 P  !D              ("!YGH  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    "  N1Z]81VL0VHT"  #:!0  &0
M            @(%K@   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( "Y'KUB"V\B @P<  (,3   9              " @2^#  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ +D>O6!:^3_C1 @
MY08  !D              ("!Z8H  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    "  N1Z]8N\ /"KL"  #F!0  &0              @('Q
MC0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( "Y'KUC]
ML%TCT 0  &L+   9              " @>.0  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ +D>O6&(O> +P!   '!P  !D
M     ("!ZI4  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "Y'KUBQ@>:4? ,  'X/   9              "
M@5*P  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ +D>O
M6&;>\#HZ P  ^@P  !D              ("!!;0  'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    "  N1Z]89NGL#_<.  #,VP  &0
M        @(%VMP  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( "Y'KUAGQ'']'0,  *(+   9              " @:3&  !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ +D>O6'G8I)5@ P  S H
M !D              ("!^,D  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    "  N1Z]8X9;?G($#  "%#@  &0              @(&/S0
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( "Y'KUA*DQ_C
M<@0  ( 4   9              " @4?1  !X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ +D>O6!K^-C-$"@  !W   !D
M ("!\-4  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  N
M1Z]8D]6T"CX"  #R!   &0              @(%KX   >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( "Y'KUC!A;B]4P,  ,X5   -
M          "  >#B  !X;"]S='EL97,N>&UL4$L! A0#%     @ +D>O6)>*
MNQS     $P(   L              ( !7N8  %]R96QS+RYR96QS4$L! A0#
M%     @ +D>O6%%1C1G+ P  A1D   \              ( !1^<  'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( "Y'KUBWO<)+@0$  "D7   :
M      "  3_K  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( "Y'KUACUHH4FP$  )07   3              "  ?CL  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     N "X >0P  ,3N      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>113</ContextCount>
  <ElementCount>203</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - CONDENSED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/DisclosureOrganization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Financings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/Financings</Role>
      <ShortName>Financings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/NetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Joint Venture</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/JointVenture</Role>
      <ShortName>Joint Venture</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Organization (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationPolicies</Role>
      <ShortName>Organization (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://alaunos.com/20240331/taxonomy/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20240331/taxonomy/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20240331/taxonomy/role/NetLossPerShare</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://alaunos.com/20240331/taxonomy/role/StockBasedCompensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Organization - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails</Role>
      <ShortName>Organization - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Financings - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails</Role>
      <ShortName>Financings - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails</Role>
      <ShortName>Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://alaunos.com/20240331/taxonomy/role/FairValueMeasurementsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Net Loss Per Share - Potentially Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Potentially Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Stock-Based Compensation Expense Included in Statement of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails</Role>
      <ShortName>Stock-Based Compensation Expense Included in Statement of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails</Role>
      <ShortName>Stock-Based Compensation - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Stock-Based Compensation - Stock Option Activity Under Stock Option Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity Under Stock Option Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Warrants - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails</Role>
      <ShortName>Warrants - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="tcrt-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Joint Venture - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails</Role>
      <ShortName>Joint Venture - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="tcrt-20240331.htm">tcrt-20240331.htm</File>
    <File>tcrt-20240331.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="270">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>52
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tcrt-20240331.htm": {
   "nsprefix": "tcrt",
   "nsuri": "http://alaunos.com/20240331",
   "dts": {
    "inline": {
     "local": [
      "tcrt-20240331.htm"
     ]
    },
    "schema": {
     "local": [
      "tcrt-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    }
   },
   "keyStandard": 163,
   "keyCustom": 40,
   "axisStandard": 21,
   "axisCustom": 3,
   "memberStandard": 18,
   "memberCustom": 26,
   "hidden": {
    "total": 6,
    "http://fasb.org/us-gaap/2023": 2,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 113,
   "entityCount": 1,
   "segmentCount": 46,
   "elementCount": 512,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 270,
    "http://xbrl.sec.gov/dei/2023": 30,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://alaunos.com/20240331/taxonomy/role/CoverPage",
     "longName": "100000 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets",
     "longName": "100010 - Statement - CONDENSED BALANCE SHEETS",
     "shortName": "CONDENSED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_289f7d65-cf86-4803-859d-4037fea6fa0f",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_289f7d65-cf86-4803-859d-4037fea6fa0f",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical",
     "longName": "100020 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_289f7d65-cf86-4803-859d-4037fea6fa0f",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_289f7d65-cf86-4803-859d-4037fea6fa0f",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations",
     "longName": "100030 - Statement - CONDENSED STATEMENTS OF OPERATIONS",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquity",
     "longName": "100040 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "shortName": "CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_f7de99b6-d374-4e48-911c-1cd00129ec98",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f7de99b6-d374-4e48-911c-1cd00129ec98",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows",
     "longName": "100050 - Statement - CONDENSED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:Depreciation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganization",
     "longName": "995455 - Disclosure - Organization",
     "shortName": "Organization",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://alaunos.com/20240331/taxonomy/role/Financings",
     "longName": "995465 - Disclosure - Financings",
     "shortName": "Financings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "tcrt:FinancingArrangementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "tcrt:FinancingArrangementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://alaunos.com/20240331/taxonomy/role/SummaryOfSignificantAccountingPolicies",
     "longName": "995475 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://alaunos.com/20240331/taxonomy/role/DisclosureDebt",
     "longName": "995485 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://alaunos.com/20240331/taxonomy/role/FairValueMeasurements",
     "longName": "995495 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://alaunos.com/20240331/taxonomy/role/NetLossPerShare",
     "longName": "995505 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://alaunos.com/20240331/taxonomy/role/RelatedPartyTransactions",
     "longName": "995515 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://alaunos.com/20240331/taxonomy/role/CommitmentsAndContingencies",
     "longName": "995525 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://alaunos.com/20240331/taxonomy/role/StockBasedCompensation",
     "longName": "995535 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://alaunos.com/20240331/taxonomy/role/Warrants",
     "longName": "995545 - Disclosure - Warrants",
     "shortName": "Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "tcrt:WarrantTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "tcrt:WarrantTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://alaunos.com/20240331/taxonomy/role/JointVenture",
     "longName": "995555 - Disclosure - Joint Venture",
     "shortName": "Joint Venture",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://alaunos.com/20240331/taxonomy/role/SubsequentEvents",
     "longName": "995565 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationPolicies",
     "longName": "995575 - Disclosure - Organization (Policies)",
     "shortName": "Organization (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://alaunos.com/20240331/taxonomy/role/FairValueMeasurementsTables",
     "longName": "995585 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://alaunos.com/20240331/taxonomy/role/NetLossPerShareTables",
     "longName": "995595 - Disclosure - Net Loss per Share (Tables)",
     "shortName": "Net Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://alaunos.com/20240331/taxonomy/role/StockBasedCompensationTables",
     "longName": "995605 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
     "longName": "995615 - Disclosure - Organization - Additional Information (Details)",
     "shortName": "Organization - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_289f7d65-cf86-4803-859d-4037fea6fa0f",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cc6be139-4d29-491a-ac06-ae207788d63f",
      "name": "tcrt:StrategicAdvisorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
     "longName": "995625 - Disclosure - Financings - Additional Information (Details)",
     "shortName": "Financings - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_8c27b046-6702-4a71-8e61-6ba81f191fea",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5c46026b-b792-4f5a-b3d6-cd9c0eb096c3",
      "name": "tcrt:NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "tcrt:FinancingArrangementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
     "longName": "995635 - Disclosure - Debt - Additional Information (Details)",
     "shortName": "Debt - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_289f7d65-cf86-4803-859d-4037fea6fa0f",
      "name": "us-gaap:LongTermDebtNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_289f7d65-cf86-4803-859d-4037fea6fa0f",
      "name": "us-gaap:LongTermDebtNoncurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "longName": "995645 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_170c0509-c56f-4761-bdf6-22de08ad77fe",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_170c0509-c56f-4761-bdf6-22de08ad77fe",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsDetails",
     "longName": "995655 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_69b6b7d3-41a2-4d80-aee3-85fbf3416f62",
      "name": "us-gaap:FairValueNetAssetLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_69b6b7d3-41a2-4d80-aee3-85fbf3416f62",
      "name": "us-gaap:FairValueNetAssetLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://alaunos.com/20240331/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
     "longName": "995665 - Disclosure - Net Loss Per Share - Potentially Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Potentially Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "longName": "995675 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_82df7c7b-262a-4272-aced-862f49a97569",
      "name": "us-gaap:PaymentsToFundLongtermLoansToRelatedParties",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_82df7c7b-262a-4272-aced-862f49a97569",
      "name": "us-gaap:PaymentsToFundLongtermLoansToRelatedParties",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "995685 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8c27b046-6702-4a71-8e61-6ba81f191fea",
      "name": "us-gaap:RoyaltyExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails",
     "longName": "995695 - Disclosure - Stock-Based Compensation Expense Included in Statement of Operations (Details)",
     "shortName": "Stock-Based Compensation Expense Included in Statement of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
     "longName": "995705 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_USDollarShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails",
     "longName": "995715 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Details)",
     "shortName": "Stock-Based Compensation - Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_f31836bd-3d73-434a-8f8e-640ba5edfd54",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8c27b046-6702-4a71-8e61-6ba81f191fea",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails",
     "longName": "995725 - Disclosure - Stock-Based Compensation - Stock Option Activity Under Stock Option Plan (Details)",
     "shortName": "Stock-Based Compensation - Stock Option Activity Under Stock Option Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_307719b1-83d4-4843-8da2-94558ade533e",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_307719b1-83d4-4843-8da2-94558ade533e",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
     "longName": "995735 - Disclosure - Warrants - Additional Information (Details)",
     "shortName": "Warrants - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_8c27b046-6702-4a71-8e61-6ba81f191fea",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "tcrt:StockOptionsAndRestrictedStockAwardsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_131aee97-1b4f-446a-8c75-66998adcc711",
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "tcrt:WarrantTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
     "longName": "995745 - Disclosure - Joint Venture - Additional Information (Details)",
     "shortName": "Joint Venture - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_3cf7f842-3616-4d7d-a8d1-b72415a7dc2e",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3cf7f842-3616-4d7d-a8d1-b72415a7dc2e",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tcrt-20240331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r564"
     ]
    },
    "tcrt_AccrualsPriorToFirstMarketingApproval": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "AccrualsPriorToFirstMarketingApproval",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments due prior to the first marketing approval for TCR products.",
        "label": "Accruals Prior to First Marketing Approval",
        "terseLabel": "Payments due prior to the first marketing approval"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accrued Liabilities, Current, Total",
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r615"
     ]
    },
    "tcrt_AdditionalLoansCommitted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "AdditionalLoansCommitted",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Loans Committed",
        "label": "Additional Loans Committed",
        "documentation": "Additional loans committed."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AdditionalNumberOfWarrantsIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "AdditionalNumberOfWarrantsIssued",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional number warrants issued",
        "label": "Additional Number Of Warrants Issued",
        "documentation": "Additional number of warrants issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "tcrt_AdditionalPaidInCapitalCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "AdditionalPaidInCapitalCommonStockMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock [Member]",
        "terseLabel": "Additional Paid In Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r304"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AggregateAmountPotentiallyReimburseableAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "AggregateAmountPotentiallyReimburseableAmount",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reimbursement of historical costs",
        "label": "Aggregate Amount Potentially Reimburseable Amount",
        "documentation": "Aggregate Amount Potentially Reimburseable Amount."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AggregatePotentialBenchmarkPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "AggregatePotentialBenchmarkPayments",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate potential benchmark payments",
        "label": "Aggregate potential benchmark payments",
        "documentation": "Aggregate potential benchmark payments."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r586",
      "r597",
      "r607",
      "r632"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r589",
      "r600",
      "r610",
      "r635"
     ]
    },
    "tcrt_AgreementTerminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "AgreementTerminationDate",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Agreement termination date",
        "label": "Agreement Termination Date",
        "documentation": "Termination Date of CRADA Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AgreementTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "AgreementTypeAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Type Axis",
        "label": "Agreement Type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AgreementTypeAxisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "AgreementTypeAxisAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Type Axis Axis",
        "label": "Agreement Type Axis [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AgreementTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "AgreementTypeDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Type Domain",
        "label": "Agreement Type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r593",
      "r601",
      "r611",
      "r628",
      "r636",
      "r640",
      "r648"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of financing costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r276",
      "r371",
      "r671"
     ]
    },
    "tcrt_AmountOfPrepaymentsPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "AmountOfPrepaymentsPremium",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of prepayments premium",
        "label": "Amount Of Prepayments Premium",
        "documentation": "Amount Of Prepayments Premium."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AnnualExpenseIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "AnnualExpenseIncurred",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual expense incurred",
        "label": "Annual Expense Incurred",
        "documentation": "Annual expense incurred."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AnnualLicenseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "AnnualLicenseFees",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual license fee",
        "label": "Annual License Fees",
        "documentation": "Annual License Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r119",
      "r140",
      "r174",
      "r180",
      "r184",
      "r223",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r341",
      "r343",
      "r362",
      "r430",
      "r494",
      "r564",
      "r577",
      "r695",
      "r696",
      "r738"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r124",
      "r140",
      "r223",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r341",
      "r343",
      "r362",
      "r564",
      "r695",
      "r696",
      "r738"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "At The Market Offering [Member]",
        "documentation": "At The Market Offering Member",
        "terseLabel": "Market Offering [Member]",
        "label": "At The Market Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53"
     ]
    },
    "us-gaap_BankingAndThriftInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BankingAndThriftInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Banking and Thrift, Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_BlackScholesModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "BlackScholesModelMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Black-Scholes Model [Member]",
        "label": "Black Scholes Model [Member]",
        "documentation": "Black-Scholes Model [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganization"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Business",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r88",
      "r89"
     ]
    },
    "tcrt_CRADAAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "CRADAAgreementMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CRADA Agreement [Member]",
        "documentation": "CRADA Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_CantorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "CantorMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cantor [Member]",
        "label": "Cantor [Member]",
        "documentation": "Cantor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts included in accrued expenses and accounts payable related to property and equipment",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash balance",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "terseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r118",
      "r547"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r85",
      "r137"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r85"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer",
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r121",
      "r122",
      "r123",
      "r140",
      "r160",
      "r161",
      "r164",
      "r166",
      "r172",
      "r173",
      "r223",
      "r245",
      "r247",
      "r248",
      "r249",
      "r252",
      "r253",
      "r282",
      "r283",
      "r285",
      "r286",
      "r288",
      "r362",
      "r452",
      "r453",
      "r454",
      "r455",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r482",
      "r503",
      "r526",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r654",
      "r673",
      "r679"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "tcrt_ClassOfWarrantOrRightAxisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "ClassOfWarrantOrRightAxisAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Axis [Axis]",
        "documentation": "Class Of Warrant Or Right Axis."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_ClassOfWarrantOrRightDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "ClassOfWarrantOrRightDomainDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Domain [Domain]",
        "documentation": "Class Of Warrant Or Right."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant exercise per share",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants issued",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants",
        "verboseLabel": "Number of securities into which the class of warrant converted",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "tcrt_ClassOfWarrantOrRightWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "ClassOfWarrantOrRightWarrantsExercised",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right warrants exercised.",
        "label": "Class Of Warrant Or Right Warrants Exercised",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_ClinicalExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "ClinicalExpenses",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical expenses",
        "label": "Clinical Expenses",
        "documentation": "Clinical expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "tcrt_CollaborationAgreementWithSolasiaPharmaKkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "CollaborationAgreementWithSolasiaPharmaKkMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Agreement with Solasia Pharma KK [Member]",
        "label": "Collaboration Agreement With Solasia Pharma KK [Member]",
        "documentation": "Collaboration agreement with solasia pharma K.K."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments and contingencies (Note 8)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r60",
      "r431",
      "r481"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_CommitmentsAndContingenciesDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued Payments",
        "label": "Commitments and Contingencies Disclosure [Line Items]",
        "documentation": "Commitments and Contingencies Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_CommitmentsAndContingenciesDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Table]",
        "label": "Commitments and Contingencies Disclosure [Table]",
        "documentation": "Commitments and Contingencies Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r239",
      "r240",
      "r542",
      "r688"
     ]
    },
    "us-gaap_CommonStockCallOrExerciseFeatures": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCallOrExerciseFeatures",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price",
        "label": "Common Stock, Call or Exercise Features",
        "documentation": "Describe the call and/or exercise rights, prices and dates of common stock."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r68"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock reserved for future issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r568",
      "r569",
      "r571",
      "r572",
      "r573",
      "r574",
      "r676",
      "r677",
      "r732",
      "r750",
      "r752"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, par value",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r482"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r68",
      "r482",
      "r500",
      "r752",
      "r753"
     ]
    },
    "us-gaap_CommonStockSharesSubscribedButUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesSubscribedButUnissued",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Subscribed but Unissued",
        "terseLabel": "Common stock",
        "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock $0.001 par value; 34,666,667 shares authorized, 16,012,522 shares issued and outstanding at March 31, 2024 and at December 31, 2023",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r432",
      "r564"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r341",
      "r342",
      "r343",
      "r344",
      "r380",
      "r543",
      "r694",
      "r697",
      "r698"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r141",
      "r341",
      "r342",
      "r343",
      "r344",
      "r380",
      "r543",
      "r694",
      "r697",
      "r698"
     ]
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses, Related Party",
        "terseLabel": "Fees and Expenses, Related Party",
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued",
        "terseLabel": "Warrants issued",
        "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r27"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r139",
      "r254",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r270",
      "r277",
      "r278",
      "r280"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r65",
      "r66",
      "r103",
      "r104",
      "r141",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r372",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r674"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility, interest rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument description of variable rate basis",
        "label": "Debt Instrument, Description of Variable Rate Basis",
        "documentation": "Description of reference rate used for variable rate of debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r279",
      "r372",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r674"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDateRangeStart1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDateRangeStart1",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Maturity Date Range, Start",
        "terseLabel": "Debt instrument, initial maturity date",
        "documentation": "Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r141",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r372",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r674"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Instrument, Periodic Payment, Total",
        "terseLabel": "Debt instrument, periodic payment",
        "label": "Debt Instrument, Periodic Payment",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r62"
     ]
    },
    "tcrt_DebtInstrumentPrepaymentPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "DebtInstrumentPrepaymentPremium",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument prepayment premium.",
        "label": "Debt Instrument Prepayment Premium",
        "terseLabel": "Prepayment premium"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Debt Instrument Redemption Period One",
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "Debt Instrument Redemption Period Three Member",
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Debt Instrument Redemption Period Two Member",
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r38",
      "r41",
      "r54",
      "r55",
      "r57",
      "r61",
      "r95",
      "r96",
      "r141",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r266",
      "r267",
      "r268",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r279",
      "r372",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r674"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Issuance Costs, Net, Total",
        "terseLabel": "Issuance costs",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r700"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Total",
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r32"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-Based Compensation Expense on All Employee and Non-Employee Awards",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r47"
     ]
    },
    "us-gaap_Dividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Dividends",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Dividends, Total",
        "terseLabel": "Dividends",
        "label": "Dividends",
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r97"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_DueDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "DueDateAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due Date Axis",
        "label": "Due date [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_DueDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "DueDateDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due Date Domain",
        "label": "Due date [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_DuneLakeCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "DuneLakeCapitalMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dune Lake Capital [Member]",
        "documentation": "Dune Lake Capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share, Basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r157",
      "r160",
      "r164",
      "r165",
      "r166",
      "r170",
      "r353",
      "r354",
      "r428",
      "r438",
      "r548"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share, Diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r160",
      "r164",
      "r165",
      "r166",
      "r170",
      "r353",
      "r354",
      "r428",
      "r438",
      "r548"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net Loss per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r167",
      "r168",
      "r169"
     ]
    },
    "tcrt_EdenBioCellMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "EdenBioCellMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eden Bio Cell",
        "label": "Eden Bio Cell [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_EdenBiocellMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "EdenBiocellMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eden Biocell [Member]",
        "documentation": "Eden Biocell."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_EightScheduledPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "EightScheduledPaymentMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Eighth Scheduled Payment [Member]",
        "documentation": "Eighth Scheduled Payment.",
        "terseLabel": "Eighth Scheduled Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "totalLabel": "Employee Benefit and Share-based Payment Arrangement, Noncash, Total",
        "label": "Employee Benefit and Share-Based Payment Arrangement, Noncash",
        "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected recognition period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation costs related to unvested restricted stock outstanding",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r114",
      "r127",
      "r128",
      "r129",
      "r142",
      "r143",
      "r144",
      "r146",
      "r152",
      "r154",
      "r171",
      "r225",
      "r226",
      "r290",
      "r333",
      "r334",
      "r335",
      "r338",
      "r339",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r373",
      "r446",
      "r447",
      "r448",
      "r460",
      "r526"
     ]
    },
    "tcrt_EquityDistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "EquityDistributionAgreementMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Distribution Agreement [Member]",
        "documentation": "Equity distribution agreement.",
        "terseLabel": "Equity Distribution Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r222"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity interest in affilated entity",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/JointVenture"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Joint Venture",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r221",
      "r224",
      "r655"
     ]
    },
    "tcrt_EquityMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "EquityMilestoneMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Milestone [Member]",
        "documentation": "Equity milestone."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r586",
      "r597",
      "r607",
      "r632"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r583",
      "r594",
      "r604",
      "r629"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExtinguishmentOfDebtAmount",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extinguishment of debt, amount",
        "label": "Extinguishment of Debt, Amount",
        "documentation": "Gross amount of debt extinguished."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r360"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r360"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Hierarchy [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r357",
      "r387",
      "r388",
      "r389",
      "r554",
      "r555",
      "r560",
      "r561",
      "r562"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r359",
      "r361"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel12And3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel12And3Member",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Inputs, Level 2, and Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]",
        "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3)."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r294",
      "r299",
      "r357",
      "r387",
      "r560",
      "r561",
      "r562"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r387",
      "r388",
      "r389",
      "r554",
      "r555",
      "r560",
      "r561",
      "r562"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring [Member]",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r361"
     ]
    },
    "us-gaap_FairValueNetAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueNetAssetLiability",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of assets (liabilities)",
        "label": "Fair Value, Net Asset (Liability)",
        "totalLabel": "Fair Value, Net Asset (Liability), Total",
        "documentation": "Fair value of asset after deduction of liability."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_FairValueOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "FairValueOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value of Warrants",
        "label": "Fair Value of Warrants",
        "terseLabel": "Fair value of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r279",
      "r287",
      "r351",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r437",
      "r552",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r681",
      "r682",
      "r683",
      "r684"
     ]
    },
    "tcrt_FinancingArrangementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "FinancingArrangementsDisclosureTextBlock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/Financings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financings",
        "label": "Financing Arrangements Disclosure [Text Block]",
        "documentation": "Includes disclosures related to financing receivables and financing guarantees in which the company is the guarantor."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r590",
      "r601",
      "r611",
      "r636"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r590",
      "r601",
      "r611",
      "r636"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r590",
      "r601",
      "r611",
      "r636"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r590",
      "r601",
      "r611",
      "r636"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r590",
      "r601",
      "r611",
      "r636"
     ]
    },
    "tcrt_FullyDrawnAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "FullyDrawnAmount",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fully drawn amount.",
        "label": "Fully Drawn Amount",
        "terseLabel": "Fully drawn amount"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_GainLossOnOperatingLeaseModification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "GainLossOnOperatingLeaseModification",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on lease modification",
        "terseLabel": "Gain on lease modification",
        "label": "Gain (Loss) On Operating Lease Modification",
        "documentation": "Gain (loss) on operating lease modification."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r505"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and Administrative [Member]",
        "terseLabel": "General and Administrative Expense",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r510"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r510"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total",
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "tcrt_IncreaseDecreaseInLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liabilities",
        "label": "Increase Decrease In Lease Liabilities",
        "documentation": "The increase (decrease) during the period in the carrying value of lease liabilities reported as liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "terseLabel": "(Increase) decrease in:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in:",
        "label": "Increase (Decrease) in Operating Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInReceivables",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Receivables",
        "totalLabel": "Increase (Decrease) in Receivables, Total",
        "label": "Increase (Decrease) in Receivables",
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "tcrt_IncreaseDecreaseInRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "IncreaseDecreaseInRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in the carrying amount of right-of-use assets",
        "label": "Increase Decrease In Right Of Use Asset",
        "documentation": "The increase (decrease) during the period in the carrying value of right of use asset reported as assets."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r593",
      "r601",
      "r611",
      "r628",
      "r636",
      "r640",
      "r648"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r582",
      "r652"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r582",
      "r652"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r582",
      "r652"
     ]
    },
    "tcrt_IntendedPercentageOfResductionInWorkforce": {
     "xbrltype": "percentItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "IntendedPercentageOfResductionInWorkforce",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intended percentage of resduction in workforce",
        "documentation": "Intended percentage of resduction in workforce",
        "terseLabel": "Intended percentage of reduction in workforce"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense",
        "totalLabel": "Interest Expense, Total",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r107",
      "r130",
      "r177",
      "r370",
      "r511",
      "r575",
      "r751"
     ]
    },
    "tcrt_InterestExpenseAmortizedDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "InterestExpenseAmortizedDate",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense amortized date",
        "label": "Interest Expense Amortized Date",
        "documentation": "Interest expense amortized date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest Expense, Debt, Total",
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r274",
      "r281",
      "r556",
      "r557"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r135",
      "r136"
     ]
    },
    "tcrt_IntrexonCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "IntrexonCorporationMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intrexon Corporation [Member]",
        "documentation": "Intrexon Corporation Member",
        "label": "Intrexon Corporation/Precigen [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "documentation": "Laboratory Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements [Member]",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r140",
      "r223",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r342",
      "r343",
      "r344",
      "r362",
      "r480",
      "r549",
      "r577",
      "r695",
      "r738",
      "r739"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r105",
      "r434",
      "r564",
      "r675",
      "r685",
      "r734"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r117",
      "r140",
      "r223",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r342",
      "r343",
      "r344",
      "r362",
      "r564",
      "r695",
      "r738",
      "r739"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_LicenseAgreementCommencingDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "LicenseAgreementCommencingDate",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement commencing date.",
        "label": "License Agreement Commencing Date",
        "terseLabel": "License agreement commencing date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseAgreementTermsMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement Terms [Member]",
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_LicenseAgreementWithTheNationalCancerInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "LicenseAgreementWithTheNationalCancerInstituteMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement With The National Cancer Institute Member",
        "label": "License Agreement with the National Cancer Institute [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_LicenseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "LicenseExpense",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License expense",
        "documentation": "Amount of expense related to License payments.",
        "label": "License Expense"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_LicensedProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "LicensedProductsMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensed Products Member",
        "label": "licensed products [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lender Name [Axis]",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r674"
     ]
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan and Security Agreement",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of payment terms",
        "label": "Line of Credit Facility, Frequency of Payment and Payment Terms",
        "documentation": "Description of the frequency of the required periodic payments of interest, principal, or both, and the amount, if set, or a description of a formula upon which payment is based."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Line of Credit Facility, Interest Rate During Period",
        "documentation": "The effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Lender [Domain]",
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r674"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Maximum borrowing capacity under the credit facility",
        "terseLabel": "Additonal tranche facility",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_LitigationSettlementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementExpense",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation expense",
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Debt obligations",
        "terseLabel": "Long-term debt",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "totalLabel": "Long-term debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDamagesSoughtValue",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Unspecified monetary damages",
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r689",
      "r690",
      "r691"
     ]
    },
    "us-gaap_LossContingencyNameOfPlaintiff": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyNameOfPlaintiff",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loss contingency, name of plaintiff",
        "label": "Loss Contingency, Name of Plaintiff",
        "terseLabel": "Name of Plaintiff",
        "documentation": "Identifies the plaintiff in the lawsuit."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r93"
     ]
    },
    "tcrt_MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "M D Anderson License and the Two Thousand Fifteen Research and Development Agreement [Member]",
        "label": "M D Anderson License and the Two Thousand Fifteen Research and Development Agreement [Member]",
        "documentation": "M D Anderson license and the two thousand fifteen research and development agreement."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_MaximumAmountOfAdditionalMilestonesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "MaximumAmountOfAdditionalMilestonesPayable",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected additional milestones payable",
        "label": "Maximum Amount of Additional Milestones Payable",
        "documentation": "Maximum amount of additional milestones payable."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_MaximumAmountOfRoyaltyPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "MaximumAmountOfRoyaltyPayable",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Maximum royalty amount",
        "label": "Maximum Amount of Royalty Payable",
        "documentation": "Maximum amount of royalty payable."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r301",
      "r414",
      "r445",
      "r472",
      "r473",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r544",
      "r545",
      "r551",
      "r558",
      "r563",
      "r566",
      "r699",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745"
     ]
    },
    "tcrt_MaximumRoyaltyAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "MaximumRoyaltyAmount",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of royalty.",
        "label": "Maximum Royalty Amount",
        "terseLabel": "Maximum royalty amount"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_MdAndersonAgreementAndWorldwideLicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "MdAndersonAgreementAndWorldwideLicenseMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MD Anderson Agreement and Worldwide License.",
        "label": "MD Anderson Agreement and Worldwide License [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MD Anderson License and the Research and Development Agreement [Member]",
        "documentation": "MD Anderson License and the Research and Development Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_MdAndersonWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "MdAndersonWarrantMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Md Anderson Warrant Member",
        "verboseLabel": "MD Anderson Warrant [Member]",
        "terseLabel": "MD Anderson Warrant [Member]",
        "label": "Md Anderson Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "tcrt_MilestonePaymentsMaximumAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "MilestonePaymentsMaximumAmount",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone maximum payment",
        "label": "Milestone Payments, Maximum Amount",
        "documentation": "Milestone payments maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r301",
      "r414",
      "r445",
      "r472",
      "r473",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r544",
      "r545",
      "r551",
      "r558",
      "r563",
      "r566",
      "r699",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquity",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "verboseLabel": "Net loss",
        "totalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r87",
      "r106",
      "r115",
      "r125",
      "r126",
      "r129",
      "r140",
      "r145",
      "r147",
      "r148",
      "r149",
      "r150",
      "r153",
      "r154",
      "r162",
      "r174",
      "r179",
      "r183",
      "r185",
      "r223",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r354",
      "r362",
      "r436",
      "r502",
      "r524",
      "r525",
      "r550",
      "r575",
      "r695"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss applicable to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r147",
      "r148",
      "r149",
      "r150",
      "r157",
      "r158",
      "r163",
      "r166",
      "r174",
      "r179",
      "r183",
      "r185",
      "r550"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_NewWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "NewWarrantsMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Warrants [Member]",
        "documentation": "New Warrants Member",
        "label": "New Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r590",
      "r601",
      "r611",
      "r628",
      "r636"
     ]
    },
    "tcrt_NonOperatingIncomeExpenseInducementOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "NonOperatingIncomeExpenseInducementOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash inducement warrant expense",
        "label": "Non Operating Income Expense Inducement Of Warrants",
        "documentation": "Non Operating Income Expense Inducement Of Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "tcrt_NonVestedRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "NonVestedRestrictedStockMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non Vested Restricted Stock [Member]",
        "terseLabel": "Unvested Restricted Common Stock",
        "label": "Non Vested Restricted Stock [Member]",
        "documentation": "Non Vested Restricted Stock"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_NonVestedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "NonVestedStockMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested Stock",
        "label": "Non Vested Stock [Member]",
        "documentation": "Non Vested Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "totalLabel": "Other income (expense), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "tcrt_NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of additional option available to the underwriter to purchase",
        "label": "Number Of Additional Option Available To The Underwriter To Purchase",
        "documentation": "Number of additional option available to the underwriter to purchase."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_NumberOfEmployeesExpectedToRemain": {
     "xbrltype": "integerItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "NumberOfEmployeesExpectedToRemain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of employees expected to remain",
        "label": "Number Of Employees Expected To Remain",
        "documentation": "Number Of Employees Expected To Remain"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_OneTimeBenchmarkPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "OneTimeBenchmarkPaymentsMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Time Benchmark Payments Member",
        "label": "One Time Benchmark Payments [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingCostsAndExpensesAbstract",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "terseLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r179",
      "r183",
      "r185",
      "r550"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "tcrt_OutsideTwoThousandTwelvePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "OutsideTwoThousandTwelvePlanMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outside 2012 Plan",
        "label": "Outside Two Thousand Twelve Plan [Member]",
        "documentation": "Outside two thousand twelve plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r588",
      "r599",
      "r609",
      "r634"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r591",
      "r602",
      "r612",
      "r637"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r591",
      "r602",
      "r612",
      "r637"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "tcrt_PaymentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "PaymentTypeAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Type Axis",
        "label": "Payment Type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PaymentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "PaymentTypeDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Type Domain",
        "label": "Payment Type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PaymentUnderLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "PaymentUnderLicenseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment under license agreement.",
        "label": "Payment Under License Agreement",
        "terseLabel": "Payment under license agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToFundLongtermLoansToRelatedParties",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to Fund Long-term Loans to Related Parties",
        "label": "Payments to Fund Long-Term Loans to Related Parties",
        "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r735"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "tcrt_PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales commission as a percentage of gross proceeds",
        "label": "Percentage Of Commission On Gross Proceeds From Sale Of Common Stock",
        "documentation": "Percentage of commission on gross proceeds from sale of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PercentageOfOriginalPrincipalDueAsAFinalPayment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "PercentageOfOriginalPrincipalDueAsAFinalPayment",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of original principal due as a final payment.",
        "label": "Percentage of Original Principal Due as a Final Payment",
        "terseLabel": "Percentage of original principal due as a final payment"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PercentageOfPrepaymentPremium": {
     "xbrltype": "pureItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "PercentageOfPrepaymentPremium",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of prepayment premium",
        "label": "Percentage of prepayment premium",
        "terseLabel": "Prepayment premium percentage"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PercentageOfPrepaymentsPremium": {
     "xbrltype": "percentItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "PercentageOfPrepaymentsPremium",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of prepayments premium.",
        "label": "Percentage Of Prepayments Premium",
        "terseLabel": "Percentage of prepayments premium"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PercentageOfSubLicensingIncomePayableToRelatedParty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "PercentageOfSubLicensingIncomePayableToRelatedParty",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Portion of income payable to related party",
        "label": "Percentage of Sub licensing Income Payable to Related Party",
        "documentation": "Percentage of sub licensing income, attributable to related party."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PerformanceBasedPaymentsMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "PerformanceBasedPaymentsMemberMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Based Payments Member Member",
        "label": "Performance Based Payments Member [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PlacementAgentFeesAndOtherRelatedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "PlacementAgentFeesAndOtherRelatedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Placement agent fees and other expenses",
        "label": "Placement Agent Fees And Other Related Expenses",
        "documentation": "Placement agent fees and other related expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729"
     ]
    },
    "tcrt_PocketExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "PocketExpenses",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pocket expenses.",
        "label": "Pocket Expenses",
        "terseLabel": "Pocket expenses"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PostMarketingApprovalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "PostMarketingApprovalMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post Marketing Approval Member",
        "label": "Post Marketing Approval [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PostStockSplitSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "PostStockSplitSharesAuthorized",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Post Stock Split Shares Authorized",
        "label": "Post Stock Split Shares Authorized",
        "documentation": "Post Stock Split Shares Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PreStockSplitSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "PreStockSplitSharesAuthorized",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre Stock Split Shares Authorized",
        "label": "Pre Stock Split Shares Authorized",
        "documentation": "Pre Stock Split Shares Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock par value",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r282"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r482"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses and Other Current Assets [Member]",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement [Member]",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from collateral account",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Proceeds from Issuance of Long-term Debt and Capital Securities, Net, Total",
        "terseLabel": "Gross proceeds from debt",
        "label": "Proceeds from Issuance of Long-Term Debt and Capital Securities, Net",
        "documentation": "Amount of cash inflow from long-term debt, finance lease obligation, and mandatorily redeemable capital security."
       }
      }
     },
     "auth_ref": [
      "r669",
      "r670"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from private placement",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Cash proceeds from sale of equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r452"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the disposal of property and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total",
        "verboseLabel": "Laboratory equipment, gross proceeds",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r415",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r546",
      "r559",
      "r565",
      "r658",
      "r692",
      "r693",
      "r701",
      "r749"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r415",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r546",
      "r559",
      "r565",
      "r658",
      "r692",
      "r693",
      "r701",
      "r749"
     ]
    },
    "us-gaap_ProfessionalAndContractServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfessionalAndContractServicesExpense",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consulting service amount",
        "label": "Professional and Contract Services Expense",
        "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_PropertyAndEquipmentAndRightOfUseAssetsImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "PropertyAndEquipmentAndRightOfUseAssetsImpairment",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property and equipment and right of use assets impairment",
        "label": "Property And Equipment And Right Of Use Assets Impairment",
        "terseLabel": "Property and equipment and right-of-use assets impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property, Plant and Equipment, Net, Total",
        "terseLabel": "Property and equipment, net",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r429",
      "r435",
      "r564"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "tcrt_QuarterlyExpenseIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "QuarterlyExpenseIncurred",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quarterly expense incurred.",
        "label": "Quarterly Expense Incurred",
        "terseLabel": "Quarterly expense incurred"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r293",
      "r301",
      "r328",
      "r329",
      "r330",
      "r390",
      "r414",
      "r445",
      "r472",
      "r473",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r544",
      "r545",
      "r551",
      "r558",
      "r563",
      "r566",
      "r569",
      "r686",
      "r699",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r293",
      "r301",
      "r328",
      "r329",
      "r330",
      "r390",
      "r414",
      "r445",
      "r472",
      "r473",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r544",
      "r545",
      "r551",
      "r558",
      "r563",
      "r566",
      "r569",
      "r686",
      "r699",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745"
     ]
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Receivables, Net, Current, Total",
        "terseLabel": "Receivables",
        "label": "Receivables, Net, Current",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r583",
      "r594",
      "r604",
      "r629"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r377",
      "r378",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r499",
      "r501",
      "r531"
     ]
    },
    "tcrt_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction Expenses From Transactions With Related Party Advisory Fees",
        "documentation": "Related party transaction expenses from transactions with related party advisory fees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r507",
      "r510"
     ]
    },
    "tcrt_RelatedPartyTransactionReimbursedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "RelatedPartyTransactionReimbursedAmount",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party transaction, reimbursed amount",
        "label": "Related Party Transaction Reimbursed Amount",
        "documentation": "Related Party Transaction Reimbursed Amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r377",
      "r378",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r499",
      "r501",
      "r531",
      "r737"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r457",
      "r458",
      "r459",
      "r508",
      "r509",
      "r510",
      "r529",
      "r530"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Repayments of Long-Term Debt, Total",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayment of long-term debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r455"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r731"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r731"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development expense",
        "totalLabel": "Research and Development Expense, Total",
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r336",
      "r746"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and Development [Member]",
        "terseLabel": "Research and Development Expense",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r584",
      "r595",
      "r605",
      "r630"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r585",
      "r596",
      "r606",
      "r631"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r592",
      "r603",
      "r613",
      "r638"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restricted Cash, Total",
        "label": "Restricted Cash",
        "verboseLabel": "Restricted cash",
        "terseLabel": "Restricted cash related to the Company's debt agreement",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r672",
      "r747",
      "r748"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unvested Restricted Stock [Member]",
        "terseLabel": "Restricted Stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Restructuring Charges, Total",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring costs",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r237",
      "r238",
      "r687"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated deficit",
        "verboseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r97",
      "r433",
      "r449",
      "r450",
      "r456",
      "r483",
      "r564"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r142",
      "r143",
      "r144",
      "r146",
      "r152",
      "r154",
      "r225",
      "r226",
      "r333",
      "r334",
      "r335",
      "r338",
      "r339",
      "r345",
      "r347",
      "r348",
      "r350",
      "r352",
      "r446",
      "r448",
      "r460",
      "r752"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r178",
      "r181",
      "r182",
      "r186",
      "r187",
      "r188",
      "r291",
      "r292",
      "r415"
     ]
    },
    "tcrt_ReversalOfAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "ReversalOfAccruedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reversal of accrued expenses",
        "label": "Reversal Of Accrued Expenses",
        "documentation": "Reversal of accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_ReverseStockSplitPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "ReverseStockSplitPolicyTextBlock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse Stock Split",
        "label": "Reverse Stock Split [Policy Text Block]",
        "documentation": "Reverse stock split policy text block."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty amount",
        "label": "Royalty Expense",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty [Member]",
        "terseLabel": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sale of stock consideration received on transaction",
        "terseLabel": "Issuance of common stock in connection with a public offering, net",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forecast[Member]",
        "terseLabel": "Forecast [Member]",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r302",
      "r678"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r155",
      "r302",
      "r656",
      "r678"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Potentially Dilutive Shares Excluded from Computation of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r42",
      "r43",
      "r44",
      "r45"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r222"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r356",
      "r357"
     ]
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Unvested Restricted Stock",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r506",
      "r507",
      "r510"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option Activity under Stock Option Plan",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r48"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Stock Options Assumptions Using Black-Scholes Option Valuation Model",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r40",
      "r41",
      "r95",
      "r96",
      "r97",
      "r121",
      "r122",
      "r123",
      "r172",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r452",
      "r453",
      "r454",
      "r455",
      "r558",
      "r654",
      "r673"
     ]
    },
    "us-gaap_ScheduleOfSubsidiaryOrEquityMethodInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSubsidiaryOrEquityMethodInvesteeTable",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Subsidiary or Equity Method Investee [Table]",
        "documentation": "Schedule of subsidiary's sales of previously unissued stock made to investors outside the consolidated group. This includes stock issued in a business combination in exchange for shares of an acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities Purchase Agreement [Member]",
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value Assumptions Expected volatility Rate Maximum",
        "terseLabel": "Expected volatility, Maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, Minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk-free interest rate, Maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, Minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationExpenseIncludedInStatementOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options available for future grant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, at end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, at end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options, granted",
        "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total",
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r711"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, at end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock option, outstanding",
        "terseLabel": "Outstanding options issued",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Contractual Term (Years)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise price of stock options",
        "terseLabel": "Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term A Tranche [Member]",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term B Tranche [Member]",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_ShareSubscriptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "ShareSubscriptionAgreementMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Subscription Agreement [Member]",
        "documentation": "Share Subscription Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected life in years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, at end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, at end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, at end of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r138"
     ]
    },
    "tcrt_SiliconValleyBankLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "SiliconValleyBankLoanMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Silicon Valley Bank Loan [Member]",
        "label": "Silicon Valley Bank Loan [Member]",
        "documentation": "Silicon Valley Bank loan."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_SiliconValleyBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "SiliconValleyBankMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Silicon Valley Bank [Member]",
        "documentation": "Silicon valley bank.",
        "label": "Silicon Valley Bank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r121",
      "r122",
      "r123",
      "r140",
      "r160",
      "r161",
      "r164",
      "r166",
      "r172",
      "r173",
      "r223",
      "r245",
      "r247",
      "r248",
      "r249",
      "r252",
      "r253",
      "r282",
      "r283",
      "r285",
      "r286",
      "r288",
      "r362",
      "r452",
      "r453",
      "r454",
      "r455",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r482",
      "r503",
      "r526",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r654",
      "r673",
      "r679"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r22",
      "r114",
      "r127",
      "r128",
      "r129",
      "r142",
      "r143",
      "r144",
      "r146",
      "r152",
      "r154",
      "r171",
      "r225",
      "r226",
      "r290",
      "r333",
      "r334",
      "r335",
      "r338",
      "r339",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r373",
      "r446",
      "r447",
      "r448",
      "r460",
      "r526"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r171",
      "r415",
      "r451",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r501",
      "r504",
      "r505",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r526",
      "r570"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r155",
      "r302",
      "r656",
      "r657",
      "r678"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationFairValueOfStockOptionsAssumptionsUsingBlackscholesOptionValuationModelDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r171",
      "r415",
      "r451",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r501",
      "r504",
      "r505",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r526",
      "r570"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r587",
      "r598",
      "r608",
      "r633"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock, net of expenses, (in shares)",
        "terseLabel": "Common stock issuance",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r67",
      "r68",
      "r97",
      "r452",
      "r526",
      "r538"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationStockOptionActivityUnderStockOptionPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised",
        "terseLabel": "Exercise of employee stock options (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r67",
      "r68",
      "r97",
      "r314"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock, net of expenses",
        "terseLabel": "Aggregate offering price",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r67",
      "r68",
      "r97",
      "r460",
      "r526",
      "r538",
      "r576"
     ]
    },
    "tcrt_StockOfferedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "StockOfferedDuringPeriodShares",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock issued during period",
        "label": "Stock Offered During Period Shares",
        "documentation": "Stock offered during period shares.",
        "terseLabel": "Sale of stock during period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockOptionMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "tcrt_StockOptionsAndRestrictedStockAwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "StockOptionsAndRestrictedStockAwardsTextBlock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-Based Compensation",
        "label": "Stock Options and Restricted Stock Awards [Text Block]",
        "documentation": "Stock Options and Restricted Stock Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets",
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r71",
      "r72",
      "r90",
      "r484",
      "r500",
      "r527",
      "r528",
      "r564",
      "r577",
      "r675",
      "r685",
      "r734",
      "r752"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity, Reverse Stock Split",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "tcrt_StrategicAdvisorName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "StrategicAdvisorName",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Strategic advisor name",
        "label": "Strategic Advisor Name",
        "documentation": "Strategic advisor name."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r382"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r382"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r382"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r383"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeLineItems",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsidiary or Equity Method Investee [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplementary disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_SvbWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "SvbWarrantsMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SVB Warrants [Member]",
        "label": "Svb Warrants [Member]",
        "documentation": "Svb Warrants [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "tcrt_TcellReceptorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "TcellReceptorMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "T-cell receptor [Member]",
        "documentation": "Tcell Receptor Member",
        "label": "Tcell receptor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_TenthScheduledPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "TenthScheduledPaymentMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenth Scheduled Payment.",
        "label": "Tenth Scheduled Payment [Member]",
        "terseLabel": "Tenth Scheduled Payment Member"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_TermATrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "TermATrancheMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term A Tranche [Member]",
        "label": "Term A Tranche [Member]",
        "documentation": "Term A Tranche [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_TermBMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "TermBMilestoneMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term B Milestone [Member]",
        "documentation": "Term B Milestone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_TermBTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "TermBTrancheMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term B Tranche [Member]",
        "label": "Term B Tranche [Member]",
        "documentation": "Term B Tranche."
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "TermLoanMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan [Member]",
        "label": "Term Loan [Member]",
        "documentation": "Term loan member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The University of Texas MD Anderson Cancer Center and The Texas A &amp; M University System [Member]",
        "label": "The University Of Texas M D Anderson Cancer Center And The Texas A And M University System [Member]",
        "documentation": "The University Of Texas M D Anderson Cancer Center And The Texas A And M University System"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold period for exercise or conversion of stock",
        "label": "Threshold Commitment Period for Exercise of Rights to Participate in Future Offerings",
        "documentation": "Threshold commitment period for exercise of rights to participate in future offerings."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r680",
      "r736"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Relationship to Entity [Domain]",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r279",
      "r287",
      "r351",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r437",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r681",
      "r682",
      "r683",
      "r684"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "tcrt_TriArmMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "TriArmMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TriArm [Member]",
        "label": "Tri Arm [Member]",
        "documentation": "Tri Arm"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_TwoThousandAndThreeEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "TwoThousandAndThreeEquityIncentivePlanMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2003 Equity Incentive Plan [Member]",
        "label": "Two Thousand And Three Equity Incentive Plan [Member]",
        "documentation": "Two Thousand And Three Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_TwoThousandAndTwelveEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "TwoThousandAndTwelveEquityIncentivePlanMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2012 Equity Incentive Plan [Member]",
        "label": "Two Thousand And Twelve Equity Incentive Plan [Member]",
        "documentation": "Two Thousand And Twelve Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_TwoThousandAndTwentyEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "TwoThousandAndTwentyEquityIncentivePlanMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Equity Incentive Plan [Member]",
        "label": "Two Thousand And Twenty Equity Incentive Plan [Member]",
        "documentation": "Two thousand and twenty equity incentive plan [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "tcrt_UnderwriterParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "UnderwriterParOrStatedValuePerShare",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriter par or stated value per share",
        "label": "Underwriter Par or Stated Value Per Share",
        "documentation": "Underwriter par or stated value per share."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureOrganizationPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r108",
      "r109",
      "r110",
      "r111"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureFinancingsAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729"
     ]
    },
    "tcrt_VinetiIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "VinetiIncMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vineti Inc [Member]",
        "documentation": "Vineti Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrants [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r568",
      "r571",
      "r572",
      "r573",
      "r574"
     ]
    },
    "tcrt_WarrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "WarrantTextBlock",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/Warrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Text Block]",
        "documentation": "The entire disclosure pertaining to the warrant.",
        "verboseLabel": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant expiry date",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureWarrantsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants fully vested upon issuance",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "tcrt_WarrantsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "WarrantsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Disclosure Abstract",
        "label": "Warrants Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_WarrantsExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "WarrantsExpirationDate",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expiration Date",
        "label": "Warrants Expiration Date",
        "terseLabel": "Warrants expiration date"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_WatermillAndRobertWPostmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "WatermillAndRobertWPostmaMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Watermill And Robert W Postma.",
        "label": "Watermill And Robert W Postma [Member]",
        "terseLabel": "WatermillAndRobertWPostmaMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding, diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r166"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/StatementCondensedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average common shares outstanding, basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r166"
     ]
    },
    "tcrt_ZeroMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "ZeroMilestoneMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Zero Milestone [Member]",
        "documentation": "Zero Milestone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_ZiopLicenseAgreementWithTheNationalCancerInstituteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "ZiopLicenseAgreementWithTheNationalCancerInstituteMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ziop License Agreement With The National Cancer Institute [Member]",
        "label": "Ziop License Agreement With The National Cancer Institute [Member]",
        "documentation": "ZiopLicenseAgreementWithTheNationalCancerInstituteMember"
       }
      }
     },
     "auth_ref": []
    },
    "tcrt_ZiopharmMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://alaunos.com/20240331",
     "localname": "ZiopharmMember",
     "presentation": [
      "http://alaunos.com/20240331/taxonomy/role/DisclosureJointVentureAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ziopharm [Member]",
        "documentation": "Ziopharm [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "e",
   "SubTopic": "470",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "450",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//820/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//323/tableOfContent"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "323",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481543/323-740-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>53
<FILENAME>0000950170-24-060075-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-060075-xbrl.zip
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MF*Z_@=QWFTQT1:>4"VI\%>'9M)*!CBYE1&2<X.EI,%H1![[5O=/1GU4!_<K
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MI.DQ4X>UJVNT,PKNO,EXU9RKT<1E/8-$GIPZN3Q72HTQC.9LI_$$?2K2U&>
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MS@,8#F!X[U3G,.*!#A@1DG+")*:%&-"_#;6A3?Q$JNA*1.Y^KN=5@^%5G_.
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MKXU';NT,./#(-7+[M0GK 6[6=ES!R]_35S79@8!?WIZ^H,D.#4#N>7;&:"1
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M([\\D?R6:_>^&6>34Y]]/AU[G_T&GY^VV3MX@UL]]BQ>%O5$%-A&07HZ:6;
MAV.I1R<X>+R<#/5%,YW X[]Y][I[54[I ?UQ=@/L_E"?M_Y5Z\\U[*9?):'X
M[!_6S^J_U&UMZB%(A5>S^[<=PL?7<7[ @<!_^,LEW^>W_$[>X;$'5-[RUNI
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M]I\:]&0P@+9'AG4:MT;_*F!'=GC6Z68( A@%%2-[T)?:!4I'H/DP I8#+.B
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M,HD?+I-XY92R._A*&7%W#:M],@&SM]S2)Q]+?4F06^ E_"\PAY<1SJ7#6+5
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MQ$#Z+Q^^K,7<X&K\= (VP^5Y@8X$[<&O5DF5B0R-#?0SF2-2<V/T3>:3OHD
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M;[C$C671#7G6#8JKKH/\<;*OO#3@$ET:-DML'%7LD#B.;.+9<4#C)$S\S1E
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M&-B$>GN&ZAT6VSYA??OU-%*XZ>+5T.(G%" Y-O/!7CTMR^S%:WO\$".WJIN
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M+&.^;QGS.H-\L/D8Q](!)3(@H1NDH%/:+HD<UR9NZ 4L#$7(P@WS,?6<R M
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M)/" J5([#0CSG8"(@$>I<$,NO,U)3L^1A+&%M3YI)D8\#1Z+"]^A<OW0Z?
MF.]HEX]V^4@0(T&,!#&F:SQ5UY+/O1[&(PL:LV)? C/9?T8Y=2,J>$@<L%#
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M'P%,Q[E0&2+?-8P^&!#MR\LRR.B%=2G153?L:%844=#W6$KL1$@P:#%$D="
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M?3G^<O+I^'?KQ^GQZ8?/'[Z<_GC$N@I%ND,%S]$J9RN07U*\V2!4)60;5GG
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MV:TF$ !Z>^AW:$H&MWDJPXB3( 35@F(W#\;<E'C,%7&<VG'*-LL-W-CW6"+
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MY((78MH\F17%'TCA'7I2NEDI4PRZ*;P&'2FO)DW)G$;4!"Q&F593ZQ^XNC]
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MC"Q/5;RK#6/!WK^!R9I5RWJ,2^<[7 3H=-GB7&7:)+.B$%M7N>44V-+4,LX
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ME*J7)"8N:AY1WZ*;">@(EU*]IM:WFPG?/Q)OCNB;H]_>:*!EL,Q$N0S_:9+
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M.F<7$FAP:9VI@39(<2R_LDIY(7,@T+0LYD"S!8XHL2HVD]74^@%, 4>:<+G
MR1@3Z](\!CY:E<@.@,E8LZ*J9Y?D\DQ/QN&L.K=2[*ZO'XQD72SPM?"<ZAXT
M^L02Y\9S'@6.BH98 A"IQ0M@Q"S'83K]\^[( A <Q>KLW%J WI1QH,94X@0'
M19=X$P@:D"JPC8+_H63(!;S 6LQ@Z<CPF^LDD#"PN4J+A$Q6$S43!X1!LE2H
MJ.8)@,YF,,XZ-2]^+^%)"8B75E+5JR_A*T!>I N+G8&,.<-WPPM_^?_9>],F
MM[$D2_3[_ I86>9TYC-$5"Q:4_:>6:26*G5GIC129)?9^](&$I=!E$" A25"
MK%\_?MS];B!(A?:0 F-C7<H@B>5>O[[[.?=/'AZ>.'O($EVT;8]WY2>2ISE,
M[#%;9CG,G2P'""JR.1T+/+!]_]CZ?L"!^%8UT8LJ.>LOZ F2XSO!!F155?<L
M.EG"_%KF@L2C,<QJ1!O\;^$ZTMV?]2V9_%:4SE5!_R>OK]RGYX]?'9R3EI\U
M6;-)7BY!F'3\UY/DO"FR\C!YSFQ.E;#]B-<A[$SQO4*Y$(8H7/NJ;MZ0?S(G
MH9>;&URL*Z!"\1FSD=3Z$V: :@&+Q;$#/J!=(*]&1!TZLNFKJTPDQUV'O[:F
MS3#!4F0ER7?%VI5DG11PV8,3)Z6UZ%BME\6JZ-A#2UF YR23;2%O0N[4A6E2
M5O8-K8;];^AYK!IY8::CR_K;D;?7D9EHE\6:_CY73Z+)"JAZ<BIK]C7IZU6;
MS?6(6>DWU45V8>!_5%W-;TU?@1<9O$U^6;1UH_YI 0U1TUGZ$,OPK1X$6BTA
MH&'INR"/!.H$NW$V9QXRB-+KCH0L:_(V>5SGQ:*8JVC2LIV]?IPFY_6:5O/D
MZ.[!G:/T"Q"Y7=_?>DE^/OW+'=MGH@M)B.B=.E7F!\G?:KSFXYI>O=G'@?>9
M-R.-#FENA%^-CO32B*#3_R&WAT2XG[6T)QU>!,$_R?6LIA.( YT)E0VNX,XR
M$[E=\$O.Y259YFNZ]L9D]!LP7[$$Y&QLV 12V%,A$ENX-6O]FF7\(&UO\L/D
M;Z0-*OD1_#$*B'(ZX66]YN"(K&8E*I)5#;T_'4O^Q"SH(7#@6?-VQ;Q8X^[=
M,NL"U63#!M*198FPL.T7)((%KD#ON.BAR+R1I^#.!H=%DR?_ZDF%T+O1WK.)
M2U[L6*+@$K(:X?L,G@0O;]XN,SJXM#ZYH2B2SD9=#=>_GG49[2AXPW!E6D%G
MBU/L"7V%1(DL,%EI4GY](Z9\3G)'[WF!93TD_<7W)CW:Z-JOLDUR":.RHN6"
M-2&/AKV!;EFW\*ZO>-$E&IW34_)YGC/ZIM@!#F_GO6R+XYRSE@MGAAT#_C3<
MRJ:^:+(55#%%XJ8KV,O&MSHS7U;(5D&G\EN0VY1U UEHH?LO^C(CA;QQ#^3T
M>/A-,I!D$')Z;8A$N((]UAH[ '.3769%R4Q2=$8JNTQY&HH9EJLRDC6@#:4M
M*9.B:Z,W4U'D=[%K%TB$"$IK&@TJ#K^>CDANCVWZE1-!M1!+1D>1-HL$N^VB
M?5YR%D9U9N[5R%IL@'<?8HT",=JA5?#C;6& YJ1+@P*S\RI4#Z!Q+KFJ4N'+
MW*]-4U4#ZMB,:'<6P>MK=P0:1>N6B8__0(6-"[K\Z(IL_4%9U^Q'%A4R86)!
M>4V+ZK(NR?]+FJ)](U>"SXR#54D,Q!J!WIH<KAXJ805'@B,42S%*KD69;RDQ
M(;=EYQ#_A=?RM*-94O4<,M&_%W3ENFF_K6/X'7&;DBD]25Y*\/Q"@^?;HY<H
M>/RCOI3X_>0AAX\G[,1P>8H.%/L@]%2D1$QSA6 .P;=-%[/?C./Q9_CQF?^8
M@T$-6W#RZ:MM32;.74Z"*#*C&N=%:@>'B",J>![!,W3PT72OW".\\']8),?I
MO>.[Z<F=^TF[) .[(QNBOWQ6-*OD-7\OQ3/8YR5EA82)Q! _/#P\>7#O+OB
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MF2OH=A/2=[XI)#GCO/"<5I1$O=EPK=V7!Y&%S1H$;?R6:$B21H_<+#+D("5
MIC]GJ$_<GJ/_OYZ2VS?G'7)M*R</=FD!C1I):L_0.;G2A/H[]N<PV1%@#RXE
M&[U]]EP&W:QDE_M*CG7*\F;0EE#AD*3(V[,'75?<"#1RPOE*14L7(W=7VTTU
M'@[/WLAIG"%UX]I+.1>V(*7#V8&&6X@X(*CZE2UKU'V'$\<: >J)ZV:28F$?
MMMRX.)W6*M-2YD_9S\G]P_MW?^3E_&GV<U0BX:ZF=DD/_N?AZT-N>S)\>[IV
MB:)?(J*&*]TYO/OC(44V*UK=N2P+;<^ZDVT^MK%6$&L$#TROV]17W#B%0N.*
MVU?TZ<'"=F7*2R.5LWD/ 4K1HP1U)Z]&7Z)KE:7KJ:)'K5 %+O5!Y_.F%\'B
M%?VV\OW?ZGD_@]H/=GG<K%RG+YK-"_JNN=JD@E'[4%Z22-RRDY5MG=17=$$<
MJ!^.#Z/&[XS+9B6N$3D3S_BO+^6ODW1\B5?UQD##ZJ.@?V[@#YYS"\;[V 'O
M=L4_W6D?!M_CI[ !?5E7%Z9Q30&X/:R#]&1XWT;+G]P?*;GP%#T=Y 9RFX+]
M(S\Q')VVE6*J.*O__6NJ+7BL^MO.9+G8EO'[)O N2Q/<M6Y&;@>E/^((B\T9
MKBL?GA6W9AFIO/(#<O,IK19)C38N!FTD*3EA\Z54=.V:A4^\=07#%Z9?%O 9
M8<$66Q;,ZV]?\QV:357ME?V*6 3G.00'VIIB_>*55,%GOA5RSF8+?3-DF'@[
M3,9. 'I,&MJ"E@QZWI-;Z2R.:I#8V&#_G-56PQQ;^O]U>PXX17J_9YLD[$M>
M9X7H99P:V8TVVO?W,@O2/=1PC4#E0Z5JKRCY>X1;D\HSJ:,@O0C\N-X+TV:$
MV%;P.;+"L!62K-F/T8#2K J1]I/#HZ,?;Y'C/]*BS$WO5==LO+._SP$HG*UW
MP8(T#6*9L8T:<;51A>BGXF=-8%.8\>#NO;WEZ$*.JW-011O_5+AK#$IHPRL^
MEJN]WG4U_0N'@]RH.%\6!NWY-IX?B>'Y5ZR*YESQ@A#ZLNVPU(:TP>GIX>G1
M:%/XR(H/PRNZF0_,[#K;@R@) NXUDG/@ECS:B</DK!W]31K_" ^,,%_6]LYI
M>GJTOUU@>T5M!F6P(%B&X_N'=X[\TCAO *+R#WT$'W;9OZ ZS>HCSE&='A]^
M4VK[ Z?PKI_-Y$[29QB'^I:6Y2.'@Y:VP9T+1!R!D/.".:!_&RE^H4DC-S)W
M"G%ES\?U*\,ENLQ*CE"O/\=J:TR_?/TAK"\ZU:P+K# "\JPH8?R2]5UMA]?Q
M+*BBT-/CZP=EMB'+3Y=_:_)'<JOCHZ/#HQ_M#]@-7;?FEY;,,IP]NPR<BI1K
M_V6((WA9M(4T2_YB?S\&$,BWNW?O\.'#TQ^U+C3RA>/#>R?[/M[WV<GA@P>G
M1_[_[?WRC7J&/?",#_:2;XR)W#ADXW:IZWH4JN-EM\]+F?HABOQZU;5K,\=^
MC=?^+'S ]][!!_RAR+C?C@2<LQ'Y78S(T]B(?)AP?#A [#<A0),VFK315V(G
M__ZU$;S62>M,I^#6GX)W\F/>RE/P!6SOS;"U']-O=QT)^^D'R8C5?9M5>?M.
MF-5W<EK:!_Y6)>O]5-#W]N+3RWZO+SN)]'?^LA_.7?();>*WQUWRA]$9?M>I
MV_.P6/7+I_2^OQG$X ]1$U\1!O=K*(K;\+J3%'^7V_I=O>YGYV+G]R@ E*)7
M_!#VKK#HR!<)KWHT+'S>0 /Y(FA'9+C&(H+,G1#VAY?<BY?^U9VC+T&T<3/4
MS$=!Y*<//R&=ZHW=](E5Y_O;T^D@AP?Y87KZX/C[W_31@_S9V4PG!TG:DB]-
M.SE(W^X1^V+T0M^\.@7.RO')M-G3N;T)KSN=VVN[0>]N([C)&_U%?: I2?0!
M O9LR.DQ^4"?C%3O^HU-WX>V???;?_/Z^%/[41_>[?5]B,RD'R;]\#WIAY_N
MI<=W'WSOZN$FI[8^Q(N[^6[:']<=+9UT\Z<Y:S>&0OO+UPYN"9?V)RT4?NML
MVI/:F-3&I#:NHS;NIG?OG4QZXQHN'OTO4!EN!5S%=\N)_'C(?#W25.;Q;SUD
M'*/WKSM+#-C.^J95UD&+,@Q()0^>%UQ.R5B7C+KL2K15ODU 7(!-Y%J/"+@A
M.FG,ASS;)%G.JPK0/ 5N >TW<%F&0"L!M'N8[+UW>._>_1]CX/U@LX%R,XJP
MWW99TSWBC3V@'5NUO\S(I2^+RFR)@-^2T\/3T],?OZ),G![>O7]\].#.\8.3
M.W=.[QX]]&]>5'CX UZ /6\LJ;.3>^[@!.OJD%J&5_TZ(O]'71VP#'M!XIT2
MG$,F1J+;S0OEKLU6=>-)EHO5.BL:08I>TH8:IB&NYV\.9DQ"R'R752LHB@*/
MQ71*-61=$+$/ZL4!J#8%$_L1ON5D$NCY'D-_DLW;)IN/ ^Y5K^984%B:RD)X
M':'R+)#UHF0X0@!7@Z8+U"N&Z6%GIKLRIE*Z<-;7%F#70EM*GJ%M:XB[R94+
M*J#)%LC2I5QEPVJ6+E5?5/2:.8LT\RX*IINCASS<(=#?,7Z8&U?2*:5Q,W5]
M8#! 3?YP?/C0HALS#S"T2Z:XJ]6U;BC<>AXC^;H/<"KH>6%.:M<-H>C\#?'<
M !+/FH*A;9TO,* 5MC9YXL+YPH)Z<C1QX=P\+IQO5>U!25Q/$[V?ZO,J!+#P
MRFGL_'B& /5DF'OPW"F^_IROG^ZY]><6-8EQE,'FAZ/#$Z?D:7DJZ^3N=FV%
M<&Z?[YKALIYR-#0&%DC9\GV2>1I^+NC/#LT?6_;  5I$WP>F+X"4"W\]817E
M0-&R5:@;A L='9[:I[I%,,M;+D8QTN LCL/1USL2R=<[$M=6,6GD2?UP<NKD
M\L,=I"CQ4=7CFY-[_D%'PF*:HLZ'WAWS^-('C7X^<59\E1,VEI%Z7R?^:"!M
M]P)-_:'2MM/+EE@OB/# ;7' I&:YF3$$."XG= XY*=RJ[A#1,1D7/_2WQ:7[
M@5C8[YZI?9RM@9+-=LC^^RF,4UYT/47!KSQ#QBU"R08!3]45X%OHC @1'#*8
M'7"ZXHM%U1LGUZ H;XT1!NL>"\?X\2270X4L.>)YO^I%EG.SH-L(Y4*V7C?U
M6Y+VSI"T__ 0Z._._B<O)+L,<A!-3?N=25;9)KD$AQM^W A=G?*KUT"4+[.J
M8@;T>=8+4WJ65#TCY-._%W3=NF&8_GG9,]U$$,;*"\Y[T,#8*%43+ )3CW?*
MS:4IZ[7E'+QHLM5MXH0;W^PKDRRS?+BO=PZ/0Q=V9P\,TQ^4./>NN%!5Y&V"
MZ:7M /M]4<RY:$'VL["Y6Z7EJZS=)4^3%D ^HLOX'V8E24K%3(/1SLMNSHM6
MB<J7],7DJF[>@$\ 'YX_?G5PGOQ6S!H(W$NFJ#C^ZTER#KE+=TJ#3Q/;N^"B
M='+F1@@:_(%CU@21\9;^/;?G;@:L^@4.C!'V)'#:A9Q%R.0Y6HB.68'^U6>-
MLL2QVL>B<H3.R1I[D ?7F)E-K5?&T:9GP5EM^NHJVX1K55 $8L" A)4(KT?_
MEH4W.U<<)$-XJ<J(26LR<#\$U!QS4<>63@E,UTSCQ#S2'1[(+@Z.\];OA":/
M_#4P:XM=M>_BQ,ZO;\'V_BIK\H.RKM_PRU7TEY5(#JM <O7J\A*%LJ)]TRJY
MC-)^"$FDY991/>5)CYBUP\8\%#*5^9:ZXD@LOS1-BU/")&>2=-VAK9@FC==$
MPCJ^!:D 7+)-F">M[5=KV5!^?BA)H"P9I4VZ:FH0FV:ZTX/G"[_9DH(I2.Y(
M1NG9EG0F;67ORGFX_ I6A ])%U39A;"^Y#5=% [(FZJ^0I:9X[U@Q[S[9<4<
M2\ZT7HOLDDXO1Y9L.,Q:* 7HN?I6,M80(/"2D#""6:4L2<8A$""2ZB*)PG&1
M&B*>QK.Q\F4LV15+)I9J!NI1>S,Z&VT!]B#LRT7-)J+&YHMS%QY+)70O,#Q"
M"AD/;MZ"\)!?"\SFXT?B%IF+?Y#FXR6T1W7$?(A7?>?P@4^-@SFRT'KO AZV
MI]9%,V6<0(!8_W <..'!5X+Z"AVCT8=Q##K6-9?GN>=3$EO/\\!_MNMY3L8?
M.7R>K]^2<--:+KX?_G ?=_R&^.X6113,(H?C?7R"XW3\<(P?LN2@-W-T8<P?
M#<5*%HB=;3HR?Z_!UUQ!U?_^)#D#"5S+!KJI^XME<D;>8,FL5Q0Q5,D+,I5,
M7'MWYUTK23^.W3LP'?H87)S-9G H0<ZX]53V,9Z96=/#P-.3W.<GD0>[S[KD
M:.0Q+'M7:[/@YJVJEM(F3_41/^%#.24GZS/Z8-'Z!%?E&G*X!5*H#F <K_NH
M6WOWX!:9PN>5?V\E315G(6>F.B>/<.K)(V+6:O8Q94,LQ;H078LEB@_,KS6V
M*Z7C1V[Z?$GA;X?8:@=_J@J;WHFMW!@;Z)K\HRRN1@2_218&"0"W^R"MM@[\
MS+"OQ??))4;/0+9XT*);,I/@W'+I64;6T5=BKU3R=__95X:9J6&\BX[NU,J-
MZ)WE2QH3Z2_#"_Y'2Q)9Y;37?"G:F7^25^\)]X2M[AK;(#FYL6VX9>+L&!Y/
M4ULC:G)R\(U?T*&V=3)?[U)*3J^0/N)0I-/XG"]G-S#:GDAL2)1.TY.3!TF+
MB-A 1+M G:7)N7F;T;E@WD.-O)1=WO?-R&-;;TUBMNUF+WM<5O3MWJ:#CQ\&
M13'MYK$U@L9<,ONI7%ZSNN(Q<DK7H/E2WBCY@Z(RR^QX>HL$BZR5>_60BQ:+
M%%@A[I^QXI"*A GC<H^0G(+4D>/;\NKF6]X"7WQHN+4=R[;*1D+6U?#_:%>/
M[Z1'I_=#64L3XYBR_8O<M6G_2.JN3/C@V1LS)#S7ZJC/HPW.P2V2B[V91[?7
MN?0H._=;MUWS-70<D:FR"2:OQ.5 2L*)SV0:=C63W5K632=E%_[JMU54^=31
MS:MZDY6J%7^C0U'1VCTSMR[*V8!4>&>,@^P81_RR/MD6T_U+^8(N8.IMYA^/
MGTL:,W+8XJ][)ZUOK9^FOR5=416K?H4L.I*3#>]6X6L</EL9-EY8C7?%2<&
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MPS%Y'@N[U" ]BP]5N)B U=&AYGX]N53[T&LB]*1Q4R9&H768NUOQ*?.N.;A
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M[2 .$B=NN=U*9\)]Q^F\B"3%L9/L!!2S !_C%*(!60BG# 4@=6<:\!\!?-P
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M>?AK$9;HTX=HE-M'4,(<=;*\AS7F5WE$0W&)<M+FC(GA^O%A5^W<OCTK1<7
MG.+VXVZ>E\T_.5=:)9/B-'+(!8>3JP9!T>^&@+>CCL2XP=VZNWU^7C4Q?V/E
M.0'LEHD5SJ8(PHO^A&ZX&G9:+)H,PNK,GC9<C#[KT\<.,66G>W(8]C\,VS-&
MWW9IQ%40E!7,7<W0I!#, #EQ _"!NFDR/]AFBA KM=1W(O@%<+G:!BBMS(QZ
M[)_;21NNZO+Q;HT06,HGTCWG!5#)LB.T;-I.L@TZDB(K7P275;';XK18>F,W
M]^0[OIM[3%_0[4/(QM@PR225K)N+7?8+M4#"[@]0U.2.69[MN0&OH^Q\:6-
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MQVAB8YK.=U&4-=P.TZQTO.*@7PO<2UD&CO&R=B T'^Z%3J)Z.T25J0Y9Y05
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MQ\FGL\K-6R&%+R1,\^$<@# 6S)>%N71AO;"=<WY&)ZJD,H'V*\MN[3(U8]0
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MAYS^4/8WMAZV+RR]PB[AM?;KLIU**B2/!WL'^Q2?SMQ94G3BUTU2.8V(/.V
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M%_#J4@&J^D-W4->4N+!T1R:UD-\1I4TTO^,22I<'BA.3)1@(D4L@F@AW)#B
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M2[%HM8R3='>HJJN37\(I*;AT)3-6X(X8,\9@A6[W=F"[B^%>X4,4*A@VX,
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M3VU)1(S8H._5.<7(\%#Y5"<KS!DG<4&9RLC<QN6LM;,?L7+I'S1LG4)G$TE
M'7VW.J[X'?(Z[4FN_EE_>=:F9ZZ12Q&/_F"&+*.CYJCKGUG_W8*S/#BB$VN/
MOG6*[/UT:.X?\C]?<8\H;=CRL;0I5[?%L6[MT-\SEWX;^.$5(]3\H]'KBN>+
M?]\GC?Y1C"V:ST721O(6&!C "^;">T(]B9PB59O\_P8[C@SJ<$\-JG-F=[@V
M+)B_&VGS- <Q ;592K$-E0_]) EI-HE&Y SC9'LUC'#,GF;XRM.D2-+$A)%E
M,;3F7WXYY1MDA+#V*O&R$ 67%RPJM4 W6\T8:-MP(8!ADC3F0(TFF86A@>FX
M7AP7XW'+8$A6K^#SI>]3=&*LJ2H!<^$! <95".GX^FL/$^(6!&8$0IGB)U_"
MVO#\ENB>"F)4 =)@D$IK$L7VRTODJUM&FT1%G\,#F3?"/Y+=<'Y02YW7/KG!
MQP5N,6<XM,1GJQ*.3 P(42XG0EX-7]&WJ;/W=(9UY*;\H;+IB?6.&1G+ZC\$
M;I8Q8H+1,H28XN?&8O&]9Q-A#4OM,.[3WP_VK\PE1):VP$K^O 6S0)LYX4 .
MO]Q--+JA/.Z=EGKN(3%$Y^P;7#2?DZRF1A@846WP'I VDN)%^L:_(=T%IQGQ
M<>S'H(@YP0E&3!H55*%'S!*&IJOPUS"8$Y('/+'LDSLX,MLVT^.,'EB(DT_B
M,ROXJXUYO'9H=46FUY. BR03'.+6>E%0C :?HPW0>6?_5G=_C]YT.' ?Z\M&
M5V/<ZM.H!DRO%Q_F"0/&\+G\DL%>IY;E:QYB$XAL@_U!0J(6<[R3X/O\!L-@
M@[<F^QJ'A7H:"3"@OH XM"%LG.^;^CCB+40VUVS+<!%[BN,FF7L]"KCS77"^
MT<\8KH'.%T) &QQS%#TP?B_<?F>?^25GH:K?FW[LE(DD^**JS3S+LXC 8@CC
M!TYS. [^/ON;^.R:WCBQJ)V5&*PYXY9-T1[YL7803XB(*L90TH;:D2W3[\<*
M)1;Y'7MVJ(HRI[4\0MH]>^;918:S"(5K<,-Q65\3@\2\3O=^CI0Z6/N?H;DL
M^"DF<@.\J;BK@:,I!%O%?HR0>'"^XV\]G1!9[=X3S?L7228^A/ZP_\34&\BK
MX7J^S^!I<@NW]MW^H?/R)]/3"W4*$KAG$Y)5:^L]["4,HQ"2D!O")#P15TAD
M$MYAL#Z:-/8H4N-$]'36$(9.+X1:UFS (;28^NE1&=I@")1"<\TUP4DFU(1J
MDG<>ED<9#OH(FF0D,F"IP2RR>BY70Z=SB(U94;]ND.]#9]A"X8/[?:%>H66-
M<"C8 H<6N;2"P@MJN<?6TA<#L9N "RW]FL*U9,(U#I.TT(#;6>M?&@(.IL]T
M#',9SS+X2(_-9J]11<FEYE7$'48='!Z>50TYK-'.X=T<LM,X[9QS)3:C:JH'
M-TS]9#3#.T+[TI(MUEUE4BJ.X47RDE3GJ;1D<VTMY=#FH:.3QL_G:/#3Z$:#
MH+L-I"EX97<61GO)\;3Y.U.)'/.QSW&K9KJ+ZM6;*W<>E$U#=>6*\>^F6"E4
M:U@V(K($K-)4V5D)#LO0*R+S)^* )82S4S"&^XTYW\*4NC\,.EQ\W Q>A_D<
ML6TX34F?U:<EQ1 YJ7?EGH*M7^*I.[>%O@:><%+%5_=$E9R;"7[.4&8--=1Q
MJ^&K@$TI]2.MDNIZ>N^CEN$%1]"$5GYOYNC4%*Q^5QITBO41V?AVVK^:"L?G
M%<R&TRNX3^[7#OV:T?A,$X;X!]4FRM<"E.H57(U)00@43=LLJJ3E D@R0V:S
MB-88K4\C5K#NN4R=0E9"REM\K4LG,3SQ0%@,7!P#WCWB7WXW5KF-V7@8X#)J
MWF[-X4.-AD'<XUJF,26N!+-2[61L,).H>.G93- UNJK"1J;OUC*DG\%Z-4N<
M(T.KUKE@EX1\QG:&-XG;3$,1Z+H=9<<1*/1:\3>I6ET.;C*=!U.L9X4V)@S3
M>L,\A0J6XWD HPY=5)[WVS".P\U"KUB%W]^F3*E(<=O%Z/"I:SV( VG/G*M(
MSWX_D9Z5CRJ&6;AXYWL*V2@;KK=37G=$<GT2)-?^B.3ZS$BN43+Z6Y2,5N]^
M F';SM^S^;M9,G]'Q9"V<5,_S4,G@ZLCMT[%U0O1S@A1)7[$8_LCG+YMS0_-
M-!#[6F72(3_/86K#9BPO5#$\F@'B"#A^E.DMZNI[Y(/4HKD:.*/1\/-LEC54
MA1DJO];TC4:0!I@[T7_Z\B55:M;<D5^VA5.51]MF4THVJO72 %"+U3SZ"WR-
MAL(7F*))BXZA#!SG,,[&(+@4T^9)<@E'3IF;S,+K5X@:KO)C#)H44TS!-<_$
MFT#\+GB\1G4B(L16-.J@S_BV<H"C7_EJ_<K/8E#<%J#YGXKZB#GDB3G2).1)
M!KNRFX^BD?U,'WC*'SB9>P$#+9TG9EC1;X>$YQBHH2LM@4LD7,_=C+""V@W
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M%\U84]V=;LB+<XO^4[IP;F7A[O]#<@INW/CC3GG^BYU;'2D8P7-N1[% $1V
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M#4*=J%53[#])1YQ/>AQ+FS>&IMY^VS]$7;J%L$>O10NS'/]I8\ZG(9B34-&
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M5Y>%J/OP%;TND+"0EI:TP758(E0<E]O!'@4LG14.7X+.4.@<^ZNQ+J%CX(/
M*Z)XGWH<O&*:2O(>ER\AF-[.,+XXV^[/<\.F$!$APO]X\DL1P[5J!3?RLYTD
MQJQWW,6?F8LAA_==SY.5YP/P)/]=#4V:CS4TJT*SP.D?-A<O$VY4%A"X0>Q0
M#T"N='0B&HG:C/GOA4A"1:L4NP&-/.U"D3OH9!/)#=W;!NQW0_&8)#[7\1)W
MGY]W*;I-Z %1D&?+F)=.!;'S=4S@$ND;6)Y9[%'C*T#BJ#,7:1I(A$9-($\\
MSDQ!.#3BJ(;D4RQ?&O)>5TNMR)?C+VL8D5$-6,)"[#K75\7KUEF34T"Y,E+O
MN"@SH>36\#@B[UF$]7AJ*.\]T!4-A"42;ZAKFKD\<Q?:"",HGJ6,$0">$Q58
M)AP"UU^7MH-[YH%MV-I(A;XY3&_YR?(;V_-U>TQ3%-E;+'!#J@A^+I3^I:[+
M.7=(E>-F.>WL%.[ZYNXL]M?&5\=/SN@]RQFHS]!,I7/(BQ/,7S3>^H9<-;8P
MI(&^H?Y&^8F<L^JR9&(+TKO.J<V4"769>P(J'X0H^IPX6:3PK / DOSZV6>-
MZ#6&P_#!QWYY)%,APPN>OM<S47D*+8N,A*6UU9P'CF=5(#S7,@]Q. 2M,(\[
MIE*6-=Y!S?*B4VLW5_7>6M(*!2IX\: 8T>>E!T*$,Y#KI0Z>;,71';D@0@ ,
M^2">D4:E-1PKF>'4.77VL;Q/-8,T68*O]W,C\H(AF5_EK)'$TV6Q6:2(&TG)
M^<*#F"H5W_!4#&%]Y'675:<OE;H\60_%]UWB-5X(S_R[]&Z:"Z.WN.F]GH!%
M"NW5/"KWRP!(M]P56$C$OJ2\Q;*B!%7[JX1#R[QB1OX$?Q!.>285E2_V+(#[
M4\P.* &6R#/\)2!N=CE>UQ6"(:W4H>?S&\"TQ@9O*8"L?/YF/=F&^EZXJ0T&
MS&,"_I(6VN7'M@10=ZTSW(I)KF]J6R >$R)I##2MF@N-%866A'#(:6>T/\PT
M7+&44*N\1&1GY1D Q)P()@@>/6M:&E\(?2VCDVMTBJ,/=R4*[U=^_#4W^%^1
MC]%<2A'*OJG>FZ+1O@1[!\@)*"BC\/TBJ;*2-&O $'$>!X[JM)RW=**2?DU=
M,XVHPS1T[>MM4I1BA\A06X3ERH0]\Z2(S]9L!*QLSM4X 9CT5SI7: H$!NV<
M=X##@2$:32:3+#!CB6^"XS2[EA%0L#7NKVA#*LE&HXX'3 H.,U@=ESBR5(?3
MA7B(H$9B.PR8YMFTCJQJ/?F^K*XKD?R-J"1+^*V.+D]9Y2DLW!G]]<YO"LW%
MAN_YF*!KE)9K96AW062]:5<9!7-EPX(O^W9>OP4B=19MK25XNM"I(W6V5<UY
MF=)I,M?'C,H_O&%U$31?253%N#0L;4?8;#JUYO.R2J/=9\#_S(.DR2!F+H&*
MBAD5,M)4LYL8EQ::2,D,GD3)8P)X -+JXPG!P7IZAYV,BA$!*YXC.D\'*N,2
ML)R9/K.T;WIW\ENT5.'-$AX!ADM=M_#DRF5OSZDZ8ID_-9;Y>,0RCUCFN[IA
MX4QD34<M]--P-155IE1<;GDB0S0&*4&EBI=/TQDU@OX2/C.OLIGC:16^$C(9
MEL6..1WHT&9B:W]UUCGT)UL=SH5 Z+]0;%,(TL*@#ZP<XE!3UZ%"@OP#-4;X
MDP7[WVDTC$?,$-3@-+-.M,M-*J3%*S-7@K3M\"%Z%)*A,:F/ZKZ/).V?56HM
M: B$(75?P?&#ID9U@'H*FT8!?3\*![$8,^C,[&,02?1EE0X;Y<_4V68.SJ!/
MWJ?*VMR5:Z_2L/;]EIZLIQ$OCB;PO)*E@4$FDXK()!&#Y-5<B5I-,T)N5EY=
M.L6-../;HNFTJEPG.<+6!L0_?,;)2L%3F<V42O^X53Y7J57=+]/9F>E.$L1Q
M'D'"S%GY.I#M^.%.:S$R <JA/L]=*E.>%>:(1FLY_CW++JPPATRO>L1)K+NL
M5U%JM6GG[\IT B='H@US^SU,2"H[V6F*S*92B] RX<BR)3=,!>A;\P\X!5!)
M!4T^(W;90OOT'/[S8U+9$1S(3NKSR2(O+SW!&\O'[$Z>AV8GO=&:V;DW+Y8F
MI['H#*D-KC5?FPZ3G*$8F:.(CC"ZH$H\%9MSY)05QQ;U2JH!KX")D:^ 1Y[7
M(/RB059/$,"3K@;*B?94S;*FDB/\51'=W' ;2-^RE &\05GQY.$RJ+:9_4SI
MZ(@^T[A(0*Q8_FJL+TR#(^@K@E>6Q3J"Z$8?M>P0(0[48UGD"2,&">G!6J?'
MX'KK[?ADKFU796K545JOL#[@]CQ9H+=/Y25C_X%C -+"^9JM$#^]E7887(>@
M I,YN)@@^V.[Y5?!P G<H*2D$4,='(]".FYJ?$LD>L)Y%450!_4@IFA&&+?B
MCDB+SA'5G/%[NM;*W7R1EFK8"[\G#7%^X&*Q8JY)F-)C#*_28P&283Z^"=%F
MMK52D/&VPA>'Q]T*:]X&1(&/YXR8Y?$<RW@2YGK0+EPH\7,O,2(NK)3I2N"+
M#A?(X<_,KCOLR8CT@/E'3%?-9!IMW1TF,Y"+CWE!)9]\$;4[=^QXX4+6.S'D
M$_ 8(?@I- )!?&[=Z+GMQ>P&H"$1\D0"PG"+X:B]\=JK6 G.\\I?^2W)E7H
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M;$18OOWE^9O)FQ>G?S^=O'G^\N3M\V>3MZ\FKWY_,WGZZM?7)[_]S[UZ.G?
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M\1SM'A\\^ES& S]V^/!+&L_1[L-C2*4?/3AZ?'#X\.CAP?'7;#VOR9^BN[Q
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M-05V4B=MF$P#5CNV%+;$SVK1JG#4?DJR-)B'I@DQ=YM(.HIE8;:+P(BF4^-
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M5!]=PFN([GGRC=.DFB6%JW=>O<_=FJX-?SG8VSL8*U)C1>H>/K_Q[+B;L^,
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MM7_J6/]?JO<7(X,X':03^KXE35MR@]/K*$EN<7R_8GJGV(SR+]NWX0]O*MO
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MQVS G*3-!X+/8C4C7MR7LMG ;^%G;EO:PE55C"W.9F,?8' "2T=K5RV;#+B
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M-ZQ),'#[74>^1V]7;/A!B3B<#.)T7.3.@%/B+%NX81G'X-\X0_DNN$D]-L!
M32214T;TFN4D(%Z\TZ"YA^#,Z.#;KIX3<PEMMD32KRWQ;R0Y]:!TP)'$4ZDI
M0[ 6(.S7A7(-K'0@H/VYDP\%G+CE@V2!):KS(JDB058!W=B-@K; 4\6TP;5T
MR5MAHV1 H=WL'[/,E6W(N1W"R1&LJ!"+)> 67M'H96@IH1R%%\)X 4*#4W48
M/U&7-S</-]O4-$J:EIFOI^@=-7^TC34>4J?_6PRKYQ!6*L^ZQ$_3K/>W7KR(
M^5D,.!L*WFDX&+@RSI] #2#T#,2/D"]:8$@F13'B8)41Y.7V9QA65F_7<^HE
M28;NLHCO0-@ L7> $,UI:@@N:!$C3A<!41>&#:-<E=[#=NZLF_PO97B_1 2K
M%XIO(E$X,>"29<(#)O2_GT=)>A.E?\4INT"BIQ JW(M7]2J*Y:^@W:! +LA_
M]>$\QSE!1\_KM!>I1F/(-(%<63A!V025@@ S8K]-T0X#I**:5 8BN61WB#8Q
M!YC ;#O3W2TC +54P(:Y$8H8@,H/N$&NH_#I])H7NGI@DR-,$1)UV%VIY/X*
M!UMN4#C81_(P-$A(32)+I>P(ODTZ:F#Q"7V]2T>;5FV([\CVJB5YR=[##''U
MI<MMF]\&3YNZG2\7"OY&HHVLOI3E-T*IRX<5OO%$+O<YY*3'$-],TFUJH" "
MC)F5?,JS1WDU4#8N4@,C,3+*AOZZEH1^7XUF@?+08<>!_"]',@^[L(H% #8R
ML'FCB!\GB[2.-[U@0R6 VZZ_9X4_A(0G<:2[Q?(!?_&2]Q>J4)TX6N<8@OS9
M[UACWF#&?GZ?=[O?,3G4!"0P^\ISJK 6?#2D5\Z3'[^8$K=K0"_1;H;^'V^]
M^5_HO4Y%3,Z1\VSDQ:2UZ[C(UA$U+N2LM)#P[V]V&<O^2VO+:3U%BT"]FS 8
M5"0H(^(HM^+P2>LE!A21R<Z6.IJHB+<6:LL'.*UE:6)H1+74B+9 &U$IOWF*
MNF7P-X-\J8=9\L-I5N71HV&GD-K6OD>6+W/V5P 3R&N[9'8RY:Q>++F--'F(
MH.P@\<F&"4#S\&J;;F.\D#7<!]T'V2R4<Q*L83@#1HFA@*C,9,V<?E_ILM#R
MBN0ST$V%.FJ,F 9*(Z1-!*)DQ510-I>O=,DJ H%:.C]?NMISM41QMG2;XM(M
MQ=)%:D[6?0.SX+^WB:BM]! U0-]Q4]=CV2IWA_^Q)4QL419SL>J:+9G[I(;(
M&+/;^?E)O7E2MWEG&85+'J6<I+I!VY%X,KEE+%>ZEPOH:R-_:VM"JZ>JQ9/2
M>JJ<A0UP#P:@[VA@.=*I'RS"S)7/&NB.?"CFG0QV)C2$3'1$$#CQ&(RV/I60
MBRFL!D3NP/\'9]JS1S&'GD[2F( K%?[ V"_^0FLIOJUJMK=/MP C>?G%7\%'
M<<<>J$OV*AT<:P3#GH@@(VUT6#XU,22:P"J6?EGL(<61FD1R_M6*>2,U<00S
M1V+JW_9&E&O\!G((Q$&58>EY%26<3XGO19SO!?S=]AK^AD,HY\I6:A:L24@@
M$ UP1"0TM@F7EQR"<U<<Q%D0NA4N]<N[A<=+NS6QK+)(^W+G+IU@8(@Y4U.6
MF(#4GZ5$#L,KY39'2B>0"VJ1<WN!]-JL',%Z=@..&S%8"TF."2>8!\D(( -8
M$(GIR)\!+6;R-,:4QQ:R+XNMIR_2.=*5ER+6"5KC+SY.$I[-H:(KP6B2B)!$
M\6_X0D5>6%(:.TI74 FU<:B?Y&/.]B$*Z:XPM^*<7K&)B(:;&#/%&8+.J\U^
M_ F]]W;H$;-G##X/,.ZPA^UQ*UXV"<0N?ZBPE_^%R98;NF4GA;%:JDE@UZQI
MZYPHO:@G/+T;;X\M9AN*2W".YZ$K!-D\XFD6IB2 >K/LP[@'Q8&K,)?B0 ?@
M9(8+;2L^XL6R7 'WX-CQDD\]2ME%0=AWL1/5;^$E%=D22,U%?+7:;.#+D*5R
M$<B3UQQ"QG8(\G264#T^6O28/A64SZ5]#:LEB*7BB!R$XT-2[3D@&C)58 !V
MP#G',&0TG, #,!T*0VU%)EM>X&=,(QY"JCWV"A'T(6)KNHSB-7O5%_#>)(/C
M3-78_&731B]:C]0$N'5<3($;DL0D3A!,PE%@*OLT0=.\C2/P*09GNP\)X'%F
M%55G -,H0)X-8!5S=7W)LXC$*Y\5;O6R<7X]?I9IKD9SCM50(&6^@M'8\_FC
M5K4V']$5QII(]M<K "8&2@ *JL6BAHF3JH;F^*$%5A806Y6S<GM4K)1$_%:6
M+ NG3T\Q5T,S4:)2T'#0N5/DT4;19Y*\*FVH6#TV#NG7S%SY;/9BTNXA?1^H
MR"P51\$CQ1K$"14(,2Q<78L&4V$C(#DP.0 UBQ)9G+,37<OELI319 8MC]W3
M<B>,$A RL'O(#0EWF*P?M^QJ"H9C'LDA>!3 3K=6G* X&T;:3XZ15UIDDY-'
M&GV4#^ "&,D2EZ4SO0>W=@_P1Q+BE,Q#?] -)JB ,<[-;31PUF6K9S9[RS&'
M,K%1SVD$;Q\$^BR63",0GNKY>N.1V$2 I1R/7XY8C2@<=CRSF(GH6[A,^;"(
M9.,>]RK(,YEQ/Y-U@^3# *YCSCT3@3\D,@$T0?.OA/MB88+V W :+4_='P H
M_Y'7^AA<?;Y<Z0NJGY",O*:#*A74[D=NF#MYF#E7.5E-=W.BC1IFJGA&R_LS
MLM/97-R 5R!_9&SID2#=KG1'(92&>>P=*6";KQ)PG(";E*GN>B5A"$KSC92)
M\R3JF_*8"C].E ]U@AYAL*/FG):85E!WY5K2>DWD$W1V]'SKW^XAS%O^FD5,
M_DOTL(JV"1N8FQ*8NB[ BID8#J:?9TB4#8<[<.&WJFQD1AI29$-'*8D6^93G
MFPV!U!@R@9"-\K4R74ZIV(-YJSR+$2_@[8" $0AS,F(=E)SHA%T;_XRS5MI#
MR6*@L^@H#] X:S5(\B-MG0%/.+B@!]6],ND)MUPRBQ^'W]@($*.RR!W!UQ#_
M_#X*R)+X_+P."[V$$:!F$.5AU6N-[O$P5A=+_/6P136.7@'Q'Z'Z5>ZGYP.@
M]\?,8NG^%:Q2SBK$&V6L5G?3>K)A0US&%0F]T+<>BK)4PTP@%,4@R_)(=X2B
M9 .Z#46I@!</A[C+,(M=H=,-FCH=:]8=F'H"(EL$O<L3L>,S,X*V+,'--T(J
MDN0ET$#A;S8E]_&60FUZ5XZI&/0D7R%W<9_5Q6EPCB9GN\)?3$)4-GI*F5S(
M;J_BGYU_.!87A![;6M0G\NA?#J27B 2@)-FNQ>_,72A:+G)6:D55&-$&1!\2
M>.+.J.=_/F6SCZ#BJ[QJL@F">(<=AOB/L78U!ZPE^:FPGB?:2NE+ZS8F_4)*
ML5<D@8I/$M'#WQZ,J"3I(4%0)1%SDLZRU9F,QEW *EE]-_B3>%:?A'3SOJ)Y
M'OR/Q\,7+7_E)SRC1. WO\K('A%'NIF^DRTG-GD<KV?PK+ KP0 H(U3OFB%)
MSUT1LF$<T&.>?%W]-'=,Y ;'>J'(<+F69FGHB!FD7;RA?!"GM5@R[?2:A'C.
M?AQ6(RG7=8$>X@2/@(>JJNY@^L)1$>#PC$3GF%(S/A=&#S&"""A.>^;*$:;/
MV-EE-C!S='C\=R%?-,GS17$A7]0OYHMBE2^Z@?QYF,B)Y1#Q4=>+UBS5X:FU
M)R[BS',H0H"F @\8FP0.?39?[1D9:DG11N$NN,(XQ:?$JK7 ,LOTF^*V7#EJ
M(EQGH4VB@)4)%"9)*G%VVP^:.RU,VHW.D&FC65FRH4EX13.:(CIU)BK6@6.:
M?+/)YL4R!YE&$^T\FNX.C176M3)!R9&T,6S>M#AE1\&^1O%I=-2=R4^<5N?L
M[&8OIC ,50#+^1@NM5@(!LG?^-V%M_:><'(?;9]6Z1#06X[-HQ$^09(T$K2%
MT=_ZYV&</?US^1 F&^R3)6'* #N#./7B'0K$$(YDBT2E>^EAWN^]%)05QFTZ
MB#\E>^ O&\(Y2^WG+EABJRA-"=%6PLD7(M;5&.C"(K-2HJ?LGU'L%<)$H:;6
M?42]A'BW3'M<>W\Q<JUK0VDQHR]0TTR.AL1PZ"]_<2-J6F:?MG/^Z>OEO*+/
MZ2O@%?<^D2NPD2OPTU^<E08^PR%>$OZA-U:^!?3?82K?6$CTMKG4G7UJ+"0'
MXW=;9PT#.;"C5#O;ZT$[EZ*]A+$+G&D)QUT"X9ZEY^Q-VK''YR!QI%2!'L(Q
M'ST*@+Q'R8Y^KCDSW 15 63W(/)4#*/<W$Z.L1V>RQ'$P',9&/TH.1.U:.Z9
M6)P>M*=G^(F$(8^O.N(S+5;A,@P.6H-++I@>]0+0_?EV@B1>J0)311)_;$ 2
MEW6>P (^!TSG,"$^G_C;(5^_BB_$.76^-I@M&@ @6D4&G][2R'-C$FO]4E_9
M;'INSESN.QE4=MX,_K(0C&L6554S@/6E%&42E2PU<YK]@L_&05W+41=-&>AR
MMU<IKK7I0":M)])Q:.MEF))TIQE<*\  A\K;G' !K/VD!@A@G"B!&V]]8+II
M8\!$3IQI#8R\]3126QS2*3!7@H(<Y"TMHSP&.<JCLF+:+4AODIGB5:TC5CKU
M!AOB1O^:CIT7^=W4'2_;;'#<_(@=C8%IFYR&PT3,CSCA".B' ^!+"I;1ZZLY
M('_%7FPR P3HV<W_$/9EZB5)%CZPB+F;0SD^5(':O0L?E<W*,(@64P"U:00,
MI HRR,K/!G8Q-^RPJSX6SN8B"_Y BUCB/6:>I&R((^2RQMFG[9MUWRP3-IY$
M0BQ.4\KEYF&Q%SE%E),\<16*89 ??6,TIK ;1NX]GD4(XCP(@HNEEC(P2-X$
MPGDZI1/Y,G.P'5J%I8(JKSQH'$<&*$Y[_DK4+\[;3268RR_P<&])LH*1%TL(
M=!D>PUZD"N<I8'1=A:2;XXDVL7/!V;$;-@[BCM3X=JK2*WSLAW[9DE1>!1>(
M6?TR_D8B[K<>),DK(FZTD&%3+MU$SJ:>(\N\S'P?#B4[K[=Q%+(??6'MNHTH
M\7?B?XVDX[&Q4#X8*HYV[(S2'CR>(#$(^KO\K\/LO%M5U%(S%LZVZ2J*R3^'
M"9FWQ7*9)PHJULNH'Q=OM,Q6T08Z<\;6X;;QYMJX)519I67<QL0?Z.2>2KW@
MD1=E#P=7NS^AJYKP":H ]ZJ)(SYSJZ_>/$QQ&+ %9B/"\_7$H6Z28,L5BGGX
M*8H_+Z/XX/53],%!*@< *2K.AH"%>%&#'">KI;?_6V!9OS(:^77)+HC,U_C)
MH\+M=8@R5M#K@122+C3[MLV!,Z?.)YU!I @@08_F&1(#&,BH%1(NG##2%ML.
MX!I&K'?++914?L8)7/;;#7P:2;)U$3MDFCU:XJPI9!]HV_>>7ZYQ_,3&^RV.
M7M(5/-->>"CJD/Q\%$DD:"))U"8O,W;< ^[AH-ZA3O^,!@(B#O"TWQ/*CG,4
M#L/@D?#9&3&78.<#.:@'.%\KHI;KC&GONO'ZL;>%Y[RFPN\Q\::4P9RG$4K]
MFF6IH+MW[95=OJ(D%2K[AI+4J$V"498>"4[;G?)N@3'Z%?)4OC-&XTU).E#6
M)EDL-1NA0:L@)PY?6$Y^3%N@'5[U[R]CF-U1B=IFZUX<\2YC=F2">0CB,O?F
MO(1L8BNRR>^Z8;%;\JDF3'UE$X)2@LA;+HF 8\-<##Q:3DMR%1\ Y2.<H&P,
ME ]B]=JYP2]*6Q@>J@;6>6>(,6:F7[HH"QPXB'X</'\ZULK_#<>1&2T#*+G6
M,0S,ONQ:=,M%EGU4%^24%;/+PI///7 >G.TN/7]5;#OH>\\JV641;& YL2]-
M..=:'M4LA.]3'L+'Z9WH5?URW#LQ ?!#P!0JO:P><3#XD !KE> >7C U5=5/
M4D?OWKQ]9[^TFWE>:)&-0A$[0=MAM3[S[)4N)\5FRMA,%9NI8'/CC,U[P@3@
M*/P('\7NS L_7T<FCJ(DBP1=!(014#XZINA7QD_I$-;Q11EQN_:J61AN/2IC
M2N<ANYKC8;8/05#%E3+U1)"</A.T,'^5M#@_FOF7HTKK]\'::<K]&E=,RA//
M_:"03.'1 &)2>)CRS-7=E,LV,S]U,7D1RL^DIB@V@.K$Z3C"+!HP9WI<TRTG
MNG!2=J]U\&":$1]XC09W[^NPB=,CG'-=30QX]]':JGTEAS,4OG2($ ?8(G@E
M]@\\+]HH.?ID]$AEDHGUZ%HS/!0B:1C%TQ2V A(!CF/^5)LZ/T4BZ%^ RT-0
MP+F@JQ )B7U(24,;HT$XN=T8P)4I(=?<82B6[:<XD,@VQ5]H+8VA^I21FT[<
MPK<X780R=-5)A7N^)'$V'G(%M.9N"4J(92<U\$;Y8"@[)N7?%3HX S-SMDQT
MKQ4ZZ5JBKVIMZF'2^GU+)^@Q TFS?L=P^>D# !^\L!<)Q[=>O(AY]:* (RBI
MLBO#,)4S\FCCQ6!>3O@($L8^*T%S;$S2*G^W@C]!7!8:R.K&'!M_)<FX]S[:
M5:WFH1]#V?D++/X[#[FS8K'\D&!>%;$WF[\(-D/\!%QDLK,@"X[]=(79)RE1
M[$0N*H]1A_%.H^7IEC4313./A.-REH5D->-Y'DHLA,42,>*BRN1Q\596YU;<
M]B;8>Q7(47Y$ 9/ V:;"#HL;MK+?68T- 8+!?LBVFUW9FRB&D^\E\@!81UG6
M8=/TE")9"? \2M*D@N*7#$26Z0#:=8@Y(Z.5$C8+P%D['Z[)*(I(DCQ1^IDC
M8<T01[KI7W&T$22/@P/:L1UN"W\,R$.IU/QPDH)2G+Y(#B2^_%B'?!\E=DZ0
MHJUN D??B5D&M<^%,T@T!C>*01D&?52<U1_"ZJ[99FK!5M&#J%+I3AND?O,#
MAB)%4GG3K"N+@YF0NY'14?Y,ZS,_&.LW*U/&I*[M6@'_;C#HI6!"W!OKMVB2
MU@JO:0,@-0)/^7K[[2Q.$?Q&K@$E2ZYV[+ 7?T,'I4;6/! 4NOZ0G11/F?TJ
M:%EYEF>LS=U4U9MG7!3!'45R\O2,540!(U,$B-_A9SC%>5;(H"@IC?SOD!@
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MBX\5H( $4;@T/2GHV"Y 9I8;6F)DL41*8K-=C\PL(R4II6UGK+L8V><K3%@
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M9%VH +>[?1 =$2KW2\W)7/:OG&$?J"IRM^CGK70JJ&9,^UIP*Y\-81%N?@$
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M6C;8/B@W*:(;X59\KOT&@JB>HC JTK0RF4!22EPX& 0H\I>#]2 76RBT)X,
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M^MVGR";&][Z?G\!1F= V_$IN]2S JV,U)B_]SGS6RL0/PU\!P$?Y6ZS[]ZE
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MN7>R-<+P]V\]%%[YD8N"0'S0W4$6!8B8B3@%/NKG(Q0?)%,,H_,WLC+>^4%
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MA#X+LA>_/]U!IM_#\BX^I]C=$I6H/$')JZB<!.O(&TIU^6/);419U*>M9?B
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M0Z#C!ZBOQ5C/Q(@(T'XFM*S>LT"&6H&:/*#]^)^.\7WB"#GG>9":\8? RX\
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M5AP&Y$(RIHF!*V-"1H!A_M OA@5RX9FAV(3$ @49'0:9ALDX(<A%:8:B((E
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M(06WBCMDN!UP3T@PR/0N$&9" F%]5TY,">%8JQ8B/BBM><:]]XAVSA9CJSG
M>'A-G#PZ^ NBS_QJ3PNKR"((9,.-L(48N=]^1(?O/.1G'('\HV($Y'_\?DLD
M$L'U[_QL&%GD6?TE] \(Q^03Z\T;^NK$CS=$=B!_(;>;O;37A%X0)G\C@]F
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M,#(T,#,S,2YX<V102P$"% ,4    "  N1Z]8N<^O0CD!   M @  #P
M        @ &$]P( =&-R="UE>#$P7S$N:'1M4$L! A0#%     @ +D>O6.#%
MD7&C!P  GC$   \              ( !ZO@" '1C<G0M97@S,5\Q+FAT;5!+
M 0(4 Q0    ( "Y'KUB7)J64< 0  /4:   /              "  ;H  P!T
D8W)T+65X,S)?,2YH=&U02P4&      4 !0 U 0  5P4#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>tcrt-20240331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:tcrt="http://alaunos.com/20240331"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tcrt-20240331.xsd" xlink:type="simple"/>
    <context id="C_e2f5fa39-2c4c-4a31-9dba-9b302e6163aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-08-17</startDate>
            <endDate>2015-08-17</endDate>
        </period>
    </context>
    <context id="C_0e2a059d-282e-4250-8c99-11315e2fb9ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_db32a880-2ad0-470e-8702-ccd0f5ec87bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="C_a3ae250c-9ef9-4e50-b001-e026832b5546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_a6c29fff-7446-403d-9ae5-f2ab3b978cc5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_2a4ac29e-7e17-4f4e-8ca5-1a9b13dce527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_3f929b6c-a393-480f-b2d8-4b64cbcc35fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="C_afd87759-7cd4-4535-a126-67b00b692ba6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:NewWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-12</instant>
        </period>
    </context>
    <context id="C_06f78440-3bd6-4263-b564-21c6263d6ac1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_318d2bef-2b78-48b2-9bf0-7f8d81ddf304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:AgreementTypeAxisAxis">tcrt:CantorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-29</startDate>
            <endDate>2022-11-29</endDate>
        </period>
    </context>
    <context id="C_5e421c5e-d96b-4a7c-84cb-11656fb4e700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_69b6b7d3-41a2-4d80-aee3-85fbf3416f62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel12And3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_0a4a2144-53c6-473a-a17e-948eca082f68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-03</instant>
        </period>
    </context>
    <context id="C_699c4514-89e0-4171-a8dd-a4bb94caddc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2004-08-24</instant>
        </period>
    </context>
    <context id="C_05086637-454b-451e-ba2f-b6e9dac6f1bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_7f5ae535-f6d0-484b-b23f-ef9a9da46789">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:DuneLakeCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_bf8b4b8c-26b2-4415-90c9-ba9e666f9956">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_1a9f3d32-f84f-4b13-8b49-7ba3cda42ef8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_373d470e-fec0-416f-bd2c-474750080aee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="C_5aaa9322-5f00-4afe-8d8b-410a6b78fc05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="C_86b01827-f0d2-4c97-bbb5-1f488e3fa49f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_95a30d90-929e-45eb-82ad-23f6fc64e994">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:AgreementTypeAxis">tcrt:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-11</startDate>
            <endDate>2018-11-11</endDate>
        </period>
    </context>
    <context id="C_fe3fc5c4-0c6a-404b-8a06-a203f7a1b9c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_dae15987-4a72-452e-bffe-37b8c8ff2004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-05</instant>
        </period>
    </context>
    <context id="C_7868565d-837f-4c4e-a465-218189cb407e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_96de5e3d-ec20-471c-8b74-4754e48554be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4794af2c-583f-4aeb-8161-0074b8016cb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_4dd2c47b-4df3-4a07-bb67-521f620934a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_87dc43db-b832-4e32-9d47-a96ea1328b91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2023-03-17</startDate>
            <endDate>2023-03-17</endDate>
        </period>
    </context>
    <context id="C_5c448816-7d5b-4d6c-8eae-4e4d68502072">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_eb264759-9de1-4b9f-acc7-aa907a4f72c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:DuneLakeCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_aeb70e75-70ac-4afa-88cd-62bbcaee35fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_94aa9eb4-37eb-4c0d-b5f9-9e0dd0d7fb5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tcrt:TcellReceptorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:IntrexonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-05</instant>
        </period>
    </context>
    <context id="C_f3cf5907-2650-4723-90f5-2fbb4565112b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_170c0509-c56f-4761-bdf6-22de08ad77fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_8c27b046-6702-4a71-8e61-6ba81f191fea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_3cf7f842-3616-4d7d-a8d1-b72415a7dc2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">tcrt:ZiopharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">tcrt:EdenBioCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-05</instant>
        </period>
    </context>
    <context id="C_3efa5cb2-5a15-4829-bf1f-70ca2555bcc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_4bd3b321-13c5-4e4c-a083-a14aeb2b41c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:NewWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-12</startDate>
            <endDate>2019-09-12</endDate>
        </period>
    </context>
    <context id="C_459f2708-7ef7-43f4-a5f4-b66c0656e6b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:AgreementTypeAxisAxis">tcrt:CantorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-05</startDate>
            <endDate>2023-01-05</endDate>
        </period>
    </context>
    <context id="C_31821ab4-d999-49bb-b9d4-9b4dd0c91cb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_3354c043-11e9-441d-8243-0c39e040d0c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6270e901-6735-4c63-9513-8fb545fff59f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_729e1616-09f9-46a9-a428-b5c7fb8de61a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_58a539c3-32e6-40ab-81e3-7460cfa16a02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-08-17</startDate>
            <endDate>2015-08-17</endDate>
        </period>
    </context>
    <context id="C_081cf75e-7342-44b3-be87-434671a576d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-22</instant>
        </period>
    </context>
    <context id="C_47601be9-83e3-443d-bbcb-b0ba3efb137d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_307719b1-83d4-4843-8da2-94558ade533e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_84fba74a-d852-4278-a598-763f3de703a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_0bc55a8f-887f-4070-9865-fd66f24117bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-12</startDate>
            <endDate>2019-09-12</endDate>
        </period>
    </context>
    <context id="C_499d880c-c83e-4094-9801-9f067ded9cb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_4c893ed4-2fab-4607-8dfd-4e3ede2ebc02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_5e6444ec-337d-440e-ae0f-2c013e8670a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-11</startDate>
            <endDate>2018-11-11</endDate>
        </period>
    </context>
    <context id="C_35078a72-b5fc-4657-9c90-f59660c54ff7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-11</instant>
        </period>
    </context>
    <context id="C_9a6df5e6-87bf-4b67-8430-063789b2272d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_6046fec4-c22d-43b6-ba9b-95ebb064d3de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-12</instant>
        </period>
    </context>
    <context id="C_727a2f22-62eb-4547-b383-db9f11e5e1ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-28</instant>
        </period>
    </context>
    <context id="C_b46b0e83-a6fe-4373-960c-564ab0754cde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2024-05-12</instant>
        </period>
    </context>
    <context id="C_8f534694-1370-4e1c-8929-649408ad27f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_dbfeed30-f20b-44da-b3ca-39d3d35097bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_289f7d65-cf86-4803-859d-4037fea6fa0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_655a3713-d843-4e68-b88b-1e572769c0e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-28</instant>
        </period>
    </context>
    <context id="C_b01cd0f9-f0ef-4fe1-89dd-e53ec38d0b9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:LicenseAgreementWithTheNationalCancerInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_e9263274-e6c8-4931-ba30-9ba9d76c89f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_481d4dca-c2e0-4a6d-a1aa-cb7b99c9e7e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_06ec8ddd-a6ca-4458-b361-e0082cad4a4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_04d2b6bc-59f0-497b-ad0b-246c6e2342a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:BlackScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-28</startDate>
            <endDate>2021-12-28</endDate>
        </period>
    </context>
    <context id="C_82917f35-4e10-4373-8317-e2e998187578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="C_c8496d52-7c42-49e6-b1a1-90623138bd33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_bbf27f91-17b6-4ae0-ad7c-8ead5a875486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_ad2cf5bf-7a86-4612-a507-a31f59be56ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:AgreementTypeAxisAxis">tcrt:CantorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-29</startDate>
            <endDate>2022-11-29</endDate>
        </period>
    </context>
    <context id="C_feb2760d-82be-46cd-ac00-b75cb7214032">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_d9ea1296-e67e-4c96-9b52-f8fb4490bf1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="C_8baabce6-ac11-4af5-8a5f-c37dac90e95a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:NonVestedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_30b081ac-90e4-47f2-90f6-835d27c36c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_8013c772-ccba-4aa2-b4a1-652bb9ef35c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">tcrt:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="C_5f3c58ea-f897-4151-a1ad-8f8690250ebe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_8cb0a4ff-691a-4757-b2eb-fbbd3b39dfe9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-22</startDate>
            <endDate>2019-10-22</endDate>
        </period>
    </context>
    <context id="C_131aee97-1b4f-446a-8c75-66998adcc711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2019-09-12</startDate>
            <endDate>2019-09-12</endDate>
        </period>
    </context>
    <context id="C_cc6be139-4d29-491a-ac06-ae207788d63f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="C_0fe9cdfc-046e-4935-a0e2-2577ae6a7cf2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_58b07922-742e-4d1e-8e94-cc27df08f5e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_05763aa1-65a6-4ed2-aa0e-21d87146369c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-22</instant>
        </period>
    </context>
    <context id="C_82df7c7b-262a-4272-aced-862f49a97569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:EdenBiocellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-18</startDate>
            <endDate>2018-12-18</endDate>
        </period>
    </context>
    <context id="C_a620055d-3725-42b7-9bb4-54550ba559d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_62447313-6131-42f8-98d0-6c78900cb176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_e202e528-177e-4db6-adec-6869d8137344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_5c46026b-b792-4f5a-b3d6-cd9c0eb096c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tcrt:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-29</startDate>
            <endDate>2022-11-29</endDate>
        </period>
    </context>
    <context id="C_27f693e7-6abd-4a93-b50d-4206e1b22623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2023-10-20</startDate>
            <endDate>2023-10-20</endDate>
        </period>
    </context>
    <context id="C_a5053d79-f95f-4469-83c1-e72e88a19a19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="C_cd66aa2a-1923-408f-ad01-68d671934a39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="C_f17db39b-f553-4323-b229-bec623ac9226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_3afa3256-b142-4067-84fa-31003618cdf3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonAgreementAndWorldwideLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-13</startDate>
            <endDate>2015-01-13</endDate>
        </period>
    </context>
    <context id="C_b1da774e-81d4-427f-b25c-7a2574c834ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:MDAndersonLicenseAndTheTwoThousandFifteenResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_478a5db8-cf73-4704-b31d-d3f5d829c87e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_529a077c-2067-46ae-a95e-3d29d884679c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <context id="C_f31836bd-3d73-434a-8f8e-640ba5edfd54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_98a802f2-0e70-4585-9cc4-a79b60e487e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-28</startDate>
            <endDate>2021-12-28</endDate>
        </period>
    </context>
    <context id="C_d87a9b62-f8b3-496c-813b-ff57b12f4f20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tcrt:CollaborationAgreementWithSolasiaPharmaKkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_2118d568-df96-4de0-9724-e8edfa283612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <startDate>2024-01-31</startDate>
            <endDate>2024-01-31</endDate>
        </period>
    </context>
    <context id="C_d188ee19-8efb-40f4-bfc1-15d99d4dcdb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tcrt:EdenBiocellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-18</instant>
        </period>
    </context>
    <context id="C_52953abd-cae9-408c-bc3a-1c32bbcbd88a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">tcrt:SvbWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-06</instant>
        </period>
    </context>
    <context id="C_cf29daca-a7b6-4083-bfa6-78d85df7567f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tcrt:TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_f5aa7ee8-5428-4b9d-b069-2e72b206cbaa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:MdAndersonLicenseAndTheResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_b355e022-e0e9-4da2-8a04-f3b2546fe32b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">tcrt:CRADAAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_eb3569a0-1c09-487b-a964-8d604ab02e26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tcrt:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-12</startDate>
            <endDate>2022-08-12</endDate>
        </period>
    </context>
    <context id="C_f7de99b6-d374-4e48-911c-1cd00129ec98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d9080476-f0f7-430a-80b4-880ed65fc6e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:ClassOfWarrantOrRightAxisAxis">tcrt:MdAndersonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-22</instant>
        </period>
    </context>
    <context id="C_228ec118-b1e2-4f75-9b40-90b271c238f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
        </entity>
        <period>
            <instant>2018-10-05</instant>
        </period>
    </context>
    <context id="C_a0e1c5bb-bb46-4bb5-b672-44110a621fdf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tcrt:AdditionalPaidInCapitalCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f2998239-c729-4024-b9be-d75e1a53f26d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tcrt:AgreementTypeAxisAxis">tcrt:CantorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-29</instant>
        </period>
    </context>
    <context id="C_c594780d-4524-4d01-9ec4-b90f13b9d953">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">tcrt:SiliconValleyBankLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-28</instant>
        </period>
    </context>
    <context id="C_531cd4a1-a78c-4276-b3b6-3bea9219ed8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001107421</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_573aa50a-8660-4899-8300-e5834ed98d42">0001107421</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_be485a2c-e9b1-4a7d-988e-fb85faee85f6">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_912f67c0-ee7a-4ea9-a9f6-fa771e079b85">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_e866ea43-ac5b-4c3c-b32e-8d305031edcb">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      id="F_d489a1a3-4066-4111-8fa4-da4de611e5f0"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      id="F_4fe26983-f996-40e5-8f1c-85312879ee23"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_851be3c1-43fa-4eee-b985-0ef8bff5134f">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_3d87f659-7701-4f74-8a74-195a1ccfffd0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_283d6365-48a8-43c9-b2a0-d765f6a0ff89">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_91dfe2c9-5afa-4a6e-b257-5cd42c9749da">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_1c4a916e-1d42-4a8c-a07b-f9deb7bf6c16">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_6352218d-10ab-4bb0-aeba-e06793b143c0">001-33038</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_e2131396-9084-471f-a623-f20839fbc93e">Alaunos Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_aba7ba88-b747-435d-8490-13926b06333d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_070610bd-b6d0-4dc8-bdce-0bd83b060422">84-1475642</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_20c73e40-f0da-4e02-9a82-4fd6d4081236">2617 Bissonnet Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_d7b10b2d-a98b-4780-b000-5b1b68a6e6fe">Suite 225</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_347fe572-2cc0-45a7-886b-71a237b6fdf5">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_f805550c-276a-4c23-a45a-3ba945ca4c0d">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_5db5ce42-4a7f-4cbb-802f-af10d581349c">77005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_e235c9ce-7e58-4bb5-9f27-3adbe8a65659">346</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_07c3a9b7-ae2c-4715-af93-d1f4f3fbd41c">355-4099</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_66e548cb-cb26-45e4-b676-e43989489b58">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_5b6448a1-921f-4210-88c0-9e8f022fe4f4">TCRT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_cc4b0799-2f24-4ba5-82d1-ce7dd15d65f2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_bdbb4d79-27a0-4760-95f0-38822708d9b2">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_ed0e4e1e-bb31-4a8d-9701-e36baef19ff5">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_3263ff9a-433b-4669-aa5e-9ec76aa30c1e">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_ee46cc66-4ab9-41e4-b127-a573d243fe4e">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_02e27e78-c266-432c-bccf-6e2df7e0f285">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_66449430-63f8-4471-961b-be86b7232c11">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_b46b0e83-a6fe-4373-960c-564ab0754cde"
      decimals="0"
      id="F_293f3114-9249-4246-862e-143b9a0764af"
      unitRef="U_shares">16012522</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="-3"
      id="F_74266b1d-2b11-4426-a87b-ea4770e960ef"
      unitRef="U_USD">4145000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="-3"
      id="F_8e46a84e-3639-42ba-8325-b0b757651d80"
      unitRef="U_USD">6062000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="-3"
      id="F_007d05ed-3817-421f-aff9-5f4d33a30502"
      unitRef="U_USD">1000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="-3"
      id="F_4dcd67c7-8320-4994-9188-700498a65ee7"
      unitRef="U_USD">1000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="-3"
      id="F_4b0ac75a-9e80-4fb2-8c4b-33d28eaa7c35"
      unitRef="U_USD">1891000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="-3"
      id="F_c100ff4d-5575-43e2-9079-1ecc64ef22ab"
      unitRef="U_USD">2198000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="-3"
      id="F_a61df71e-fed9-43ac-8b95-26c57fb3e168"
      unitRef="U_USD">6037000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="-3"
      id="F_467318fe-0830-48a9-bc49-8f35be900a5a"
      unitRef="U_USD">8261000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="-3"
      id="F_bbf31f63-57cb-4754-9fce-1e99712e48d3"
      unitRef="U_USD">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="-3"
      id="F_83592d24-ab09-4b94-9e49-e0f3f717bc55"
      unitRef="U_USD">2000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="-3"
      id="F_0eea78db-e9b9-441e-a9cf-24044702ec02"
      unitRef="U_USD">6037000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="-3"
      id="F_3e5e0455-e13d-4726-9e7f-fe2141b7c6e3"
      unitRef="U_USD">8263000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="-3"
      id="F_5897c1ff-969a-40ed-9e95-3d1abb345875"
      unitRef="U_USD">597000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="-3"
      id="F_89c57997-18fe-42d1-b5c2-25f3ab3699d4"
      unitRef="U_USD">616000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="-3"
      id="F_303c12e4-69a9-44e4-88ca-ad85d8da8485"
      unitRef="U_USD">643000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="-3"
      id="F_d007039f-1c4f-42e1-895e-11ab939a6d96"
      unitRef="U_USD">1340000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="-3"
      id="F_9efcb91a-77e9-43cf-98ca-d0fab3919cd2"
      unitRef="U_USD">1240000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="-3"
      id="F_5ceeaad7-d70f-403a-ab6f-b77df975e7f0"
      unitRef="U_USD">1956000</us-gaap:LiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="-3"
      id="F_370d52b1-5f66-443e-bc4b-b330d66f25fb"
      unitRef="U_USD">1240000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="-3"
      id="F_47dff093-b7b0-4afa-8c4f-3cb53bda5ca9"
      unitRef="U_USD">1956000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="3"
      id="F_7628467a-aa1c-488e-bc6e-9fb59a48bcf7"
      unitRef="U_USDollarShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="3"
      id="F_b3c0bd6e-7f77-4cf5-a13d-5bda0407948b"
      unitRef="U_USDollarShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="INF"
      id="F_1aaf42a8-287d-4d96-bce1-4f031ba5644d"
      unitRef="U_shares">34666667</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="INF"
      id="F_59fb5d68-87b6-4a2d-9e66-39650a06d931"
      unitRef="U_shares">34666667</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="INF"
      id="F_6e0e7b13-e1d6-4328-b0bc-4e866d239592"
      unitRef="U_shares">16012522</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="INF"
      id="F_668e483a-4311-4ed8-92e9-b41515bf829b"
      unitRef="U_shares">16012522</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="INF"
      id="F_462a1030-adf1-4189-ad0e-3e27009af99d"
      unitRef="U_shares">16012522</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="INF"
      id="F_08f5ae8e-6cdf-49ca-b552-ee399efd0640"
      unitRef="U_shares">16012522</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="-3"
      id="F_5bf9b8d9-e5d3-4b89-b7d9-a4e37ad4955e"
      unitRef="U_USD">16000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="-3"
      id="F_db82c6ff-ace6-4b7a-ade1-ac7e07f21672"
      unitRef="U_USD">16000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="-3"
      id="F_81921160-9eb5-4185-9789-05f25cdecba7"
      unitRef="U_USD">922230000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="-3"
      id="F_0f6b0be5-0b0d-45bd-93f6-c75795d7d81d"
      unitRef="U_USD">922058000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="-3"
      id="F_4b760a1a-1977-490c-a3ef-ad270bc1a280"
      unitRef="U_USD">-917449000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="-3"
      id="F_eb1a0a75-4747-4d0f-a4d2-ed4d09f371e1"
      unitRef="U_USD">-915767000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="-3"
      id="F_f7269fde-c067-445d-834d-83bf3415d2d8"
      unitRef="U_USD">4797000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="-3"
      id="F_4f88c12c-d7cc-44b9-9432-8bf36e98817b"
      unitRef="U_USD">6307000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="-3"
      id="F_d5c37d3c-d184-41d3-9e97-a2ba195bf5d0"
      unitRef="U_USD">6037000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="-3"
      id="F_00dbf9c0-0deb-4550-a407-9e20b2841e61"
      unitRef="U_USD">8263000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_8aa47a7a-efa7-4958-9767-fead4a3e72f5"
      unitRef="U_USD">1000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_b56888ab-6ff5-4f8a-8fe1-a2d7cac7435a"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_aeb7230c-3c53-4b86-922b-ccfb253c9c4c"
      unitRef="U_USD">126000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_07a5eb0e-8ecd-4bc4-a292-6efc10e7ef59"
      unitRef="U_USD">6504000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_e286f9d2-12fc-4cc4-a13e-88843e9ccef2"
      unitRef="U_USD">1617000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_9bd3991c-36de-4f2f-af34-8251d4433e73"
      unitRef="U_USD">3168000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_0d3e3ff0-0ab9-41d2-a90a-9c988baf0936"
      unitRef="U_USD">1743000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_8069b38a-6c99-4ddc-9b0f-389c7315ddb3"
      unitRef="U_USD">9672000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_8f7154f2-ba3d-440e-ba57-7dfe6f5121ad"
      unitRef="U_USD">-1742000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_d523636f-7627-4173-a5a6-bfa9912e258c"
      unitRef="U_USD">-9672000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_570d3a24-98f2-4a54-aed8-6828c1798157"
      unitRef="U_USD">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_80acac51-69b7-4eb9-a055-c93c88f02108"
      unitRef="U_USD">853000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_374c834f-d309-4b23-a75e-0fa9dc1ace5a"
      unitRef="U_USD">60000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_2d41ac6e-c055-4ac5-825a-ac4b03c9e38b"
      unitRef="U_USD">477000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_8b98f058-1281-4aea-8c99-504e1093f0ef"
      unitRef="U_USD">60000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_d5166143-fe9b-4071-b281-41544e4e6b31"
      unitRef="U_USD">-376000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_f28820d1-3be3-46ef-b4c5-c45073c45180"
      unitRef="U_USD">-1682000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_9472aec7-ccd5-470f-9d67-b7906c948a88"
      unitRef="U_USD">-10048000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="2"
      id="F_b1037fb9-3317-409b-9dad-9802a272a8d5"
      unitRef="U_USDollarShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="2"
      id="F_f9320b6b-f07f-4405-9a98-54a3a307b5e3"
      unitRef="U_USDollarShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="2"
      id="F_096a80d8-97b5-415b-8c8c-1f28e46f687f"
      unitRef="U_USDollarShare">-0.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="2"
      id="F_581e973d-a526-456d-b063-572b3bd7f462"
      unitRef="U_USDollarShare">-0.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="0"
      id="F_f0c9f40c-3937-4404-a6ee-d24ed9d9c1ca"
      unitRef="U_shares">16012522</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="0"
      id="F_8a555777-dee5-4281-9cfa-7ec2a79958de"
      unitRef="U_shares">16012522</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="0"
      id="F_4c67f139-a326-49b4-a6e9-95975228ae0b"
      unitRef="U_shares">15978623</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="0"
      id="F_76be8e3b-4fe5-4d76-966f-e4a8b2f8508f"
      unitRef="U_shares">15978623</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="C_47601be9-83e3-443d-bbcb-b0ba3efb137d"
      decimals="INF"
      id="F_6f6d4a47-9950-4a39-beef-b70fb6c5370a"
      unitRef="U_shares">16012522</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_47601be9-83e3-443d-bbcb-b0ba3efb137d"
      decimals="-3"
      id="F_3ad0cb87-bcb4-4cdb-9757-060a0530c566"
      unitRef="U_USD">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a0e1c5bb-bb46-4bb5-b672-44110a621fdf"
      decimals="-3"
      id="F_9c7a98f0-bdf0-4be4-858c-1b132ffa84ae"
      unitRef="U_USD">922058000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a6c29fff-7446-403d-9ae5-f2ab3b978cc5"
      decimals="-3"
      id="F_fcafd41f-3229-464b-8dbe-688a663df3d2"
      unitRef="U_USD">-915767000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="-3"
      id="F_bc9e9282-8184-43d2-976d-be8bc07d0653"
      unitRef="U_USD">6307000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_1a9f3d32-f84f-4b13-8b49-7ba3cda42ef8"
      decimals="-3"
      id="F_778b3ce2-fa9c-4941-b7e9-e5123821beb3"
      unitRef="U_USD">172000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_76348105-b4e8-4fc8-bcc0-a442811b2566"
      unitRef="U_USD">172000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_30b081ac-90e4-47f2-90f6-835d27c36c54"
      decimals="-3"
      id="F_1e6b0a88-7987-4ba1-b6ca-eeda582672fa"
      unitRef="U_USD">-1682000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_5b311968-d326-4afb-8e5c-2b8275732378"
      unitRef="U_USD">-1682000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_7868565d-837f-4c4e-a465-218189cb407e"
      decimals="INF"
      id="F_89ac2196-d5e5-46d8-8575-7ea59c02b392"
      unitRef="U_shares">16012522</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_7868565d-837f-4c4e-a465-218189cb407e"
      decimals="-3"
      id="F_f933b7bb-f211-4918-88b7-5c9f1bb44363"
      unitRef="U_USD">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4c893ed4-2fab-4607-8dfd-4e3ede2ebc02"
      decimals="-3"
      id="F_bfdd9a1a-0c1a-4866-b108-d0b0fdd69462"
      unitRef="U_USD">922230000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9a6df5e6-87bf-4b67-8430-063789b2272d"
      decimals="-3"
      id="F_50b8a568-80cc-4bfa-8b56-25f5d978c929"
      unitRef="U_USD">-917449000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="-3"
      id="F_69f29f87-39ef-4ca5-bc3c-f7ebdb7b76f4"
      unitRef="U_USD">4797000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="C_a620055d-3725-42b7-9bb4-54550ba559d3"
      decimals="INF"
      id="F_4dbf77c2-40a1-47c1-9336-a383ab5f7d57"
      unitRef="U_shares">16027384</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_a620055d-3725-42b7-9bb4-54550ba559d3"
      decimals="-3"
      id="F_b87a22ee-a089-496a-9c72-27082d0a13dd"
      unitRef="U_USD">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e9263274-e6c8-4931-ba30-9ba9d76c89f4"
      decimals="-3"
      id="F_ffff30e8-63a2-4aab-94f8-fed6ae16fdb7"
      unitRef="U_USD">919166000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3354c043-11e9-441d-8243-0c39e040d0c6"
      decimals="-3"
      id="F_be26a904-64c1-440b-846c-4416be6de625"
      unitRef="U_USD">-880627000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f7de99b6-d374-4e48-911c-1cd00129ec98"
      decimals="-3"
      id="F_e86144a3-b775-4dcd-9b49-fb9451fa4641"
      unitRef="U_USD">38555000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_06ec8ddd-a6ca-4458-b361-e0082cad4a4b"
      decimals="-3"
      id="F_67b96971-d061-41be-ba94-0c321636c669"
      unitRef="U_USD">910000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_a96e9ecc-e636-4588-9601-a4c862891abb"
      unitRef="U_USD">910000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_aeb70e75-70ac-4afa-88cd-62bbcaee35fe"
      decimals="INF"
      id="F_f7ed8673-683c-44bc-8a7f-ad6daf8f8e1d"
      unitRef="U_shares">14420</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_06ec8ddd-a6ca-4458-b361-e0082cad4a4b"
      decimals="-3"
      id="F_d8b38c0b-e3e6-4a34-90db-aa210de0ce38"
      unitRef="U_USD">92000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_fee01773-540f-4f85-9877-6b556897adfb"
      unitRef="U_USD">92000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="C_531cd4a1-a78c-4276-b3b6-3bea9219ed8e"
      decimals="-3"
      id="F_bf91f24a-12c4-4ba7-8526-39134ce40c09"
      unitRef="U_USD">-10048000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_3617f72d-f85e-4326-bf65-15eed130d5a1"
      unitRef="U_USD">-10048000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_86b01827-f0d2-4c97-bbb5-1f488e3fa49f"
      decimals="INF"
      id="F_5f3966e7-ff77-4e36-9eba-88551e9c281a"
      unitRef="U_shares">16041804</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_86b01827-f0d2-4c97-bbb5-1f488e3fa49f"
      decimals="-3"
      id="F_95b8733d-f6a8-4495-b5fb-b5aebc24053e"
      unitRef="U_USD">16000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_feb2760d-82be-46cd-ac00-b75cb7214032"
      decimals="-3"
      id="F_9a9b898f-651a-44b9-92c7-5a413323a709"
      unitRef="U_USD">920168000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5e421c5e-d96b-4a7c-84cb-11656fb4e700"
      decimals="-3"
      id="F_af012b05-a035-4272-a575-a60be9118b9a"
      unitRef="U_USD">-890675000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2a4ac29e-7e17-4f4e-8ca5-1a9b13dce527"
      decimals="-3"
      id="F_cefe3a19-91f6-403c-9b92-568c799d2fe6"
      unitRef="U_USD">29509000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_e775f89f-3e26-48f8-b0ce-c35ea3a29b9a"
      unitRef="U_USD">-1682000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_0c859709-d76e-4d40-8a03-5d5a0b91a385"
      unitRef="U_USD">-10048000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_49fd7a3b-06ef-49c4-9d9f-71998e0afdfc"
      unitRef="U_USD">2000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_447d54d2-90f5-4671-a8db-90c94bf81a42"
      unitRef="U_USD">696000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_b2137dc4-0ea1-4420-ac40-a9425d94b982"
      unitRef="U_USD">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_1fe19a3e-98f3-4c64-8ad7-8863b2799c56"
      unitRef="U_USD">472000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_093c36bd-8ed3-42a8-bfc6-1894061ff0c2"
      unitRef="U_USD">172000</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_94c3d5f7-51a9-433e-b563-7937b8bc57a9"
      unitRef="U_USD">910000</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <tcrt:IncreaseDecreaseInRightOfUseAsset
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_a4d009d2-972f-4707-bb01-c1f893132f3f"
      unitRef="U_USD">0</tcrt:IncreaseDecreaseInRightOfUseAsset>
    <tcrt:IncreaseDecreaseInRightOfUseAsset
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_7e10005c-8bad-450d-8d78-4efcc65d5c0e"
      unitRef="U_USD">-113000</tcrt:IncreaseDecreaseInRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_2e9f4436-3008-4b5c-9778-e5c7fec832f0"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_ce678647-d3e3-4355-b129-550bbf62dde8"
      unitRef="U_USD">-4000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_08266003-c48f-47bc-8a4f-973bd07bddfa"
      unitRef="U_USD">-307000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_1ae84cec-01d9-4b2a-bbdc-ba378afc8688"
      unitRef="U_USD">-49000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_eb2b7357-97e7-4600-bec7-0d2e81efd364"
      unitRef="U_USD">-19000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_02f3b87e-a531-40db-b90d-fbea63113f89"
      unitRef="U_USD">-110000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_ff7ce97f-0e9a-4feb-b151-b7b0466c9a42"
      unitRef="U_USD">-697000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_540cb493-f2b0-4f4b-a3d5-2c3ac6eb5e30"
      unitRef="U_USD">-1334000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <tcrt:IncreaseDecreaseInLeaseLiabilities
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_1ad2dcbe-6a5f-44ce-b401-93c9cc8efc55"
      unitRef="U_USD">0</tcrt:IncreaseDecreaseInLeaseLiabilities>
    <tcrt:IncreaseDecreaseInLeaseLiabilities
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_cf1a75fb-44e7-4f84-a9cb-56d2e019492c"
      unitRef="U_USD">-133000</tcrt:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_a9b5b3e6-325d-47d2-852a-1319d9b534ad"
      unitRef="U_USD">-1917000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_7764264c-4452-493c-8495-b18c4e0c6b76"
      unitRef="U_USD">-9381000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_b45b3596-53d1-40b5-bde6-de0cb89114db"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_e15664ba-b039-4305-bc8f-88462f20a510"
      unitRef="U_USD">61000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_3b3fe3b2-5313-4cb6-b6cf-4f44a5695b61"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_5434c18c-b8c0-4629-a09d-5f2c5ce1317e"
      unitRef="U_USD">38000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_6b17757c-de85-47d3-9f15-95c07c3d6f2c"
      unitRef="U_USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_7077d67b-7759-4151-83a4-bf44d99182eb"
      unitRef="U_USD">-23000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_182563df-c8f4-40cd-b3a2-956b8fcecb47"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_81840fdf-e9ab-483d-a5c7-b830201d4dcf"
      unitRef="U_USD">92000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_d25dfbc2-914d-4234-b74a-a8e6785bc212"
      unitRef="U_USD">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_be48337e-4edb-48bd-8653-4e1d42bfd9d9"
      unitRef="U_USD">6250000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_9ffe9cdb-f2b2-4b82-9c48-fa3a7d838136"
      unitRef="U_USD">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_1657050c-a048-4ef1-9f3a-a6201318204f"
      unitRef="U_USD">-6158000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_6f3bd36d-c8eb-44a0-867f-443ea6490676"
      unitRef="U_USD">-1917000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_29831922-77a7-4940-bc05-a32945ff259a"
      unitRef="U_USD">-15562000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="-3"
      id="F_fcb80498-6114-4be2-ab91-7fa2fafd2d85"
      unitRef="U_USD">6062000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_f7de99b6-d374-4e48-911c-1cd00129ec98"
      decimals="-3"
      id="F_a38d38f8-5c61-467a-86f2-997d5b25c653"
      unitRef="U_USD">52996000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="-3"
      id="F_a903917f-b6d1-4c8b-b79c-52bbdd1c2b2d"
      unitRef="U_USD">4145000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2a4ac29e-7e17-4f4e-8ca5-1a9b13dce527"
      decimals="-3"
      id="F_a8b67575-8fa5-4c0c-bbb7-190d40a2750c"
      unitRef="U_USD">37434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_c89bd954-892e-4cc6-8e7c-616da4acc80c"
      unitRef="U_USD">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_862b8a18-9286-4889-8691-b801613cb112"
      unitRef="U_USD">439000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_de88ae31-bd49-4ef5-b88b-8488ab388c4c"
      unitRef="U_USD">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_fa8355c3-38cf-4f15-9bcb-52bee55740e2"
      unitRef="U_USD">101000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_992aebda-be25-4a10-8182-5de0d05457a2">&lt;div style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;1.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Overview&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Alaunos Therapeutics, Inc., which is referred to herein as &#x201c;Alaunos,&#x201d; or the &#x201c;Company,&#x201d; is a clinical-stage oncology-focused cell therapy company that was historically involved in the development of adoptive TCR therapies, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. The Company is leveraging its proprietary, non-viral &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;gene transfer platform and its novel cancer mutation hotspot TCR library to design and manufacture personalized cell therapies that target neoantigens arising from common tumor-related mutations in key oncogenic genes, including &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;KRAS, TP53 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;EGFR.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s operations to date have consisted primarily of conducting research and development and raising capital to fund those efforts.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of March 31, 2024, there were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,012,522&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;shares of common stock outstanding and an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,714,489&lt;/span&gt;&lt;span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;shares of common stock reserved for issuance pursuant to outstanding stock options and warrants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 14, 2023, the Company announced a strategic reprioritization of its business and wind down of its TCR-T Library Phase 1/2 Trial. In connection with the reprioritization, the Company has significantly reduced its workforce and continues working to reduce costs in order to extend its cash runway. The Company continues to explore strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. The Company has engaged Cantor Fitzgerald &amp;amp; Co., or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Cantor&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, to act as strategic advisor for this process.  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company follows the guidance of Accounting Standards Codification, or ASC, Topic 205-40, Presentation of Financial Statements - Going Concern, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its condensed financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management's plans that have not been fully implemented as of the date the condensed financial statements are issued. When substantial doubt exists, management evaluates whether the mitigating effect of its plans sufficiently alleviates the substantial doubt about the Company's ability to continue as a going concern. The mitigating effect of management's plans, however, is only considered if both (i) it is probable that the plans will be effectively implemented within one year after the date that the condensed financial statements are issued and (ii) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity's ability to continue as a going concern within one year after the date that the condensed financial statements are issued.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has operated at a loss since its inception in 2003 and has no recurring revenue from operations.&#x202f;The Company anticipates that losses will continue for the foreseeable future. As of March 31, 2024, the Company had approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of cash and cash equivalents. The Company&#x2019;s accumulated deficit at March 31, 2024 was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;917.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&#x202f;Given its current development plans and cash management efforts, the Company anticipates cash resources will be sufficient to fund operations into the third quarter of 2024.&#x202f;The Company&#x2019;s ability to continue operations after its current cash resources are exhausted depends on future events outside of the Company's control, including its ability to obtain additional financing or to achieve profitable results, as to which no assurances can be given. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If adequate additional funds are not available when required, or if the Company is unsuccessful in entering into partnership agreements for further development of its product candidates, management may need to curtail its development efforts and planned operations to conserve cash until sufficient additional capital is raised. There can be no assurances that such a plan would be successful.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Based on the current cash forecast and the Company's dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the condensed financial statements, and substantial doubt as to the Company's ability to continue as a going concern exists. This forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying unaudited interim condensed financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information and note disclosures required by generally accepted accounting principles in the United States, or GAAP, have been condensed or omitted pursuant to such rules and regulations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;It is management&#x2019;s opinion that the accompanying unaudited interim condensed financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair presentation of the financial position of the Company and its results of operations and cash flows for the periods presented. The unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2023, included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on April 1, 2024, or the Annual Report.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The results disclosed in the statements of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full fiscal year 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 31, 2024, the Company filed a Second Amended and Restated Certificate of Incorporation (the &#x201c;Charter Amendment&#x201d;) with the Secretary of State of the State of Delaware in order to effect a reverse stock split of the Company&#x2019;s common stock at a ratio of 1-for-15 (the &#x201c;Reverse Split&#x201d;). The Charter Amendment decreased the number of authorized shares of common stock from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;520,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,666,667&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Charter Amendment does not affect the par value of the Company&#x2019;s common stock or change the number of authorized shares or par value of the Company&#x2019;s preferred stock. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Charter Amendment became effective on January 31, 2024 at 5:00 p.m. Eastern Time, at which time every 15 shares of the Company&#x2019;s issued and outstanding common stock automatically combined and converted into 1 share of common stock.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;No fractional shares were issued in connection with the Reverse Split. Stockholders of record who would otherwise have been entitled to receive fractional shares as a result of the Reverse Split received a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing sales price per share of the common stock (as adjusted for the Reverse Split) on The Nasdaq Capital Market on January 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All share and per share amounts of common stock, options, warrants, and restricted stock in the accompanying financial statements and notes thereto have been retroactively adjusted for all periods presented to reflect the Reverse Split as if it had occurred at the beginning of the earliest period presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_7868565d-837f-4c4e-a465-218189cb407e"
      decimals="INF"
      id="F_5cae25bf-c01d-4cae-a5af-eb0cf014ad89"
      unitRef="U_shares">16012522</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_7868565d-837f-4c4e-a465-218189cb407e"
      decimals="INF"
      id="F_5e71b1c8-9055-4bcf-8e6d-516cc5b71c3e"
      unitRef="U_shares">1714489</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <tcrt:StrategicAdvisorName
      contextRef="C_cc6be139-4d29-491a-ac06-ae207788d63f"
      id="F_042a5e23-1ae8-48b8-a902-42d6e0e92463">Cantor</tcrt:StrategicAdvisorName>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="-5"
      id="F_25aa6d75-56d4-4655-b61b-538f27106ac1"
      unitRef="U_USD">4100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="-5"
      id="F_efedfe9d-ac83-4531-8b10-60685e327c82"
      unitRef="U_USD">-917400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_783b033d-291f-4f4f-a57e-9cc12621fc40">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying unaudited interim condensed financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information and note disclosures required by generally accepted accounting principles in the United States, or GAAP, have been condensed or omitted pursuant to such rules and regulations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;It is management&#x2019;s opinion that the accompanying unaudited interim condensed financial statements reflect all adjustments (which are normal and recurring) that are necessary for a fair presentation of the financial position of the Company and its results of operations and cash flows for the periods presented. The unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2023, included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC on April 1, 2024, or the Annual Report.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The results disclosed in the statements of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full fiscal year 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_c1d97f28-dd3d-42ca-a520-22a492c0d5cd">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <tcrt:ReverseStockSplitPolicyTextBlock
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_9ef53936-ef80-41f8-bf77-a9fff97f2358">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Reverse Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 31, 2024, the Company filed a Second Amended and Restated Certificate of Incorporation (the &#x201c;Charter Amendment&#x201d;) with the Secretary of State of the State of Delaware in order to effect a reverse stock split of the Company&#x2019;s common stock at a ratio of 1-for-15 (the &#x201c;Reverse Split&#x201d;). The Charter Amendment decreased the number of authorized shares of common stock from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;520,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,666,667&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Charter Amendment does not affect the par value of the Company&#x2019;s common stock or change the number of authorized shares or par value of the Company&#x2019;s preferred stock. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Charter Amendment became effective on January 31, 2024 at 5:00 p.m. Eastern Time, at which time every 15 shares of the Company&#x2019;s issued and outstanding common stock automatically combined and converted into 1 share of common stock.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;No fractional shares were issued in connection with the Reverse Split. Stockholders of record who would otherwise have been entitled to receive fractional shares as a result of the Reverse Split received a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing sales price per share of the common stock (as adjusted for the Reverse Split) on The Nasdaq Capital Market on January 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All share and per share amounts of common stock, options, warrants, and restricted stock in the accompanying financial statements and notes thereto have been retroactively adjusted for all periods presented to reflect the Reverse Split as if it had occurred at the beginning of the earliest period presented.&lt;/span&gt;&lt;/p&gt;</tcrt:ReverseStockSplitPolicyTextBlock>
    <tcrt:PreStockSplitSharesAuthorized
      contextRef="C_3f929b6c-a393-480f-b2d8-4b64cbcc35fd"
      decimals="INF"
      id="F_24c5c592-062b-49c1-a243-dbb7bf8e16a3"
      unitRef="U_shares">520000000</tcrt:PreStockSplitSharesAuthorized>
    <tcrt:PostStockSplitSharesAuthorized
      contextRef="C_3f929b6c-a393-480f-b2d8-4b64cbcc35fd"
      decimals="INF"
      id="F_d98a3e97-713a-42f2-9574-2f4ddf5510a4"
      unitRef="U_shares">34666667</tcrt:PostStockSplitSharesAuthorized>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_2118d568-df96-4de0-9724-e8edfa283612"
      id="F_55e3e490-1366-45a2-8628-fbd91efcdf65">The Charter Amendment became effective on January 31, 2024 at 5:00 p.m. Eastern Time, at which time every 15 shares of the Company&#x2019;s issued and outstanding common stock automatically combined and converted into 1 share of common stock.</us-gaap:StockholdersEquityReverseStockSplit>
    <tcrt:FinancingArrangementsDisclosureTextBlock
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_852161d7-2f90-45fe-81ed-fbe5957358b9">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financings&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2021 Loan and Security Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 6, 2021, the Company entered into a Loan and Security Agreement, or the Loan and Security Agreement, with Silicon Valley Bank and affiliates of Silicon Valley Bank, or collectively, SVB. The Loan and Security Agreement provided for an initial term loan of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million funded at the closing, or the Term A Tranche, with an additional tranche of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million available if certain funding and clinical milestones were met by August 31, 2022, or the Term B Tranche.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Effective December 28, 2021, the Company, entered into an amendment to the Loan and Security Agreement, or the First Amendment. The First Amendment extended the interest-only period through August 31, 2022. The First Amendment also eliminated the Term B Tranche, which remained unfunded, leaving only the Term A Tranche, or the SVB Facility. Under the amended Loan and Security Agreement, the SVB Facility was to mature on August 1, 2023. On May 1, 2023, the Company repaid its outstanding debt obligations under the amended Loan and Security Agreement in their entirety.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Refer to Note 4, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;for further discussion of the Loan and Security Agreement and the First Amendment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2022 Equity Distribution Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 12, 2022, the Company entered into an Equity Distribution Agreement, or the Equity Distribution Agreement, with Piper Sandler &amp;amp; Co., or Piper Sandler, pursuant to which the Company can offer and sell, from time to time at its sole discretion, shares of its common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million through Piper Sandler as its sales agent in an "at the market offering." Piper Sandler will receive a commission of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of the gross proceeds of any common stock sold under the Equity Distribution&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Agreement. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;During the three months ended March 31, 2024 and 2023, there have been &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; sales of the Company's common stock under the Equity Distribution Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2022 Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On November 29, 2022, the Company entered into an underwriting agreement, or the Underwriting Agreement, with Cantor as the sole underwriter, relating to the issuance and sale in an underwritten offering, or the Offering, of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,615,248&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares, or the Firm Shares, of the Company&#x2019;s common stock to Cantor at a price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.2865&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The net proceeds to the Company from the Offering were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (before accounting for the partial exercise of Cantor's option as described below) after deducting underwriting discounts and commissions and offering expenses payable by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the terms of the Underwriting Agreement, the Company granted Cantor an option, exercisable for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;30 days&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, to purchase up to an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;242,287&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, which we refer to, together with the Firm Shares, as the Shares, at the same price per share as the Firm Shares. On January 5, 2023, Cantor partially exercised its option to purchase an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,420&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;</tcrt:FinancingArrangementsDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="C_a5053d79-f95f-4469-83c1-e72e88a19a19"
      decimals="-5"
      id="F_409b94a4-c95e-4f6f-80d2-5af4c716de60"
      unitRef="U_USD">25000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_82917f35-4e10-4373-8317-e2e998187578"
      decimals="-5"
      id="F_33b4bfb6-cbb5-4e78-bb15-b20b76f778fa"
      unitRef="U_USD">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_eb3569a0-1c09-487b-a964-8d604ab02e26"
      decimals="-5"
      id="F_4d351761-11d8-4d9d-9c63-fe8fd9036192"
      unitRef="U_USD">50000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <tcrt:PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock
      contextRef="C_eb3569a0-1c09-487b-a964-8d604ab02e26"
      decimals="3"
      id="F_578c24b5-5eea-4e7f-af36-71369fa37a09"
      unitRef="U_pure">0.03</tcrt:PercentageOfCommissionOnGrossProceedsFromSaleOfCommonStock>
    <tcrt:StockOfferedDuringPeriodShares
      contextRef="C_e202e528-177e-4db6-adec-6869d8137344"
      decimals="INF"
      id="F_01d708c0-5eb3-407b-81d4-3702b2a9bd9a"
      unitRef="U_shares">0</tcrt:StockOfferedDuringPeriodShares>
    <tcrt:StockOfferedDuringPeriodShares
      contextRef="C_c8496d52-7c42-49e6-b1a1-90623138bd33"
      decimals="INF"
      id="F_41507a27-0df7-47ff-bd10-155127e661a8"
      unitRef="U_shares">0</tcrt:StockOfferedDuringPeriodShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_318d2bef-2b78-48b2-9bf0-7f8d81ddf304"
      decimals="0"
      id="F_2f162e14-a964-4c56-be55-7aa8cc04e038"
      unitRef="U_shares">1615248</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <tcrt:UnderwriterParOrStatedValuePerShare
      contextRef="C_f2998239-c729-4024-b9be-d75e1a53f26d"
      decimals="4"
      id="F_9dc68dc2-4cab-4f30-868d-6794cd5c81a9"
      unitRef="U_USDollarShare">9.2865</tcrt:UnderwriterParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_ad2cf5bf-7a86-4612-a507-a31f59be56ae"
      decimals="-5"
      id="F_3bf70ead-ea95-49d2-a510-9eb244043f06"
      unitRef="U_USD">14700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <tcrt:ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings
      contextRef="C_318d2bef-2b78-48b2-9bf0-7f8d81ddf304"
      id="F_16b2a474-c8e1-4d25-83f1-80ba62af2d92">30 days</tcrt:ThresholdCommitmentPeriodForExerciseOfRightsToParticipateInFutureOfferings>
    <tcrt:NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase
      contextRef="C_5c46026b-b792-4f5a-b3d6-cd9c0eb096c3"
      decimals="0"
      id="F_286b00bb-cfc7-49fb-835c-450a70dd6fe4"
      unitRef="U_shares">242287</tcrt:NumberOfAdditionalOptionAvailableToTheUnderwriterToPurchase>
    <tcrt:StockOfferedDuringPeriodShares
      contextRef="C_459f2708-7ef7-43f4-a5f4-b66c0656e6b2"
      decimals="0"
      id="F_4e3d7551-9245-47bb-82a3-4b13ddb2baf3"
      unitRef="U_shares">14420</tcrt:StockOfferedDuringPeriodShares>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_857bc0bb-4532-469a-917c-4232c813a4e6">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;3.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s significant accounting policies were identified in the Company&#x2019;s Annual Report. There have been no material changes in those policies since the filing of its Annual Report.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_905999eb-d6bd-4853-ae50-013d5e9f9fdb">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;4.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; debt obligations outstanding at March 31, 2024 and December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 6, 2021, the Company entered into the Loan and Security Agreement with SVB. The Loan and Security Agreement provided for the funding of the Term A Tranche at the closing, with the Term B Tranche available if certain funding and clinical milestones were met by August 31, 2022. The SVB Facility and related obligations under the Loan and Security Agreement were secured by substantially all of the Company's properties, rights and assets, except for its intellectual property (which was subject to a negative pledge under the Loan and Security Agreement). In addition, the Loan and Security Agreement contained customary representations, warranties, events of default and covenants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On December 28, 2021, the Company entered into the First Amendment to the Loan and Security Agreement. The First Amendment eliminated the unfunded Term B Tranche, among other things. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The SVB Facility bore interest at a floating rate per annum on outstanding loans, payable monthly, at the greater of (a) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and (b) the current published U.S. prime rate, plus a margin of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All outstanding obligations under the amended Loan and Security Agreement were due and payable on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;August 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. In connection with the payment of all of the Company's outstanding obligations, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the Company also owed SVB &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the original principal amounts borrowed as a final payment, or the Final Payment. Effective March 30, 2023, the Company entered into a Third Amendment to the Loan and Security Agreement, or the Third Amendment. Under the terms of the Third Amendment, the Company was no longer required to maintain all of its operating accounts, depository accounts and excess cash with SVB or one of its affiliates, and was instead only required to maintain a single operating or depository account at Silicon Valley Bank. The Third Amendment also modified the cash collateralization requirement, such that the Company was required to cash collateralize the entire sum of the outstanding principal amount of the SVB Facility, plus an amount equal to the Final Payment, which amount was to be reduced commensurate with each regularly scheduled monthly payment of principal and interest on the SVB Facility.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On May 1, 2023, the Company paid SVB an amount equal to the entire outstanding principal amount under the SVB Facility, all accrued and unpaid interest and the Final Payment. In accordance with the First Amendment, the payment was subject to a prepayment premium of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%. During the second quarter of 2023, the Company recorded the remaining amounts associated with the Final Payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and the prepayment premium of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as interest expense within the condensed statement of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with its entry into the Loan and Security Agreement in August 2021, the Company issued to SVB warrants to purchase (i) up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,856&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock, in the aggregate, and (ii) up to an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,856&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, in the aggregate, in the event the Company achieved certain clinical milestones, in each case at an exercise price per share of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with its entry into the First Amendment in December 2021, the Company amended and restated the warrants issued to SVB. As amended and restated, the warrants are for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,308&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company's common stock, in the aggregate, with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.40&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, or the SVB Warrants. The SVB Warrants expire on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;August 6, 2031&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The issuance costs for the Loan and Security Agreement, including the First Amendment, were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and primarily related to the issuance of the SVB Warrants, which were amortized into interest expense over the term of the loan. Interest expense,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;including &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the amortization of issuance costs, was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for the three months ended March 31, 2024, compared to $0&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the three months ended March 31, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="INF"
      id="F_74634eb2-86be-4883-8b05-50d34f172f27"
      unitRef="U_USD">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="INF"
      id="F_ac6f7c99-9e5d-445f-a41d-05c26c64f243"
      unitRef="U_USD">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="C_bf8b4b8c-26b2-4415-90c9-ba9e666f9956"
      id="F_a3f724f9-8aca-4c8a-a591-a80a6f8bc0ec">The SVB Facility bore interest at a floating rate per annum on outstanding loans, payable monthly, at the greater of (a) 7.75% and (b) the current published U.S. prime rate, plus a margin of 4.5%</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_8013c772-ccba-4aa2-b4a1-652bb9ef35c1"
      decimals="4"
      id="F_d5964862-5996-4442-b241-3812393eb3c5"
      unitRef="U_pure">0.0775</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="C_529a077c-2067-46ae-a95e-3d29d884679c"
      decimals="3"
      id="F_0c697fbd-23c1-4d58-a0a2-73a98204ab26"
      unitRef="U_pure">0.045</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1
      contextRef="C_bf8b4b8c-26b2-4415-90c9-ba9e666f9956"
      id="F_40c65851-331c-497f-87f4-f26c040826c7">2023-08-01</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms
      contextRef="C_cd66aa2a-1923-408f-ad01-68d671934a39"
      id="F_f8336203-1713-48de-bb88-cf14ec8275f9">the Company also owed SVB 5.75% of the original principal amounts borrowed as a final payment, or the Final Payment. Effective March 30, 2023, the Company entered into a Third Amendment to the Loan and Security Agreement, or the Third Amendment. Under the terms of the Third Amendment, the Company was no longer required to maintain all of its operating accounts, depository accounts and excess cash with SVB or one of its affiliates, and was instead only required to maintain a single operating or depository account at Silicon Valley Bank. The Third Amendment also modified the cash collateralization requirement, such that the Company was required to cash collateralize the entire sum of the outstanding principal amount of the SVB Facility, plus an amount equal to the Final Payment, which amount was to be reduced commensurate with each regularly scheduled monthly payment of principal and interest on the SVB Facility.</us-gaap:LineOfCreditFacilityFrequencyOfPaymentAndPaymentTerms>
    <tcrt:PercentageOfOriginalPrincipalDueAsAFinalPayment
      contextRef="C_8013c772-ccba-4aa2-b4a1-652bb9ef35c1"
      decimals="4"
      id="F_e207f2e0-4b96-4b10-a628-74208cc9bfe5"
      unitRef="U_pure">0.0575</tcrt:PercentageOfOriginalPrincipalDueAsAFinalPayment>
    <tcrt:PercentageOfPrepaymentsPremium
      contextRef="C_06f78440-3bd6-4263-b564-21c6263d6ac1"
      decimals="4"
      id="F_c5949b23-02e4-4e0b-9e2e-67c0fd98c409"
      unitRef="U_pure">0.02</tcrt:PercentageOfPrepaymentsPremium>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="C_bf8b4b8c-26b2-4415-90c9-ba9e666f9956"
      decimals="-5"
      id="F_f09c1bf1-ecf9-4055-9570-4122c3db4351"
      unitRef="U_USD">500000</us-gaap:ExtinguishmentOfDebtAmount>
    <tcrt:AmountOfPrepaymentsPremium
      contextRef="C_bf8b4b8c-26b2-4415-90c9-ba9e666f9956"
      decimals="-5"
      id="F_197bd815-21fc-425c-9458-c17453b90219"
      unitRef="U_USD">100000</tcrt:AmountOfPrepaymentsPremium>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_5aaa9322-5f00-4afe-8d8b-410a6b78fc05"
      decimals="0"
      id="F_8f59ae81-2184-4a8f-aa1e-7caa3ff97c35"
      unitRef="U_shares">28856</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <tcrt:AdditionalNumberOfWarrantsIssued
      contextRef="C_5aaa9322-5f00-4afe-8d8b-410a6b78fc05"
      decimals="0"
      id="F_d050810d-50b4-4bb9-8848-3ce2dbc2062c"
      unitRef="U_shares">28856</tcrt:AdditionalNumberOfWarrantsIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_5aaa9322-5f00-4afe-8d8b-410a6b78fc05"
      decimals="2"
      id="F_108b14bc-aef9-4873-824f-936e94d6e36e"
      unitRef="U_USDollarShare">33.3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="C_98a802f2-0e70-4585-9cc4-a79b60e487e1"
      decimals="0"
      id="F_5d34f0e6-a4d3-48d3-b80d-29d4377cac7d"
      unitRef="U_shares">43308</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_c594780d-4524-4d01-9ec4-b90f13b9d953"
      decimals="2"
      id="F_72b613fc-02fb-4493-8e4f-b8485bf3f8a1"
      unitRef="U_USDollarShare">17.4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tcrt:WarrantsExpirationDate
      contextRef="C_98a802f2-0e70-4585-9cc4-a79b60e487e1"
      id="F_ed52ddc6-1230-49e4-96e9-8c9d06ba9547">2031-08-06</tcrt:WarrantsExpirationDate>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="C_655a3713-d843-4e68-b88b-1e572769c0e4"
      decimals="-5"
      id="F_b4d301ee-4a21-4717-82a4-83aef44668c5"
      unitRef="U_USD">1200000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:InterestExpenseDebt
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-6"
      id="F_f7ca8929-6960-4423-be11-171de425815e"
      unitRef="U_USD">0</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-5"
      id="F_c686fbf9-10ce-4a10-b76f-36d23a64e007"
      unitRef="U_USD">900000</us-gaap:InterestExpenseDebt>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_48900eab-6ea2-4d45-ab7d-fcd4f86e963b">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;5.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2&#x2014;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of March 31, 2024 and December 31, 2023 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.603000000000002%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.542%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.302%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.302%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance as of&lt;br/&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets/Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.203999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.924999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.303999999999998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.303999999999998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance as of&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets/Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The cash equivalents represent demand deposit accounts and deposits in a short-term United States treasury money market mutual fund quoted in an active market and classified as a Level 1 asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There have been no changes to the valuation methods during the three months ended March 31, 2024. We had &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; financial assets or liabilities that were classified as Level 2 or Level 3 during the three months ended March 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_90d7d9e7-8476-4672-911f-47c0ca33d6b3">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Assets and liabilities measured at fair value on a recurring and nonrecurring basis as of March 31, 2024 and December 31, 2023 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.01%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.603000000000002%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.542%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.302%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.302%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance as of&lt;br/&gt;March 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets/Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:10.203999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.924999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.303999999999998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.303999999999998%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;($ in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Balance as of&lt;br/&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Quoted Prices in&lt;br/&gt;Active Markets&lt;br/&gt;for Identical&lt;br/&gt;Assets/Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,744&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_170c0509-c56f-4761-bdf6-22de08ad77fe"
      decimals="-3"
      id="F_e56673c3-7de1-4b0b-8a72-1656b4f02a47"
      unitRef="U_USD">3832000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_dbfeed30-f20b-44da-b3ca-39d3d35097bf"
      decimals="-3"
      id="F_e52a3b0b-000c-4c63-bcc7-63ba818d71a2"
      unitRef="U_USD">3832000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_4dd2c47b-4df3-4a07-bb67-521f620934a2"
      decimals="-3"
      id="F_99528e78-f276-4ca0-96fc-6a343f9ac26a"
      unitRef="U_USD">5744000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_96de5e3d-ec20-471c-8b74-4754e48554be"
      decimals="-3"
      id="F_42a2f2f6-be3f-4a8b-8342-f7b93afbfcbd"
      unitRef="U_USD">5744000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:FairValueNetAssetLiability
      contextRef="C_69b6b7d3-41a2-4d80-aee3-85fbf3416f62"
      decimals="-3"
      id="F_68785316-4f7d-47e5-9fe1-75081a659f0f"
      unitRef="U_USD">0</us-gaap:FairValueNetAssetLiability>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_9645b3b3-e60c-48f0-8588-b333b6d8972f">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;6.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;net loss per share of common stock is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share is computed using the weighted-average number of shares of common stock outstanding during the period, plus the dilutive effect of outstanding options and warrants, using the treasury stock method and the average market price of the Company's common stock during the applicable period, unless their effect on net loss per share is antidilutive. The effect of computing diluted net loss per common share was antidilutive for any potentially issuable shares of common stock from the conversion of stock options, unvested restricted stock and warrants and, as&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;such, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;have been excluded from the calculation. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Such potentially dilutive shares of common stock consisted of the following as of March 31, 2024 and 2023:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;251,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;887,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,452,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,528,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,703,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,475,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_b201cc05-890f-4c20-a712-f704046b7509">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Such potentially dilutive shares of common stock consisted of the following as of March 31, 2024 and 2023:&lt;/span&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:2.315%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;251,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;887,549&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;59,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,452,399&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,528,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,703,856&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,475,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_729e1616-09f9-46a9-a428-b5c7fb8de61a"
      decimals="0"
      id="F_6f456f46-4a02-448d-85ff-aceb368cf83c"
      unitRef="U_shares">251457</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f3cf5907-2650-4723-90f5-2fbb4565112b"
      decimals="0"
      id="F_197dccd4-73b5-4461-9497-5d6abaf054d9"
      unitRef="U_shares">887549</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_bbf27f91-17b6-4ae0-ad7c-8ead5a875486"
      decimals="0"
      id="F_92ae7939-6144-442f-aa04-b79d54f33153"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_499d880c-c83e-4094-9801-9f067ded9cb2"
      decimals="0"
      id="F_07fb49ca-1950-4158-b460-9194851f6500"
      unitRef="U_shares">59875</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0e2a059d-282e-4250-8c99-11315e2fb9ce"
      decimals="0"
      id="F_f279461f-be77-4ce5-a30a-04dc2241ca57"
      unitRef="U_shares">1452399</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_84fba74a-d852-4278-a598-763f3de703a2"
      decimals="0"
      id="F_40dfc5a8-c82a-468d-83ac-38af5219dd75"
      unitRef="U_shares">1528156</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="0"
      id="F_41dd81b7-0a34-42a8-8d7c-01bc5ca79273"
      unitRef="U_shares">1703856</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="0"
      id="F_4babf3c6-540b-4b76-8e30-776c042432bf"
      unitRef="U_shares">2475580</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_3e2a0006-6f69-4cbe-bed9-597daaba90cd">&lt;div style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;7.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Related Party Transactions&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Joint Venture with TriArm Therapeutics/Eden BioCell&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On December 18, 2018, the Company and TriArm Therapeutics, Ltd., or TriArm, launched Eden BioCell, Ltd., or Eden BioCell, as a joint venture to lead commercialization of the Company&#x2019;s &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-generated CAR-T therapies in the People&#x2019;s Republic of China (including Macau and Hong Kong), Taiwan and Korea. The Company licensed to Eden BioCell the rights in Greater China for its third-generation &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-generated CAR-T therapies targeting the CD19 antigen. Eden BioCell is owned equally by the Company and TriArm and the parties share decision-making authority. TriArm contributed $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to Eden BioCell and has committed up to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to this joint venture. TriArm also managed all clinical development in the territory pursuant to a master services agreement between TriArm and Eden BioCell. James Huang was the founder and serves as managing partner of Panacea Venture, which is an investor in TriArm. Mr. Huang was the Chair of the Company's board of directors until September 22, 2023 and had been a director since July 2020. He also serves as a member of Eden BioCell&#x2019;s board of directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2021, TriArm and Alaunos mutually agreed to dissolve the Eden BioCell joint venture. The joint venture agreement has been terminated and the Eden BioCell entity has been dissolved as of July 2023. Refer to Note 13, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Joint Venture&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, for further details.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Collaboration with Dune Lake Capital&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2023, the Company entered into a consulting agreement with Dune Lake Capital, LLC, or Dune Lake Capital, which was founded by Dale Curtis Hogue, Jr., the Company's interim Chief Executive Officer. During the three months ended March 31, 2024 and 2023, the Company recorded expenses of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand, respectively, for consulting services performed by Dune Lake Capital.&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="C_82df7c7b-262a-4272-aced-862f49a97569"
      decimals="-5"
      id="F_46a0eab3-19f0-4ead-a0fe-09d8ab73f1fe"
      unitRef="U_USD">10000000</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <tcrt:AdditionalLoansCommitted
      contextRef="C_d188ee19-8efb-40f4-bfc1-15d99d4dcdb1"
      decimals="-5"
      id="F_ac770fc0-6dd4-4820-a152-a58ab8b2b71b"
      unitRef="U_USD">25000000</tcrt:AdditionalLoansCommitted>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="C_7f5ae535-f6d0-484b-b23f-ef9a9da46789"
      decimals="-3"
      id="F_98f668a0-eeaf-449b-a0a3-8f03801ca706"
      unitRef="U_USD">0</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="C_eb264759-9de1-4b9f-acc7-aa907a4f72c5"
      decimals="-3"
      id="F_07ed8fde-9c59-469e-81d8-35e4982b58ed"
      unitRef="U_USD">7000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_3b6e2a66-6657-4e23-8b2e-3d4f75e1caa1">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;8.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Exclusive License Agreement with Precigen&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On October 5, 2018, the Company entered into an exclusive license agreement, or License Agreement, with PGEN Therapeutics, or PGEN, a wholly owned subsidiary of Precigen Inc., or Precigen, which was formerly known as Intrexon Corporation. Except where the context otherwise requires, the Company refers to PGEN and Precigen together as Precigen. Pursuant to the terms of the License Agreement, the Company had exclusive, worldwide rights to research, develop and commercialize (i) TCR products designed for neoantigens for the treatment of cancer, (ii) products utilizing Precigen&#x2019;s RheoSwitch&#xae; gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products and (iii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) BCMA for the treatment of cancer, subject to certain obligations to pursue such target under the License and Collaboration Agreement effective March 27, 2015 between the Company, Precigen and ARES TRADING S.A., a subsidiary of Merck KGaA, as assigned by Precigen to PGEN. Under the License Agreement, the Company also had exclusive, worldwide rights for certain patents relating to the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company was responsible for all aspects of the research, development and commercialization and was required to use commercially reasonable efforts to develop certain products.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In consideration of the licenses and other rights granted by Precigen, the Company was required to pay Precigen an annual license fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, reimburse Precigen for certain historical costs, pay Precigen milestones up to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for each exclusively licensed program upon the achievement of certain milestones, and pay Precigen tiered royalties up to a maximum royalty amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in the aggregate. The Company was also obligated to pay Precigen &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of any sublicensing&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;income &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;received by us relating to the licensed products. The Company was responsible for all development costs associated with each of the licensed products.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Precigen was obligated to pay the Company royalties up to a maximum royalty amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; royalty amounts were incurred during the three months ended March 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On April 3, 2023, the Company entered into the Amended and Restated Exclusive License Agreement with Precigen, or the A&amp;amp;R License Agreement, which restated and amended the License Agreement in full. Under the A&amp;amp;R License Agreement, the Company still has exclusive, worldwide rights to research, develop and commercialize TCR products designed for neoantigens or driver mutations for the treatment of cancer and non-exclusive rights to use non-driver mutation TCRs. The Company further maintains its exclusive, worldwide rights for certain patents relating to the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;technology to research, develop and commercialize TCR products for both neoantigens and shared antigens for the treatment of cancer, referred to as TCR Products.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;margin-right:4.63%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company remains solely responsible for all aspects of the research, development and commercialization of the exclusively licensed products for the treatment of cancer. The (i) products utilizing Precigen&#x2019;s RheoSwitch&#xae; gene switch, or RTS, for the treatment of cancer, referred to as IL-12 Products and (ii) CAR products directed to (A) CD19 for the treatment of cancer, referred to as CD19 Products, and (B) BCMA for the treatment of cancer, subject to certain obligations to pursue such target under the License and Collaboration Agreement effective March 27, 2015 between the Company, Precigen and ARES TRADING S.A., a subsidiary of Merck KGaA, as assigned by Precigen to PGEN are no longer exclusively licensed to the Company. The Company is no longer obligated to use commercially reasonable efforts for the exclusively licensed products. The A&amp;amp;R License Agreement further eliminates any royalty or milestone obligations to Precigen, with an annual license fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand due on the anniversary of the A&amp;amp;R License Agreement effective date. Precigen is no longer obligated to pay the Company royalties on the net sales derived from the sale of Precigen's CAR products.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;License Agreement and 2015 Research and Development Agreement &#x2014;The University of Texas MD Anderson Cancer Center&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 13, 2015&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company, together with Precigen, entered into a license agreement, or the MD Anderson License with MD Anderson (which Precigen subsequently assigned to PGEN). Pursuant to the MD Anderson License, the Company, together with Precigen, holds an exclusive, worldwide license to certain technologies owned and licensed by MD Anderson including technologies relating to novel CAR T-cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer, or NK Cells, and TCRs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 17, 2015, the Company, Precigen and MD Anderson entered into the 2015 R&amp;amp;D Agreement to formalize the scope and process for the transfer by MD Anderson, pursuant to the terms of the MD Anderson License, of certain existing research programs and related technology rights, as well as the terms and conditions for future collaborative research and development of new and ongoing research programs. The rights and obligations of Precigen under the 2015 R&amp;amp;D Agreement were assigned to the Company pursuant to the Fourth Amendment to 2015 R&amp;amp;D Agreement which was entered into on September 19, 2019 (the &#x201c;Fourth Amendment&#x201d;) with an effective date of October 5, 2018. The activities under the 2015 R&amp;amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As provided under the MD Anderson License, the Company provided funding for research and development activities in support of the research programs under the 2015 R&amp;amp;D Agreement for a period of three years and in an amount of no less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and no greater than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million per year. On November 14, 2017, the Company entered into an amendment to the 2015 R&amp;amp;D Agreement, extending its term until April 15, 2021. In connection with the execution of the 2019 R&amp;amp;D Agreement described below, on October 22, 2019, the Company amended the 2015 R&amp;amp;D Agreement to extend the term of the 2015 R&amp;amp;D Agreement until December 31, 2026 and to allow cash resources on hand at MD Anderson under the 2015 R&amp;amp;D Agreement to be used for development costs under the 2019 Research and Development Agreement, or the 2019 R&amp;amp;D Agreement, which the Company entered into on October 22, 2019, with MD Anderson, pursuant to which the Company agreed to collaborate with respect to the TCR program. The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t incur clinical costs from MD Anderson related to the 2015 R&amp;amp;D Agreement for the three months ended March 31, 2024 and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The term of the MD Anderson License expires on the last to occur of (a) the expiration of all patents licensed thereunder, or (b) the twentieth anniversary of the date of the MD Anderson License; provided, however, that following the expiration of the term of the MD Anderson License, the Company, together with Precigen, shall then have a fully-paid up, royalty free, perpetual, irrevocable and sublicensable license to use the licensed intellectual property thereunder. After ten years from the date of the MD Anderson License and subject to a 90-day cure period, MD Anderson will have the right to convert the MD Anderson License into a non-exclusive license if the Company and Precigen are not using commercially reasonable efforts to commercialize the licensed intellectual property on a case-by-case basis. After five years from the date of the MD Anderson License and subject to a 180-day cure period, MD Anderson will have the right to terminate the MD Anderson License with respect to specific technology(ies) funded by the government or subject to a third-party contract if the Company and Precigen are not meeting the diligence requirements in such funding agreement or contract, as applicable. MD Anderson may also terminate the agreement with written notice upon material breach by the Company and Precigen, if&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;such breach has not been cured within 60 days of receiving such notice. In addition, the MD Anderson License will terminate upon the occurrence of certain insolvency events for both the Company and Precigen and may be terminated by the mutual written agreement of the Company, Precigen, and MD Anderson.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2019 Research and Development Agreement&#x2014;The University of Texas MD Anderson Cancer Center&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the 2019 R&amp;amp;D Agreement, the Company and MD Anderson will, among other things, collaborate on programs to expand the Company's TCR library and conduct clinical trials. The activities under the 2019 R&amp;amp;D Agreement are directed by a joint steering committee comprised of two members from the Company and one member from MD Anderson.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company will own all inventions and intellectual property developed under the 2019 R&amp;amp;D Agreement and the Company will retain all rights to all intellectual property, patentable or not, for oncology products manufactured using non-viral gene transfer technologies under the 2019 R&amp;amp;D Agreement, including the Company's&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; Sleeping Beauty&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; technology. The Company has granted MD Anderson an exclusive license for such intellectual property to develop and commercialize autologous TCR products manufactured using viral gene transfer technologies and any products outside the field of oncology and a non-exclusive license for allogenic TCR products manufactured using viral-based technologies.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the 2019 R&amp;amp;D Agreement, the Company agreed, beginning on January 1, 2021, to reimburse MD Anderson up to a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for development costs under the 2019 R&amp;amp;D Agreement, after the funds from the 2015 R&amp;amp;D Agreement are exhausted. In addition, the Company will pay MD Anderson royalties on net sales of its TCR products. The Company is required to make performance-based payments upon the successful completion of clinical and regulatory benchmarks relating to its TCR products. The aggregate potential benchmark payments are $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, of which only $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million will be due prior to the first marketing approval of the Company's TCR products. The royalty rates and benchmark payments owed to MD Anderson may be reduced upon the occurrence of certain events. The Company also agreed to sell its TCR products to MD Anderson at preferential prices and will sell the Company's TCR products in Texas exclusively to MD Anderson for a limited period of time following the first commercial sale of the Company's TCR products. For the three months ended March 31, 2024 the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t incur clinical expenses from MD Anderson related to the 2019 R&amp;amp;D Agreement, compared to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the three months ended March 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The 2019 R&amp;amp;D Agreement will terminate on December 31, 2026 and either party may terminate the 2019 R&amp;amp;D Agreement following written notice of a material breach. The 2019 R&amp;amp;D Agreement also contains customary provisions related to indemnification obligations, confidentiality and other matters.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the execution of the 2019 R&amp;amp;D Agreement, on October 22, 2019, the Company issued MD Anderson a warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;222,222&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company's common stock, which is referred to as the MD Anderson Warrant. The MD Anderson Warrant has an initial exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.015&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, expires on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, and vests upon the occurrence of certain clinical milestones. As of March 31, 2024, the milestones have not been met.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;License Agreement with the NCI&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On May 28, 2019, the Company entered into a patent license agreement, or the Patent License, with the NCI. Pursuant to the Patent License, the Company held an exclusive, worldwide license to certain intellectual property to develop and commercialize patient-derived (autologous), peripheral blood T-cell therapy products engineered by transposon-mediated gene transfer to express TCRs reactive to mutated &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;KRAS, TP53&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;EGFR &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;neoantigens. In addition, pursuant to the Patent License, the Company held an exclusive, worldwide license to certain intellectual property for manufacturing technologies to develop and commercialize autologous, peripheral blood T-cell therapy products engineered by non-viral gene transfer to express TCRs, as well as a non-exclusive, worldwide license to certain additional manufacturing technologies. On May 29, 2019, January 8, 2020, September 28, 2020, April 16, 2021, May 4, 2021 and August 13, 2021 the Company amended the Patent License to expand its TCR library to include additional TCRs reactive to mutated &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;KRAS &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;TP53 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;neoantigens licensed from the NCI.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On October 27, 2023, the Company provided the NCI the requisite notice of its intent to terminate the Patent License, effective December 26, 2023. The Company discovered multiple proprietary TCRs targeting driver mutations through its hunTR TCR discovery platform, including many of the same &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;KRAS &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;TP53 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;mutations licensed from the NCI.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the three months ended March 31, 2024, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t incur expenses to the NCI under this agreement, compared to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the three months ended March 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Cooperative Research and Development Agreement (CRADA) with the NCI&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 9, 2017, the Company entered into a Cooperative Research and Development Agreement, or the CRADA, with the NCI. The purpose of this collaboration was to advance a personalized TCR-T approach for the treatment of solid tumors. Using the Company's&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; technology, the NCI would analyze a patient&#x2019;s own cancer cells, identify their unique neoantigens and TCRs reactive against those neoantigens and then use the Company's &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; technology to transpose one or more TCRs into T cells for re-infusion. Research conducted under the CRADA was under the direction of Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the NCI, in collaboration with the Company's researchers.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 14, 2023, the Company announced that it had provided the requisite notice to terminate the CRADA, pursuant to its terms, effective &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;October 13, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, in light of the Company&#x2019;s exploration of strategic alternatives.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t record expenses under the CRADA for the three months ended March 31, 2024, compared to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the three months ended March 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Patent and Technology License Agreement&#x2014;The University of Texas MD Anderson Cancer Center and the Texas A&amp;amp;M University System&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 24, 2004, the Company entered into a patent and technology license agreement with MD Anderson and the Texas A&amp;amp;M University System, which the Company refers to, collectively, as the Licensors. Under this agreement, the Company was granted an exclusive, worldwide license to rights (including rights to U.S. and foreign patent and patent applications and related improvements and know-how) for the manufacture and commercialization of two classes of organic arsenicals (water- and lipid-based) for human and animal use. The class of water-based organic arsenicals includes darinaparsin.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the terms of the agreement, the Company may be required to make additional payments to the Licensors upon achievement of certain milestones in varying amounts which, on a cumulative basis could total up to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. In addition, the Licensors are entitled to receive royalty payments on sales from a licensed product and will also be entitled to receive a portion of any fees that the Company may receive from a possible sublicense under certain circumstances. During the three months ended March 31, 2024 and 2023, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t incur any milestone expenses or royalty expenses on sales under this agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Collaboration Agreement with Solasia Pharma K.K.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 7, 2011, the Company entered into a License and Collaboration Agreement with Solasia Pharma K. K., or Solasia, which was amended on July 31, 2014 to include an exclusive worldwide license and amended on October 14, 2021 to revise certain payment schedule details, or, as so amended, the Solasia License and Collaboration Agreement. Pursuant to the Solasia License and Collaboration Agreement, the Company granted Solasia an exclusive license to develop and commercialize darinaparsin in both intravenous and oral forms and related organic arsenic molecules, in all indications for human use.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As consideration for the license, the Company is eligible to receive from Solasia development- and sales-based milestones, a royalty on net sales of darinaparsin, once commercialized, and a percentage of any sublicense revenue generated by Solasia. Solasia will be responsible for all costs related to the development, manufacturing and commercialization of darinaparsin. The Company&#x2019;s licensors, as defined in the Solasia License and Collaboration Agreement, will receive a portion of all milestone and royalty payments made by Solasia to the Company in accordance with the terms of the Solasia License and Collaboration Agreement with the licensors, as described above.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2022, Solasia announced that darinaparsin had been approved from relapsed or refractory Peripheral T-Cell Lymphoma by the Minis&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;try of Health, Labor and Welfare in Japan. During the three months ended March 31, 2024 and 2023, the Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t earn collaboration revenue and earned royalty revenues of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; thousand and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, of royalty revenues on net sales under the Solasia License and Collaboration Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;KBI Biopharma Litigation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On March 17, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;KBI Biopharma&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, Inc., or KBI, filed a complaint against the Company in the District Court of Harris County, Texas, 165th Judicial District, asserting breach of an Amended and Restated Master Services Agreement between the Company and KBI relating to the development of an autologous gene modified T-cell therapy product, or the KBI Agreement. KBI was primarily seeking unspecified monetary damages in excess of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. On May 1, 2023, the Company filed an answer generally denying all of KBI&#x2019;s allegations and asserting affirmative and other defenses as well as counterclaims for breach of the KBI Agreement and conversion. On October 20, 2023, the Company entered into an agreement with KBI to settle all claims asserted by KBI against the Company and the Company's counterclaims against KBI at issue in the litigation for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <tcrt:AnnualLicenseFees
      contextRef="C_dae15987-4a72-452e-bffe-37b8c8ff2004"
      decimals="-5"
      id="F_770c5d47-1ef0-4385-921a-5abd40736635"
      unitRef="U_USD">100000</tcrt:AnnualLicenseFees>
    <tcrt:MaximumAmountOfAdditionalMilestonesPayable
      contextRef="C_dae15987-4a72-452e-bffe-37b8c8ff2004"
      decimals="-5"
      id="F_1f3db4d1-73fa-476e-8e2f-5504774bb7e0"
      unitRef="U_USD">52500000</tcrt:MaximumAmountOfAdditionalMilestonesPayable>
    <tcrt:MaximumAmountOfRoyaltyPayable
      contextRef="C_94aa9eb4-37eb-4c0d-b5f9-9e0dd0d7fb5a"
      decimals="-5"
      id="F_558c18ae-a374-4c8e-838a-e8e425fa78ae"
      unitRef="U_USD">100000000</tcrt:MaximumAmountOfRoyaltyPayable>
    <tcrt:PercentageOfSubLicensingIncomePayableToRelatedParty
      contextRef="C_94aa9eb4-37eb-4c0d-b5f9-9e0dd0d7fb5a"
      decimals="2"
      id="F_7e00eb05-977c-4392-a3d3-bb25c12347e0"
      unitRef="U_pure">0.20</tcrt:PercentageOfSubLicensingIncomePayableToRelatedParty>
    <tcrt:MaximumRoyaltyAmount
      contextRef="C_228ec118-b1e2-4f75-9b40-90b271c238f4"
      decimals="-5"
      id="F_694205a6-279b-4a5b-aa3a-8ce3d7f16d75"
      unitRef="U_USD">100000000</tcrt:MaximumRoyaltyAmount>
    <us-gaap:RoyaltyExpense
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="0"
      id="F_278dd74f-f513-4d3a-ad39-117282d8e1c2"
      unitRef="U_USD">0</us-gaap:RoyaltyExpense>
    <tcrt:AnnualLicenseFees
      contextRef="C_0a4a2144-53c6-473a-a17e-948eca082f68"
      decimals="-3"
      id="F_eb8ca06d-476b-4718-9aac-99777609c229"
      unitRef="U_USD">75000</tcrt:AnnualLicenseFees>
    <tcrt:LicenseAgreementCommencingDate
      contextRef="C_3afa3256-b142-4067-84fa-31003618cdf3"
      id="F_42e32e37-6eb7-45d9-971e-411c0c1b620c">2015-01-13</tcrt:LicenseAgreementCommencingDate>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e2f5fa39-2c4c-4a31-9dba-9b302e6163aa"
      decimals="-5"
      id="F_bebd0c6f-2b17-472f-ab3d-6b03c908c7f9"
      unitRef="U_USD">15000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_58a539c3-32e6-40ab-81e3-7460cfa16a02"
      decimals="-5"
      id="F_81bf01b1-bcaa-41ac-b086-f06c018fec1b"
      unitRef="U_USD">20000000</us-gaap:ResearchAndDevelopmentExpense>
    <tcrt:ClinicalExpenses
      contextRef="C_05086637-454b-451e-ba2f-b6e9dac6f1bc"
      decimals="0"
      id="F_31aa3869-b740-44c5-96c6-ad6c53e714ab"
      unitRef="U_USD">0</tcrt:ClinicalExpenses>
    <tcrt:ClinicalExpenses
      contextRef="C_b1da774e-81d4-427f-b25c-7a2574c834ba"
      decimals="0"
      id="F_7803a340-df21-483b-8bed-e73b1df212b4"
      unitRef="U_USD">0</tcrt:ClinicalExpenses>
    <tcrt:AggregateAmountPotentiallyReimburseableAmount
      contextRef="C_081cf75e-7342-44b3-be87-434671a576d8"
      decimals="-5"
      id="F_4ea93f79-a9c0-44d4-91ac-d9647b0fba67"
      unitRef="U_USD">20000000</tcrt:AggregateAmountPotentiallyReimburseableAmount>
    <tcrt:AggregatePotentialBenchmarkPayments
      contextRef="C_081cf75e-7342-44b3-be87-434671a576d8"
      decimals="-5"
      id="F_e4fd53cd-9e8b-45a8-a0a5-90c251b1c407"
      unitRef="U_USD">36500000</tcrt:AggregatePotentialBenchmarkPayments>
    <tcrt:AccrualsPriorToFirstMarketingApproval
      contextRef="C_081cf75e-7342-44b3-be87-434671a576d8"
      decimals="-5"
      id="F_5f1105fc-b419-4e65-9428-7406af3736cb"
      unitRef="U_USD">3000000</tcrt:AccrualsPriorToFirstMarketingApproval>
    <tcrt:QuarterlyExpenseIncurred
      contextRef="C_5f3c58ea-f897-4151-a1ad-8f8690250ebe"
      decimals="0"
      id="F_c96436eb-0c6b-433c-a762-b8fb54c8d787"
      unitRef="U_USD">0</tcrt:QuarterlyExpenseIncurred>
    <tcrt:QuarterlyExpenseIncurred
      contextRef="C_f5aa7ee8-5428-4b9d-b069-2e72b206cbaa"
      decimals="-5"
      id="F_c933c366-2f89-407b-bffe-b8ba3ca4ebae"
      unitRef="U_USD">200000</tcrt:QuarterlyExpenseIncurred>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_d9080476-f0f7-430a-80b4-880ed65fc6e8"
      decimals="INF"
      id="F_c794a29a-d342-4daa-9fd8-604c1cc48d08"
      unitRef="U_shares">222222</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_d9080476-f0f7-430a-80b4-880ed65fc6e8"
      decimals="INF"
      id="F_29287a94-fa65-4b02-a46c-26ca518fb769"
      unitRef="U_USDollarShare">0.015</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_d9080476-f0f7-430a-80b4-880ed65fc6e8"
      id="F_920987ea-07be-4ef5-8035-b1e88f522f30">2026-12-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <tcrt:LicenseExpense
      contextRef="C_6270e901-6735-4c63-9513-8fb545fff59f"
      decimals="0"
      id="F_1b7214e1-5977-4d14-93a0-8325650e9cd5"
      unitRef="U_USD">0</tcrt:LicenseExpense>
    <tcrt:LicenseExpense
      contextRef="C_b01cd0f9-f0ef-4fe1-89dd-e53ec38d0b9e"
      decimals="-5"
      id="F_411444e2-fa43-4a43-b354-795d692a2b97"
      unitRef="U_USD">300000</tcrt:LicenseExpense>
    <tcrt:AgreementTerminationDate
      contextRef="C_d9ea1296-e67e-4c96-9b52-f8fb4490bf1c"
      id="F_3f6cea43-0ab0-4d31-9980-309649b7b50c">2023-10-13</tcrt:AgreementTerminationDate>
    <tcrt:AnnualExpenseIncurred
      contextRef="C_b355e022-e0e9-4da2-8a04-f3b2546fe32b"
      decimals="0"
      id="F_f56905c1-fd5e-49c6-b5da-fce00ce86fe9"
      unitRef="U_USD">0</tcrt:AnnualExpenseIncurred>
    <tcrt:AnnualExpenseIncurred
      contextRef="C_0fe9cdfc-046e-4935-a0e2-2577ae6a7cf2"
      decimals="-5"
      id="F_569c3d6c-ecc7-426a-9342-f3801608ed83"
      unitRef="U_USD">300000</tcrt:AnnualExpenseIncurred>
    <tcrt:MilestonePaymentsMaximumAmount
      contextRef="C_699c4514-89e0-4171-a8dd-a4bb94caddc4"
      decimals="-5"
      id="F_3c81dddf-815f-49b4-95da-38cbf7a247ec"
      unitRef="U_USD">4500000</tcrt:MilestonePaymentsMaximumAmount>
    <tcrt:PaymentUnderLicenseAgreement
      contextRef="C_cf29daca-a7b6-4083-bfa6-78d85df7567f"
      decimals="0"
      id="F_8a2f068b-5ea8-4c32-82c0-a18cbe000910"
      unitRef="U_USD">0</tcrt:PaymentUnderLicenseAgreement>
    <tcrt:PaymentUnderLicenseAgreement
      contextRef="C_fe3fc5c4-0c6a-404b-8a06-a203f7a1b9c0"
      decimals="0"
      id="F_6137a055-2825-466f-a591-7df9f0419390"
      unitRef="U_USD">0</tcrt:PaymentUnderLicenseAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_62447313-6131-42f8-98d0-6c78900cb176"
      decimals="0"
      id="F_756105a1-340c-48c5-a4d4-54ad2fb1c8eb"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d87a9b62-f8b3-496c-813b-ff57b12f4f20"
      decimals="0"
      id="F_0e9a6b4a-b379-4502-a03b-7f33f5a7f679"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a3ae250c-9ef9-4e50-b001-e026832b5546"
      decimals="-3"
      id="F_5f32f60c-44c8-4c85-a207-78e50368a8f0"
      unitRef="U_USD">1000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_481d4dca-c2e0-4a6d-a1aa-cb7b99c9e7e3"
      decimals="-3"
      id="F_d212e04a-7226-459c-ba14-861ae7daa342"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LossContingencyNameOfPlaintiff
      contextRef="C_87dc43db-b832-4e32-9d47-a96ea1328b91"
      id="F_c47944b7-17f9-4969-b1f7-285cc555cc4c">KBI Biopharma</us-gaap:LossContingencyNameOfPlaintiff>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="C_87dc43db-b832-4e32-9d47-a96ea1328b91"
      decimals="-5"
      id="F_2e883bdc-60ec-4d12-9171-d6946470317f"
      unitRef="U_USD">3200000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LitigationSettlementExpense
      contextRef="C_27f693e7-6abd-4a93-b50d-4206e1b22623"
      decimals="-5"
      id="F_44af67df-a5ad-4bd6-bf74-bd530e05754d"
      unitRef="U_USD">1000000</us-gaap:LitigationSettlementExpense>
    <tcrt:StockOptionsAndRestrictedStockAwardsTextBlock
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_99e19d46-726f-4e02-8120-2736a77d7a7c">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;9.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognized stock-based compensation expense on all employee and non-employee awards as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:63.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.713%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.643%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.523%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;735&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;910&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company granted an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; stock options during the three months ended March 31, 2024, with a weighted-average grant date fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, and granted an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;204,344&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; stock options during the three months ended March 31, 2023, with a weighted-average grant date fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the three months ended March 31, 2024 and 2023, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:79.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.173%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.443%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.143%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.09&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.58&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.87&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected life in years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.06&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;114.65&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89.69&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95.63&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.528%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:4.743198935713313%;display:inline-flex;justify-content:flex-start;"&gt;2.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock option activity under the Company&#x2019;s stock option plans for the three months ended March 31, 2024 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;(in thousands, except share and per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted- Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted- Average Contractual Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;465,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;254,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding, March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;251,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.92&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options exercisable, March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;161,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.53&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options available for future grant, March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,514,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At March 31, 2024, total unrecognized compensation costs related to unvested stock options outstanding amounted to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The cost is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1.28&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</tcrt:StockOptionsAndRestrictedStockAwardsTextBlock>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_a1ae826d-d95c-484e-bdbd-118960dd2b81">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognized stock-based compensation expense on all employee and non-employee awards as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:63.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.713%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.643%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.523%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;735&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;910&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="C_478a5db8-cf73-4704-b31d-d3f5d829c87e"
      decimals="-3"
      id="F_60fb5361-31f2-42e4-9381-277815d40b6a"
      unitRef="U_USD">11000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_58b07922-742e-4d1e-8e94-cc27df08f5e4"
      decimals="-3"
      id="F_8b81ee1e-9abf-4ecc-a451-b798a5585ea5"
      unitRef="U_USD">175000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_4794af2c-583f-4aeb-8161-0074b8016cb4"
      decimals="-3"
      id="F_fbafd89c-8bc9-4e41-b1ec-bd564993b76a"
      unitRef="U_USD">161000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_5c448816-7d5b-4d6c-8eae-4e4d68502072"
      decimals="-3"
      id="F_97ce42f4-41b5-4a98-b1e7-429bf937a0c5"
      unitRef="U_USD">735000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="-3"
      id="F_699f7874-6c05-4e6e-a2a2-432194a72a66"
      unitRef="U_USD">172000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="-3"
      id="F_aab17248-2142-4486-be63-f8e527c241c9"
      unitRef="U_USD">910000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="INF"
      id="F_76db299a-54a0-454f-8bdc-75cdf3ced48a"
      unitRef="U_shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="2"
      id="F_d0ec382c-fe9d-4a0b-ba35-8bf35bc2f9ef"
      unitRef="U_USDollarShare">1.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="0"
      id="F_c548dccb-2cba-48b1-9624-8e3ab7283ccf"
      unitRef="U_shares">204344</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="2"
      id="F_2b34f075-2890-4620-9425-bd71eae282f7"
      unitRef="U_USDollarShare">5.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_8bc8bfac-2da3-4135-b1b0-29eef5c72eae">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the three months ended March 31, 2024 and 2023, the fair value of stock options was estimated on the date of grant using a Black-Scholes option valuation model with the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:79.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.173%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.443%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.62%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.143%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.09&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.58&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.87&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected life in years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.27&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.06&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;114.65&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89.69&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95.63&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="4"
      id="F_bb7ebec8-7e81-4885-8504-bb14196ea90b"
      unitRef="U_pure">0.0409</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="4"
      id="F_1966c4aa-10e3-4fd7-a8fa-78a4cb9651f8"
      unitRef="U_pure">0.0358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="4"
      id="F_f037e69a-7130-4add-8363-9ad92ba08ac9"
      unitRef="U_pure">0.0387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_f406ab1a-ea54-42b3-8fbb-f474cdd2a5ff">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_f17db39b-f553-4323-b229-bec623ac9226"
      id="F_777cc266-43de-4781-a792-6c6863ab6248">P5Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_3efa5cb2-5a15-4829-bf1f-70ca2555bcc6"
      id="F_0b94a599-12d6-4cfb-8f9e-2b5301349eef">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="4"
      id="F_65ff259f-9d51-4900-80a0-199a09883566"
      unitRef="U_pure">1.1465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="4"
      id="F_2340ba04-77cd-4783-ab16-e64f42c48a42"
      unitRef="U_pure">0.8969</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="4"
      id="F_62192b92-7dad-4733-a01b-56da1db186d6"
      unitRef="U_pure">0.9563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="2"
      id="F_a833a823-15ad-4dc8-85bc-34e9aa9570f4"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_8c27b046-6702-4a71-8e61-6ba81f191fea"
      decimals="2"
      id="F_3b45e234-f059-4787-b420-35b85c8c70cd"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_f9b9f256-e0ed-43a5-8c1c-277de144e6b4">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock option activity under the Company&#x2019;s stock option plans for the three months ended March 31, 2024 was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.11%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.942%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.662%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.22%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.182%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;"&gt;(in thousands, except share and per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted- Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted- Average Contractual Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;465,898&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;254,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.61&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding, March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;251,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.92&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options exercisable, March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;161,844&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28.28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.53&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options available for future grant, March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,514,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="0"
      id="F_4c08beae-dd05-423a-b241-cfa65e10d9e8"
      unitRef="U_shares">465898</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_307719b1-83d4-4843-8da2-94558ade533e"
      decimals="2"
      id="F_20d17d07-17c6-4c6d-af07-9b756baf2e65"
      unitRef="U_USDollarShare">26.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="INF"
      id="F_6a6ae238-77d4-46a1-9b8a-dc338fa96ee1"
      unitRef="U_shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="2"
      id="F_3061e5ca-b67f-4b15-9554-7e23b91b01e9"
      unitRef="U_USDollarShare">1.8</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="0"
      id="F_120ee62c-e1b4-4b4f-9c3e-f81678db8705"
      unitRef="U_shares">254441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      decimals="2"
      id="F_89b3c607-634f-40f6-a516-d6c8fd27cd38"
      unitRef="U_USDollarShare">19.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="0"
      id="F_34284dc7-1318-4301-b725-af2942f2ecab"
      unitRef="U_shares">251457</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="2"
      id="F_864b24a2-94bc-48f3-bc45-0c6eea11f736"
      unitRef="U_USDollarShare">21.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_42aeb63d-c457-49e2-9f12-91f039ce81a1">P6Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="-3"
      id="F_202f55c8-b693-4c75-a987-1d0c395d7ebe"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="0"
      id="F_839d04e3-f912-4105-9547-ffbef8e82039"
      unitRef="U_shares">161844</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="2"
      id="F_a2c8d332-1324-4ac2-819a-274efb6e3a3b"
      unitRef="U_USDollarShare">28.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_15d352a8-19bf-4b5e-a172-1aeba347b60e">P5Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="-3"
      id="F_8756a0f1-190c-4a02-b392-484d48888d54"
      unitRef="U_USD">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_289f7d65-cf86-4803-859d-4037fea6fa0f"
      decimals="0"
      id="F_c0b1a5c7-99d8-4cd0-8a16-082dc2c8b089"
      unitRef="U_shares">1514087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_31821ab4-d999-49bb-b9d4-9b4dd0c91cb9"
      decimals="-5"
      id="F_1259fbe4-62a3-48b1-a677-c7735763f97a"
      unitRef="U_USD">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_8baabce6-ac11-4af5-8a5f-c37dac90e95a"
      id="F_3d240d50-23d1-4473-b5cf-2c4cf2744677">P1Y3M10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <tcrt:WarrantTextBlock
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_f5baf808-cb23-4f85-a2f3-30dd54e4c552">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;10.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the Company&#x2019;s November 2018 private placement that provided net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;47.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, the Company issued warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,262,626&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, which became exercisable six months after the closing of the private placement, or the November 2018 Warrants. The November 2018 Warrants had an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45.15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and have a five-year term. The fair value of the November 2018 Warrants was estimated at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million using a Black-Scholes model with the following assumptions: expected volatility of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, risk free interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.99&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, expected life of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; dividends.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 26, 2019 and September 12, 2019, the Company entered into agreements with existing investors whereby the investors exercised the November 2018 Warrants for an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,186,869&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45.15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. Proceeds from the warrant exercise after deducting placement agent fees and other related expenses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million were approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company issued participating investors new warrants to purchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,186,869&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; additional &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;shares of common stock (the "2019 Warrants") as consideration for the warrant holders to exercise their November 2018 Warrants. The 2019 Warrants will expire on the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;fifth &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;anniversary of the initial exercise date and have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The 2019 Warrants were valued using a Black-Scholes valuation model and resulted in a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;60.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million non-cash charge in the Company&#x2019;s statement of operations in 2019.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On October 22, 2019, the Company entered into the 2019 R&amp;amp;D Agreement with MD Anderson. In connection with the execution of the 2019 R&amp;amp;D Agreement, the Company issued the MD Anderson Warrant to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;222,222&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock. The MD Anderson Warrant has an initial exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.015&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and grant date fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The MD Anderson Warrant expires on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2026 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;and vests upon the occurrence of certain clinical milestones. The Company will recognize expense on the MD Anderson Warrant in the same manner as if the Company paid cash for services to be rendered. For the three months ended March 31, 2024 and 2023, the Company did not recognize any expense related to the MD Anderson Warrant as the clinical milestones had not been achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On August 6, 2021, the Company entered into the Loan and Security Agreement with SVB. Refer to Note 4, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. In connection with the Loan and Security Agreement, the Company issued SVB warrants to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28,856&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;33.30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. The warrants have a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; life and were fully vested upon issuance. The fair value of the warrants was estimated at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million using a Black-Scholes model with the following assumptions: expected volatility of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, risk free interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, expected life of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; dividends. On December 28, 2021, the Company entered into the First Amendment, as described in Note 4, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;in connection with which, the original warrants issued to SVB were amended and restated. As amended and restated, the SVB Warrants are for up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43,308&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock, in the aggregate, with an exercise price of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;$17.40 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;per share. The SVB Warrants expire on August 6, 2031 and were fully vested upon issuance. As of March 31, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;none&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of the SVB Warrants have been exercised.&lt;/span&gt;&lt;/p&gt;</tcrt:WarrantTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_95a30d90-929e-45eb-82ad-23f6fc64e994"
      decimals="-5"
      id="F_40665e34-8015-460d-ac88-17612ad34cdd"
      unitRef="U_USD">47100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_35078a72-b5fc-4657-9c90-f59660c54ff7"
      decimals="0"
      id="F_180eb886-aea1-4e0e-8358-230c072b0cdb"
      unitRef="U_shares">1262626</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_35078a72-b5fc-4657-9c90-f59660c54ff7"
      decimals="2"
      id="F_5daa3b3d-dc1b-4e19-8fd6-cd27437e3f8d"
      unitRef="U_USDollarShare">45.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tcrt:FairValueOfWarrants
      contextRef="C_5e6444ec-337d-440e-ae0f-2c013e8670a1"
      decimals="-5"
      id="F_4a8959be-7a2c-4ec2-87ce-f356c0617a91"
      unitRef="U_USD">18400000</tcrt:FairValueOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_5e6444ec-337d-440e-ae0f-2c013e8670a1"
      decimals="2"
      id="F_ebc52f90-ebc8-4048-a01b-5f4b93dab526"
      unitRef="U_pure">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_5e6444ec-337d-440e-ae0f-2c013e8670a1"
      decimals="4"
      id="F_80aeaed5-5a5b-463d-93c7-51adef660856"
      unitRef="U_pure">0.0299</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_5e6444ec-337d-440e-ae0f-2c013e8670a1"
      id="F_955be387-a409-4568-b5db-fb1323adb54e">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:Dividends
      contextRef="C_5e6444ec-337d-440e-ae0f-2c013e8670a1"
      decimals="INF"
      id="F_cce479a5-aaad-40e0-8aef-84bd5486b5ec"
      unitRef="U_USD">0</us-gaap:Dividends>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_6046fec4-c22d-43b6-ba9b-95ebb064d3de"
      decimals="0"
      id="F_8e5e2b07-c475-4f12-bf1a-eeee96f7fb83"
      unitRef="U_shares">1186869</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_6046fec4-c22d-43b6-ba9b-95ebb064d3de"
      decimals="2"
      id="F_076a3b93-a316-4a08-9138-0a13a611fc59"
      unitRef="U_USDollarShare">45.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tcrt:PlacementAgentFeesAndOtherRelatedExpenses
      contextRef="C_0bc55a8f-887f-4070-9865-fd66f24117bf"
      decimals="-5"
      id="F_d093dcbf-7742-4466-8c40-dcf607aee663"
      unitRef="U_USD">1100000</tcrt:PlacementAgentFeesAndOtherRelatedExpenses>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="C_131aee97-1b4f-446a-8c75-66998adcc711"
      decimals="-5"
      id="F_8843e8af-0bde-4686-ab46-d2de571d82c0"
      unitRef="U_USD">52500000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_afd87759-7cd4-4535-a126-67b00b692ba6"
      decimals="0"
      id="F_562bac86-3dc0-4279-bc3e-c2f06c35ce06"
      unitRef="U_shares">1186869</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_afd87759-7cd4-4535-a126-67b00b692ba6"
      decimals="2"
      id="F_dad7f986-7c8d-4d54-8258-48d1f527e499"
      unitRef="U_USDollarShare">105</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tcrt:NonOperatingIncomeExpenseInducementOfWarrants
      contextRef="C_4bd3b321-13c5-4e4c-a083-a14aeb2b41c5"
      decimals="-5"
      id="F_00c0205d-af3b-4904-97c7-18460068b870"
      unitRef="U_USD">60800000</tcrt:NonOperatingIncomeExpenseInducementOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_05763aa1-65a6-4ed2-aa0e-21d87146369c"
      decimals="INF"
      id="F_a1a5d07a-464c-4759-be42-ab613b27adfd"
      unitRef="U_shares">222222</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_05763aa1-65a6-4ed2-aa0e-21d87146369c"
      decimals="3"
      id="F_83724884-8620-4cc0-a6b8-4318978b3a19"
      unitRef="U_USDollarShare">0.015</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <tcrt:FairValueOfWarrants
      contextRef="C_8cb0a4ff-691a-4757-b2eb-fbbd3b39dfe9"
      decimals="-5"
      id="F_8cc46161-ae67-4f65-b47b-de4412c0eab5"
      unitRef="U_USD">14500000</tcrt:FairValueOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_05763aa1-65a6-4ed2-aa0e-21d87146369c"
      id="F_3e59d907-1bd3-4e1e-91b9-b2ef30552405">2026-12-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="C_52953abd-cae9-408c-bc3a-1c32bbcbd88a"
      decimals="0"
      id="F_c0cfe78c-677b-43d1-aa2f-3a2d99f09fa6"
      unitRef="U_shares">28856</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:CommonStockCallOrExerciseFeatures
      contextRef="C_db32a880-2ad0-470e-8702-ccd0f5ec87bd"
      id="F_f74e1d87-2ba5-4702-96c3-910351e28369">33.30</us-gaap:CommonStockCallOrExerciseFeatures>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_52953abd-cae9-408c-bc3a-1c32bbcbd88a"
      id="F_fed6ca2e-76b6-444a-967f-86d793e487b0">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <tcrt:FairValueOfWarrants
      contextRef="C_373d470e-fec0-416f-bd2c-474750080aee"
      decimals="-5"
      id="F_30d196d6-ebc6-4278-916b-c59b0cd01b88"
      unitRef="U_USD">800000</tcrt:FairValueOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_373d470e-fec0-416f-bd2c-474750080aee"
      decimals="2"
      id="F_6fada389-953a-4709-bd7c-ce0dd7dcf4a4"
      unitRef="U_pure">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_373d470e-fec0-416f-bd2c-474750080aee"
      decimals="4"
      id="F_c9e4ff37-8d72-4d9a-962a-eafdce7d0289"
      unitRef="U_pure">0.0131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_373d470e-fec0-416f-bd2c-474750080aee"
      id="F_e6be1bfd-ba5c-4df0-90a0-c57398c3da21">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:Dividends
      contextRef="C_373d470e-fec0-416f-bd2c-474750080aee"
      decimals="INF"
      id="F_23becda1-b01a-4b03-bd96-f007faa28571"
      unitRef="U_USD">0</us-gaap:Dividends>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_727a2f22-62eb-4547-b383-db9f11e5e1ac"
      decimals="0"
      id="F_929ddcf2-c402-47f3-9343-23ef21946dfd"
      unitRef="U_shares">43308</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:CommonStockCallOrExerciseFeatures
      contextRef="C_04d2b6bc-59f0-497b-ad0b-246c6e2342a9"
      id="F_9e050702-1611-4c5f-ac33-427049ba84e8">$17.40 </us-gaap:CommonStockCallOrExerciseFeatures>
    <tcrt:ClassOfWarrantOrRightWarrantsExercised
      contextRef="C_8f534694-1370-4e1c-8929-649408ad27f3"
      decimals="INF"
      id="F_8aec0f2d-058b-4c00-a3a8-1b814e6937b5"
      unitRef="U_shares">0</tcrt:ClassOfWarrantOrRightWarrantsExercised>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_05636566-7ce5-4ad9-ae32-7058d2d46333">&lt;div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;11.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Joint Venture&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On December 18, 2018, the Company entered into a Framework Agreement with TriArm whereby the parties agreed to launch Eden BioCell, to lead clinical development and commercialization of certain &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sleeping Beauty&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-generated CAR-T therapies as set forth in a separate license agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 3, 2019, Eden BioCell was incorporated in Hong Kong as a private company. Eden BioCell, the Company and TriArm entered into a Share Subscription Agreement on January 23, 2019, where the Company and TriArm agreed to contribute certain intellectual property, services and cash (only with respect to TriArm) to Eden BioCell to subscribe for a certain number of newly issued ordinary shares in the share capital of Eden BioCell.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The closing of the transaction occurred on July 5, 2019. The Framework Agreement and Share Subscription Agreements were each respectively amended to be effective as of this date. Upon consummation of the joint venture, Eden BioCell and the Company also entered into a license agreement, pursuant to which the Company licensed the rights to Eden BioCell for third generation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; Sleeping Beauty&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;-generated CAR-T therapies targeting the CD19 antigen for the territory of China (including Macau and Hong Kong), Taiwan and Korea. TriArm and the Company each received a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% equity interest in the joint venture in exchange for their contributions to Eden BioCell.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determined that Eden BioCell was considered a variable interest entity, or VIE, and concluded that it was not the primary beneficiary of the VIE as it did not have the power to direct the activities of the VIE. As a result, the Company accounted for the equity interest in Eden BioCell under the equity method of accounting as it had the ability to exercise significant influence.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2021, TriArm and the Company mutually agreed to dissolve the joint venture, which has now been terminated. The Eden BioCell entity has been dissolved as of July 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_3cf7f842-3616-4d7d-a8d1-b72415a7dc2e"
      decimals="2"
      id="F_885b4c31-92ab-49c1-bc4f-91ce000307c4"
      unitRef="U_pure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_4ce16218-e257-4305-af61-598df4ea005f">&lt;div style="display:flex;margin-top:2pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;12.&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Subsequent Events&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has evaluated subsequent events from the balance sheet date through the date on which these condensed financial statements were issued. Other than as described in the notes above, the Company did not have any material subsequent events that impacted its condensed financial statements or disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_92a1b3bb-ed14-465e-a889-5489b84a881c">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_a11ec5a3-4cdc-42a2-95e5-786c139d6e73">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_df9917c6-29db-4b0a-9da5-d8122f069d10">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_f31836bd-3d73-434a-8f8e-640ba5edfd54"
      id="F_c1c5f3bb-b115-4459-81a0-7a960debfe53">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
